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Abstract 
 
 This thesis describes the use of Brønsted acid catalysis to promote 6-exo-trig cyclisations in the 
synthesis of N-heterocyclic compounds. 
 In Chapter one, a general overview of alkaloid structures is given, together with a number of 
general ways for their synthesis, with a particular focus on the Bischler-Napieralski and Pictet-Spengler 
methods. Hydroamination as a synthetic method is then briefly reviewed to set into context the present 
project to develop and optimize an acid-catalysed hydroamination method as an alternative protocol to the 
Picted-Spengler reaction. 
 Chapter two describes different synthetic routes towards the construction of 2-
vinylphenylethylamines and their subsequent cyclisations into tetrahydroisoquinoline alkaloids via the 
acid-catalysed hydroamination methodology. Key aspects of the diastereochemical outcome of the 
reaction are discussed, as well as the spectral features and limitations of the researched chemistry. 
 Chapter three describes application of the acid-catalysed hydroamination in the making of more 
complex, polycyclic structures. Synthesis of polymethoxylated tetrahydroisoquinolines, benzhydryl 
derivatives and a relay synthesis of racemic salsolidine is described. An attempt to synthesise racemic 
alkaloid, crispine, is briefly discussed, as well as synthesis of an aporphine and a berberine skeleton. 
 Chapter four covers the attempt to extend the acid-catalysed hydroamination chemistry to 
unprotected indoles and trans-annular cyclisations. Future work and areas of chemistry in which the acid-
catalysed hydroamination underperformed or failed to deliver the desired results altogether are briefly 
discussed. 
 Chapter five contains the experimental remarks and characterisation data. 
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 Ac acetyl 
 app. apparent  
 APCI atmospheric pressure chemical ionisation 
 Ar aromatic 
 b.p. boiling point 
 Boc tert-butyloxy carbonyl 
 br. broad 
 Bu butyl 
 Bz benzoyl 
 cat. catalytic 
 CI chemical ionisation 
 COSY correlation spectroscopy 
 cy cyclohexane 
 d day(s) 
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 DEPT distortionless enhancement by polarization transfer 
 DMAP 4-dimethylaminopyridine 
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 d.r. diastereomeric ratio 
 EI electron ionisation 
 eq. equivalent(s) 
 ES electrospray 
 ether diethyl ether 
 Et ethyl 
 EWG electron withdrawing group 
 g gram 
 GC gas chromatography 
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 ∆ heat 
 h hour(s) 
 HMBC heteronuclear multiple quantum coherence 
 HPLC high pressure liquid chromatography 
 HRMS high resolution mass spectroscopy 
 HSQC heteronuclear single quantum coherence 
 Hz hertz 
 IR infra-red 
 J coupling constant 
 k kilo 
 kg kilogram 
 lit. literature 
 m meta 
 m multiplet 
 M molar 
 mCPBA 3-chloroperoxybenzoic acid 
 Me methyl 
 MHz megahertz 
 mol micromole(s) 
 min. minute(s) 
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 mmol millimole(s) 
 m.p. melting point 
 MS mass spectrometry 
 NMR nuclear magnetic resonance 
 nOESY nuclear Overhauser enhancement spectroscopy 
 Ns para-nitrobenzenesulfonyl 
 o ortho 
 p page 
 p para 
 Ph phenyl 
 Pr propyl 
 ppm parts per million 
 py pyridine 
 q quartet 
 r.t. room temperature 
 sept  septet 
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 σ sigma 
 s singlet 
 t triplet 
 td triple doublet 
 THF tetrahydrofuran 
 THIQ tetrahydroisoquinoline 
 TLC thin layer chromatography 
 tol. toluene 
 Ts toluenesulfonyl 
 UV ultra-violet 
 w/w weight for weight
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1.1 Heterocycles  
 
 Heterocycles form a vast family of organic compounds. Their characteristic feature is the 
presence of at least one lone pair of electrons on a non-carbon atom within the ring structure. Nitrogen, 
oxygen and sulfur containing heterocycles such as the four-membered azetidines 1, furans 2, pyridines 3, 
or thiiranes 4, (Scheme 1) are by far the most abundant in nature and industry. However, phosphorus,
1
 
arsenic
2
 and several other
3
 atoms that do not carry a lone pair, such as silicon,
4
 or boron,  are also known 
to form heterocyclic ring systems with carbon.  
 
 
 
 
Scheme 1. Heterocyclic rings: azetidine, furan, pyridine and thiirane.  
 
 The presence of the lone pair on a heteroatom in such structures provides a basis for hydrogen 
bonding, coordination, increased reactivity and resonance properties of the molecules. This very 
important group of compounds was shown to possess a wide range of biological properties and to play 
central roles in the world and within our lives.  Heterocyclic moieties can be found in DNA, amongst the 
vast majority of pharmaceuticals, dyes and agricultural products, as well as in hormones and vitamins. 
  Studies of heterocyclic systems comprise an important part in the history of organic chemistry. 
Several of those compounds were made and characterised some two hundred years ago, yet due to their 
anomalous reactivity profiles they proved quite elusive to study and categorise. For a long period, 
heterocycles were not included in most introductory level organic chemistry books. Alan Katritzky had 
influence on introducing perhaps the first, basic, comprehensive courses
5
 in heterocyclic chemistry and 
was a key contributor in this field.  
 Major changes in the world of science began in 1828 with Wöhler’s revolutionary production of 
urea from inorganic materials, which was a very important step in the development of organic chemistry. 
Until that finding, many believed in vitalism, a doctrine stating that there is a fundamental difference 
between biological organisms and other matter and that living entities contain some special, non-physical 
element often referred to as “vital spark”. Even though urea was first detected and described by several 
scientists (Boerhaave, Rouelle, Berzelius, Prout) more than fifty years before Wöhler’s breakthrough 
discovery, it is still an extremely important compound used primarily as a fertiliser and produced in 
excess of 150 million tonnes per year. 
 The few initial heterocyclic compounds were first produced soon after and isolated in the early 
19
th
 century; Brugnatelli’s synthesis of alloxan 5 from uric acid and Wöhler and Liebig’s synthesis of 
purines 6 and pyrimidines being the first two examples (Scheme 2).
6
 Further, important discoveries by 
Perkin allowed a synthesis of benzofuran,
7
 proved that indole formed the core of the indigo dye 7
8
 and 
 3 
 
that pyrrole, isolated by Perkin and described by Anderson,
9
 was an important constituent of hemin, 
bilirubin and chlorophyll. 
 
 
 
 
 
Scheme 2. Alloxan, adenine (with purine core highlighted) and indigo (with indole core highlighted). 
 
 Heterocyclic chemistry has been an active area of research for over two centuries and the last few 
decades conveyed some major improvements, especially in terms of analysis, synthesis and applications 
of heterocyclic compounds. A great number of projects and patents of industrial giants such as Bayer, 
Pfizer, BASF and GSK are based on heterocycles and the work around them never stops. A good example 
is aripiprazole,
10
 one of the top ten best-selling drugs in 2013
11
 making over $6,400,000,000 (6.4 billion 
dollars) during the same year, sold as an antipsychotic drug used to tread schizophrenia, depression and 
bipolar disorder. A few more famous examples, due to their important position in history and structural 
complexities are penicillin 8 and taxol 9 (Scheme 3). In 1945, Florey, Fleming and Chain shared a Nobel 
Prize for their ground-breaking work on penicillin. It was proved to be a very effective antibacterial drug 
and its discovery began the modern era of antibiotic research. Mass production of this famous drug began 
in the same year. Interestingly, the chemical structure of penicillin was first determined by Dorothy 
Hodgkin - also in 1945. Her work in the field of analytical chemistry was recognized somewhat later and 
culminated in her receiving Nobel Prize in 1964, “for her determinations by X-ray techniques of the 
structures of important biochemical substances.” 
 
 
 
 
 
 
 
Scheme 3. Penicilin, structure of Taxol and the Pacific yew tree.
12
 
 
 Taxol 9,
13
 which was discovered in 1962 and first isolated in 1964-1967 from a Pacific yew tree 
species, is used cancer therapy
14
 and in HIV-associated Kaposi’s sarcoma.15 It is still one of the most 
effective anti-cancer drugs available and functions by inhibiting mitosis through stabilisation of 
microtubules, through boosting the polymerisation of tubulin.
16
 The material was incredibly difficult to 
come by in its early stages of development; processing 1200 kg of tree bark delivered roughly 28 kg of 
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crude extract, which was then further processed to provide only 10 g of the pure material. This amounted 
to approximately 0.00083%, which rendered the process very inefficient. 
  Reports of taxol’s interesting biological properties, i.e. anti-leukemia in mice,17 caused a rapid 
increase in demand and it was calculated that 360,000 trees would be required annually to satisfy only the 
USA’s needs. This stimulated organic chemists to devise a way for accessing taxol synthetically and 
prompted several companies to get involved. The future saw Bristol-Meyers Squib (BMS) obtaining 
almost exclusive rights to study and manufacture taxol for a number of years, in collaboration with Robert 
Holton’s group in Florida. Extensive efforts were undertaken to address the supply issue and the problem 
was resolved by the group of Potier, who managed to isolate 10-deacetylbaccatin from the needles of 
European Yew. This highly functionalised precursor of taxol could be isolated in large quantities from a 
cheap and sustainable source and allowed production of taxol in a short semi-synthesis. Not soon after, 
BMS patented an improved, semi-synthetic process to the drug, one not relying on destroying Pacific yew 
trees and thus quenching the controversial, ecological debate over taxol’s manufacture. The molecule was 
also accessed completely synthetically; two earliest, elegant syntheses, by Holton
18,19
 and 
Nicolaou
20,21,22,23
, were published in 1994. More recently, emphasis was put on the biosynthesis of taxol
24
 
and the relatively expensive, semi-synthetic pathway is being abandoned for the cheaper and more 
economically viable biotechnological
25
 production of taxol on industrial scale by plant cell cultures.
 Vancomycin 10 (Scheme 4) is a very effective antibiotic used in the treatment of problematic 
bacterial infections. It is most effective against Gram-positive bacteria and belongs to the family of 
glycopeptide antibiotics. The structure of vancomycin is relatively big and contains 66 carbons and 24 
oxygens; its molecular mass is almost 1.5 kDa. The mechanism through which the drug exhibits its anti-
bacterial properties was deciphered and reported recently.  
 
 
 
 
 
 
 
 
 
 
 
 
(1S,2R,18R,19R,22S,25R,28R,40S)-48-{[(2S, 
3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)- 4- amino-5-hydroxy-
4,6-dimethyloxan-2-l]oxy}-4,5-dihydroxy-6-(hydroxyl 
methyl)oxan-2-yl]oxy}- 22- (carbamoylmethyl)- 5,15- 
dichloro- 2,18,32,35,37- pentahydroxy- 19- [(2R)- 4- 
methyl-2-(methylamino)pentanamido]- 20,23,26,42, 
44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaaza 
octacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.0
34,39]pentaconta- 3,5,8(48),9,11,14,16,29 
(45),30,32,34,36,38,46,49- pentadecaene- 40- 
carboxylic acid 
 
 
Scheme 4. Vancomycin and its systematic (IUPAC) name. 
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 Vancomycin is involved in inhibiting the growth of bacterial cell walls and can form a five-point 
binding interaction with specific proteins in the outer wall of Gram-Positive bacteria. The cell walls of 
gram-negative organisms are composed of different proteins and do not bind efficiently to vancomycin 
and thus are resistant. 
 The first total synthesis of vancomycin was reported in 1999 by Nicolaou and concluded an effort 
that spanned many years and required considerable research by several synthetic groups, for example 
Rao’s, Boger’s, Evans’ and many others.26 At the present time, most investigation is carried out in an 
attempt to synthesise analogues of vancomycin which exhibit a similar spectrum of antimicrobial activity 
against both vancomycin-sensitive and vancomycin resistant bacteria.
26
 
 Another important heterocyclic molecule often classified as an oxygen-based sesquiterpene, 
Artemisinin 11, belongs to a new generation of drugs used in the treatment
27
 of malaria (Scheme 5). Its 
recent rediscovery
28
 goes back to the 1960s, as in the case of taxol. Conversely, the earliest historical 
records of its use go back over two millennia.
29
 They were found in a collection of antique prescriptions 
uncovered in ancient, Chinese tombs originating from the Han Dynasty. Its unusual structural feature, a 
peroxide bridge, is believed to be crucial in its mechanism of action, most likely based on formation of 
oxygen free radicals. 
 
 
 
 
 
 
Scheme 5. Artemisinin and artesunate with the peroxide bridge highlighted and Artemisia annua,
30
 the parent plant. 
 
 At the moment, there is no general, accepted mechanism through which Artemisinin 11 acts. The 
active species, dihydroartemisinin, is nonetheless believed to act whilst the parasites are inside red blood 
cells. One of the possible mechanisms involves action of iron in heme on the peroxide bridge which in 
turn could potentially generate iron-oxo species ultimately resulting in a sequence of reactions that 
generate oxygen radicals that kill the parasite.
31
 High demand for this molecule prompted many chemists 
and engineers to look for faster and more efficient methods for extractions of Artemisinin from natural 
sources, using less toxic solvents and more sustainable methods.
32
 A review published in 2010 by Lapkin 
covers a number of well-known and emerging technologies for extraction of Artemisinin from plant 
material, i.e. with super-critical carbon dioxide or ionic liquids.
33
 Artemisinin itself has relatively low 
bioavailability; a number of more water or lipid soluble, semisynthetic derivatives has been screened, 
namely artesunate or artemether. Artesunate 12 is an ester derivative of the parent compound and due to 
the presence of a carboxylic acid group shows much higher water solubility and can be administered 
intravenously. Artemether, in turn, has an ether functionality which renders it more lipophilic and 
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increases its oral bioavailability. Malaria is one of the major causes of death worldwide as over one 
million people die as a result of the disease annualy and drugs from the Artemisinin family have a 
profound impact on controlling outbreaks of the disease and reducing the mortality rates. Artemisinin 
combination therapy (ACT) has played an imperative role in treatment of uncomplicated malaria over the 
past ten years and is now the recommended first-line treatment.
34
 Unfortunately, the efficiency of the 
treatment could be threatened by malaria’s resistance towards Artemisinin, and the first reports of 
tolerance to the treatment were recently reported in Cambodia.
35
 
 To summarise, the history of heterocyclic compounds is over two hundred years old and they still 
play a very important role and have a profound impact on mankind in modern life. They range from very 
simple and inactive compounds to extremely complex, very active biological molecules and powerful 
drugs. Finally, the research in heterocyclic chemistry never stops and immense quantities of literature are 
published regularly, describing advances in design, synthesis, application and understanding of 
heterocycles. 
 
1.2 Alkaloids 
 
 Alkaloids are a large group of chemical compounds which are best defined as containing a basic 
nitrogen atom and are produced by various different organisms including plants, animals, fungi and 
bacteria. Isolation of morphine, quinine 13 (Scheme 6) and strychnine between 1804 and 1820 began the 
era of studies of alkaloids, leading in 1886 to a first total synthesis of coniine 14
36
 by Ladenburg, a 
neurotoxin fatal to humans in quantities less than 0.2 g. 
 
 
 
 
 
 
Scheme 6. Quinine and (racemic) coniine with its parent plant: Sarracenia flava.
37
 
 
 Alkaloids have been used by humans for over four thousand years and have played an incredibly 
important role in the history of humanity, as mankind has always sought to cure diseases and alleviate 
pain.  A plethora of different pharmacological properties they possess is the key motive behind why they 
were used in tribal rituals, as recreational drugs, but also as analgesics, antibacterials or local anesthetics. 
It is also in our nature to seek remedies for coughs, runny noses or fevers, depression or to stay awake 
when needed and, in different ways, different properties of various alkaloids have helped mankind to stay 
alive and in control of their lives. Simultaneously, in recent times, a broad variety of medicine based on 
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alkaloids such as anti-inflammatory, analgesic or antidepressant are available over the counter. Some 
alkaloids are incredibly potent and even very small doses can induce a substantial biological response in 
living organisms. Exceeding certain, tolerable limits for a drug can cause serious side effects such as 
headaches, confusion, pains, nausea and also death.
38
 Compounds from the family of ergot alkaloids
39
 
such as ergotamine 15 (Scheme 7), which are amongst the most important toxins in human history, are 
known to have a harmful effect on many living creatures, from herbivorous insects to large mammals.
40
 In 
small, carefully controlled doses, however, it can be used in management of migraines
41
 and in treatment 
of tumours.
42
 
 
 
 
 
 
 
 
Scheme 7. Ergotamine and pancuronium bromide. 
 
 Darker and grimmer aspects of alkaloids were also explored by scientists and compounds such as 
pentobarbital and pancuronium bromide 16
43
 (marketed under the name Pavulon) are two infamous 
compounds used in a deadly cocktail of chemicals during capital punishment
44
 procedure in the USA.
45
 
The lethal cocktail is designed to induce unconsciousness, paralysis, cardiac arrest and death, and is 
introduced in three steps, as mixing all the compounds together would cause them to precipitate.  During 
the Second World War, many aircraft pilots were given amphetamine 17 (Scheme 8) to keep them awake 
and sharpen their senses during extremely long flights in difficult and demanding conditions. The typical 
and very well known everyday examples of stimulant alkaloids include caffeine 18 and nicotine 19, 
present in coffee and tobacco, respectively.  
 
 
 
 
 
Scheme 8. Important alkaloids: caffeine, nicotine and amphetamine. 
 
 The psychoactive opioid drug morphine, first isolated in 1804 is, alongside heroin, codeine and 
oxycodone, one of at least fifty different alkaloids present in the opium poppy and is still the most widely 
used pain-relieving drug in clinical medicine. Its mode of action involves direct interaction with the 
central nervous system and it thus alleviates pain. Remarkably, the infamous recreational drug, heroin, is 
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itself inactive, but inside the human body it is converted into 6-acetylmorphine.
46
 When administered 
intravenously, heroin is almost four times more potent than morphine. Opioid drugs create an intense 
feeling of relaxation and euphoria and are used recreationally. Regular use, however, is associated with 
tolerance and physical dependence on the drug develops fast. 
 Another example is lacing arrows with toxic alkaloids, for instance tubocurarine 20 (Scheme 9), 
which was a crucial implement used to hunt and incapacitate prey by South American Indians. 
 
 
 
 
 
 
 
 
Scheme 9. Tubocurarine and rapacuronium bromide. 
 
 Tubocurarine 20 and rapacuronium bromide 21 are neuromuscular-blocking drugs and cause 
paralysis of skeletal muscles.
47
 Tubocurarine does not easily cross the mucous membranes and, 
subsequently, consumption of the contaminated flesh does not produce any negative effects. It belongs to 
a family of tetrahydroisoquinoline alkaloids (vide infra), an important group of compounds displaying 
interesting biological properties. 
 
1.3 Tetrahydroisoquinolines 
 
 The bicyclic isoquinoline 22 and 1,2,3,4-tetrahydroisoquinoline 23 (THIQ) ring systems are 
incorporated into a vast amount of compounds (Scheme 10); over a thousand of these alkaloids have been 
described to date. Various natural and synthetic analogues of THIQs display different biological and 
physiological activities and form a very important family of bioactive compounds. They have played an 
important role in traditional, oriental medicine and are still of great interest in the modern, 
pharmacological world.  
 
 
 
 
Scheme 10. Isoquinoline and tetrahydroisoquinoline cores. 
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 Typical examples of simple isoquinoline alkaloids, which are often substituted at the C(1) 
position with a carbon chain, are lophocerine 24, the biosynthesis of which was described in 1968,
48
 and 
salsoline 25
49
, a cytotoxin selective towards dopamine neurons. Salsolinol
49
 and norsalsolinol,
50
 
metabolites of salsoline, were proven to be endogenous neurotoxins and might be responsible for 
Parkinson’s disease (Scheme 11). 
 
 
 
 
Scheme 11. Lophocerine and salsoline. 
 
 Laudanosine 26 (Scheme 12) is a tetrahydroisoquinoline alkaloid that interacts with the central 
nervous system and has stimulating properties.
51
 It is also a metabolite of an important drug, atracurium, a 
quaternary amine, bis-benzyltetrahydroisoquinoline muscle relaxant similar to tubocurarine 20, used 
along with anaesthetics during tracheal intubation procedures, surgery or artificial respiration.
52
 Since it 
was shown that laudanosine 26 has epileptogenic and cardiovascular effects, further studies were carried 
out to show whether it could potentially cause seizures and other, unwanted side-effects. Further studies 
showed, however, that the plasma levels of laudanosine are too low to cause any adverse effects, 
especially related to seizures, and that atracurium is a safe drug.  
 
 
 
 
 
 
Scheme 12. (S)-Laudanosine, (S)-diclofensine and racemic nomifensine 
 
 Diclofensine 27
53
 and nomifensine 28
54
 are two significant isoquinoline alkaloids discovered in 
the 60s and 70s.
55
 It was shown that the mechanism of action of nomifensine involves increasing the 
available norepinephrine and dopamine by blocking their respective reuptake transporters and both 
compounds were investigated for use as antidepressants.
56
  Successful human trials were run in the 
1980s.
57
 Relatively few side effects of diclofensine made it the drug of choice in treatment of symptoms 
associated with depressions. It was later discovered that nomifensine could cause haemolytic anaemia, a 
condition related to abnormal breakdown of red blood cells, and between 1990 and 1992 both drugs were 
withdrawn from the market. Another important property of the compounds was their mechanism of 
action, which is parallel to the mechanism of recreational drugs such as cocaine. Concerns about their 
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high abuse potential played a major role in retracting the approval for the drugs and removing them from 
the market. 
 Typical chemistry employed in the synthesis of those alkaloids would often feature Bischler-
Napieralski or Pictet-Spengler reactions. 
 
1.4 Bischler-Napieralski 
 
 The Bischler-Napieralski
58
 reaction was first discovered in 1893 and allows preparation of 3,4-
dihydroisoquinolines 29 by reacting -arylethylamides 30 or -arylethylcarbamates with a strong 
dehydrating agent (Scheme 13). Phosphoryl chloride, phosphorus pentoxide, zinc chloride and a number 
of strong Brønsted and Lewis acids can be used in catalytic or in stoichiometric quantities to induce the 
desired transformation. 
 
 
 
 
Scheme 13. The Bischler-Napieralski reaction. 
 
 This classic and important reaction allowed access to the isoquinoline skeleton and synthesis of 
many complex molecules, for example in Woodward’s reserpine59 synthesis. Two possible intermediates 
are proposed for the transformation, involving reaction of the -arylethylamide 29 with phosphoryl 
chloride. The first reaction leads to the formation of 31, which then converts to either a nitrilium species 
32 or a dichlorophosphinic intermediate 33 (Scheme 14), depending on the exact reaction conditions and 
the reagents used.  
 
 
 
 
 
 
 
 
Scheme 14. Two possible mechanisms of a Bischler-Napieralski reaction. 
   
 The main difference between the two pathways lies in the carbonyl elimination step. In the 
pathway A, the carbonyl group leaves prior to the cyclisation and the ring-closure occurs via the nitrilium 
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intermediate 32. In the second instance, pathway B, the cyclisation occurs prior to the exclusion of the 
amide group, which is eliminated at a later step.  The existence of pathway A was reported by Fodor and 
Nagubandi and they postulate that the initial step in the mechanism involves dehydration of the amide to 
form nitrilium salt.
60
 The formation of styrenes 37 in a retro-Ritter side reaction (Scheme 15) provides 
evidence for intermediacy of the nitrilium intermediates 36 in the reaction and can be rationalised by 
formation of a stable, highly conjugated system. A second product formed in the reaction is nitrile 34. 
 
 
 
 
Scheme 15. Formation of styrenes in a retro-Ritter reaction. 
 
 Products arising from the von Braun reaction
61
, alkyl chlorides 35, were also detected in the 
reaction mixtures and are most likely the result of decomposition of the same intermediate 36. Fodor also 
found that Lewis acids increase the rates of Bischler-Napieralski reactions, which delivers further 
indication of nitrilium salt intermediacy. 
  
 A crucial step in the mechanism of the reaction is the electrophilic aromatic substitution and 
rearomatisation, which afford the protonated, cyclised product. As a general rule, the more electron-rich, 
activated substrates perform much better than electron-poor ones. Nonetheless, even the activated 
methoxy-substituted analogues require extensive heating and the standard reaction conditions for the 
Bischler-Napieralski reaction often involve prolonged reflux in toluene or xylene. This is a major 
drawback of the reaction and the non-activated, electron-poor substrates are well known to give poor 
yields – if any. Another downside of this classic reaction is that mono-substituted analogues 38 can give 
rise to different, difficult to separate isomers 39 and 40 (Scheme 16), depending on the reaction pathway, 
in a typical non-selective ortho vs para electrophilic aromatic substitution reaction. 
 
 
 
 
 
 
 
 
 
 
Scheme 16. Routes to different isomers in the electrophilic aromatic substitution. 
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 Another reported side-product in the Bischler-Napieralski reaction is the regioisomer 42, which 
presumably results from an ipso attack of the aromatic carbon to give the spiro-intermediate 41, which 
then rearranges to give 42. 
 An interesting and unprecedented anomalous behaviour of the reaction was reported by 
Yamaguchi (Scheme 17), where evidence for a POCl3-mediated carbon insertion into a benzene ring is 
described. Instead of the expected tetrahydroisoquinoline derivative 43 a rearranged product was 
observed,  allowing the synthesis of azaazulenes 45 (7-5 rings, which are valence isomers of the 6-6 
isoquinolines) from precursors 44.
62
 
 
 
 
 
 
 
Scheme 17. Anomalous Bischler-Napieralski reaction. 
  
 The mechanism involves an initial ipso attack onto the formyl carbon followed by abnormal ring 
expansion and is a direct result of the particular substitution pattern of the electron-donating groups on the 
benzene ring of 44. Various analogues with different substituents on the ring system proved to follow a 
different reaction pathway and gave the expected tetrahydroisoquinolines or, in some extreme cases, de-
formylated procucts. 
 Abnormal reaction products were also studied by Sato, Doi and Shirai (Scheme 18).
63
 In their 
work, they showed that reactions of similar substrates 46 with phosphorus pentoxide in toluene indeed 
proceed via the nitrilium intermediates 47. The authors, however, obtained a mixture of two different 
products, 50 and 51, and to rationalise the formation of the minor product 51, they invoke the existence of 
the spiro-intermediate 48.  Interestingly, reactions of the same set of substrates (e.g. 46) with phosphoryl 
chloride go through the dichlorophosphinic acid esters 49 and give only one product, 50.  
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Scheme 18. Doi’s mechanistic investigation into the Bischler-Napieralski reaction. 
 
 Comparable spiro intermediates 53 were previously reported by Medley and Movassaghi,
64
 who 
were able to obtain spirocyclic indolines 54 in an interrupted variation of the Bischler-Napieralski 
cyclisation (Scheme 19) starting from 52.  
 
Scheme 19. Interrupted Bischler-Napieralski reaction. 
 
 The Bischler-Napieralski synthesis continues to be the primary method of making 
dihydroisoquinolines and form an interesting research theme. A large number of papers on this topic are 
published every year describing various modifications such as microwave-assisted variants
65
, solid phase 
synthesis
66
, reactions in ionic liquids,
67
 or as important steps in total syntheses of various natural products 
such as a potent anti-cancer and anti-inflammatory agent (S)-tylophorine,
68
 made in a one-pot 
Schmidt/Bischler-Napieralski/imine reduction in 84% yield starting from the precursor 55, via the 
formamide 56 and imine 57, to give the final product 58 after the reduction (Scheme 20). A Bischler-
Napieralski reaction was also used to construct the THIQ skeleton in the early steps of a synthesis of a 
close relative of morphine, (-)-thebaine.
69
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Scheme 20. Wang’s synthesis of (S)-tylophorine. 
 
1.5 Pictet-Spengler Reaction 
 
 The Pictet-Spengler
70
 reaction (Scheme 21) is very closely related to the Bischler-Napieralski and 
involves reaction of a phenylethylamine 59 with an aldehyde or a ketone to form an imine 60, followed 
by ring-closure to form a new carbon-carbon bond. Concomitant re-aromatisation by proton loss yields 
the tetrahydroisoquinoine 61. The reaction is generally catalysed by protic or Lewis acids; in addition, a 
number of thermally-mediated examples have been reported in the literature. 
 
 
 
 
Scheme 21. Classic Pictet-Spengler reaction. 
 
 The Pictet-Spengler transformation was discovered in 1911 and quickly became the standard 
method of synthesizing tetrahydroisoquinoline alkaloids 61 and in 1928 it was also successfully extended 
to indoles 62 (Scheme 22) and opened up an easy pathway to the carboline moiety 63. 
 
 
 
 
Scheme 22. Classic Pictet-Spengler synthesis of a carboline moiety. 
 
 The reaction can be classified as an intramolecular Mannich reaction, where the reactive imine 
(iminium) intermediate is trapped, instead of by an enol, by a benzene ring. The Pictet-Spengler reaction 
mechanism has been studied under acid-catalysed and superacid-catalysed conditions and a clear 
correlation had been found between the strength of the acid employed in the reaction and its efficiency. In 
1987 the reaction mechanism was probed in more detail by Bailey,
71
 who reported the existence of spiro-
intermediates 64 (Scheme 23) involved in the reaction. 
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Scheme 23. Spiro-intermediates in the Pictet-Spengler synthesis of carbolines. 
 
  
 In 1977 Stöckigt and Zenk showed that nature also uses the Pictet-Spengler reaction to synthesize 
alkaloids. In their report, the first enzymatic condensation of tryptamine 65 and secologanin 66 in the 
presence of the strictosidine synthase (STR1) enzyme was shown, the first “Pictet-Spenglerase”.72 Since 
then, it was reported that the occurrence of THIQ alkaloids in humans most likely is related to their 
synthesis in situ; consequently, enzymes catalysing Pictet-Spengler reactions are also, reportedly, present 
in humans.
73
 
 
 
 
 
Scheme 24. Condensation of tryptamine and secologanin to strictosidine. 
 
 The product of the enzymatic transformation, strictosidine 67,
74
 was synthesized on a relatively 
large scale, derivatized and compared to an authentic standard and its absolute configuration was 
established to be (R). Strictosidine was also proven to be an important biological intermediate in the 
synthetic pathway of the indole and bisindole cores
75
 and to many important compounds from 
Aspidosperma, Iboga and Corynanthe
76
 families. Experiments where 
14
C labelled strictosidine was fed to 
carefully selected families of plants revealed that it occupies a central position in the synthesis of complex 
indole and monoterpenoid alkaloids (Scheme 25). A detailed study of the mechanism of strictosidine 
synthase was published in 2008 by Stöckigt et al., fourty years after its initial discovery.
77
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Scheme 25. Involvement of strictosidine in biosynthesis of various alkaloids. 
 
 The strictosidine skeleton is incorporated into quinine,
78
 the first effective anti-malarial used for 
many years, gelsemine,
79
 a structurally rare and complex alkaloid with a cage-like structure, the highly 
toxic alkaloid strychnine,
80
 a member of heteroyohimbine alkaloids and a cardiovascular agent 
ajmalicine,
81
 the anti-tumour
82
 and anti-cancer drug camptothecin,
83
 vindoline, a precursor to the anti-
cancer agent vinblastine,
84
 and many others. 
 
 Work in the area of Pictet-Spengler chemistry is mainly focused on achieving good 
stereochemical control of the reaction and investigating the scope and extending the synthetic 
methodology to produce enantioenriched substances. Studies also revealed that, in some cases, the 
condensation proceeds under non-acidic, non-classical conditions.
85
 This was a substantial improvement 
to the original method, as some of the substrate amines and more likely aldehydes could be acid-labile.
76
 
 Due to the common electrophilic aromatic substitution step, both Bischler-Napieralski and Pictet-
Spengler reactions suffer from the same problems. Aromatic compounds which contain electron-donating 
substituents are the most reactive substrates for the reaction. Electron-poor rings react very slowly or not 
at all, reactions of ring-substituted substrates produce mixture of isomers and harsh reaction conditions 
are required to push the reaction to completion.
86
 The vast majority of THIQ alkaloids present in nature 
are highly decorated with methoxy groups, which is quite fortunate. Nonetheless, the methodology is not 
universal and modified protocols of the classic reaction are still being researched, in the hope to increase 
the efficiency and the substrate scope. 
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 An interesting calcium-catalysed Pictet-Spengler reaction was reported by Stambuli (Scheme 26) 
and is a comparatively very mild protocol.
87
 The reaction performs very well even at room temperature 
and provides good to excellent yields of THIQs 69 from phenylethylamine substrates 68 for a range of 
aldehydes. Notably, the hydroxyl-group activation is required; less activated substrates such as tryptamine 
were also exposed to the reaction conditions, however, only the resultant imine could be detected and no 
cyclisation took place. 
 
 
 
Scheme 26. Calcium-catalysed Pictet-Spengler reaction. 
 
 An enantioselective version of the reaction has been developed by List who reported in 2006 that 
it can deliver enantioenriched tetrahydro--carbolines 71 in good to excellent yields (Scheme 27). Chiral, 
BINOL-based phosphoric acids 72 served as the catalysts in the reaction and produced good to excellent 
enantioselectivities. A number of aliphatic and aromatic aldehydes are tolerated, which is a major 
improvement on previous work in this area. The major drawback of this protocol is the necessity for the 
two ester groups on substrate 70 which, according to the authors, provide the required  
Thorpe-Ingold
88
 steric compression required for the cyclisation to occur. Further functionalisation via 
decarboxylation is naturally possible, as is selective hydrolysis of the trans ester group; nevertheless the 
requirement for a geminal diester functionality is a significant limitation. 
 
 
 
 
 
Scheme 27. Enantioselective Pictet-Spengler reaction. 
 
 The Pictet-Spengler reaction has been a central reaction employed in synthesis of numerous 
tetrahydroisoquinoline and -carboline natural products. Cyclisation of the hydroxy-lactam 73 to the 
corresponding intermediate 74 is an elegant example of this chemistry (Scheme 28) and allowed 
assembling the desired tetracyclic core en route to a total synthesis of (-)-eburnamonine 75.
89
 
 
 
 
 
 
Scheme 28. Synthesis of eburnamonine. 
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 In a recent paper by Hiemstra, the enantioselective Pictet-Spengler reaction was successfully 
applied in the synthesis of yohimbine (Scheme 29) from an indole derivative 76 and aldehyde 77.
90
 As 
before, the catalyst of choice was a BINOL-phosphoric acid derivative 79,
91
 producing a 92:8 
enantiomeric ratio of the desired final product 78 in 88% yield. 
 
 
 
 
 
 
 
 
Scheme 29. Hiemstra’s yohimbine synthesis. 
 
 Interestingly, a similar approach was also applied to facilitate Sato’s synthesis of (-)-
corynantheidine,
92
 where the cis-selective Pictet-Spengler reaction delivered a -carboline intermediate in 
74% yield. 
 
1.6 Baldwin’s Rules 
 
 According to literature resources, 90% of all the molecules discovered in nature to date contain 
either a carbocyclic or heterocyclic ring.
93
 It is therefore important for chemists to understand what rules 
govern the key bond-forming processes and whether it is possible to control them and apply successfully 
in synthesis. Due to the large amount of different cyclisation modes i.e. carbon/oxygen/nitrogen ring 
closure onto a carbonyl/double/triple bonds in an endo or exo fashion (Scheme 30), forming a 3-7 
membered rings, substantial consideration needs to be done before certain trends become obvious. 
Understanding why certain reactions perform better than others is also quite a challenge. The key set of 
such rules
94
 was published in 1976 by Baldwin and still remain one of the most cited articles in the 
history of the RSC Chemical Communications journal. The guidelines not only provide the now widely 
accepted nomenclature required to describe and categorise such transformations and processes, but also 
go into more detail and describe the information behind regioselectivity in the ring-closure reactions. The 
physical centre of the rules lies within the requirements of the transition state and thus is based on the 
kinetic favourability of a reaction. In order to achieve cyclisation, a molecule needs to adopt a certain 
conformation, which allows optimal overlap of suitable orbitals and leads to the reaction product.  The 
optimal trajectory of approach for a nucleophilic atom onto a digonal, sp systems is 120°, 105-109° - the 
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Bürgi-Dunitz angle - for trigonal cyslisations and 180° for an sp
3 
centre, which is the classical SN2 
backside approach angle. Since the outcome of a cyclisation relies on the stereochemical requirements for 
the transition state of a particular transformation, some reactions occur very slowly or not at all. In some 
cases the length of the linking chain prevents the cyclising atom from being able to access the site of 
attack at a desired angle and the activation energy for accessing a certain transition state geometry will be 
high and may prevent the reaction from happening. Baldwin’s rules describe ring-closures in three ways: 
by the number of atoms in the new ring (3,4,5 etc.), by position of the bond that is being broken relative 
to the new bond (endo broken bond is within the new ring, exo if the broken bond is outside of the new 
ring system) and by geometry of the electrophilic site (tet, trig, dig, corresponding to sp
3
, sp
2
 and sp 
geometries, respectively.). The nomenclature introduced by Baldwin (Scheme 30) takes the form A-B-C, 
where the three abovementioned parameters correspond to the A, B and C letters, i.e. 6-endo-trig for a 
cyclisation in which a 6-membered ring is formed (6-endo-trig), the bond which is being broken is inside 
the new ring system (6-endo-trig) and the electrophilic site has sp
2 
geometry (6-endo-trig). 
 
 
 
 
 
Scheme 30. Example of an exo and endo reaction (left); 5-endo-trig and 5-endo-dig cyclisations (right). 
 
 
 To sum up, the stereochemical requirements for certain types of cyclisation reactions to occur 
vary between different systems and Baldwin’s rules summarise those trends and restrictions. 
 
 For tetrahedral systems: 
i. 3 to 7-exo-tet favoured 
ii. 5 to 6-endo-tet disfavoured 
 
 For trigonal systems: 
i. 3 to 7-exo-trig favoured 
ii. 3 to 5-endo-trig disfavoured 
iii. 6 to 7-endo-trig favoured 
 
 For digonal systems: 
i. 3 to 4-exo-dig disfavoured 
ii. 5 to 7-exo-dig favoured 
iii. 3 to 7-endo-dig favoured 
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 This thesis will be mainly concerned with overall 6-exo-trig cyclisations, which are all favoured 
in formation of 3 to 7 membered ring systems driven by anionic or radical processes. 
 In some cases the outcome of a cyclisation reaction can be predicted intuitively, as in the mercury 
acetate catalysed cyclisation of nitrogen onto the triple bond in the synthesis of (+)-preussin 81 in ~80% 
yield (Scheme 31) from the aminoalkyne 80.
95
 Formation of a four-membered ring in the product 79 
would create substantial ring strain and consequently it is plausible to assume that a five-membered 
product of the reaction would be much more stable and require meeting much lower activation energy for 
the transition state. Not all reactions, however, are as instinctive as the above mentioned one and quite 
often the result of radical or cationic cyclisations are much harder to predict. Rules for ring-closure of 
cyclic aldol reaction substrates involving enolate intermediates have also been described.
96
 
 
 
 
 
 
 
 
Scheme 31. 4-exo-dig vs. 5-endo-dig cyclisations in the synthesis of Preussin (new bond in red). 
 
 Not all cyclisations conform to the Baldwin’s rules at first sight and exceptions are known. More 
complex, polyfunctional (i.e. highly conjugated, within a rigid ring system or with a restricted access to 
the electrophilic site) systems sometimes follow the “seemingly” disfavoured reaction pathway; this is 
due to the specific properties and structural features of a molecule and results in lowering of the activation 
barriers for the disfavoured pathway and the associated transition states. Also, due to their larger orbital 
radii, different bond lengths and availability of d electrons reactions of third-row and larger elements (i.e. 
sulfur) can yield the “disfavoured” reaction product, as they can access geometrical conformations which 
are much more difficult to occur for second row elements (i.e. carbon, nitrogen).
97
 During his initial 
studies on oxepanes, tetrahydrofurans and tetrahydropyrans, in a project directed towards the synthesis of 
brevetoxins, Nicolaou published his findings on 6-endo vs 5-exo
98
 and 7-endo vs 6-exo
99
 epoxide-ring 
opening with a hydroxyl group and showed that outcome is dependent on the steric as well as electronic 
properties of the substrate 82 (Scheme 32). In the oxepane 83 vs tetrahydropyran 74 experiment (7-endo 
vs 6-exo), introducing a remote ester moiety helped trapping the alcohol 85, resulting from 6-exo-trig 
cyclisation in 100% selectivity (70% yield). However, using the same chain-length ester but an ,-
unsaturated one, increases the charge-stabilisation on the furthest epoxide carbon and increases its 
electrophilicity; this caused  22% of 7-endo adduct formation. More -rich, chlorine-substituted double 
bond caused the selectivity to shift to 92% in favour of the 7-endo product. 
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Scheme 32. Nicolaou’s work on exceptions to Baldwin’s rules. 
 
 Another important finding by Knight, Redfern and Gilmore showed that a furan moiety 
conjugated to the alkenyl cyclisation site can also have an impact on the outcome of ring formation.
100
 
Building on their previous research in the area of synthesising pyrrolidines and prolines,
101
 they 
synthesized a series of alkenyl sulfonamides and attempted their cyclisation. In the case of unsubstituted 
analogues the reaction proceeded via the 5-endo-trig pathway, yielding 86 (Scheme 33). Introduction of 
an alcohol group in the molecule 87 opened up a new possible pathway, 5-exo-trig, which is more 
favourable according to Baldwin’s rules, and the cyclisation does not proceed through the sulfonamide 
and yields a tetrahydrofuran 89, via the iodonium intermediate 88, instead. 
 
 
 
 
Scheme 33. 5-exo-dig vs 6-exo-dig cyclisation. 
 
 This was on the other hand, not the case for furan-substituted substrates such as 90 and the 
apparent 5-exo pathway is favoured over the 5-endo pathway. However, the cyclisation is also controlled 
by the substituent on the double bond and, in this case, involvement of the furan oxygen lone pair 
(Scheme 34). Presumably, the iodonium intermediate 91 is ring-opened by the oxygen, forming a highly 
electrophilic system 82 which can now undergo a 5-exo-dig to form 93, or the less favoured 6-exo-dig (in 
blue) pathway. 
 
 
 
 
Scheme 34. Knight’s 5-exo-trig sulfonamido THF synthesis. 
  
  In conclusion, this type of arrangement is an example of a multifunctional, complex system that, 
upon closer inspection, follows the Baldwin’s rules. A similar observation was also made by Baldwin 
himself in a publication describing base- and acid-catalysed cyclisation reactions of various 
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hydroxyenones 94 (Scheme 35), where an apparent disfavoured transformation (5-endo-trig) occurs via a 
conjugated transition state 95 and is hence best categorized as a 5-exo-trig process.
102
 
 
 
 
 
 
Scheme 35. Cyclisation reactions of hydroxyenones. 
 
 
1.7 Hydroamination 
 
 In a hydroamination reaction, an N-H functionality is added across an unsaturated carbon-carbon 
bond of an alkene, alkyne or an allene (Scheme 36). The transformation can be carried out between two 
species in an intermolecular fashion to furnish an amine, or in an intramolecular fashion to give an N-
heterocyclic ring.  
 
 
 
 
Scheme 36. Inter- and an intramolecular hydroamination. 
 
 Hydroamination reactions can be highly atom-efficient reaction process that can be used in an 
intramolecular or intermolecular fashion to create N-heterocyclic compounds. The high activation barrier 
of the reaction
103
 stems possibly from the electrostatic repulsion of the -bond and the nitrogen lone pair. 
The thermodynamics of a hydroamination are close to neutral,
104
 however, the intermolecular reaction is 
entropically unfavourable and, according to several reviews, should benefit from being performed at 
lower temperatures. Logic behind this reasoning invokes the temperature dependence of the equilibrium 
constant of an exothermic reaction. Increasing the temperature of an exothermic reaction decreases the 
value of the equilibrium constant. This implies that as the temperature is increased, the position of the 
equilibrium will move to the left (Scheme 37). Opposite behaviour would be expected if the reaction was 
endothermic. 
 
 
 
Scheme 37. Equilibrium in an intermolecular hydroamination. 
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 Two common approaches to effect a hydroamination reaction are often adopted and involve 
activation of either the -system or the amine. The activation of alkenes is usually done with transition 
metals and a number of procedures describing the to use of aluminium,
105
 zirconium,
106
 palladium,
107
 
gold,
108
 bismuth,
109
 yttrium,
110
 and indium 
111
 are known. The mechanism of organolanthanide-catalysed 
hydroamination is a well-studied topic and high turn-over frequencies and excellent stereoselectivities are 
some of the striking features of this methodology. Use of intelligent ligand-design allowed for 
development of enantioselective hydroaminations, as exemplified by concise synthesis of (+)-coniine
112
 
(Scheme 38) employing a catalyst of high complexity. 
 
 
 
 
 
 
 
Scheme 38. Coniine synthesis. 
 
 The initial samarium complex-catalysed reaction proceeds in 91% yield and affords the 
carboxybenzyl-protected product in 63% ee. The mechanism of the reaction is believed to proceed via an 
initial association of the amine with the lanthanide complex, followed by a four-point transition state 
(Scheme 39) leading to the olefin insertion. Note that a diene moiety is required for the reaction to take 
place and that simple alkenes have a different reactivity profile. The final step involves protonolysis of 
the Ln-C bond and yields the cyclised product. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 39. Catalytic cycle of “lanthanocene” hydroamination reaction. 
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 Very good yields and enantioselectivities were recently reported by Sadow in his hydroamination 
protocol for synthesis of 2-methylpyrrolidines from unactivated alkenyl amines.
113  
Oxazolinylborate-based species are used as the catalysts with either ytterbium or zirconium, to provide 
the hydroamination products in excellent yields and enantioselectivities. A thought-provoking 
phenomenon was also observed by the authors, specifically, two opposite enantiomers could be produced 
in a reaction with identical oxazolinylborate ligands but when different metals are used. The absolute 
configuration of the ligand was identical in both cases and thus an issue of different mechanistic 
pathways, depending on the metal, was highlighted (Scheme 40). 
 
 
 
 
 
 
 
Scheme 40. Sadow’s ytterbium and zinc hydroamination. 
 
 Hydroamination approaches utilising alkali metals including lithium114 and calcium,115 developed 
by Ward and his group at Cardiff University, rely on deprotonation of the amine 
(to give N
-
), which renders it nucleophilic enough to attack the double bond. In many cases, however, 
stoichiometric quantities of metals are required in the reaction
116
 and the substrate scope is very limited. 
Subsequently, no universal method to afford a hydroamination is available and this specific research field 
remains very active, as there is still need for new, efficient amination processes. Since the shift from 
stoichiometric to catalytic metal quantities in synthesis, the topic was reviewed a number of times, 
recently by Beller and Múller
117
 in 1999.  
 Recently, more emphasis is also being put on developing hydroaminations performing well at 
ambient temperature
118
 and delivering enantioenriched products (Scheme 41).
119
 In a recent publication 
by Jacobsen, a reverse Cope hydroamination
120
 of bis-homoallylic hydroxylamines 96 catalysed by 
thiourea species 98 was reported. The reaction provides access to enantioenriched, substituted 
pyrrolidines 97 and does it at room temperature and very good overall yields.  
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Scheme 41. Jacobsen’s reverse Cope hydroamination. 
  
 Good to excellent enantioselectivities were obtained in the reaction, however, the reaction scope 
seems limited, as only alkyl and arylphenyl/halophenyl substituents were reported. The complex nature of 
the catalyst employed and a possible lack of functional group tolerance is making this reaction, at least in 
its current state, not very useful. 
 
1.8 Acid-catalysed intramolecular hydroamination 
 
 Trifluoromethanesulfonic
121
 (triflic) acid, first reported in 1954, is a super acid, which by 
definition implies that it is stronger than sulfuric acid. It belongs to a special family of compounds and is 
one of the strongest known Brønsted
122
 acids and has a pKa of approximately -12.
123
 Another way of 
measuring the strength of a Brønsted acid is related to the rate at which it exchanges aromatic hydrogens 
and it has been reported that the proton-exchange rate of triflic acid in benzene is more than 220 billion 
times faster (2.2 x 10
11
) than with trifluoroacetic acid. Apart from its high acidity, its important features 
also involve high thermal stability and resistance to oxidation and reduction. Unlike sulfuric and halo-
sulfuric acids, triflic acid does not induce sulfonylations of unsaturated systems. This important set of 
properties make this acid an important reagent in organic synthesis and chemists continue to employ its 
special reactivity to find new and interesting applications. Trifluoromethanesulfonic acid was 
demonstrated to be an effective catalyst in Friedel-Crafts reactions, cationic polymerisations
124
 of 
alkenes,
125
 ethers and siloxanes, Diels-Alder
126
 reactions, as well as various rearrangements and 
cycloadditions,
127
 and oxygen or nitrogen cyclisations. The high reactivity of triflic acid makes it sensitive 
to water. It fumes in humid air and upon reaction with water, forms a stable monohydrate: CF3SO3H.H2O. 
This is a significant drawback and triflic acid-catalysed reactions need to be carried out under inert 
atmosphere and anhydrous conditions. 
 Since a vast number of nitrogen-containing heterocycles are synthesized from amino-olefins, the 
intramolecular hydroamination protocol is of great interest to many organic chemists. One of the first 
examples in the area of acid-catalysed intramolecular hydroamination of alkene sulfonamides 99 was 
reported by Hartwig and Schlummer (Scheme 42) in 2002.
128
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Scheme 42. Hartwig’s acid-catalysed hydroamination. 
  
 The reaction affords substituted pyrrolidines 100 which are important synthetic intermediates and 
natural products, as their core is incorporated into such important compounds as nicotine, cocaine and 
proline. The overall yields are good to excellent; however, the substrate scope is quite limited. Upon 
extension of the chemistry to styryl double bonds, the electron-rich substrates underwent decomposition 
and the electron poor ones did not undergo cyclisation at all. 
 Acid-catalysed hydroamination chemistry is a very central research topic within the Knight group 
and is a result of previous research into iodocyclisations (Scheme 43).
129
 An observation was made that 
formation of iodopyrrolidines 102 proceeds to give a mixture of diastereomers 101a and 101b in the 
presence of base but a single diastereomer 101a is formed if the reaction is carried out without base.
130
 
This was thought to occur due to the presence of hydroiodic acid causing a proton-induced ring-opening 
and cyclisation, effectively pushing the equilibrium towards the thermodynamic cis-product 101b. 
 
 
 
 
Scheme 43. Iodocyclisations of homoallylic sulfonamides. 
 
 When such iodine-induced cyclisations were performed in the absence of base, deiodinated 
reaction products 103 were also observed. Since these by-products could not be formed through 
deiodination, this pointed towards a different reaction mechanism – one that does not involve formation 
of iodonium intermediate. One of the possibilities was that direct acid-catalysed cyclisation was occurring 
to a small degree. 
 Interestingly, hydroiodic acid-catalysed intermolecular hydroamination and hydroarylation was 
reported by Marcseková in 2007. The electronic properties of the olefin and of the amine were found to 
play important roles in the selectivity of the reaction. Addition of hydrogen iodide to the olefin followed 
by a nucleophilic substitution was postulated as a possible reaction mechanism 
 Contemporaneously, Haskins and Knight showed that tosic acid, triflic and sulfuric acid catalyse 
the overall 5-endo-trig
 
cyclisations
131
 and the methodology has been utilized to synthesize numerous 
heterocyclic compounds (Scheme 44), for example, pyrrolidines 105 from prenyl derivatives 104 in 
excellent yields. 
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Scheme 44. Knight’s acid-catalysed hydroamination procedure. 
  
 This was an improvement on the iodine-mediated cyclisations, as catalytic amounts of acid could 
have been used instead of ~3.0 equivalents of molecular iodine. The reaction was found to need 
stoichiometric quantities of tosic acid to go to completion and require temperatures in excess of 70 °C. 
Fortunately, further optimisation of the reaction conditions showed that the reaction performs very well 
with sub-stoichiometric amounts of triflic acid with chloroform or dichloromethane as solvent and that 
full conversion of the prenyl derivatives to the pyrrolidines is achieved in 15 minutes at 0 °C. No 
cyclisation was observed at -78 °C and slow conversion of about 70% in 6h was observed at -40 °C. The 
general conditions adopted for the reaction were 0.4 equivalents of triflic acid at 0 °C. Lowering the 
quantity of acid to 0.1 or 0.03 equivalents resulted in a drastic drop in yield, which could indicate the 
sensitivity of the reaction to trace amounts of water. Further optimisation involved syntheses of analogues 
106, 107 and 108 with different substituents on the olefin and probing the performance (Scheme 45). 
 
 
 
 
 
Scheme 45. Optimisation of hydroamination (yields of corresponding products are given). 
 
 A clear trend in the reactivity could be observed, related to the generation of a more or less stable 
carbenium ion. The highly stabilised tertiary cations arising from prenyl analogues 106 required low 
temperature and short reaction times to achieve full conversion and products could be obtained in 97% 
yield. Cinnamyl derivatives and thus the secondary benzylic cations, for example 107, needed more 
forcing conditions and substantially longer reaction times and products were synthesized in 95% yield. 
The least stable, secondary olefins 108 could only be cyclised at significantly higher temperature  
of 62 °C; a yield of 94% was obtained, nevertheless. Additional experimentation showed that non-
enolisable aldehydes, remote double bonds and sulfonyl groups were tolerated under the reaction 
conditions (Scheme 46). Dienes 109 and 111 were successfully cyclised to the corresponding pyrrolidine 
derivatives 110 and 112 in 64-72% yield. 
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Scheme 46. Acid catalysed hydroaminations. 
 
 Additional development involved probing the nitrogen-protecting group and it was discovered 
that nitrophenylsulfonyl (nosyl) protecting groups, first introduced by the Fukuyama group, work very 
well. Nosyl protecting groups are much easier to remove as they are prone to an ipso attack by a thiolate 
ion and thus can be removed with thiols, including thioacetic or thioglycolic acid. Even though there are a 
large number of protocols available in the arsenal of synthetic chemists to remove tosyl protecting groups, 
usually involving Birch-like reducing conditions, the reactions often do not perform very well. Somewhat 
lower yields were obtained in comparison to the tosyl series, but efficient cyclisation of nosyl derivatives 
113 and 114 was nonetheless an improvement (Scheme 47). 
 
 
 
 
 
 
 
 
 
Scheme 47. Acid catalysed hydroaminations (yields of corresponding products are given). 
 
 Unfortunately,  carbonyl protecting groups such as carbamates and amides do not perform in the 
cyclisations all that well. Carbamate substrates are limited to the most reactive, prenyl derivatives 115. 
More forcing reaction conditions are required, 2h at 25 °C, in comparison to the tosyl-protected 
compounds (i.e. 106), which cyclise in 15 min at 0 °C. No product could be obtained in an attempt to 
cyclise the cinnamyl and crotyl derivatives 116 and 117. Also, much more forcing reaction conditions 
involving refluxing in toluene had to be applied to transform the acetyl-protected, prenyl substrate 118. 
 This methodology was also applied to synthesis of more complex molecules in a cascade 
cyclisation of a polyalkene to form larger cyclic systems (Scheme 48).
132
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Scheme 48. Hydroamination of polyene substrates. 
 
 Geranyl 119 (and farnesyl, not shown) derivatives cyclised in approximately 80 – 90% yield to 
give the corresponding polyclic structures 120. The chemistry was also used in the synthesis of aza-
steroids 122, which could be successfully obtained from the geranylgeranyl substrates 121. Unfortunately, 
the obtained products were obtained in various diastereochemical ratios, approximately 3:1 to 3:2 for 
geranyl and 3:3:1:1 for farnesyl products. The diastereomeric composition of the azasteroids could not be 
accurately determined, due to the complexity of the NMR data. 
 The acid-catalysed intramolecular hydroamination methodology was also extended to the 
synthesis of isoindolines (Scheme 49). Henderson and Knight reported that cyclisations of 2-
alkenylarylmethylamine derivatives 123 gave isoindolines 124, most likely via benzylic carbenium ion 
generation.
133
 
 
 
 
Scheme 49. Synthesis of isoindolines. 
 
 As before, the tosyl group was chosen as the nitrogen-activating group. Exposure of the 
substrates 123 to catalytic (~ 0.5 eq.) quantities of triflic acid in dichloromethane resulted in smooth 
transformation into the corresponding isoindolines 124 in very good yields.  
 After initial probing of the scope and limitations of this methodology, an idea arose to prove its 
utility in a synthesis of more complex targets. More recently, Knight’s hydroamination was effectively 
applied in the synthesis of a pentacyclic alkaloid, -cyclopiazonic acid 127 (Scheme 50).134 
 
 
 
 
 
 
Scheme 50. Synthesis of -cyclopiazonic acid. 
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 The key step involved a cascade cyclisation of a nosyl-protected nitrogen in 125 onto a double 
bond and terminating on a protected, benzylic alcohol, presumably via a carbenium-ion intermediate. The 
transformation delivered the desired tetracyclic product 126 in 74% yield, which was further developed to 
the target material 127. 
 
 Establishing that the acid catalysed hydroamination performs well in the area of synthesis of 
crowded amines, focus was put on extending it to the production of other alkaloid cores. Since a clear 
relationship between the outcome of the cyclisation and the relative stability of the postulated 
carbocationic intermediate was observed, it was envisioned that the benzylic stabilisation could provide 
the extra reactivity – as in the synthesis of isoindolines.  In 2012, Henderson reported the synthesis of 
tetrahydroisoquinoline ring system 129 from the corresponding 2-vinylphenylethylamines 128 (Scheme 
51).
135
 
 
 
 
 
 
Scheme 51. Synthesis of tetrahydroisoquinolines. 
  
 These encouraging results prompted further research in this field and permitted gaining access to 
an important and valuable moiety in an unconventional, yet effective way and delivered a number of 
novel chemical compounds relatively quickly.  
 
1.9 Conclusions 
 
 A vast number of academic institutions and chemical companies work in the area of N-
heterocyclic chemistry. Acid catalysed hydroamination has a potential of delivering complex, high value 
compounds in a transformation which is very efficient and atom-economical. An important advantage of 
the Knight hydroamination over the classical methods developed for synthesis of heterocyclic compounds 
is that it is not as sensitive to unactivated substrates. In fact, none of the compounds reported by 
Henderson had any electron-donating substituents on the ring. The requirement for an electron-rich ring 
on the cyclising substrate could, therefore, be somewhat alleviated, making Knight’s methodology the 
preferred technique for synthesis of numerous alkaloids. 
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Chapter 2: Synthesis of tetrahydroisoquinolines. 
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2.1 Tetrahydroisoquinolines 
 
 Tetrahydroisoquinoline alkaloids often exhibit strong biological responses and belong to an 
important class of chemical compounds. They have been extensively studied for their muscle-relaxing 
(vide supra), antidepressing and antidopaminergic effects,
136
 neurotoxic and cytotoxic properties,
137
 and 
many others.
138
 A number of important drug molecules which are currently being prescribed to patients 
contain the tetrahydroisoquinoline moiety. Solifenacin 130 (Scheme 52) is a muscarinic receptor 
antagonist
139
 and by 2008 it had been used in almost 50 countries worldwide and prescribed to over 2.2 
million patients for the treatment of Overactive Bladder Syndrome.
140
 Another important drug which 
presently, in December 2014, is in Phase III trials for treatment of ovarian cancer and Phase II for prostate 
cancer is Trabectedin 131.
141
 Its structure comprises of 3 tetrahydroisoquinoline moieties and a total of 8 
rings, including a 10-membered heterocyclic macrocycle. In 1996, Corey published the first total 
synthesis of trabectedin, employing a series of exotic Pictet-Spengler-type cyclisations to construct the 
THIQ moieties.
142
 
 
 
 
 
 
 
 
Scheme 52. Solifenacin and trabectedin. 
 
 Alkaloids from the tetrahydroisoquinoline family constitute a valuable group of bioactive 
chemical compounds. The classic methods of synthesising these compounds, the Bischler-Napieralski and 
Pictet-Spengler reactions, are somewhat limited in their scope and efficiency and there is a need for 
development of new, more universal routes to access the THIQ skeleton.  
 Knight’s acid-catalysed hydroamination methodology has the potential for delivering the THIQ 
products without the necessity for electron-donating substituents on the ring of the substrate, which is a 
requirement in the Pictet-Spengler and Bischler-Napieralski reactions. In the synthesis of -cyclopiazonic 
acid and in the synthesis of isoindoline and other, simple isoquinoline systems, the cyclisations onto 
stable benzylic cations were largely successful. Installing the double bond on intermediate 132, prior to 
formation of the THIQ heterocyclic part, to form 133, ensures the necessary C-C bond is in place; 
subsequent hydroamination provides the ring-closed product 134 (Scheme 53). An additional advantage 
over the classic methodology is the selectivity; the ortho substitution almost guarantees only one 
regioisomer as the sole product of the reaction. It is possible, however, that the suggested spiro-
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intermediates (vide supra), which play an important role in some of the postulated Pictet-Spengler 
reaction mechanisms, could also potentially prove problematic under the superacid-catalysed reaction 
conditions and lead to unwanted byproducts. 
 
 
 
 
 
Scheme 53. Knight’s hydroamination in the synthesis of THIQ alkaloids. 
 
 It needs to be noted that the synthetic scheme depicted above is largely different from the 
classical approach to molecules of this type. It was speculated that the R
1
 substituent will now most 
probably have a large effect on the reaction rate and that the steric compression introduced by R
2
 might 
also play an important role. The substituents para to the vinyl moiety will also have an influence on the 
rate of the reaction, however, most likely it will not govern the overall outcome of the transformation, as 
it is usually the case in electrophilic aromatic substitution-driven reactions, such as Bischler-Napieralski 
and Pictet-Spengler.  
 The topic of this thesis will mainly describe synthesis, substituent effect and nitrogen protecting 
group influence on the outcome of 6-exo-trig cyclisations of 2-vinylphenylethylamines 133 to the 
corresponding tetrahydroisoquinoline alkaloids 134. 
 
2.2 Preparative Chemistry 
  
 The ability to quickly and efficiently make any of the starting materials for any planned reaction 
is an important part of any synthesis, especially if a large library of compounds needs to be synthesized or 
an extensive optimisation of the reaction performed. The efficiency of a particular chemical reaction 
becomes not as important if one cannot access the required compounds to accomplish it; thus, to some 
extent a reported chemical procedure is only as good as the accessibility of the starting material for it. 
 In the early stages of the project an emphasis was put on developing a comprehensive set of 
organic reactions which would allow construction of the desired 2-vinylphenylethylamines 133. The main 
idea was to access a set of synthetic methodologies which would permit manipulation of various parts of 
the precursor 135: the groups present on the ring (R), the substituents on the double bond (R
1
) and on the 
phenylethyl chain (R
2
) and the protecting group (PG) on the nitrogen (Scheme 54). Since a universal 
procedure granting access to all the needed precursors for the acid-catalysed cyclisation could not be 
found, several diverse approaches were defined and are depicted below. 
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Scheme 54. Preparative chemistry behind the synthesis of the cyclisation precursors. 
 
 It was envisioned that the synthesis of the required cyclisation precursors could start with 
functionalization of 2-bromobenzaldehyde 136. The vinyl group could be installed in a standard double-
bond formation reaction, such as Wittig, Petersen or Julia. The 2-vinyl substrate 137 could be then used to 
ring-open a substituted N-tosylaziridine 138 to yield the final target 135 in only two steps. 
 Homologation of 2-bromobenzaldehyde to phenylacetaldehyde derivative 139 followed by 
functionalization with a Grignard reagent, conversion to the amine and installation of the double bond in a 
Heck,
143
 Suzuki
144
 or Stille
145
 reaction would provide the desired precursor 135, albeit in a minimum of 7 
steps. 
 Condensation of 2-bromobenzylbromide 140 with enolates 141 followed by hydrolysis could 
afford phenylpropionic acids 142, which after Curtius rearrangement and introduction of the double bond 
would furnish the final product 135. 
 Another useful approach involved condensation of a nitroalkene 143 with 2-bromobenzaldehyde 
136, which after dehydration, reduction, protection and introduction of the olefin could afford the target 
molecule 135. 
 All the aforementioned routes were tested experimentally and their synthetic value examined. The 
efficiency, scope, limitations and strengths and weaknesses of the procedures will be discussed in greater 
detail later in this chapter.  
  
 There are many other possible routes which potentially could deliver the necessary substrates 135 
(Scheme 55), for example, ring-opening of an epoxide 144 by intermediate 145,
145
 followed by further 
elaboration of the phenethyl alcohol 146, a simple reductive amination of homobenzylic aldehydes 139 to 
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access the unsubstituted analogues 147, or addition of nucleophiles to phenylacetonitriles 148 and 
reductive work-up to afford primary amines 149. 
 
 
 
 
 
 
 
 
 
Scheme 55. Alternative routes for the synthesis of the cyclisation precursors. 
 
2.3 Aziridine route 
  
 Aziridines are the nitrogen equivalents of epoxides. Their biological properties
146
, synthesis
147
 
and reactions
148
 have been reviewed many times, more recently in 2014 by Degennaro and Luisi.
149
 The 
ring-opening of an aziridine reagent is an established methodology used for introducing an ethylamine 
moiety.
150
 One of the major areas of research where aziridines are frequently used is the ring-opening of 
N-sulfonyl aziridine-2-carboxylate esters with carbon nucleophiles as a method for preparation of 
aminoacids.
151
 
 One of the major drawbacks of the aziridine route is the inability to tolerate any highly 
electrophilic, reactive functional groups as they would react in preference to the aziridine. Consequently, 
the carbonyl group of 2-bromobenzaldehyde 136, which was the starting material of choice mainly due to 
its availability and low price, had to be functionalised prior to the ring-opening reaction. Fortuitously, the 
2-vinylbromoarenes 137/150 could be synthesized in a Wittig reaction of 136 (Scheme 56) with various 
phosphonium salts 152, which were either commercially available or made in the laboratory in a very 
good yield from the respective alkyl halides 151. 
 
 
 
 
 
 
Scheme 56. Synthesis of 2-vinylbromoarenes. 
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 The Wittig reaction delivered the products mostly in very good to excellent yields, although as a 
mixture of inseparable cis 150 and trans 137 isomers. A very interesting publication by Gilheany covers 
some of the basic aspects of E/Z selectivities in Wittig reactions.
152
 The publication also reveals that 
column chromatography causes slow isomerisation of the olefins from cis to trans. Similar behaviour was 
observed in several cases for a number of stilbene derivatives in our laboratory, where the initial Wittig 
product would be synthesized as a 10:1 mixture of cis and trans isomers and taking the olefin through to 
the next synthetic steps would change the mixture’s composition to 7:1 cis and trans and later to 4:1 cis 
and trans. The accurate isomeric ratios are reported in the experimental section. 
 It was realized that the stereochemistry of the double bond could prove problematic if the 
reactivity of substrates under hydroamination conditions was different. It was later discovered that this 
was indeed the case. On the other hand, it was a good opportunity to study the effect of the double bond 
geometry on performance of the cyclisation reactions. 
 The main benefit of the synthetic route to tetrahydroisoquinoline 153 involving the ring-opening 
of an aziridine 154 with a Grignard reagent 137b was the quick installation of the phenylethylamine 
chain, including the tosyl protecting group, in one step (Scheme 57).  
 
 
 
 
 
 
 
Scheme 57. Aziridine route to the 2-vinylphentylethylamines . 
 
 Aziridines can be accessed in many different ways and the preparation of substituted aziridines 
usually involves nitrene insertions into alkenes, via aza-Darzens type reactions or Mitsunobu reactions of 
-hydroxy--aminoesters. The N-tosyl aziridines such as 154 used in the synthesis of 
tetrahydroisoquinolines were prepared by a one-pot double tosylation and concomitant ring-closure of 
1,2-aminoalcohols 155. In addition, aziridines have also been used as sources of chirality in 
stereocontrolled reactions and can be used to access enantiomerically pure cyclisation precursors 156 
(Scheme 58). Optically active aziridines can be synthesized via cyclisation of the 1,2-aminoalcohols 157, 
which are in turn derived from their respective aminoacids and can be purchased in enantiomerically 
enriched forms. A range of racemic and optically pure N-tosyl aziridines are also commercially available 
and would potentially allow synthesis of 2-vinylethylamines such as compound 158. 
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Scheme 58. Aziridine route to the optically pure 2-vinylphentylethylamines . 
 
 According to some literature sources, synthesis
153
 of aziridines from their respective 
aminoalcohols is an easy, one step, one-pot procedure (Scheme 59) yielding 86 – 93% of the desired 
aziridine product on a 1 to 10 g scale.
154
 When attempted in the laboratory, however, the yields obtained 
were poor (30 – 45 %) and the purification painstakingly slow and costly, mostly due to large amounts of 
toluenesulfonic acid and tosyl chloride present in the crude reaction mixture. Another major problem was 
related to the conversion of the tosylated aminoalcohol 159 into the aziridine 154.  
 
 
 
Scheme 59. One-pot aziridine synthesis. 
 
 Analysis of the crude reaction mixtures showed the aziridine as well as the mono- and bis-
tosylated material present, which would not ring-close, even at prolonged reaction times or mild heating. 
This is in accordance with several other publications, where the reported yields for synthesis of aziridines 
from 1,2-aminoalcohols vary between approximately 40 and 60 %.
155
 
 Several experiments were carried out in an attempt to try and improve the yield for aziridine 
synthesis - unfortunately, no major improvement could be attained. Changing the solvent from 
dichloromethane to acetonitrile
156
 had almost no effect; attempts to mediate the ring-closure with a 
stronger base, e.g. sodium hydroxide in methanol, resulted in formation of large quantities of methyl 
tosylate 160, which could not be separated. The idea of using a strong, inorganic base to achieve the ring-
closure was inspired by a publication by Daub and Overman, who reported a sequential bis-tosylation of a 
1,2-aminoalcohol to obtain the product using pyridine as solvent, followed by a separate 
cyclisation/elimination step with KOH in methanol, to yield an aziridine.
157
 A literature search revealed 
that Di Vitta and Marzorati encountered similar problems and could only obtain 60% yield of a very 
similar aziridine, unless phase-transfer catalysis was employed, in which case their yields had reached 
>90% but significant problems associated with purification of the final product arose.
158
 Increasing the 
reaction time or the temperature of the original, reaction performed in dichloromethane caused an 
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increased formation of unidentified impurities and in the case of NaOH/MeOH reaction, the ring-opened 
product 161
159
 was mainly detected (Scheme 60).  
 
 
 
Scheme 60. Side products in the aziridine synthesis. 
 
 Reactions using potassium carbonate
158
 in methanol or dichloromethane both at low and high 
temperatures also did not provide any better results and either incomplete conversion or complex reaction 
mixtures, which were difficult to purify by means of column chromatography, were obtained.  
 Further optimisation showed that the ring-closure can be induced by careful reaction of the crude 
residue after removal of DCM with KOH in MeOH at low temperature. Stirring for 90 minutes at 0 to 21 
°C and monitoring by 
1
H NMR spectroscopy allowed improving the yield by roughly 10 - 15%. The only 
other minor improvement to the original procedure was reducing the equivalents of tosyl chloride and 
triethylamine from 2.5 and 3.0 to 2.05 and 2.1 respectively. No drop in yield and no major changes in the 
reaction rate were observed. In the end, by careful column chromatography purification it was possible to 
obtain a 60% yield of the aziridine (Table 1), of pristine purity. It was also decided that, in other cases, 
yields of 40-60% are acceptable, since 1 g of the aminoalcohol generates 1 g of the aziridine, assuming 
~35% reaction yield. 
Aminoalcohol Conditions Aziridine Yield 
155 
 
 
2.5 TsCl 
3.0 NEt3 
DCM, r.t, 24h 
 
154 
 
40% 
155 
 
2.5 TsCl 
3.0 NEt3 
DCM, r.t, 24h, then 
KOH/EtOH 
 
154 
 
44% 
155 
 
2.05 TsCl 
2.1 NEt3 
DCM, r.t, 24h 
 
154 
 
60% 
157 
 
2.05 TsCl 
2.1 NEt3 
DCM, r.t, 24h 
 
157 
 
39% 
162 
 
2.05 TsCl 
2.1 NEt3 
DCM, r.t, 24h 
163 
 
56%
a
 
 
a - After recrystallization from ethanol. 
   
Table 1. Aziridine synthesis. 
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 Application of the aziridine ring-opening with nucleophiles such as phenylthiolates and azides is 
a known strategy in synthesis of N-heterocycles.
160
 Another interesting example involving a ring opening 
of enantiopure aziridine 164 with allylsilyllithium intermediate 165 was reported by Kagoshima et al. and 
yielded a mixture of syn- and anti- stereoisomers 166 (Scheme 61).
161
 Subsequent cyclisation of a single 
diastereomer 166 and conversion of the silicon group of intermediate 167 to an alcohol afforded 
tetrasubstituted pyrrolidines 168 in enantiomerically enriched forms.  
 
 
 
 
 
 
 
Scheme 61. Ring-opening of aziridine followed by cyclisation to a pyrrolidine. 
 
 The presence of an appropriate electron-withdrawing group on the aziridine nitrogen is necessary 
for an effective ring opening reaction. Several protecting groups employed to assist in the nucleophilic 
attack on the aziridine ring, which serve as activators, are often sulfonamides, diphenylphosphinyl and 
diethoxyphosphoryl groups. Carbonyl protecting groups and also more reactive groups, i.e. nosyl, are too 
electrophilic and react with the nucleophile. An interesting publication by Nenajdenko describes the 
synthesis of racemic and optically pure aryl and heteroaryl ethylamines utilising the aforementioned 
approach (Scheme 62).
162
 Reactions of a series of aryl and heteroaryl Grignard reagents 169 with N-
sulfonylaziridines 170 in presence of catalytic amounts of copper iodide were investigated. It was 
envisioned that this methodology could very quickly provide the desired precursors 171. 
 
 
 
 
 
Scheme 62. Ring opening of aziridines by Nenajdenko. 
 
 In the vast majority of cases reported in the paper, only a single reaction product was detected; 
the only exception being 3-indolylmagnesium bromide producing a regioisomeric mixture of two ring-
opened compounds. The two products came from the attack of the nucleophile on both aziridine ring-
carbons, and their ratios varied from 1:1 to 3:1, depending on the aziridine employed. The authors 
postulate that the difference in the reactivity for this particular substrate stems from the fact that diethyl 
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ether was used as solvent instead of tetrahydrofuran, due to issues with solubility of 3-indolylmagnesium 
bromide. In all other experiments very good yields were obtained, ranging from 64 to 89% and only a 
single product was detected, arising from the attack of the Grignard reagent at the less substituted carbon 
of the aziridine. Interestingly, the authors also mention that various other organometallic reagents, such as 
lithium and zinc derivatives, were also tested but only with the Grignard reagents were they able to 
generate the ring-opened products. No explanation for this phenomenon was provided in the publication; 
however, the Lewis acidity of magnesium could potentially be invoked. 
 The yields of ring-opening reaction products 172 of N-tosyl aziridines 173 with 2-vinylbenze 
Grignard reagents 174 (Scheme 63) were generally very good and compare very well with the yields 
reported in the original paper. 
 
 
 
 
 
Scheme 63. Ring opening of aziridines with lithium and magnesium reagents. 
  
 Unsuccessful generation of several Grignards, however, brought several test experiments to 
confirm whether the lithiated organometallic intermediates indeed do not react under the reported reaction 
conditions to give the phenylethylamine products. Since the lithium-halogen exchange process is 
relatively simple, it would be highly advantageous to be able to carry out the process using either a 
magnesium intermediate or a lithiated species. Unfortunately, only very small quantities of the desired 
products could be observed and thus the attempts to facilitate the reaction via the lithiation method were 
abandoned. For substrates from which it was difficult to make a Grignard reagent, an efficient alternative 
methodology was developed and is discussed later. 
 The first cyclisation precursor was synthesized as a mixture of cis 175a and trans 175b isomers 
from the two cis and trans alkenes 176a and 176b obtained in a Wittig reaction of 2-bromobenzaldehyde 
136 and ethyltriphenylphosphonium bromide 177, and successive reaction with the 2-ethyl-N-tosyl 
aziridine 154 (Scheme 64). Very good yields were obtained for both steps. 
 
 
 
 
 
 
Scheme 64. Synthesis of the cyclisation precursors. 
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 In the original procedure reported by Nenajdenko, two equivalents of the Grignard reagent are 
used per one equivalent of the aziridine. The authors do not comment on why such an excess of the 
nucleophile was used. In the laboratory, an observation was made that occasionally, small quantities of 
the unreacted aziridine (~5 – 10%) were present after the completed reaction, even though two 
equivalents of the nucleophile were used. The unreacted or dehalogenated aryl bromide could be easily 
separated by column chromatography; however, the residual aziridine would often co-elute with the 
product of the reaction and was somewhat difficult to remove. On this basis it was decided that no further 
optimisation of the ring-opening reaction will be undertaken and the 2:1 ratio of Grignard to aziridine will 
be used, predominantly because the aryl halides were the cheaper and more readily available starting 
materials and that the full consumption of the aziridine allowed for easier isolation of the final reaction 
products. 
  
 The E/Z mixture of the first cyclisation precursor, 175a and 175b, was then exposed to the 
standard hydroamination conditions described below. It should be noted that for all cyclisation reactions 
carried out above 0 °C, the addition of triflic acid to the substrate in solvent occurred after initial cooling 
to 0 °C, after which the reaction mixture was stirred for a further 5 minutes at the same temperature and 
then warmed up to the temperature reported. This approach was employed to minimise the outcome of 
any exothermic effects associated with brief existence of high-concentration triflic acid droplets during 
the addition. The initial step concerning the pre-cooling, addition of triflic acid and 5-minutes stir at 0 °C 
will be omitted for all further cyclisation reactions discussed.  
 Previous reaction conditions used to afford triflic acid-catalysed hydroaminations employed 0.4 
equivalents of acid in a chlorinated solvent such as dichloromethane or chloroform and temperatures of 0 
to 68 °C. To accurately define the reactivity of the new system, most of the preliminary experiments were 
designed to explore the low-end of the reactivity window of the substrate. Later it was also shown that 
low temperature allows accessing the kinetic product of the reaction in substantially higher quantities. 
Thus, stirring of the first substrate 175a/175b in dichloromethane with 0.4 equivalents of 
trifluoromethanesulfonic acid at 0 °C for several hours showed very little conversion and that almost no 
reaction was occurring (Scheme 65). The small quantity of product 178a/178b (vide infra) which could 
be observed (<10 %) was attributed to the initial cyclisation occurring due to the “hot-spots” present for a 
very short time immediately after the addition of neat triflic acid. Fortunately, increasing the temperature 
to 23 °C (room temperature) showed that cyclisation does occur and uncovered an interesting 
phenomenon.  
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Scheme 65. Cyclisation reaction. 
 
 Out of the two isomers present in the reaction mixture, 175a and 175b, only the trans isomer 
175b cyclised at 23 °C to give the final product as a mixture of cis and trans diastereoisomers 178a and 
178b. The cis isomer 175a of the starting material was separated in 55% yield from the product by 
column chromatography and  easily identified using NMR spectroscopy, as one pair of the resonances 
coming from the trans double bond (d, J 16 Hz) disappeared, leaving the other pair of the peaks (d, J 12 
Hz) intact (Scheme 66). The NH peak was found to drift and could be found around ~4.5-5.0 ppm. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 66. Identification of the isomers. 
 
 This result was somewhat surprising, as it was anticipated that the cis double bond is more 
strained and more open towards the nitrogen attack and also for the postulated intramolecular proton 
transfer between the sulfonamide and the olefin. It was speculated that the difference in the reactivity 
could come from the steric interactions between the methyl group of the cis isomer and the benzene ring, 
perhaps twisting the -system out of conjugation and affecting the approach of the nitrogen.  
 
2.4 Computational Study 
  
 Often, a detailed visual analysis of a compound can deliver important information about it, such 
as its conformation, bond angles and interatomic distances. It was thought that the position of the double 
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bond with respect to the benzene ring could have a major influence on the outcome of the cyclisation. A 
computational analysis of the energy-minimised structures for the trans and cis isomers 175a and 175b 
indicated that the dihedral angle between the phenyl ring and methyl group varies very little between the 
two compounds. Values of 49° and 65° for trans and cis were obtained from ChemDraw3D MM2 force 
field analysis (Scheme 67), showing a difference of 15°  between the two angles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 67. MM2 energy-minimised structures of 175b and 175a. 
 
 More advanced density functional theory (DFT) calculations,
163
 namely B3LYP/6-31G(d), 
(Scheme 68) gave very similar outcome and angles of 36° for trans and 51° for cis were obtained. The 
two values for the tetrahedral angles were approximately 15° smaller than the MM2-calculated ones; 
however, the overall difference between the cis and trans dihedral angles was also 15°, which compares 
with ChemDraw calculations reasonably well. The calculations also revealed that the trans form is 8 kJ 
per mol more stable than the cis, which is opposite to the kinetic behaviour observed in hydroaminations. 
 
 
 
 
 
 
 
 
 
 
Scheme 68. The B3LYP/6-31G(d) energy-minimised structures of 175b and 175a. 
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 The two most unanticipated structural features observed for the energy-minimised structures of 
trans was how large the dihedral angle between the ring and the olefin was. Even though it was predicted 
that the ortho-substitution pattern would possibly introduce some degree of steric interactions between the 
two ring substituents, the entire -system was expected to remain flat and the benzene ring to be in 
conjugation with the alkene. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 69. MM2 energy-minimised structures of 179b and 179a. 
 
 Similar relationship between the bond angles was also observed in the structures of B3LYP/6-
31G(d) optimised stilbene derivatives 179a and 179b (Scheme 69),
163
 which was again unanticipated, 
especially for the trans form, as the two rings were expected to exist in full cross-conjugation through the 
double bond. 
 Future work in this are could potentially involve modelling of possible transition states and 
looking into the protonation barriers. These, however, are notoriously difficult to calculate due to changes 
in charge and require accurate models of solvent, which introduces further problems. A literature screen 
revealed that a very interesting, detailed, mechanistic study of an analogous cyclisation reaction on a 
similar system was published by Widenhoefer. 
 
2.5 Reaction Mechanism 
 
 Screening the literature for acid-catalysed hydroamination mechanisms pointed towards only 
several relevant papers, mostly based on computational calculations for transition states predicted for 
intermolecular reactions of unactivated amines with simple olefins, frequently using metal catalysts. One, 
very relevant paper by Widenhoefer describes a detailed, mechanistic examination of an intramolecular, 
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transannular, acid-catalysed hydroamination of 180 with trifluoromethanesulfonic acid to yield the 
product 181 (Scheme 70).
164
  
 
 
 
 
Scheme 70. Widenhoefer’s hydroamination study. 
 
 Absence of the alkene isomerisation in the unreacted starting material and the lack of deuterium 
incorporation in the alkene bond argue against a mechanism including simple protonation of the olefin 
followed by trapping by sulfonamide. Widenhoefer also discredits the hydroamination mechanism 
originally proposed by Hartwig, where a rapid, intramolecular proton transfer between the sulfonamide 
and the olefin occurs, followed by the cyclisation of nitrogen on the carbocation. The mechanism is 
rejected on the basis that anti stereoselectivity is observed in the product (Scheme 71).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 71. Widenhoefer’s proposed hydroamination mechanism. 
 
 Subsequently, according to Wiedenhoefer, the transition state for the reaction involves an initial 
pre-association state 182 of a molecule of protonated sulfonamide 183 and a neutral molecule 184. An 
intermolecular, irreversible proton-transfer along the double bond then occurs between the two species, 
together with the formation of a C-N bond (Scheme 72). If the reaction indeed proceeds via the anti 
transition state 182, this pre-association mechanism could to some extent explain why the 175a cis olefin 
reacts slower. The trans isomer 175b in transition state 185 is potentially more open than the 
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corresponding cis isomer 175a for which the steric interactions in the transition state 186 would make the 
process higher in energy and thus render the substrate less reactive in the cyclisation. 
 
 
 
 
 
 
 
 
 
Scheme 72. Wiedenhoefer’s postulated hydroamination mechanism extended to Knight’s hydroamination. 
  
 Further, more detailed information, including deuterium labelling studies and kinetic isotope 
effect calculations, which are key pieces of the puzzle that led to understading the mechanism of this 
transformation, can be found in the original paper. 
 
2.6 Cyclisations 
 
 As mentioned before, apart from the cis isomer 175a recovered from the reaction mixture, the 
cyclised product could also be isolated. The tetrahydroisoquinoline compound was separated as a 2:1 
mixture of two diastereoisomers in 35% yield, later assigned as cis 178a and trans 178b. The overall 
yield of the unreacted starting material and the product were 55% and 35%, and, therefore, very good. 
 The 
1
H NMR spectrum of the isolated product showed complete disappearance of the olefin 
resonances, as well as the N-H signal. Correspondingly, two distinctive sets of two triplets were observed 
for the two ethyl groups, two methyl groups’ signals coming from the tosyl group and two distinctive 
ABX resonances for the benzylic CH2-CH-N system. Another characteristic set of peaks was observed at 
4.7 - 5.0 ppm, where sharp resonances corresponding to the benzylic CH, next to the nitrogen appeared 
(Scheme 73), also in 2:1 ratio. It was therefore clear that those two groups of peaks correspond to the two 
diastereoisomers. 
 
 
 
 
Scheme 73. Characteristic benzylic resonance. 
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 The diastereomeric outcome of the reaction was the next issue to be probed.  In the following 
experiments it was established that one of the stereosimers is the thermodynamic product of the 
hydroamination reaction 
 
 
 
 
 
 
 
 
 
Scheme 74. Equilibration in the hydroamination reaction. 
 
 Reaction of the starting material 175a and 175b with 0.4 eq. of triflic acid in refluxing 
dichloromethane for 3 hours furnished the cyclised tetrahydroisoquinoline as a single diastereoisomer 
(Scheme 74). Subsequently, it was discovered that treating the separated, unreacted cis isomer 175a with 
triflic acid at 41 °C also gives the thermodynamic product as a single reaction product. In addition, when 
the 2:1 mixture of the already cyclised product 178a and 178b was reacted under the more forcing 
conditions, again only single reaction product 178a was observed. In conclusion, the reaction at room 
temperature afforded roughly 2:1 trans to cis mixture of the cyclised products, most probably exclusively 
from the trans starting material 175b. The less reactive cis alkene 175a was converted to the product 
under similar reaction conditions but at higher temperature and yielded the thermodynamic product 178a 
exclusively. The minor, thermodynamic isomer 178a could also be solely obtained by exposing either the 
mixture of the E/Z starting materials, or the diastereomeric mixture of tetrahydroisoquinolines 178a and 
178b to triflic acid at elevated temperatures. 
 With the Widenhoefer reaction mechanism in mind it was decided to probe whether more 
sterically hindered precursors would cyclise successfully. Using almost the same preparative chemistry as 
before, 2-bromobenzaldehyde 136 was reacted with phosphonium salt 187 and the product 188 was 
obtained in 73% in a Wittig reaction (Scheme 75). The bromoolefin 188 was used in an aziridine ring-
opening reaction to quickly deliver the desired precursor 189. 
 
 
 
 
Scheme 75. Cyclisation reaction. 
 48 
 
 It was anticipated that the reaction will be very sluggish or not occur at all at room temperature; 
however, the reaction of the cyclisation precursor 189 with 0.4 equivalents of triflic acid in 
dichloromethane at room temperature gave the cyclised product 190 as a mixture of diastereoisomers in 
approximately 54% yield by NMR, after 5 hours (Scheme 76). Interestingly, extending the reaction time 
to 18 hours improved the overall conversion by only a few percent and the reaction seemed to have 
equilibrated.  
 
 
 
 
 
 
 
 
 
Scheme 76. Equilibration in the hydroamination reaction. 
 
 Similarly as before, at low temperature the cyclised product was obtained as a mixture of two 
diastereomers, this time in 1:1 ratio and in 60% yield. The product 190 was then reacted with triflic acid 
at higher temperature. As before, a single diastereoisomer 190a was obtained exclusively, after 4 hours at 
41 °C in 80% yield. Applying the more forcing reaction conditions to the starting material 189 also 
resulted in complete conversion to the single diastereoisomer 190a, which was obtained in 87% yield as 
colourless crystals. An X-Ray structure (Figure 1) was obtained from a single crystal of an analytical 
sample of compound 190a and confirmed the stereochemichal assignment of the thermodynamic isomer 
as cis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. An X-ray of the thermodynamic isomer 190a. 
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2.7 Diastereochemistry and Spectral Analysis 
 
 It can be clearly seen from the X-ray analysis that both substituents are on the same side of the 
piperidine ring. Interestingly, due to the presence of the double bond and the nitrogen atom, the shape of 
the six-membered ring is distorted and resembles a traditional boat configuration, rather than a 
cyclohexane or cyclohexene shape. It was also somewhat surprising to see one of the ring hydrogens from 
the tosyl group pointing directly into the aromatic ring of tetrahydroisoquinoline. To help establish that 
the two pseudoaxial protons of the piperidine ring are cis, a nOe signal between the two was expected. 
Yet, no interaction was observed. The fact that the tosyl group “wedges” itself in between the two protons 
effectively pushing the two protons apart could explain why no nOe was detected. It is possible, however, 
that the pseudoequatorial substituents are somewhat brought together, as the nitrogen pulls the ring down. 
Incidentally, it was possible to detect an nOe interaction between one of the diastereomeric protons of the 
benzylic CH2 group, and the CH proton of the isopropyl group (Figure 2). The benzylic hydrogen 
displaying the nOe enhancement is most likely the equatorial one (J 7.3), as the resonance from the other 
benzylic hydrogen is slightly broader (J 11.1) and therefore belongs to the benzylic, axial hydrogen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Important through-space interactions of compound 190a. 
 
 The second, broader resonance, most probably from the benzylic hydrogen displaying the diaxial 
coupling, correlates strongly to the neighbouring hydrogen atom next to the nitrogen. The assigned NMR 
signals are relatively strong and the observed Overhauser enhancement is relatively strong. Since it would 
be impossible for those two pairs of hydrogens to interact through space if the two piperidine substituents, 
ethyl and isopropyl, were on the opposite sides of the ring as in 190b (Figure 2), this supports the cis 
configuration of the thermodynamic stereoisomer 190a.  
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Figure 3. 
1
H NMR spectrum of 190a. 
 
 The resonances on the 
1
H NMR spectrum of compound 190a are relatively easy to read, as almost 
no overlaps occur (Figure 3). Two doublets at 0.74 and 1.28 ppm with J value of 6.5 Hz can undoubtedly 
be assigned to the two methyl groups of the isopropyl moiety. The triplet at 1.04 ppm, J 7.5 Hz in 
between the two doublets, comes from the isolated methyl group on the ethyl substituent. Additionally, all 
these resonances integrate to 3 protons. The characteristic singlet at 2.22 ppm can also be unambiguously 
assigned to the CH3 group of the tosyl moiety. 
 Further downfield, at 1.75 and 2.32 ppm are the two signals from the two diastereotopic protons 
of the distal CH2 group, attached to methyl and NCH moiety. These resonances were identified as 
possible double-double-quartets and should in theory display a total of 16 overlapping lines (as do dddd). 
Even though only 10 out of the 16 lines could be identified, careful analysis of the multiplet revealed that 
there are indeed 16 lines hidden within the resonance. Clear “shoulders” on some peaks could be 
observed and eventually deconstructed to unveil a doublet quartet of doublets. Extracting the smallest 
coupling constant (between the outmost peak and the next one) helped with initial establishment of the 
quartet coupling. This could be done with a ruler, simply by measuring the distance between the first and 
second peak and then appropriately fitting it onto signals, working backwards to create a coupling tree. A 
graphic representation of the coupling tree is shown and the black, violet, green and red quartets analysed.  
 
 A journal article describing systematic procedures allowing more detailed analysis of first-order 
1
H NMR spectra was published by Hoye.
165
 It discusses three slightly different approaches for extracting 
J values from a diverse range of resonances, i.e. doublets, doublets of doublets, ddds, dddds and briefly 
covers interpretation of ddddds. Various examples are also shown and interactions between dissimilar 
protons are pointed out. In combination with general knowledge of 
1
H NMR spectroscopy, information 
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about the structure of the compound being investigated and thorough analysis, the publication provides a 
practical set of guidelines which allows for a deeper understanding of multiplets, especially useful for 
beginner chemists and analysts. A few years later, in another paper by Hoye,
166
 a very simple approach to 
quickly find a J value was shown, simply based on the relative distances between specific peaks in a 
single resonance. According to the publication, the distance between the first and the second peak for a 
dddd is always J1, the J2 value is the distance between the first and third peak and the next coupling 
constant is unravelled by skipping the resonance formed from addition of J1 and J2 values and taking the 
distance to the next one.  Such approach does not necessarily function very well when applied on its own, 
but to a certain degree speeds up the process of peak analysis, when combined with other, thorough 
methods. 
  
 In the case of the 1.75 ppm resonance of 190a, the signal is composed of four quartets, each of 
1:3:3:1 ratio. These four quartets can be further disconnected to a doublet of doublets and the resultant dd 
becomes a doublet (Figure 4). The quartet coupling constant is the smallest and can be easily observed on 
the NMR spectrum and equals the distance between the first and second peaks, which is 7.3 Hz. The two 
doublet couplings cannot be directly extracted but “travelling” up and down the disconnection tree and 
choosing distances between the appropriate peaks allowed to determine that the two J values are 9.6, from 
the vicinal N-CH coupling, and 13.5 Hz, the larger value coming from the geminal coupling. 
 
  
 
 
 
 
 
 
 
  
  
Figure 4. Resonance at 1.75 ppm from 
1
H NMR spectrum of compound 190a. 
  
 The width of the whole resonance, from the first to the last peak is 45.11 Hz. It is known that the 
sum of all the coupling constants is equal to the width of the resonance in Hz. Since the Ha hydrogen of 
190a couples to three protons of the methyl group, the “quartet” coupling constant needs to be multiplied 
by 3 and the other J values added only once. Thus, 3 x 7.4 + 9.6 + 13.5 = 45.3 (Hz), which corresponds 
very well to the 45.11 Hz observed for the multiplet. 
 
 52 
 
 The other resonance for the diastereomeric CH2 group appears at 2.33 ppm. At the first 
inspection, the shape of the peak does not resemble a standard dddd or ddq pattern. Careful and thorough 
analysis allowed deciphering the signal (Figure 5) and showed the hidden configuration. 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
Figure 5. Resonance at 2.33 ppm from 
1
H NMR spectrum of compound 190a. 
 
 Just as its sibling Ha, the signal of the Hb proton could be taken apart to a double-doublet of 
quartets. The largest, geminal coupling was 13.5 Hz, which naturally matches the coupling of Ha. 
Unsurprisingly, the quartet coupling was found to be 7.5 Hz (7.4 Hz for Ha) and the smallest, doublet 
coupling constant was 4.3 Hz. To confirm the analysis the arithmetical calculation was carried out:  
3 x 7.5 + 4.3 + 13.5 = 40.3 (Hz). The width of the peak was found to be 40.18 Hz, which corresponds to 
the calculated value of 40.3 Hz very well. 
 
 The next peak in the analysis was the signal belonging to the CH of the isopropyl group at 1.93 
ppm (Figure 6). The proton in question couples to two CH3 groups, which appear as two triplets with J of 
6.5 Hz, and also with a benzylic CH, which in turn appears as a doublet with J of 10.6 Hz. The resulting 
doublet of septets, which upon closer inspection appears to look more like symmetric doublet of quartets 
or a ddq, could be deciphered relatively easy. Careful investigation confirmed that the coupling constants 
were in agreement and were found to be 6.5 and 10.6 Hz, as expected.  
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Figure 6. Resonance at 1.93 ppm from 
1
H NMR spectrum of compound 190a. 
 
 The benzylic AB protons of the cyclised compound 190a presented themselves as a set of two 
very well defined double doublets (Figure 7). They were also very useful, as they straightforwardly 
delivered the important AX, BX and AB coupling constants, potentially valuable in confirming the 
stereochemistry of the compound. 
 
 
 
 
 
 
           X      A       B 
 
 
 
 
 
 
Figure 7. The ABX system at 2.50 – 3.60 ppm from 1H NMR spectrum of compound 190a. 
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 The geminal coupling for the benzylic CH2, found in both A and B proton resonances, was found 
to be 15.3 Hz. The smaller, pseudoaxial-pseudoequatorial AX coupling at 2.86 ppm was determined to be 
7.3 Hz, whereas the slightly larger, pseudodiaxial BX coupling of the 2.61 ppm resonance was 11.1 Hz. 
This information proved beneficial in resolving the coupling constants of the HX proton, which should 
appear as a dddd resonance on the proton NMR. (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The 3.59 resonance of the ABX system at 3.60 ppm from 
1
H NMR spectrum of compound 190a. 
 
 As anticipated, the J values for the HX proton matched the resonances already observed. The four 
coupling constants extracted were 4.0, 7.4, 10.5 and 10.5 Hz. The width of the peak was found to be 32.0 
Hz and related well to the calculated value of 32.4 Hz. Two out of four values matched the previously 
extracted coupling constants of 4.3 and 7.5 Hz, for the CH2a+bCH3. Due to the peak broadening and 
averaging of peaks during the analysis, the remaining two coupling constants, 9.7 and 11.1 Hz observed 
in the ABX system, could be  averaged to 10.5 and 10.5. Since 10.5 + 10.5 = 21.0 and 9.7 + 11.1 = 20.8, 
this explains why mathematically the resonance appears to have been resolved accurately. Due to the fact 
that the broadening of the lines cannot be avoided and that the peak indeed appears to have four couplings 
of 4.3, 7.5, 10.5 and 10.5 Hz, extraction of the coupling constants from less overlapped resonances can 
aid with accurate determination of J values. Resonances as the previously mentioned AB protons deliver 
some of the desired numbers in great accuracy. Consequently, it was decided that the more accurate 
values derived from unambiguous signals will be reported, unless impossible otherwise. 
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 The final and possibly most important and characteristic signal for compound 190a was the 
benzylic proton next to nitrogen at 4.25 ppm (Figure 9). It appeared as a doublet and shared the coupling 
constant of 10.9 Hz with the doublet of septets already described. Signal from this proton appears furthest 
downfield, not counting the aromatic protons. 
 
 
 
 
 
 
 
 
 
Figure 9. The benzylic CH resonance at 4.25 ppm from 
1
H NMR spectrum of compound 190a. 
 
 For majority of the reported compounds, as much as possible of the aromatic region of the proton 
NMR spectrum was fully interpreted, in terms of integration and coupling constants. Not all of the ring-
hydrogens were definitely and unambiguously assigned, as it was deemed unnecessary.  
 Two sets of doublets with a J value of ~8 Hz and integrating to a total of 4 protons, characteristic 
for the tosyl group, could be easily found for most compounds. They appear at 6.87 and around 7.30 ppm 
for compound 190a, however the right-most tosyl signal overlaps with two signals out of the two doublets 
and the two triplets from the four ortho and para protons on the tetrahydroisoquinoline ring (Figure 10). 
The second tosyl doublet could be seen but not clearly described due to an overlap with another aromatic 
signal. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The aromatic resonances of compound 190a. 
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 Several, complex peaks were deconstructed in this way, to show a general approach and prove 
that if needed, it could be done. This was found to be tremendously time consuming, as there are several 
of such composite peaks present in a single isomer and in some cases identification of two isomers arising 
from one hypothetical reaction would deliver several of such peaks. In many cases, the coupling constants 
extracted from the highly overlapping or coinciding resonances were found to be inaccurate. Focus was 
put on extracting coupling constants from the more “simple” resonances, which also delivered valuable 
and more precise information about the structure. 
 To establish a quick and robust method allowing fast discrimination between the cis and trans 
tetrahydroisoquinolines several trends were analysed. It was hypothesised that 
1
H NMR shifts of one of 
the diastereoisomers could point towards a specific isomer. In many cases the signal from the benzylic 
hydrogen next to the nitrogen of the trans isomer (Figure 11) was the furthest downfield aliphatic signal. 
It was later established that there is a number of exceptions to this rule and that it can be only used as a 
guide. Unfortunately, thorough analysis of several compounds proved that the shifts could not be 
predicted and do not follow any pattern. 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. The resonances of compounds 190 and 191; cis isomer on the bottom. 
 
 It was previously reported by Cook and Mokry that the 
13
C NMR signals of -carbolines follow a 
specific pattern.
167
 Namely, the C1 and C3 of a cis 1,3-disubstituted-1,2,3,4-tetrahydro--carboline are 
downfield relatively to the C1 and C3 resonances of the trans isomer. This relationship was applied more 
recently by Sato and co-workers to establish the stereochemistry of a carboline derivative in their 
synthesis of (-)-corynantheidine.
92
 The reported difference between the two signals for the two isomers 
was approximately 4 ppm, which is relatively large. In an attempt to apply similar rules to the 
tetrahydroisoquinoline derivatives synthesized in the laboratory it was observed that the resonances of the 
C1 and C3 carbons of cis and trans isomers occasionally follow a similar pattern, for instance compound 
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190, yet quite often tend to be very close to each other and frequently overlap (Figure 12). Analysis of 
tetrahydroisoquinoline 191 revealed an opposite trend, where the C1/C3 resonances of the cis isomer are 
upfield of those of the cis.  In conclusion, all the efforts to quickly differentiate between the isomers 
based on information from NMR spectra did not provide a fast method for their assignment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. The spectra of compounds 190 and 191, C1 and C3 resonances on the bottom. 
 
2.8 Hydroamination Scope 
 
 The use of diphenylphosphinyl (Dpp) group as an alternative activating group for ring-opening of 
the aziridine ring allowed the assessment of  its synthetic utility in the acid-catalysed cyclisations of the 
prepared substrates into the N-Dpp protected THIQ alkaloids. 2-ethyl-N-diphenylphosphinyl aziridine 192 
was synthesized from the corresponding 1,2-aminobutanol 155 in 44% yield (Scheme 77). Remarkably, 
due to its sluggishness, the reported synthesis of such N-Dpp aziridines involves a two-step process: a bis-
phosphinylation in presence of excess triethylamine followed by cyclisation induced with 5 equivalents of 
sodium hydride.
168
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Scheme 77. Synthesis of N-Dpp aziridine. 
 
 The ring-opening protocol of N-Dpp aziridines 192 was explored by Cantril and is somewhat 
different to the procedure used for reacting N-tosyl aziridines. Reactions of such diphenylphosphinyl 
aziridines with ethylmagnesium bromide yield no product even in refluxing THF and exposure to lithium 
nucleophiles, higher-order cuprates or methanol and BF3.OEt2 only yield the products arising from attack 
at phosphorus.
169
 Fortunately, addition of catalytic amount of CuBr.SEt2 to an excess of Grignard reagent 
(~ 5 eq.) in THF, followed by heating under reflux for several hours afforded the ring-opened product in 
good yield. When applied to the synthesis of cyclisation precursors, ring opening of aziridine 192 with 
excess (2-(2-methylprop-1-en-1-yl)phenyl)magnesium bromide 193 afforded the ring-opened product 194 
in 35% yield (Scheme 78). 
 
 
 
 
 
Scheme 78. Ring-opening of N-Dpp aziridine. 
  
 The synthesis and reactions of diphenylphosphinyl-protected aziridines allowed entry into 
phenylethyl-N-diphenylphosphinyl amines 194 and their reactivity in hydroamination reactions could be 
probed. Regrettably, at 0 °C no reaction was observed after 15-30 minutes. Extending the reaction time 
beyond 1 hour or increasing the temperature to 23 °C produced only a complex mixture (Scheme 79) and 
the product 195 could not be seen. Proton NMR analysis of the crude sample showed only broad, 
undefined peaks and nothing meaningful could be isolated by column chromatography. It was decided 
that N-Dpp activating group does not trigger the cyclisation and that only extensive decomposition 
occurs. 
 
 
 
 
Scheme 79. Cyclisation attempt on a N-Dpp protected substrate. 
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  The purpose of the next reactions was to probe the reactivity of stilbene derivatives. A Wittig 
reaction of 2-bromobenzaldehyde 136 with benzyltriphenylphosphonium bromide 196, made from benzyl 
bromide, afforded the brominated stilbene derivative 197 as a 1:5 mixture of E and Z isomers in 95% 
yield. Ring-opening of the aziridine 154 afforded the desired cyclisation precursor 179a/179b as a 1:5 
mixture of E and Z isomers in 72% yield (Scheme 80). 
 
 
 
 
 
 
 
 
 
Scheme 80. Synthesis of the stilbene substrate 179. 
 
 A cyclisation attempt using the standard reaction conditions of 0.4 equivalents of triflic acid in 
dichloromethane at 0 °C did not deliver any product. Similarly, at room temperature only the starting 
material could be recovered. Refluxing the substrate 179 in dichloromethane with the same amount of 
acid showed slow isomerisation of the cis 179a into the more stable isomer 179b (Scheme 81).  
 
 
 
  
 
 
 
Scheme 81. Isomerisation of the stilbene substrate 179a. 
 
 This result was very puzzling, as it was anticipated that the isomerisation most likely occurred via 
the carbocationic species 198a and 198b (Scheme 81). Therefore, it was reasonable to 
expect for the carbenium ion to be trapped by the nitrogen atom. Strangely, the tetrahydroisoquinoline 
product was not observed in refluxing dichloromethane. Repeating the reaction under more forcing 
conditions, in 1,2-dichloroethane as solvent and at 60 °C, showed that full reisomerisation could be 
achieved. Several distinctive resonances could be followed by 
1
H NMR to observe the complete 
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reisomerisation of 179a into 179b (Figure 13; note: the 
1
H NMR spectra were taken on differet 
spectrometers).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Relevant 
1
H NMR resonances of compound 179 isomerisation (spectra ran on different machines).  
 
 The figures above show the most noteworthy resonances in the transformation of the cis isomer 
179a into the trans isomer 179b, as the reisomerisation proceeded, top to bottom. First left hand side part 
shows the disappearance of the two “roofing” doublet resonances from the two cis hydrogens of 179a at 
6.53 ppm and appearance of one of the doublets from the trans isomer 179b at 6.89 ppm. The second and 
third spectra fragments show the same trend, but for the NH peaks (~4.8 ppm) and the ABX system (3.4 – 
2.6 ppm). Identical observations could be also made for the singlets arising from methyl of the tosyl 
group. Remarkably, very small quantities of product could be observed in the reaction mixture but upon 
prolonged refluxing either equilibration was observed or poor yields were obtained. 
 This phenomenom of the cis isomer interconverting to trans prior to cyclisation does not 
correspond accurately to the properties of the cis/trans alkyl-substituted isomers, where the cis isomer 
was more reactive than the trans.  
 Briefly, the styryl cis isomer converts to trans isomer and then can be cyclised at higher 
temperature, whereas in the vinylalkyl series the trans isomer reacts first leaving the cis isomer untouched  
(Scheme 82), which then can be successfully cyclised under slightly more forcing conditions. 
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Scheme 82. Reisomerisation during hydroamination. 
 
 The issue associated with unusual reactivity of cis and trans isomers of the synthesized substrates 
could be overcome by designing a route to deliver exclusively the more stable trans compound which is 
described in the next part. Furthermore, to ascertain that the lower reactivity of the stilbene substrates 
comes from the electronic and not steric effects, a cyclohexane derivative 200 was also synthesized. 
 
 
 
 
 
Scheme 83. Cyclisation of cyclohexyl derivative. 
 
 The acid-catalysed cyclisation proceeded very well and at room temperature, as it was the case 
with the alkyl derivative 175. Similarly as before, a 2:1 mixture of diastereoisomers 201 was obtained, in 
81% yield, the major product being the kinetic, trans product (Scheme 83). Exposure of the starting 
material to triflic acid in refluxing dichloromethane resulted in formation of the thermodynamic cis 
product in approximately 20:1 ratio favouring the trans material and the final product 202 was isolated in 
an overall 95% yield. Extended reflux allowed pushing the thermodynamic equilibrium towards a single 
reaction product and a single recrystallisation delivered the cis product 202 exclusively. 
 
 The two main advantages of the aziridine route are its shortness and very good reaction yields. 
Several important limitations exist, especially related to the protecting group and potential presence of 
other, reactive functionalities. First of all, only tosylated, diphenylphosphinyl aziridines could be 
successfully ring-opened with an organometallic reagent. Further limitations are imposed by the reaction 
procedure. Functional groups such as alcohols, amines, ketones, esters and a few others would not survive 
the reaction conditions. 
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2.9 Henry Route 
 
 The second route which effectively delivered a number of cyclisation precursors was based on a 
nitro-aldol reaction. It was thought that the amine group could be installed via the aldehyde functional 
group and a subsequent coupling reaction would provide the olefin functionality. The phenylethylamine 
chain was installed in a Henry reaction of 2-bromobenzaldehyde 136 with nitroethane, followed by in situ 
dehydration of 203 to nitroalkene 204 (Scheme 84).
170
  
 
 
 
 
 
Scheme 84. Henry reaction. 
 
 The Henry reaction involved 4 hour reflux in nitroethane as solvent at 115 °C and it was 
remarkably clean. Washing with water and removal of the solvent on rotary evaporator (60 °C, 5 mbar) 
delivered 102% yield of the crude product contaminated with ~5% nitroethane (HPLC analysis). Further 
azeotropic drying with toluene and overnight drying in a vacuum oven delivered essentially pure 
nitroalkene in 97% yield. The olefin as well as the nitro group was then reduced with lithium aluminium 
hydride to yield the primary amine 205 (Scheme 85). 
 
 
 
Scheme 85. Reduction of nitroalkene. 
 
 Small quantities of the debrominated material 206 were detected after isolation of the primary 
amine in an acidic work-up after the LAH reduction. This impurity was found to be very difficult to 
remove by column chromatography. A Kugelrohr distillation was attempted to remove the residual 
amphetamine 206 (lit.
171
 b.p. 81-86 °C/10-12 mm) from the reaction mixture. Majority of the unwanted 
compound could be removed at ~100 °C/20 mm; still, traces of 206 were present in the distillation base, 
even after careful and slow distillation of approximately 50% of the entire mixture. 
 Another, milder approach towards an effective and clean reduction of the brominated nitroalkene 
204 was deemed necessary. An interesting article discussing several different procedures used for 
conversion of nitroalkenes into phenylethylamines was published by Collins.
172
 Fortunately, a very 
similar compound to 204, a para-iodophenyl nitroalkene derivative, was reduced in 84% yield to the 
primary amine in Kabalka’s reported synthesis of iodo-amphetamines.173 The procedure involved slow, in 
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situ release of borane from a heated mixture of sodium borohydride and boron trifluoride diethyl etherate 
in tetrahydrofuran at 60 °C over several hours, followed by quenching and isolation with hydrochloric 
acid and base. A comprehensive review on the topic of synthesis and selective reduction of conjugated 
nitroalkenes was later written by Kabalka.
174
 
 Attempts to apply this methodology in the reduction of nitroalkene 204 were largely successful 
and delivered the desired product, albeit in 51% yield, opposed to 84% conveyed for a similar substrate 
(Scheme 86). 
 
 
 
Scheme 86. Reduction of nitroalkene 204. 
 
 The reason behind the lower yields in Kabalka’s reduction remains unknown. In most cases, the 
reaction followed by an acid-base work-up delivered relatively pure amines in good yields, i.e. 85% 
purity by HPLC and 65% mass recovery. The primary amines were usually used without any purification, 
as the next step involved protection of the amine. Tosylation of the amine 205 furnished the sulfonamide 
207 in 87% yield. Most impurities carried over from the previous steps could be removed by a simple 
acid and base wash, yielding a reasonably pure compound, which could be further purified by column 
chromatography. Importantly, no debrominated side-product 206 was detected after applying Kabalka’s 
method.  
 One of the drawbacks associated with this methodology is that both the Henry reaction and the 
reduction are potentially explosive. Nitroalkenes are highly energetic compounds and may combust 
explosively, releasing large quantities of gases.
175
 Borane-oxygen mixtures are also explosive and 
reported to be very dangerous, especially at higher temperatures.
176
 In June  2002 an explosion of a 250-
pound borane-tetrahydrofuran drum on one of the Pfizer sites nearly demolished an entire warehouse and 
injured five employees.
177
 Necessary precautions need to be taken whilst carrying out this type of 
chemistry, especially on larger scales when temperature control and avoiding thermal runaways is much 
more difficult.  After the reduction, the protected sulfonamide 207 was reacted under modified Suzuki 
coupling conditions (Scheme 87), reported by Knight and Henderson, to afford 208.
178
  
 
 
 
 
 
 
Scheme 87. Suzuki coupling reaction conditions. 
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 The original, published procedure used catalyst pre-mixes and microwave heating for 30 minutes 
at 100 °C. In the laboratory it was proved that the microwave conditions are not necessary and that the 
reaction goes to completion at 80 °C in approximately two hours. The catalyst load was reduced to 5%. 
The quick reaction time implied that the amount of catalyst used could be dropped even further, however, 
it was decided that since 5% guaranteed good yields and quick reaction times, it would be adopted as the 
default load. The species used to enable the C-C bond formation was the (1,1'-bis(diphenylphosphino) 
ferrocene)palladium(II) dichloride, which is a popular catalyst in coupling reaction. The dppf ligand has a 
wide bite angle of 99 degrees and its bulkiness assists in the reductive elimination step and improves the 
cross coupling catalytic cycle.
179
  
 
 
2.10 Optimisation of the Hydroamination Reaction 
 
 
 With the trans-exclusive compound 208, it was possible to carry out a comprehensive solvent 
screen. Literature search revealed that nitromethane, dioxane, toluene and several other solvents are often 
used in acid-catalysed hydroaminations, Pictet-Spengler and Bischler-Napieralski reactions. A parallel 
set-up of 10 reactions in which 200 mg of substrate 208 was reacted with 0.4 equivalents of triflic acid in 
2 mL of a solvent and the conversion plotted against time (Figure 14). It needs to be noted that the 
conversion does not correspond to the yield of the product but to the ratio of starting material to all 
products. Therefore, it more accurately corresponds to the rate of disappearance of starting material and 
not the rate of product formation. The temperatures at which the reactions were carried out varied from 
solvent to solvent. If no conversion was observed after 1 hour, the temperature would be increased by 10 
– 20 °C, up to the boiling point of the solvent. 
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Figure 14. Solvent screen in the hydroamination of 208. 
 
 The two most promising results point towards toluene reaction and nitromethane as potential 
solvents for the cyclisation. Both reactions were run at 70 °C. Even though over 90% of the starting 
material was consumed in both cases, large amount of impurities were formed in the process. Column 
chromatography of the toluene reaction product gave only 32% isolated yield of the product 209 and 37% 
of an unknown impurity. Proton and carbon NMR analysis of the unknown showed an extra singlet for an 
arylmethyl group, several new aliphatic and aromatic signals, and new 
13
C NMR resonances. Mass 
spectrometry demonstrated that the mass of the molecular ion (484.2) corresponds directly to the mass of 
the starting material and the mass of toluene added together (391 + 92 + H
+
 = 484). It was subsequently 
ascertained that the impurity was made in a Friedel-Crafts type reaction. Initially, it was expected that its 
structure could be 210 or 211 (Scheme 88) but further analysis of 
13
C NMR and COSY/HSQC data 
helped unravel the most fitting structure, which is 212. 
 
 
 
 
 
 
Scheme 88. Impurity formation in the toluene reaction. 
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 The two ABX systems of 212 could be easily identified and their connectivity was confirmed by 
COSY. The downfield shift of the hydrogen flanked by two phenyl moieties, from the usual benzylic 3.0 
ppm towards 4.2 ppm additionally confirmed the assignment of the structure. The NH doublet was still 
present in the 
1
H NMR spectrum and was confirmed by showing no correlation to any of the carbons on 
HSQC spectrum. The olefinic signals could not be seen but could have possibly been overlapping with 
other aromatic protons. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
Figure 15. Fragment of the COSY and 
13
C NMR DEPT-135 spectrum of compound 212. 
 
 Additionally, three CH3, two benzylic CH2 and two CH aliphatic peaks were observed in the 
13
C 
NMR spectrum and further confirm the structure (Figure 15). It was a largely unanticipated result, as 
toluene is often used as solvent in this type of reaction with strong acids.  
 
 The the nitromethane cyclisation was much more complicated and a large number of impurities 
could be seen by HPLC, structures of which were not identified. HPLC analysis of the crude reaction 
mixture after 24 hours at 70 °C mass showed approximately 25% of the tetrahydroisoquinoline product 
209 and ~70% of various side-products . Nevertheless, isolation of the reaction product gave the cyslised 
material in 23% yield. 
 Surprisingly, the reaction performed in dichloromethane at 41 °C showed lower initial conversion 
rate than the 1,2-dichloroethane reaction at 70 °C but after 24 hours both reactions equilibrated at 
approximately 50% conversion. Column chromatography purification of both reaction mixtures led to a 
43% yield from the 1,2-dichloroethane and 33% of 209 from the dichloromethane reaction. This was 
somewhat disappointing, as it was hoped that the chlorinated solvents would perform much better. It was 
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noted, however, that the quality of the cyclised material slowly degraded during the extended reaction 
times and it was hoped that the yields could be increased by careful monitoring of the reaction times. 
Further optimisation of the 1,2-dichloroethane reaction resulted in observation that the reaction reaches 
70% conversion after 10-12 hours and higher yields of the product could be isolated by stopping the 
reaction at this stage. 
 The reaction in ethyl acetate provided approximately 10% yield after 24 hours reflux. Butanol, 
heptane, acetic acid and dimethylsulfoxide produced no product at all. In addition to the 10 parallel 
experiments, another 5 reactions were performed using mixtures of 1,2-dichloroethane and heptane as 
solvent. An originally predicted trend was observed, where the addition of heptane slowed the 
hydroamination and was therefore undesireable. 
 
 After re-establishing that 1,2-dichloroethane is the optimal solvent for hydroamination of 
substrates requiring harsh reaction conditions, screening of different Lewis and Brønsted acids was 
carried out. Unfortunately out of nine acids, triflic acid, sulfuric acid, trimethylsilyl triflate (TMSOTf), 
bismuth triflate, gadolinium triflate, zinc triflate, potassium triflate, polyphosphoric acid and 
methanesulfonic acid, only triflic acid and TMSOTf showed any observable cyclisation. Doubling the 
amount of triflic acid to 0.8 equivalents roughly doubled the rate of conversion but did not result in a 
cleaner reaction. 
 
 
 
 
 
 
Scheme 89. Optimised cyclisation. 
 
 In conclusion, the solvent and the acid screen firmly established that the initial acid, solvent and 
temperature used were the optimal conditions and were later extended to 1,2-dichloroethane solvent. 
Careful monitoring by TLC and HPLC helped synthesising the 1-benzyl tetrahydroisoquinoline 209 
(Scheme 89). 
  
 
 
 
 
 68 
 
2.11 Cyclisations 
 
 To show that additional functionalities are tolerated under Knight’s hydroamination conditions, 
we decided to look at halogenated substrates. Synthesis of the triphenylphosphonium salt 213 from the 
commercially available p-trifluoromethylbenzyl bromide 214 in 96% yield and subsequent reaction with 
2-bromobenzaldehyde in a Wittig reaction yielded the olefin 215 as a cis and trans mixture in 97% 
(Scheme 90). Following a formylation with butyllithium and dimethylformamide which delivered the 
aldehyde 216 in 73% yield, the nitroalkene 217 could be obtained in 91% yield in a Henry reaction. 
 
 
 
 
 
 
 
 
 
 
Scheme 90. Synthesis of intermediate 217 via the Henry reaction. 
 
 Reduction with lithiumaluminium hydride and protection with tosyl chloride furnished the 
cyclisation precursor 218 in 45% yield over two steps. Slightly more forcing reaction conditions had to be 
applied to achieve the final transformation into the tetrahydroisoquinoline 219, 0.6 equivalents of triflic 
acid were used for 15 hours at 80 °C and gave the cyclised material in a good 65% yield, as a 
predominantly cis isomer (Scheme 91). 
 
 
 
 
 
 
Scheme 91. Synthesis of intermediate 219 via the reduction and tosylation. 
 
 The 1-benzylisoquinoline compounds form an important sub-group of isoquinolines and 
tetrahydroisoquinolines.
180
 Several important alkaloids e.g. laudanosine 26 (c.f. page 9) and papaverine
181
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belong to the aforementioned family of bioactive molecules and therefore such compounds are of large 
synthetic interest. 
 
 Another synthetic route utilising the Henry reaction was designed and allowed synthesis of 
essentially trans olefins, via Wittig chemistry (Scheme 92). 
 
 
 
 
 
 
Scheme 92. Different synthesis towardsthe  trans-stilbene isomers. 
 
 Using excess sodium hydride as the base in a Wittig reaction between 2-formylbenzoic acid 220 
and phosphonium salt 196 afforded the carboxylic acid 221 in good yield. Integration of the appropriate 
peaks on 
1
H NMR spectrum proved that the isomer ratio of cis and trans compounds was approximately 
1:10 (Scheme 93). Compound 221 was reduced with lithium aluminium hydride without further 
purification and delivered the alcohol 222 in overall 51% yield.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 93. Fragment of 
1
H NMR of compound 16. 
 
 Finally, pyridinium dichromate
182
 oxidation of alcohol 222 gave the aldehyde 223, which was 
then converted to the primary amine 225 in a Henry reaction to nitroalkene 224 followed by reduction.  
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Scheme 94. Different synthesis towards the trans isomers. 
 
 Refluxing the nitroalkene in tetrahydrofuran with 3.0 equivalents of lithium aluminium hydride 
followed by basic work-up gave the pure amine, which was in turn converted to three cyclisation 
precursors, already synthesized sulfonamide 208, nosyl-protected 226 and the carbamate 227 (Scheme 
95). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 95. Different syntheses towards the trans isomers. 
 
 All of the carbamate precursors, as well as the cyclised carbamate-protected 
tetrahydroisoquinolines, showed some interesting spectral features. Several broad signals in the proton 
and carbon NMR spectra indicated that these species exist as conformational isomers, which arise when 
the rotation about a specific, single bond is somewhat hindered. Unhindered resonances of hydrogens 
distant to the obstructed single bond in question remained well-defined. In the case of the rotameric 
carbamates synthesized in our laboratory the energy barrier required to overcome the interconversion 
between them was found to be relatively low. Usually, heating an NMR sample to 50 °C or sometimes 90 
°C usually caused the broad signals to coalesce. The rotameric properties of such molecules will not be 
further discussed and the relevant information about their spectral features can be found in the 
experimental section. 
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 In the hydroamination reaction, the nosyl-protected substrate 226 behaved slightly differently to 
its sibling precursor 208, which cyclised at 85 °C in 1,2-dichloroethane in 12 hours. Nosyl group seemed 
to have a slightly more activating effect and was also to some extent more delicate. Cyclisation of 226 
occurred smoothly at 41 °C in dichloromethane over 2.5 hours and produced tetrahydroisoquinoline 228 
in 56% yield (Scheme 96) as a single diastereoisomer.  
 
 
 
 
 
 
 
 
Scheme 96. Cyclisation of the nosyl derivative 226. 
 
 Extending the reaction time to 6 hours dropped the isolated yield to only 26%, unmistakably 
demonstrating higher fragility of the protecting group. Increasing the temperature also did not improve 
the initial outcome and carrying out the reaction at 60 °C for one hour resulted in extensive 
decomposition. 
 Attempts to cyclise the carbamate derivative 227 were met with failure. At temperatures up to  
60 °C no reaction was observed. Prolonged reflux in dichloroethane resulted in removal of the carbamate 
moiety and the primary amine 225 was recovered in 50% yield (Scheme 97). 
 
 
 
 
 
Scheme 97. Cyclisation of the carbamate derivative 227. 
 
 The COOMe protecting group is much less activating than a sulfonamide and thus the carbamate 
substrate 227 did not undergo cyclisation. On the other hand, Knight’s group had ample success in 
applying carbamate-protected amines in synthesis of functionalised heterocycles.
131
  To establish whether 
this is a more general phenomenon and whether the carbamate protecting group cannot be used in this 
chemistry, it was chosen to access cyclisation precursors which would potentially require less forcing 
conditions to cyclise. From past experience it was already known that the alkyl substituents on the olefin 
have an important on the reaction and it was decided that such carbamates needed to be prepared. 
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 All precursors synthesized so far did not have a second substituent on the benzylic olefin carbon. 
It was expected that introducing additional steric hindrance on the double bond may thwart the cyclisation 
reaction. To probe the behaviour of more sterically demanding precursors a synthetic route starting from 
2-bromoacetophenone 230 was designed (Scheme 98). Wittig reaction in refluxing tetrahydrofuran gave 
the desired bromoaryl olefin 231 in 64% yield, which was subsequently formylated with butyllithium and 
dimethylformamide to give aldehyde 232 in 86% yield.   
 
 
 
 
 
 
Scheme 98. Synthesis of intermediate 233 via the Henry reaction. 
 
 Subsequent Henry reaction supplied the intermediate 233 in a very good, 81% yield. Reduction of 
the nitroalkene 233 to the corresponding amine and protection with methyl chloroformate provided the 
carbamate product 234 in 51% yield over two steps. Attempts to cyclise substrate 234 only gave a modest 
amount of product 235. Optimised reaction conditions provided 43% isolated yield (Scheme 99) of the 
final product as a 3:1 mixture of diastereoisomers. Increasing or decreasing the amount of acid from the 
standard 0.4 equivalents, running the reaction at higher or lower temperatures and for prolonged periods 
of time did not have any significant effect on the outcome of the transformation. An observation was 
made that the reaction equilibrates at roughly 3:2 ratio of starting material to product and it was 
impossible to push the reaction to completion. 
 
 
 
 
 
 
 
Scheme 99. Synthesis of alkaloid 235. 
 
 In all the cyclisation attempts, no side-products or impurities were detected and the starting 
material could be separated from the product giving an overall mass balance of over 90% and reacted 
again to deliver the same 3:2 mixture of starting material and final product. The diastereomeric ratio of 
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the cyclised material remained constant even after prolonged reaction times and a single diastereoisomer 
could not be isolated. 
 Due to time constraints and only a small amount of material available it was impossible to probe 
the chemistry of the equivalent, tosylated substrate. 
 
2.12 Curtius Route 
 
 It was envisioned that the wanted compounds could be prepared in a relatively short sequence 
involving an enolate 141 condensation with the 2-bromobenzyl bromide 140 to yield ester 236, followed 
by hydrolysis to the acid 140 and Curtius
183
 rearrangement to yield the carbamate 237. Functionalisation 
with the already established Suzuki coupling would deliver the cyclisation precursors (Scheme 100). 
 
 
 
 
 
Scheme 100. Envisioned synthesis of thecarbamate precursors. 
 
 Due to the large amount of cheap, commercially available esters it was possible to generate a 
number of different cyclisation substrates. Freshly prepared lithium diisopropylamide
184
 was used to 
generate the enolate anions 140.
185
 The condensation process was found to be relatively poor yielding, 
most likely due to the steric hindrance introduced by the ortho bromine substituent on the electrophile. 
Screening the literature revealed that often large excess of the benzyl bromide is used to facilitate the 
condensation and that many a time yields vary between 40 and 60%.
186
 In the laboratory, though, it was 
decided that a 1:1 ratio of the nucleophile to the electrophile will be used. 
 Condensation of methyl phenylacetate 238 with 2-bromobenzyl bromide yielded the ester product 
239 (Scheme 101) in 52% yield. The product of the initial reaction was purified by column 
chromatography for yield purposes; however, the majority of the condensation reactions were taken 
through to the hydrolysis step without any purification as the pure carboxylic acid would later be isolated 
in high purity in an acid-base work-up. 
 
 
 
 
 
Scheme 101. Synthesis of the carbamate precursors. 
 74 
 
 
 The ester 239 was converted to the carboxylic acid derivative 240 in 67% yield. It was noticed 
that the hydrolysis reaction was relatively slow, as after 6 hours at room temperature it was only 60% 
complete by 
1
H NMR analysis. The reaction could be pushed to completion by increasing the temperature 
to 40-60 °C, which did not seem to have any negative impact on the formation of impurities and the 
overall outcome of the reaction. Curtius rearrangement facilitated with diphenylphosphoryl azide and a 
catalytic amount of copper chloride afforded the 2-bromocarbamate derivative 241. High temperature 
NMR analysis ran at 50 °C, allowed resolving some of the resonances for the rotamers (Figure 16).  
 
 
 
 
  Ambient temperature 
 
 
 
 
 
 
  50 °C 
 
 
 
 
 
 
Figure 16. Rotameric behaviour of compound 241. 
 
 The final step of the synthesis involved setting up of the olefin group and the Suzuki coupling 
(Scheme 102) delivered the final product 242 in 60% yield. 
 
 
 
 
 
Scheme 102. Suzuki reaction of 241. 
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 The overall yield of 242 for the entire sequence, starting from benzyl bromide, was only 12%. 
The reactions, however, were relatively quick and easy to perform and the availability and low cost of the 
starting materials are definitely beneficial in this system. 
 The relatively modest yield obtained in the Suzuki coupling of 241 to 242 seemed slightly 
suspicious and it was believed that the carbamate protecting group was slowly being removed. In an 
experiment conducted at lower temperature with carbamate 243 from a different Curtius reaction and for 
a shorter reaction time a similar yield 48% of the product 244 was obtained (Scheme 103). Further 
analysis of the 
1
H NMR spectra of the crude reaction mixtures for both Suzuki reactions revealed that the 
main reason behind the low yields was incomplete conversion of the starting material. 
 
 
 
 
 
Scheme 103. Synthesis of the carbamate precursors via Suzuki reaction and Curtius rearrangement. 
 
 Relatively harsh conditions had to be applied to affect the cyclisation of compounds 242 and 244. 
Small amount of the product and mainly unchanged starting material could be recovered after stirring of 
the substrates at 70 °C for 3 hours with 0.4 equivalents of triflic acid (Scheme 104).  
 This was somewhat disappointing; previously, it was already established that carbamate 
protecting group was being slowly removed under more forcing reaction conditions.  Fortunately, 
increasing the temperature to 84 °C and extending the time of the reaction to 6 hours delivered both 
reaction products 245 and 246 in 60-65% yield. Ratio of 3:2 of the two possible diastereoisomers was 
obtained in both instances. As before, prolongued reaction times did not have any impact on the 
composition of the final product. 
 
 
 
 
 
  
 
 
 
 
Scheme 104. Synthesis of the carbamate cyclisation products. 
 76 
 
 Substrates with a methyl substituent instead of the phenyl group were synthesized in the same 
way. Condensation of 2-bromobenzylbromide 140 with methyl propionate 247 and subsequent hydrolysis 
of the ester 248 furnished the carboxylic acid derivative 249 in 35% yield over two steps (Scheme 105).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 105. Synthesis of the carbamate cyclisation products. 
  
 The carbamate 250 was obtained in a Curtius rearrangement in 50% yield, followed by a Suzuki 
reaction with 1-hexenylboronic acid to give the desired substrate 251 in 68% yield. Monitoring the 
cyclisation reaction of 251 by TLC showed that it is somewhat slower than the transformation of the 
phenyl substituted precursor 242 and 244. This could be due the larger Thorpe-Ingold effect which the 
phenyl group of 242/244 exerts over the methyl group in 251. Allowing for a total of 10 hours reaction 
time at 84 °C successfully delivered the product 252 in 71% yield, this time in a 3:1 ratio of 
diastereoisomers. 
 
 Higher functionalization of the tetrahydroisoquinoline aromoatic ring was one of the goals of the 
project and introducing substituents such as halogens was highly desirable. It was predicted that the same 
methodology could potentially supply the desired molecules but due to the small number of commercially 
available, substituted 2-bromobenzyl bromides, an extra step was necessary (Scheme 106). 
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Scheme 106. Synthesis of the carbamate cyclisation products. 
 
 Radical bromination
187
 of 2-bromotoluene derivate 253 with N-bromosuccinimide provided the 
halogenated 2-bromo-5-chlorophenyl compound 254 in 76% yield. Condensation with methyl propionate 
247 to 255 and base hydrolysis gave the carboxylic acid 256 in 50% yield. Further elaboration by a 
Curtius rearrangement provided the carbamate 257 in a modest, 49% yield and was then coupled with 1-
hexenylboronic acid to give 258 in 67% yield under standard Suzuki coupling conditions. Cyclisation 
occurred smoothly and delivered the cyclised product 259 in 71% yield in and a 4:1 ratio of the 
diastereoisomers, indicating no major difference in reactivities towards acid-catalysed hydroamination 
between the chloro-substituted 258 and unsubstituted compound 251. 
 Similarly, a fluorinated analogue 264 was synthesized, starting from the commercially available 
2-bromo-5-fluorobenzaldehyde 259 and a Henry reaction with nitroethane (Scheme 107). The nitroalkene 
260 was obtained in 88% yield and was immediately reduced to the primary amine 261 in 63% yield. 
Protection with methyl chloroformate under Schotten-Bauman conditions furnished compound 262 in 
75% yield, which was then reacted in a Suzuki coupling to deliver the cyclisation precursor 263 in 68% 
yield. 
 
 
 
 
 
 
 
 
 
 
Scheme 107. Synthesis of the carbamate cyclisation products via the Henry reaction. 
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 Similarly as before, the carbamate substrate 263 smoothly converted to the fluorinated 
tetrahydroisoquinoline derivative 264 as a 2:1 mixture of diastereoisomers in 74% yield, using 0.4 
equivalents of triflic acid at 84 °C for 6 hours. The fluorinated compound displayed some interesting 
features on the 
13
C NMR spectra. Long distance couplings between the fluorine and carbon, of up to four 
bonds could be seen resulting in splitting of all the ring carbons (Figure 17). 
 
 
 
 
 
 
Figure 17. Approximate coupling constant values for fluorine and carbon. 
 
2.13 Homologation Route 
 
 One more route for the synthesis of carbamates and tosylates was investigated, in order to expand 
the substrate scope and extend the approachability of hydroamination chemistry. Homologation reaction 
of 2-bromobenzaldehyde based on a Wittig reaction with the phosphine salt 265 yielded intermediate 266 
which was treated with acid and gave the phenylacetaldehyde derivative 267 in 52% yield (Scheme 
108).
188
 Condensation of 267 with isopropylmagnesium bromide reagent provided the alcohol 268a in 
96% yield, which was converted to the primary amine 269 in 57% yield via a three step 
mesylation/azidation/Staudinger reaction reaction sequence.  
 
 
 
 
 
 
 
Scheme 108. Synthesis of the cyclisation substrates via benzaldehyde homologation. 
 
 Protection of the nitrogen of compound 269 with tosyl chloride delivered the sulfonamide 270 in 
94% yield and reaction with methyl chloroformate gave a 77% yield of the carbamate species 272. Suzuki 
coupling of the two substrates with 1-hexenylboronic acid afforded the cyclisation precursors 271 and 
273 in 81% yield for the sulfonamide and 73% for the carbamate (Scheme 109). 
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Scheme 109. Synthesis of the cyclisation substrates via benzaldehyde homologation. 
 
 Direct comparison of the cyclisation reactions of substrates 271 and 273, which differ by the 
protecting group only, confirmed the reactivity trends observed before. The more reactive sulfonamide 
271 cyclised smoothly when exposed to 0.4 equivalents of triflic acid at room temperature for 5 hours and 
provided the tetrahydroisoquinoline 191 in 96% yield (Scheme 110) as a 3:1 mixture of isomers. The 
carbamate precursor 273 proved more challenging to cyclise and only 53% conversion by 
1
H NMR 
spectroscopic analysis was observed after 3.5 hours at 84 °C, with the same quantity of triflic acid. 
Extending the reaction time to 7 hours delivered the cyclised material 274 in 65% isolated yield, as a 5:1 
mixture of diastereoisomers. 
 
 
 
 
 
 
 
 
 
Scheme 110. Cyclisation of carbamate and sulfonamide substrates. 
 
 The largely effective application of hydroamination chemistry in the synthesis of carbamate 
tetrahydroisoquinolines prompted a search for an alternative carbonyl protecting group. A simple acetyl 
moiety was expected to behave similarly. It was also of interest to test whether the Suzuki coupling 
carried out on an iodoarene instead of a bromoarene would allow for reducing the reaction temperature 
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and time and potentially to obtain higher yields of the transformation. Using the Henry route allowed 
quick access into the iodinated nitroalkene 276 from iodobenzaldehyde 275 (Scheme 111), which was 
reduced under Kabalka’s reaction conditions to 277 and reacted with acetyl chloride to give compound 
278. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 111. Synthesis and cyclisation attempt of the acetyl-protected substrate. 
 
 The Suzuki reaction of iodide 278 with 1-hexenylboronic acid performed better that the similar 
couplings executed on bromoarenes. Conversion of 50% was observed after only 45 minutes at 40 °C, 
which was very encouraging. The best yield was nevertheless obtained under the standard reaction 
conditions usually employed for the transformation.  Reaction time of 2 hours at the temperature of 90 °C 
with 5% palladium catalyst and 1.5 equivalents of boronic acid delivered the cyclisation substrate 279 in 
86% yield. Unfortunately, no conversion to 280 was observed in the cyclisation reaction, even after 24 
hours at 84 °C and 0.8 equivalents of triflic acid. 
 
2.14 Functionalised Aldehyde Route 
 
 The carbonyl group is highly abundant amongst organic molecules and is possibly the most 
important functionality, which is common to compounds such as aldehydes, ketones, carboxylic acids, 
esters, amides, lactones, acid anhydrides and carbonates. Carbonyl group chemistry is involved in a huge 
number of various reactions, such as aldol-type condensations, reductions like Luche, Mozingo, Wolff-
Kischner, Clemmensen or Tebbe, disproportionations such as Cannizaro or Tishchenko, double-bond 
forming reactions of Wittig, Peterson and Julia type, reactions with cyanides, hydroxylamines, sulfur 
nucleophiles or hydration to hemiacetals and acetals. One of the most reactive but also a relatively stable 
carbonyl group is an aldehyde. Acetaldehyde and formaldehyde are key components of several important 
industrial polymerisations and are soluble and water. Aldehydes of higher molecular mass are unreactive 
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towards water, albeit they may form geminal diols through the hydration process, as well as undergo 
autoxidation with oxygen in the air. They can be accessed in many ways, i.e. formylation, ozonolysis, Nef 
reaction, Wittig homologation and in oxidation of primary alcohols with mild oxidants. 
 
 The main topic of this work revolves around the synthesis and cyclisations of 2-
vinylphenylethylamines 281 to produce the tetrahydroisoquinoline scaffold 282 (Scheme 112).  
 
 
 
 
 
Scheme 112. Retrosynthetic analysis of tetrahydroisoquinoline synthesis. 
 
 All the routes designed to access the cyclisation precursors 281 suffered from a fairly limited 
flexibility in the step of introduction of the olefin. Late functionalization of the compounds from the 
Henry and the Curtius routes relied on the Suzuki coupling and therefore was restricted by the availability 
of vinylboronic acids. The route involving ring-opening of an aziridine proceeds via the Grignard reagent 
of the bromoolefin and thus is constrained to unfunctionalised substrates. 
 It was conceived that accessing compound 283 could greatly increase the number of synthetic 
transformations available to perform in the ultimate goal to access more complex cyclisation substrates 
281 and the hydroamination products 282.  
 Two primary routes intended to supply the chosen intermediate 284 were designed. The first 
approach (Scheme 113) involved synthesis of a protected phthalaldehyde 285 followed by introduction of 
the ethylamine chain in a Henry reaction, lithium aluminium hydride reduction, installation of the 
protecting group and removal of the acetal moiety to afford 284. This approach would potentially permit 
manipulation of the protecting group on the ethylamine chain and also allow setting up the alkene. 
 
 
 
 
Scheme 113. Synthesis of intermediate 284 via the Henry reaction. 
 
 The second method was somewhat shorter and relied on the ring-opening of an aziridine with 
Grignard reagent 285 and removal of the acetal group to produce 286 (Scheme 114). 
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Scheme 114. Synthesis of intermediate 286 via ring-opening of an aziridine. 
 
 The initial reaction in route one involved formylation of the 2-bromoacetal 287 with butyllithium 
and dimethylformamide, and proceeded smoothly to deliver the aldehyde 288 in 93% isolated yield 
(Scheme 115). The Henry reaction proved difficult and a large number of different impurities could be 
detected by TLC and 
1
H NMR analysis. The acetal moiety proved somewhat fragile under the reaction 
conditions and was possibly being slowly deprotected with the traces of acetic acid present in the reaction 
mixture. The nitroalkene 289 was the major component of the reaction mixture but it took some effort to 
isolate it in pure form. 
 
 
 
 
 
Scheme 115. Synthesis of intermediate 290 via the Henry reaction. 
 
 Reduction of the crude nitroalkene 289 delivered the primary amine 290 in 88% yield after an 
acid- work-up. An attempted tosylation of intermediate 290 delivered surprising results, as none of the 
sulfonamide acetal 291 could be isolated from the reaction mixture. The major product of the 
transformation was the cyclised tetrahydroisoquinoline 292 (Scheme 116). The structure was confirmed 
by 
1
H NMR analysis where only one ethoxy moiety could be detected, no NH peaks were seen and the 
presence of the tosyl group was confirmed. 
 
 
 
 
Scheme 116. Synthesis of THIQ 292 in a tosylation reaction. 
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 Since the final product 292 of the scheme was of no value at this stage, the whole sequence was 
repeated with an ethylene acetal-protected benzaldehyde, in hope that the problem of the nitrogen 
cyclisation onto the ethoxy group could be avoided. 
 A short optimisation of the reaction conditions proved that the route can deliver the product but in 
a low yield. The commercially available benzaldehyde 293 could be reacted with nitromethane in 
presence of ammonium acetate, the nitroalkene 294 reduced with LAH and the primary amine 
subsequently protected with tosyl chloride to yield the desired intermediate 295 (Scheme 117). 
 
 
Scheme 117. Synthesis of intermediate 295 via the Henry reaction, reduction and tosylation. 
 
 This time it was possible to isolate the tosylated compound 295, however in a poor overall yield. 
The purification process was also quite problematic, and since the obtained results were not satisfying, it 
was decided that the second route, involving ring-opening of an aziridine will be tested. The obvious 
limitation of this methodology was the requirement for the tosyl group on the aziridine. Nevertheless, the 
synthesis consists of only two synthetic steps (Scheme 118) to reach 291, 297 and 295, starting from the 
synthesized or commercially available aziridines 154 and 298, and the 2-bromobenzaldehyde acetals 287 
and 296. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 118. Synthesis of intermediates via the Henry reaction. 
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 The ring opening reactions were largely successful and delivered the phenylethylamines 295 and 
297 in very good yield. The lower, 48% yield does not reflect the performance of the reaction and was 
caused by low solubility of the product 295 in diethyl ether. This resulted in loss of material due to 
crystallisation of 295 on silica during purification. The next step involved deprotection of the acetal 
moiety, which was first attempted on the intermediate 297. 
  
 
 
 
 
Scheme 119. Deprotection of intermediate 295. 
 
 A number of different reagents and solvents have been employed to facilitate the desired 
transformation of 297 to 299. In the case of pyridinium p-toluenesulfonate, being used, no conversion was 
observed even after stirring for 18 hours. In the case of hydrochloric acid in tetrahydrofuran and water or 
acetone as solvent at room temperature, only complex reaction mixtures could be obtained (Scheme 119). 
The hemiacetal or the free aldehyde formed in the course of the reaction are probably too reactive in 
presence of the amine group undergo condensation-type reactions, leading to formation of byproducts. In 
any case, the aldehyde group could not be detected by 
1
H NMR analysis at any point. 
 It was decided that another protecting group should be introduced on the nitrogen to block it and 
reduce the nucleophilicity of the amine. The first group of choice was the t-butoxycarbonyl moiety and 
could be easily installed in a reaction with BOC anhydride (Scheme 120) to give compound 300 in 67% 
yield.  
 
 
 
 
 
Scheme 120. Protection of sulfonamide with Boc-anhydride. 
 
 Interestingly, the reaction would not proceed without dimethylaminopyridine and a minimum of 
0.2 equivalents of DMAP was required to achieve a sensible conversion rate. Thus, the doubly protected 
acetal 301 could be obtained smoothly in 92% isolated yield. 
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Scheme 121. Synthesis of the BOC protected intermediate 301 and subsequent deprotection. 
 
 Exposing the intermediate 301 or 303 to the reaction conditions previously used to remove an 
acetal moiety, namely: HCl in a mixture of water, THF and acetone or PPTS in dichloromethane showed 
that no reaction was taking place, even after prolonged stirring and warming. Attempts to use stronger 
acids, such as trifluoroacetic acid in dichloromethane and sulfuric acid in a mixture of water and acetone, 
resulted mainly in removal of the BOC group. Fortunately, the acetal group could be selectively cleaved 
with 3.5 equivalents of iron (III) chloride hexahydrate in dichloromethane at room temperature for several 
hours (Scheme 121).
189
 Under these conditions, the doubly protected benzaldehyde intermediate 302 was 
found to be relatively stable and, importantly, further deprotection of the Boc group did not occur. Even 
though TLC and 
1
H NMR analysis of the reaction showed complete conversion to the aldehyde, yield of 
only 71% per cent could be obtained. This reflects the issues associated with formation of large quantities 
of a slurry and brown precipitate during the work up stage. To increase the practicality of the reaction, it 
was further optimised to run with 1.1 equivalents of the reagent, which improved the yields and reduced 
the amount of solid present during the work-up stage. 
 
 In a single experiment it was also shown that the ring-opening of the aziridine 154 with 296 and 
the nitrogen protection could be carried out in one step to give intermediate 301. The yield obtained was 
good (51%) and it was decided that this protocol would not be further optimised. Overall, we were able to 
install the phenylethylamine chain and two protecting groups in a single step, which was highly 
advantageous. To further increase the usefulness of this synthetic sequence, it was decided that a greener 
protocol was required for the acetal deprotection step. Screening of several reagents showed that using 
10-25 weight% of amberlyst-15 in either dichloromethane or acetone and water delivered the desired 
aldehyde 302 in almost quantitative yield (Scheme 122).
190
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Scheme 122. Synthesis of intermediate 302 via the aziridine route. 
 
 The procedure of ring-opening of the aziridines exclusively relied on utilisation of Grignard 
reagents. Previous experiments showed that lithiated species cannot be used in place of halomagnesium 
compounds, which was an important limitation. It was envisioned, however, that the desired Grignard 
reagents could be synthesized in a sequential lithium-halogen exchange followed by addition of 
magnesium bromide. In an experiment where the aryl bromide 296 was first lithiated to 304 and then 
converted to its magnesium bromide derivative 305 by addition of solid magnesium bromide, a good 
yield of the ring-opened product 297 was obtained (Scheme 123). 
 
 
 
 
 
Scheme 123. Synthesis of intermediate 297 via lithiation-magnesiation. 
 
 It was therefore possible to carry out the standard aziridine ring-opening reaction but with pre-
formation of the Grignard reagent via lithium halogen exchange and addition of magnesium bromide. 
This opened the door towards the substrates from which the magnesio-reagents could not be formed, i.e. 
highly electron-rich, dimethoxy substituted compounds. 
 The first idea to exploit the aldehyde moiety with the ethylamine chain already installed involved 
carrying out a Wittig-type reaction with a phosphonium salt 306 containing an ester, to synthesize 
intermediate 307 (Scheme 124). The standard reaction conditions employed before worked very well and 
delivered the product in 83% isolated yield, as a mixture of cis and trans isomers. It was anticipated that 
compound 307 would undergo a smooth acid catalysed deprotection and cyclisation in a Michael fashion. 
It was surprising to see that only the deprotection of the Boc group and isomerisation of the double bond 
from cis to trans was observed, yielding product 308. Even in refluxing dichloroethane no 
tetrahydroisoquinoline could be detected. 
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Scheme 124. Synthesis of intermediate 307 via the Wittig reaction. 
 
 The failure in the attempted cyclisation of compound 308 could have been caused by the triflic 
acid preferentially protonating the ester group and effectively preventing the cyclisation from occurring. 
The low reactivity of the ester system also correlated to the problematic cyclisations of the previously 
described stilbene derivatives. Electron-withdrawing groups present on the double bond have a strongly 
deactivating effect and in case of the substrate 307, perhaps can completely stop the reaction from 
happening.   
 Encouragement from the good performance of the Wittig reaction prompted synthesis of a 
number of cyclisation precursors which due to their structural properties had been previously impossible 
to make. Synthesis of the phosphonium salt 310 from the commercially available p-nitrobenzyl bromide 
309 and sequential reaction with the benzaldehyde intermediate 302 delivered a cyclisation intermediate 
possessing a nitro group.  
 
 
 
 
 
 
 
Scheme 125. Synthesis of intermediate 311. 
 
 Previous attempts to access similar compounds possessing a nitro group were met with failure as 
the formation of a Grignard reagent could not be successfully initiated. The phosphine salt 310 was 
synthesized from the commercially available 4-nitrobenzyl bromide 309. Accessing the substrate through 
the novel, functionalised aldehyde approach proved effective and compound 311 was cyclised in a good 
51% yield to the corresponding tetrahydroisoquinoline 313.  
 To probe if the Boc group has any influence on the cyclisation progress we have decided to 
remove the carbamate with TFA in dichloromethane, which gave the sulfonamide 312 in 91% yield 
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(Scheme 126). Running the cyclisation under optimised reaction conditions and with only 0.2 equivalents 
of triflic acid led to the cyclised product 313 in 81% yield, or in 74% over two steps. 
 
 
 
 
 
 
Scheme 126. Synthesis of tetrahydroisoquinoline 313. 
 
 Generally, better cyclisation yields were obtained during the optimisation process if the Boc-free 
compound 312 was used. It therefore seemed as the Boc group plays an important role in the reaction and 
the overall outcome of the reaction to some extent depends on its presence. 
 
2.15 Conclusions 
 
 Probing of a number of different synthetic routes towards the hydroamination substrates allowed 
efficient synthesis of various cyclisation precursors, which were smoothly converted to 1,3-substituted 
THIQ alkaloids. Different alkyl- and phenyl- substituted analogues were synthesized, with a carbamate, 
tosyl or a nosyl protecting group on the nitrogen. Separation and careful spectroscopic analysis of 
diastereoisomers, along with X-ray evidence, proved that the thermodynamic product of the 
hydroamination was the 1,3-cis stereoisomer.   
 Literature search on the mechanism of acid-catalysed hydroamination proved inconclusive, 
however, a pre-association mechanism, postulated by Wiedenhoefer, appears to be the most convincing. 
Analysis of the energy-minimised structures of substrates with cis and trans olefin bonds accounted for 
the difference in reactivities between the two isomers. Furthermore, comparison of the vinyl-isopropyl 
and vinyl-phenyl substituted aminoalkenes showed that steric factors play a minor role in the reaction and 
that the electronic properties of the alkene bond have a crucial impact on the reaction. Electron poor -
bonds, e.g. with a phenyl or an ester substituent, performed poorly and either did not work at all or 
required very harsh conditions to cyclize.  
 A variety of different solvents and catalysts was screened in an attempt to find better catalyst or 
solvent system for the hydroamination reaction. Ultimately, it was shown that a combination of 0.4 
equivalents of triflic acid and dichloromethane or 1,2-dichloroethane as solvent work best and delivered 
the tetrahydroisoquinolines in good yields. 
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Chapter 3: Application to Synthesis of Natural 
Products 
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3.1 Introduction 
  
 Growing general interest in tetrahydroisoquinoline chemistry in the context of natural products, 
building blocks and pharmaceuticals has resulted in fast development of a large variety of synthetic 
approaches delivering these compounds. Different alkaloids in this family have shown diverse biological 
activities, e.g. inflammatory,
191
 neuromuscular transmission blocking,
192
 and enzyme inhibitory
193
 
properties. Compounds such as the pyrroloisoquinoline (S)-crispine A 314 (Scheme 127), first isolated in 
2002 by Zhao and co-workers, have been shown to posses anticancer properties against several human 
cancer cells.
194
 (S)-Xylopinine 315 belongs to the protoberberines, a large family of alkaloids 
characterised by their tetracyclic skeleton with an incorporated tetrahydroisoquinoline core. 
Tetrahydroprotoberberines often possess antimicrobial, antitumour and antileukemic properties.
195
  
 
 
 
 
 
Scheme 127. Crispine A and xylopinine. 
 
 The past decade saw advances in the area of tetrahydroisoquinoline synthesis. Enantioselective 
Pictet-Spengler reaction,
196
 procedures involving operations such as cyanations on 3,4-
dihydroisoquinolines,
197
 functionalisation of dihydroisoquinolines N-oxides
198
 or catalytic asymmetric 
hydrogenations
199
 of 3,4-dihydroisoquinolines have been applied in this area. The ongoing research in the 
field of THIQ is still very dynamic and many journal articles covering their syntheses are published 
annually. 
 
3.2 Methoxylated Analogues 
 
 A large number of tetrahydroisoquinoline, benzyltetrahydroisoquinoline and other isoquinoline 
natural products contain alkoxy groups on one or several rings. The hydroxy, methoxy and 
methylenedioxy substituents on ring A are usually located at the same positions, as in crispine A or 
xylopinine (Scheme 127). After proving the utility of hydroamination in the synthesis of unsubstituted 
and electron-poor tetrahydroisoquinolines it was important to test whether this synthetic methodology 
could be used to access molecules resembling natural products.  
 It was anticipated that the substituted analogues could be accessed from veratraldehyde 316 via 
the already established Henry sequence. Reaction of 316 with nitromethane delivered the nitroalkene 317 
in 68% yield. It was observed that the veratraldehyde reaction performs much worse in comparison to the 
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unsubstituted aldehydes. Fortunately, the products could be purified relatively easily by repeated 
recrystallization from petrol/ethyl acetate mixtures. Kabalka’s reduction protocol was employed to access 
the amine 318 in 58% yield, which was then used without purification in a tosylation reaction to deliver 
sulfonamide 319 (Scheme 128). 
 
 
 
 
 
Scheme 128. Synthesis of methoxylated compounds. 
 
 To avoid the laborious Kabalka reduction protocol of halogenated nitroalkenes, a synthetic route 
was also devised where the iodine substituent was introduced at a later stage, after the initial installation 
of the phenylethylamine chain. Thus, the 3,4-dimethoxyamphetamine 321 was accesed in a two step 
process by a Henry reaction followed by reduction with lithium aluminium hydride in 61% yield (Scheme 
129). 
 
 
 
 
Scheme 129. Synthesis of methoxylated compounds. 
 
 The primary amine was then converted to nosyl derivative 322 and carbamate 323 in 57% and 
65% yield, respectively. Both compounds were then iodinated using molecular iodine and silver sulfate. 
This protocol was found to be very efficient and high yielding and produced the iodinated sulfonamide 
324 in 90% and the carbamate 325 in 76% yield (Scheme 130). 
 
 
 
 
 
 
 
 
 
Scheme 130. Synthesis of iodinated methoxylated compounds. 
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 The prepared series of nosyl, tosyl and carbamate methoxy- haloarenes were then functionalised 
using the Suzuki reaction. It was anticipated that, due to the electron-rich nature of the coupling 
substrates, the rate of palladium insertion into the carbon-bromine and carbon-iodine bonds could be 
much slower or that the reaction would not proceed at all. Fortunately, all of the palladium couplings 
performed worked well and delivered compounds of interest in relatively good yields. The results are 
summarised in the table below (Table 2). 
 
 
      Starting Material  Final Product Yield
a 
324 
 
 
 
326 
 
72% 
325 
 
 
 
327 
 
54% 
324 
 
 
 
328 
 
 
 
 
82% 
319 
 
 
 
 
329 
 
77% 
 
 
319 
 
 
330 
 
53% 
 
319 
 
 
    342a 
 
 
 
 
77% 
 a
 Yields for products isolated after column chromatography.
 
 
 
Table 2. Suzuki coupling of methoxylated compounds. 
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 The yields obtained in the palladium coupling reactions were acceptable. Analysis of the crude 
reaction mixtures showed no decomposition and most likely further optimisation of the reaction 
conditions could improve the conversion and the yield for the reation. 
 
 
3.3 Cyclisations 
 
 It was correctly predicted that the electron donating substituents on the benzene ring would have 
a drastic effect on the outcome of the hydroamination reaction. Less forcing conditions could be applied 
to afford the bicyclic product, however, some of the precursors were found to be more prone towards 
decomposition. The cyclisation reaction of sulfonamide 326 proceeded to completion in less than 15 
minutes at 0 °C with 0.4 equivalents of triflic acid and delivered the tetrahydroisoquinoline 331 in 84% 
yield (Scheme 131). 
 
 
 
 
 
 
 
 
Scheme 131. Cyclisation of compound 326. 
 
 Interestingly, 
1
H NMR experiments proved that full conversion to the product could also be 
achieved at -20 °C after 20 minutes and  at -40 °C after approximately 1 hour. 
 At this stage it was also demonstrated that the electron-rich substrates could be cyclised with 
sulfuric acid as the catalyst, which is insoluble in organic solvents usually employed for this 
transformation and was also somewhat harder to quantify. Compound 326 was cyclised with a drop of 
sulfuric acid in dichloromethane in 30 minutes to furnish tetrahydroisoquinoline 331 in 87% yield.  
 To quantify sulfuric acid more accurately, a series of measurements were taken where a drop of 
sulfuric acid was discharged from a syringe and its mass accurately determined each time. Twenty 
readings gave an average mass of a “drop” to be 12 mg, which corresponds to 0.12 mmol. Generally, 1 
drop of sulfuric acid was used per 100 mg of a compound with molecular mass between 300 and 500 
Daltons. This is approximately 0.5 equivalents of the acid per 1.0 equivalent of the substrate and therefore 
corresponds well to the triflic acid-catalysed reaction conditions. The cyclisation rate of triflic acid-
catalysed reactions was found to be faster than of the corresponding sulfuric acid reactions, most likely 
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due to the fact that the second reaction is heterogenous. Most of the time, even when the reaction was 
vigorously stirred, the drop of sulfuric acid could be seen in the reaction flask. 
 
 The second reaction in the series involved a stilbene derivative 328. As before, switching from an 
alkyl to a phenyl substituent on the double bond caused the reaction to be more sluggish. The compound 
was also slowly decomposing if the reaction temperature was raised above 0 °C or upon prolongued 
stirring (Scheme 132). A small quantity of brown precipitate, insoluble in organic solvents, could be 
detected. Nevertheless, the optimised reaction conditions delivered the benzyltetrahydroisoquinoline 332 
in 87% yield. 
 
 
 
 
 
Scheme 132. Cyclisation of compound 328. 
 
 Hydroamination reaction of the electron-rich carbamate analogue 327 proved to be somewhat 
difficult. Similarly as before, higher temperature was required to cyclise the corresponding carbamate 
equivalent of 326. No reaction was seen at temperaures close to 0 °C and the corresponding cyclised 
product 333 was formed in 72% yield and a 2:1 mixture of diastereoisomers, after 1 hour at room 
temperature (Scheme 133). Only approximately 75% conversion by NMR was observed after 1 hour of 
stirring in acid, however, extending the reaction time to 2 or 3 hours resulted in a drastic drop in yield 
(<50 %) and formation of a number of unidentified impurities. 
 
 
 
 
 
Scheme 133. Cyclisation of compound 333. 
 
 The results obtained were encouraging and introducing alkoxy substituents on the second 
benzene ring became a priority. Increasing the scope of the hydroamination to highly substituted and 
electron rich compounds would possibly permit synthesis of interesting, biologically active compounds 
such as the previously mentioned xylopinine 315 and laudanosine 26 (Scheme 134).  
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Scheme 134. Xylopinine and laudanosine. 
 
 Due to the limited availability of the boronic acids, another route enabling relatively quick 
synthesis of methoxylated tetrahydroisoquinoline alkaloids was defined. As before, veratraldehyde 320 
served as a cheap and commercially available starting material and was reacted with phosphine salt 334 in 
a Wittig reaction to deliver the alkene 335 in 85% yield (Scheme 135). It was later shown that the low 
yield of a number of Wittig reactions was caused by poor quality potassium tert-butoxide used to form the 
ylide. 
 
 
 
 
 
 
 
 
Scheme 135. Synthesis of electron-rich hydroamination precursors. 
 
 The bromide 335 was then transformed into the aldehyde 336 in 52% yield by a lithium-halogen 
exchange formylation reaction with dimethylformamide used as the source of the carbonyl group. Henry 
reaction with nitromethane afforded the nitroalkene 337 in 51% yield, which was subsequently reduced to 
an amine with lithium aluminium hydride to 338 and tosylated to furnish sulfonamide 339 (Scheme 136) 
in a modest, 40% yield over two steps. 
 
 
 
 
 
 
Scheme 136. Synthesis of electron-rich hydroamination precursors. 
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 Regrettably, the standard triflic acid-catalysed reaction resulted in decomposition of the starting 
material. The cyclisation step required a lot of optimization (Scheme 137), as the substrate was 
extensively decomposing, forming a thick, black residue which could not be purified. Lowering the 
reaction temperature to -20 °C did not improve the outcome in any way and carrying out the treaction at -
50 °C completely stopped the process; in this case only unreacted starting material was recovered. It was, 
therefore, decided that any potential reactivity window between -20 and -50 °C was too small and 
optimising the reaction was not desirable. Attempt to use weaker acids such as trichloroacetic acid, 
sulfuric acid, trifluoroacetic acid proved largely ineffective. The problem was overcome by using pTSA 
in toluene.  
 
 
 
 
 
 
 
 
 
 
Scheme 137. Optimisation of the cyclisation reaction. 
  
 A small amount of the cyclised material could be obtained in a reaction with 1.0 equivalent of p-
toluenesulfonic acid at 75 °C. The optimised conditions involved heating the substrate with 0.5 
equivalents of pTSA in toluene to 100 °C for 0.5 h. Further analysis of the crude reaction mixtures 
showed that trans starting material fully converts to give the product 340, however, the cis isomer 
remains unreacted. Since approximately 40% of the cyclisation precursor existed in the trans from, it was 
unsurprising to see the the yield of the reaction close to 40% as well. This was previously observed in a 
similar system (Scheme 82, pg. 61), where a much higher temperature was required to cyclize compound 
179 to 199. It was concluded that the problem could be potentially avoided if the synthesized starting 
material 339 was exclusively trans. This idea was later successfully proved to be true via the Suzuki 
methodology and several polysubstituted, electron-rich tetrahydroisoquinolines were synthesized. The 
first tetrahydroisoquinoline synthesized in a pTSA-catalysed reaction was the trifluoromethylated 
compound 341 which gave the cyclic product in 95% yield (Scheme 138).  
 
 
 
Acid Temp. Time Yield 
TfOH 0°C 15 min decomp. 
TfOH -20 °C 15 min decomp. 
TfOH -50 °C 1 h no reaction 
TFA 25°C 1h no reaction 
TCA 25°C 1h no reaction 
H2SO4 -20 15 min no reaction 
pTSA 60° 5h 10% 
pTSA 75°C 24h 41% 
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Scheme 138. Synthesis of electron-rich hydroamination products. 
 
  Similarly to compound 264 (Scheme 107), interesting spectral features could be observed in the 
13
C NMR spectrum of compound 341; carbons up to four bonds away from the fluorines (Figure 18) of 
the -CF3 group were split into quartets. The J values for the couplings fitted well into the ranges 
previously reported (Figure 18) and ranged between 3 and 250 Hz. 
 
 
Figure 18. Splitting patterns due to carbon-fluorine coupling. 
  
 It was soon discovered that this methodology is very general and tolerates different substituents 
on the second benzene ring. Predictably, the chlorinated derivative 330 also cyclised under the same 
reaction conditions and gave tetrahydroisoquinoline 342 in 95% isolated yield (Scheme 139). 
 
 
 
 
 
 
Scheme 139. Synthesis of electron-rich hydroamination product 342. 
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 The highly electron-rich substrates 343 and 345 were also accessed through the Suzuki coupling 
in a 93% and 53% yield respectively, and were quickly converted to their cyclised counterparts 344 in 
88% and 346 in 95% yield (Scheme 140). 
 
 
 
 
 
 
 
 
 
Scheme 140. Synthesis of electron-rich hydroamination products. 
  
3.4 A formal total synthesis of (R/S)-salsolidine 
 
 The synthesis of polyalkoxy substituted tetrahydroisoquinolines was also successfully extended 
to the previously described functionalised aldehyde route. Acetal protection of 2-bromoveratraldehyde 
cleanly delivered the bromo-derivative 347 which was converted to the sulfonamide 348 in a one-pot 
lithium-halogen exchange followed by an in situ formation of a Grignard via addition of solid magnesium 
bromide and finally ring-opening of an aziridine 154 in an overall 45% yield. The sulfonamide 348 was 
then protected with a Boc group to furnish doubly-protected amine 349 which could not be efficiently 
deprotected to deliver 350 (Scheme 141). The substrate was exposed to a number of different reagents in 
an attempt to remove the acetal but only extensive decomposition or complex reaction mixtures 
containing multiple products could be obtained. 
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Scheme 141. Functionalised aldehyde synthesis. 
 
 It was later discovered that amberlyst-15 provides a very clean and efficient transformation of 
acetals such as 349 into their corresponding aldehydes; this methodology was applied to acetal 352 to 
yield aldehyde 353. 
 To sum up, the acetal 349 can be accessed in a relatively short sequence of reactions. The 
installation of the acetal was not a problem, as well as the introduction of the Boc group and most 
probably removal of the dioxolane at the end. The protecting-group manipulations were the price to pay 
to access a highly functionalised and dynamic intermediate such as 350. Unfortunately, due to intensive 
experimentation and time constraints no further synthesis using compound 350 was carried out; however, 
a similar set of transformations was used to access compound 353, which differs only by not having an 
ethyl substituent on the ethylamine chain. 
 
 
 
 
 
 
Scheme 142. Functionalised aldehyde synthesis. 
 
  (R/S)-Carnegine
200
 355a and (R/S)-salsolidine 355b are a simple, model tetrahydroisoquinoline 
alkaloids and often serve as test molecules for new THIQ-making methodologies. In an attempt to access 
racemic carnegine through Knight’s hydroamination the aldehyde 353 was transformed into the alkene 
354 in a simple Wittig reaction (Scheme 142). 
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Scheme 143. Synthesis of electron-rich hydroamination products (left) and carnegine and salsolidine (right). 
 
 The subsequent cyclisation of the Boc protected sulfonamide 354 under the standard pTSA-
catalysed reaction conditions gave the tetrahydroisoquinoline 355 in only 35% yield and a number of 
impurities which could be isolated but were not identified (Scheme 144). This relatively poor result might 
be due to the Boc interfering with the hydroamination or due to the higher reactivity of the terminal 
double bond. 
 
 
 
 
Scheme 144. Synthesis of racemic salsolidine precursor. 
 
 Exposing the isolated cyclisation product 355 to the reaction conditions for 24 hours resulted in 
its full recovery, thus proving its stability. Due to time constraints the cyclisation reaction was never fully 
optimised. Nevertheless, the reductive deprotection of the sulfonamide 355 under dissolving-metal 
reaction has been previously reported by Ponzo and Kaufman and a formal synthesis (Scheme 145) was 
therefore established.
201
 The amine 356 could also be accessed in a two step process involving a one-pot 
elimination and aromatisation of the B ring with sodium hydroxide in hot DMSO reported by Shi and co-
workers,
202
 followed by high-pressure hydrogenation of isoquinoline 357 over Raney Nickel.
203
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 145. Relay synthesis of racemic salsolidine. 
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3.5 Crispine 
 
 A similar approach was used in an attempted synthesis of (R/S)-crispine 358, where the 
installation of a four-carbon chain with an alcohol group would be used to form the five-membered ring 
in the final product (Scheme 146). 
 
 
 
 
 
Scheme 146. Retrosynthetic analysis of crispine. 
 
 The initial effort was directed towards probing the behaviour of the alcohol group under acid-
catalysed hydroamination conditions. It was plausible to expect that a primary alcohol might dehydrate 
when treated with a strong acid, or cyclize onto the double bond to form an oxygen heterocycle. 
 Happily, the alcohol 360 could be easily accessed in a simple Wittig reaction of aldehyde 302 and 
phosphine salt 359 to furnish the cyclisation precursor in 41% yield. Exposing 360 to 0.4 equivalents of 
triflic acid in dichloromethane at ambient temperature gave only the deprotected product 360a in 59% 
yield. However, more forcing conditions delivered the desired cyclic product 361 in 40% yield. 
Additionally, reacting the deprotected compound 360a with triflic acid in refluxing dichloromethane also 
gave the desired tetrahydroisoquinoline 360, in somewhat higher yield of 50% (Scheme 147). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 147. Towards synthesis of crispine. 
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 A considerable effort was dedicated to proving the true structure of 361. Extensive analysis of the 
chemical shifts and connectivity ascertained that the cyclised compound was indeed a 
tetrahydroisoquinoline formed in a 6-exo fashion and not a tetrahydrofuran 362, which could arise from a 
5-endo-trig cyclisation of the oxygen onto the alkene. With this data, the research then shifted to the 
dimethoxybenzene analogues. 
 It was possible to synthesise the alcohol 363 in a Wittig reaction of aldehyde 353 and phosphine 
salt 359, however in only 18% yield (Scheme 146). Taking the Boc-protected sulfonamide straight to the 
hydroamination, which could be triggered under less forcing conditions than hydroamination of 360, 
delivered the cyclised product 364 in 70% yield. As before, it was noticed that the cyclisation reaction 
could also potentially occur through the oxygen atom, via the 5-endo pathway, to give a furan product 
365. Careful analysis of the 2D NMR spectrum revealed that the product was indeed a nitrogen 
heterocycle 361. In both cases this was somewhat unsurprising, as all (3 to 7)-exo-trig cyclisations are 
favoured according to the Baldwin’s rules, whereas all (3 to 5)-endo cyclisations are disfavoured in 
trigonal systems (Scheme 148). 
 
 
 
 
 
 
 
Scheme 148. Towards synthesis of crispine. 
  
 The next steps involved deprotection of the sulfonamide group and intramolecular cyclisation. It 
was highly possible that the alcohol group would interfere with the harsh reaction conditions required to 
remove a tosyl group. The issue could be overcome by introducing a protecting group on the oxygen 
atom, which would additionally block the suspected 5-endo cyclisation. An acetate protecting group could 
also serve as a leaving group and induce the 5-membered pyrrole ring-closure at a later stage. Protection 
of the alcohol 363 with acetic anhydride was achieved in 66% yield to give the cyclisation precursor 366. 
The hydroamination proceeded smoothly and delivered the acetate protected tetrahydroisoquinoline 367 
(Scheme 149) in 59% yield. 
 
 
 
 
 
Scheme 149. Towards the synthesis of crispine. 
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 The final step of the synthesis was supposed to involve a deprotection of the tosyl group to the 
intermediate 368 and a simultaneous cyclisation of the nitrogen atom onto the acetate carbon would 
deliver the racemic crispine 358. Regrettably, the detosylation attempts were ineffective and due to time 
limitations the final product could not be synthesized (Scheme 150). 
 
 
 
 
 
Scheme 150. Final steps in the synthesis crispine. 
 
 Another area of research involved synthesis of a stilbene-type precursor decorated with methoxy 
substituents on the bottom ring, but not the top. It was anticipated that the reduced reactivity would cause 
problems and that the cyclisation might occur via the 7-endo instead of 6-exo fashion and potentially 
produce a 7-membered ring. 
Scheme 151. Synthesis of intermediate 371 via the Wittig and Henry reactions. 
 
 Previously established methodology was used to access the cyclisation precursor 374. Wittig 
reaction of bromoveratral 320 and 2-bromobenzyltriphenylphosphonium bromide 366 (Scheme 152) 
delivered the alkene 369 in a modest, 40 % yield. The 2-bromostilbene derivative 369 was then 
formylated to 370 in 66% yield and transformed into nitroalkene 371 in 93% yield via a condensation 
with nitroethane. Subsequent reduction with LAH furnished the primary amine 372 in 96% yield, 
followed by tosylation to the final compound 373 in 60% yield (Scheme 152). 
 
 
 
 
 
Scheme 152. Synthesis of intermediate 373 via the Henry reaction. 
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 Unfortunately, attempts to cyclise the sulfonamide derivative 373 were met with failure. Even 
under carefully controlled conditions only complex reaction mixtures containing multiple products could 
be obtained. The desired tetrahydroisoquinoline 375 was not observed by 
1
H NMR spectroscopy and the 
mixtures were not analysed further. Further optimisation attempts did not afford any major reaction 
product. In a series of overnight experiments where p-toluenesulfonic acid was employed at 65 or 100 °C, 
a complete isomerisation to the trans isomer 377 was observed; yet no tetrahydroisoquinoline product 
could be detected. 
 
 
 
 
 
 
 
Scheme 153. Attempted cyclisation of 373. 
  
3.6 Benzhydryl Analogues 
 
 Apart form ability to interact on central nervous system and antitumour and antimicrobial 
properties, several tetrahydroisoquinoline derivatives, such as chelidoneme 377 and magnoflorine 378, 
are known for their anti-HIV activity (Scheme 154).
204
 Compounds such as 378 have been recently 
accessed in an iridium complex-catalysed hydrogenation/tosylation of the corresponding imines.
205
 
Another recent publication by Efange and co-workers revealed that 1-aryl tetrahydroisoquinolines also 
display antimalarial properties.
206
 
 
 
 
 
 
Scheme 154. Structures of chelidoneme and magnoflorine. 
 
 It was envisioned that perhaps a double bond is not required to generate a carbocation on the 
benzylic position to facilitate a hydroamination reaction. Instead, a departing molecule of water would 
serve as a leaving group (Scheme 155). 
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Scheme 155. Hydroamination reaction terminating on a benzylic alcohol. 
 
 With the previously synthesized aldehyde 302 it was possible to quickly test the idea. First, it was 
attempted to synthesise a substrate which could potentially dehydrate during the cyclisation. 
Condensation of aldehyde 302 with butylmagnesium bromide delivered the alcohol 379 in approximately 
40% yield. It was discovered that the Boc group migrates between the nitrogen and oxygen (Scheme 
156). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 156. Boc group migration in a condensation reaction. 
 
 At first it was expected that the presence of the Boc group on either of the heteroatoms will not 
have any major influence on the outcome of the cyclisation reaction. It was later discovered that the final 
product could 378 only be obtained from the N-Boc protected material 379 and that the O-Boc substrate 
380, when exposed to triflic acid, produces only very small amounts of product 381. Separation of 
compound 379 and subsequent reaction with a catalytic amount of triflic acid delivered the product 381 in 
73% yield. Interrupting the cyclisation reaction before reaching completion showed that it occurs via the 
dehydrated alkene 382. The initial rate of dehydration was relatively fast with the cyclisation occurring 
relatively slow. This was possibly caused by the water coming from the dehydration step and could be 
overcome by using larger quantities of triflic acid (0.8 – 1.2 eq.) to afford the transformation. 
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 The next substrate tested was designed not to dehydrate in the process, with no hydrogens 
available for elimination. Condensation of the aldehyde 302 with phenylmagnesium bromide delivered a 
mixture of two products, 383 and 384 in a good overall yield (Scheme 157).  
 
 
 
 
Scheme 157. Boc group migration in a condensation reaction. 
 
 As before, however, only modest quantities of product 385 could be isolated if a mixture of both 
of the condensation products 383 and 384 were exposed to hydroamination conditions (Scheme 156). 
Extending the reaction time had no positive effect on the outcome of the transformation. An attempt to 
use TFA to afford deprotection and cyclisation resulted in similar results and only delivered the product 
in very low quantities (Figure 19) amongst several impurities which were not identified. 
 
 
 
 
 
 
 
Figure 19. HPLC trace of the crude mixture of a TFA (red) and TfOH (blue) reaction of crude 380/381. 
  Product at 7.75/7.78 min. 
 
  It was decided that the methodology would benefit from a short and simple procedure allowing 
for a complete removal of the Boc group; therefore, it was then attempted to cleave off the Boc protecting 
group from both the nitrogen and oxygen in a single step. Attempts to optimise the acid-catalysed 
deprotection did not deliver any positive results and a base-catalysed approach was then tried. A reaction 
with potassium carbonate in methanol under reflux conditions successfully delivered the product 386 as a 
single species (Scheme 156), although in a relatively long reaction time. This was unsatisfactory, as it was 
more desirable to design a faster and more robust transformation which could be employed as a short and 
simple, post work-up procedure after the condensation reaction. 
 
 
 
 107 
 
 
 
 
 
 
 
 
 
 
Scheme 158. Boc group deprotection attempt. 
 
 During further optimisation process it was determined that concentrated sodium hydroxide in 
methanol at 60 °C cleanly produced the deprotected cyclisation substrate 386 in a virtually quantitative 
yield (Scheme 159). Most importantly, no purification was required. 
 
 
 
 
 
Scheme 159. Optimised Boc deprotection. 
 
 The cyclisation reaction of substrate 386 proceeded very fast and delivered the 1-aryl 
tetrahydroisoquinoline 385 in 90% yield (Scheme 160) as a predominantly single diastereoisomer. 
 
 
 
 
 
Scheme 160. Optimised benzhydryl cyclisation. 
 
 With the new, optimised conditions it was possible to synthesise several of the benzhydryl 
analogues and perform their cyclisation. Reaction of the aldehyde 302 with 4-fluorophenylmagnesium 
produced the mixture of Boc protected products 387 and 388 which were then converted to the 
fluorinated tetrahydroisoquinoline 389 in 90% yield over two steps (Scheme 161). 
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Scheme 161. Fluoroaryl benzhydryl cyclisation. 
 
 Similarly, reaction of the aldehyde 302 with 4-methoxyphenylmagnesium bromide gave 
compounds 390 and 391 as a mixture which was treated with sodium hydroxide and then triflic acid to 
provide the THIQ product 392 in an overall 86% yield over 3 steps (Scheme 162). Interestingly, the 
activating properties of the methoxy group allowed for the reaction to reach completion in one minute and 
gave the product as a single diastereoisomer. 
 
 
 
 
 
 
 
Scheme 162. Synthesis and cyclisation of a methoxylated benzhydryl derivative. 
 
 The ultimate goal of this approach was to introduce a heterocyclic moiety in the 1-position to 
potentially synthesise a novel family of compounds and access a new, previously unexplored chemical 
space (Scheme 163). The reaction conditions used to achieve the hydroamination reaction are relatively 
mild and it is highly possible that moieties such as 2-methylfuran or thiophene would survive the 
transformation. 
 
 
 
 
Scheme 163. Potential future work in the benzhydryl family. 
 
 In conclusion, a short synthesis of 1-aryl substituted tetrahydroisoquinoline alkaloids was 
devised. The starting material (aldehyde 302) can be accessed in 3 steps from commercially available 
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acetals of 2-bromobenzaldehyde and 1-tosyl aziridines in a good yield. The condensation of the aldehyde 
with a Grignard reagent and subsequent removal of the Boc protecting group was optimised, as well as 
the final cyclisation to afford several 1-aryl tetrahydroisoquinoline alkaloids in very good yields. 
 
3.7 Aporphine Skeleton 
 
 The aporphine nucleus consists of four 6-membered rings, including one nitrogen atom – as in 
393. They form a family of compounds which often possess divergent biological properties and exert 
anticolvunsant activity. Glaucine 394 is an aporphine alkaloid found in several species of Papaveraceae 
family
207
 which displays antifungal and anti-inflammatory properties and is used as antitussive medicine 
in several countries.
208
 It is also a psychoactive drug and can produce hallucinogenic effects. Nuciferine 
395 is a pharmacologically active compound which acts by blocking dopamine receptors and can induce 
sedation, hypothermia and catalepsy.
209
 
 
 
 
 
 
 
 
Scheme 164. Aporphine alkaloids. 
 
 It was envisioned that the acid catalysed hydroamination methodology could be applied to build 
the tetrahydroisoquinoline part of an aporphine moiety. Cyclisation of substrate 398 would deliver the 
intermediate 397 which would then need to be ring-closed. Often, a Pschorr reaction, the intramolecular 
variant of the Gomberg-Bachman
210
 reaction, or a radical tin-mediated coupling would be employed to 
connect such two rings to form a biaryl system; however, a literature search revealed that a palladium-
mediated ortho-arylation
211
 reaction should easily furnish the tetracyclic core of 396. A simple 
retrosynthetic analysis is shown below (Scheme 165). 
 
 
 
 
 
Scheme 165. Retrosynthetic analysis of compound 396. 
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 The synthesis started with preparation of the cyclisation substrate 397, which was assembled in 
two steps via a Wittig reaction of aldehyde 302 to give alkene 396, which was isolated in 79% yield. 
Subsequent deprotection of the Boc group with excess of trifluoroacetic acid delivered compound 397 in 
86% yield. 
 
 
 
 
 
 
Scheme 166. Synthesis of cyclisation precursor 397. 
 
 The cyclisation reaction in presence of 0.4 equivalents of triflic acid in refluxing dichloroethane 
proceeded smoothly and tetrahydroisoquinoline 398 was obtained in 70% yield as a 9:1 mixture of 
isomers. Ortho-arylation with palladium acetate in dimethylacetamide gave compound 399 in 67% yield 
(Scheme 167). The yield of the final step could most likely be improved, since a large amount of 
literature covering the topic of inter- and intramolecular arylations is published every year. 
 
 
 
 
 
 
Scheme 167. Synthesis of cyclisation precursor 397. 
 
 In conclusion, the previously synthesized aldehyde intermediate 302 was transformed into the 
aporphine derivative 399 in four steps. Yields for each transformation were over 65% and the final 
product 399 was synthesized in 32% yield, starting from 302. 
 
3.8 Berberinone and Berberine Alkaloids 
 
 Another fused, heterocyclic ring system which was synthesized via the Knight’s hydroamination 
methodology was berberine core 400. The actual berberine alkaloid 401 (Scheme 168), which belongs to 
the protoberberine alkaloids family and is also known as umbellatine, can be found in the roots, stems and 
bark of several families of plants, e.g. berberis, Coptis chinensis or Phellodendron amurense. Berberine 
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is a dietary supplement available without prescription and has been used as traditional medicine in China. 
Pharmacologically, it was shown to exhibit a wide range of various activies such as antifungal
212
 and anti-
inflammatory
213
, antitumour
214
 and anticancer.
215
 Berberine has also been shown to reduce elevated blood 
glucose
216
 and has been successfully applied in the treatment of type 2 diabetes
217
 and dyslepidemia.  
 
 
 
 
 
Scheme 168. Berberine core and barberine alkaloid. 
 
 It was thought that the berberine skeleton could be synthetically accessed via the reduction of 
berberinones 402, which could be in turn made from tetrahydroisoquinolylbenzoate esters 403. It was 
previously shown that remote esters survive the cyclisation conditions and thus exposing compounds such 
as 404 to triflic acid should result in formation of the tetrahydroisoquinoline heterocyclic system. 
 
 
 
 
 
Scheme 169. Synthesis of cyclisation precursor 397. 
 
 Closer examination of the synthetic routes to intermediate 403 (Scheme 170) revealed that a 
possible condensation of a dianion of o-toluic acid 404 with aldehyde intermediates 405, followed by 
dehydration and deprotection would deliver the required cyclisation substrates 406 
 
 
 
 
 
 
Scheme 170. Synthesis of cyclisation precursor 397. 
 
 The condensation reaction was found to be self-titrating and relatively easy to perform. Excess of 
the deep-red dianion 404 would be prepared and then transferred via a cannula to a solution of aldehyde 
302 until the red colour persisted. 
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Scheme 171. Condensation reaction. 
 
 Careful analysis of the crude mixture revealed that the condensation reaction proceeded very well 
but several different species were formed during the reaction (Scheme 171). The migration of the Boc 
group, previously reported in the benzhydryl series, was observed, as well as complete deprotection of the 
Boc group – most likely due to excess dianion 404 reacting with the carbonyl moiety of the carbamate 
group. Some dehydrated, alkene product could also be detected. Attempts to fully dehydrate and deprotect 
all compounds from the crude mixture to afford the final product 406 failed and only resulted in isolation 
of compounds 407 and 408. Further optimisation revealed that the most effective way to access the target 
berberinone 409 involved exposing the entire crude mixture from the condensation reaction to 1.5 
equivalents of triflic acid in refluxing toluene over 16-24 hours. This resulted not only in a global 
dehydration and Boc-deprotection, but also in a loss of the tosyl group during the cyclisation. Two 
possible mechanisms involving an intramolecular tosyl group loss and lactamisation followed by 
hydrolysis of tosyl group are shown below (Scheme 172). This treatment delivered the tetracyclic lactam 
409 in 65% yield. The final product was obtained as a 4:1 mixture of diastereoisomers, however, a single 
recrystallization afforded exclusively the major, cis-isomer in an overall 45% yield.  
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Scheme 172. Two-step synthesis of a berberine moiety and two tentative mechanisms for loss of tosyl group. 
 
 An X-Ray crystal structure was obtained for the compound and ultimately proved that the 
thermodynamic product of the acid-catalysed hydroaminations is the 1,3-cis diastereoisomer. The 
hydrogen atom on the bridge is pointing in the opposite direction to the ethyl substituent on the carbon 
next to the nitrogen.  
 
 
 
 
 
 
 
 
 
 
Figure 20. X-Ray structure of berberinone 409. 
 
 An identical reaction sequence was applied to aldehyde 300b. Condensation of 300b with the 
dianion of o-toluic acid and subsequent treatment of the crude reaction mixture with triflic acid in 
refluxing toluene delivered the analogous berberinone 410 in a two process in 76% yield (Scheme 173). 
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Scheme 173. Synthesis of berberinone 410. 
 
 The ultimate goal of the synthetic sequence was to reduce the berberinones to the corresponding 
berberines. This step is already known in the literature and the transformation was easily achieved using 
lithium aluminium hydride in refluxing tetrahydrofuran over 1 hour. The unsubstituted product 412 was 
obtained in 91% yield and the ethyl-substituted compound 411 was synthesized in 62% yield. 
 
 
 
 
 
 
Scheme 174. Reduction of berberinones 409 and 410 to berberines 411 and 412. 
 
3.9 Conclusions 
 
 A modified protocol of Knight’s hydroamination was successfully applied in the synthesis of a 
number of electron-rich, polymethoxylated THIQ alkaloids, analogues of which can often be found in 
nature. Efficacious hydroamination of a cyclisation substrate containing a terminal, monosubstituted 
double bond ultimately led to a short, formal synthesis of racemic salsolidine. A successful acid-catalyzed 
hydroamination carried out in presence of a free alcohol and, also, on a substrate with an acetate-
protected OH group allowed accessing a synthetic intermediate which could potentially lead to synthesis 
of racemic crispine-A. A hydroamination of an ortho-bromo substituted derivative followed by an ortho 
arylation reaction opened up a synthetic pathway to a tetracyclic aporphine skeleton. Finally, a novel, 
double cyclisation involving a hydroamination step and a lactam formation from a tertiary, N-tosyl 
substituted nitrogen atom opened up an interesting synthetic pathway towards the berberinone alkaloids 
and eventually delivered berberines. These efforts ultimately proved that triflic acid catalysed, 
intramolecular 6-exo-trig hydroamination of alkenes with activated amines is a powerful protocol that has 
been effectively used to access a variety of sterically hindered N-heterocyclic compounds. 
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Chapter 4: Challanges and Future Work 
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4.1 Addition to Grignard reagents 
 
 A large amount of time was dedicated to successfully perform an addition of a Grignard reagent 
to a homobenzylic nitrile
218
, potentially yielding the corresponding substituted imine, which in turn could 
be reduced in a one pot-manner and would provide a quick access to the substituted phenylethylamines. 
The idea was based on a number of similar experiments previously reported in the literature (Scheme 
175).
219
  
 
 
 
 
Scheme 175. Condensations of nitriles with Grignard reagents. 
 
 Unfortunately, none of the reactions performed delivered any of the desired products and only 
complex reaction mixtures or starting material could be recovered. Addition of copper,
220
 changing the 
solvent or increasing the temperature had no positive effect on the reaction and no product could be 
observed at any point in any of the crude reaction mixtures. After extensive experimentation the nitrile 
route was abandoned. Interestingly, in case of the 2-iodobenzonitrile experiments, magnesium-halogen 
exchange was observed and the de-iodinated product was exclusively obtained in the reaction (Scheme). 
 
4.2 Isoquinuclidines 
 
 Isoquinuclidines form a family of pharmacologically active compounds and are also valuable 
synthetic intermediates in the synthesis of alkaloids and various pharmaceutical products. A good 
example is catharantine 413, which is a precursor in the biological and laboratory synthesis of vinblastine. 
Recently, the topic of trans-annular cyclisations (Scheme 180) of cyclohexene derivatives such as 414 is 
being revisited in the Knight group to access compounds such as 415.  
 
 
 
 
 
 
 
Scheme 180. Trans-annular cyclisations. 
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 A lot of effort was dedicated towards developing a quick synthesis of cyclisation substrates to be 
able to quickly probe if the trans-annular cyclisations of these substrates would deliver the bicyclic 
products. The structure of these compounds looks relatively simple, as the basic skeleton is based on a 
cyclohexene ring and a single ethylamino- substituent. The synthesis of such compounds, however, is not 
trivial and often involves Birch reduction-type processes or long sequences of transformations (Scheme 
181). The first route to the substrate 416 consisted of 7 steps and involved a Wittig reaction followed by 
hydrogenation, deprotection of the acetal group, condensation with a Grignard reagent, dehydration, 
hydrolysis and a Curtius rearrangement. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 181. Preparative chemistry: route 1. 
  
 The second route (Scheme 182), which was being developed parallel to the first one, was based 
on a double Michael addition of ethylacetoacetate to ethyl acrylate, a Dieckman cyclisation, 
decarboxylation, double protection of the acetal and ester, ester reduction, tosylation and azide 
displacement, hydrogenation to primary amine, protection with a tosyl group, acetal deprotection and then 
condensation followed by dehydration of the alcohol. That was approximately 10 synthetic steps. 
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Scheme 182.Preparative chemistry: route 2. 
 
 At this stage we have discovered that the synthesized compounds are very stable and indeed very 
resistant to the cyclisation (Scheme 183). Even under the most forcing conditions i.e. refluxing 1,2-
dichloroethane or refluxing toluene with catalytic or excess quantities of triflic acid delivered no cyclised 
product whatsoever. No cyclisation and no decomposition was observed - only the starting material was 
recovered. 
 
 
 
 
 
. 
 
 
Scheme 183.Trans-annular cyclisation attempt. 
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 This was very disappointing, as the Knight group had plenty of success
221
 in the synthesis and 
hydroaminations of very similar molecules in the past. 
 
4.3 Phenanthrenes 
  
 An alternative way which could lead to the tetracyclic hydroamination products was also 
examined by the Knight group. It was thought that cyclisation of phenanthrylethylamine compounds 
could deliver the aporphine alkaloids (Scheme 184). The synthesis of the cyclisation precursor was 
relatively straightforward and involved a ring-opening of an aziridine with a Grignard reagent derived 
form 2-bromophenanthrene. 
  
 
 
 
 
Scheme 184.Phenanthrylethylamines - cyclisation attempt. 
 
 Unfortunately, no product could be obtained in the cyclisation, even under very harsh reaction 
conditions. Only starting material could be recovered after prolongued refluxing in dichloromethane or 
dichloroethane. A long reaction in toluene with excess triflic acid yielded only impurities which were 
later disovered to be Friedel-Crafts adducts from a reaction of the starting material with the solvent. 
 It was thought that the idea of obtaining an aporphine ring in a hydroamination reaction could be 
realized on a more reactive, methoxy-substituted substrate.  
 
 
 
 
Scheme 184.Phenanthrylethylamines – alternative substrates. 
 
Due to time constrictions, this was never attempted in the laboratory. 
 
4.4 Indoles 
 
 An attempt was also made to extend the Knight’s hydroamination chemistry to the synthesis of 
carbolines, as it was also the case with the classic Pictet-Spengler reaction. The starting material was 
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quickly accessed by tosylation and bromination of tryptamine, followed by a Suzuki reaction (Scheme 
185). 
 
 
 
 
 
 
 
 
Scheme 185.Indoles - cyclisation attempt. 
 
 Even though a full disappearance of starting material was observed during the hydroamination 
attempts, no product could be isolated. HPLC analysis of the crude reaction mixture revealed that the 
material formed during the reaction is extremely greasy and non-polar and most likely is a dimeric or 
polymeric derivative of the starting material. Further attempts to synthesise the product using molecular 
iodine or sulfuric acid also failed and this area of research was abandoned. 
 It is possible that the free N-H bond of the indole is responsible for much higher reactivity of the 
system and hence the inability of the hydroamination reaction to proceed. Protection of the nitrogen group 
with an electron withdrawing group, such as sulfonamides, could potentially lead to a successful 
cyclisation outcome. This was, however, never attempted in the laboratory. 
  
4.5 Conclusions 
 
 Countless nitrogen-containing compounds are being synthesized every day by different academic 
groups, research institutions and industrial companies. New, more atom-efficient, greener and superior 
reaction protocols for synthesis of N-heterocycles are being developed. The area of intramolecular and 
intermolecular hydroamination, due to its atom-efficiency, is very popular and there is much more needed 
to be done in this particular field of research. Expanding the Knight’s hydroamination to more advanced 
azasteroids, application in the synthesis of spiro-derivatives and accessing more advanced natural product 
are of high interest. More detailed investigation of the reaction mechanism, deuterium labelling studies 
and stereochemical outcome of the reaction would also be very interesting. Performing the reaction on 
more electron-poor cyclisation substrates and exposing analogues with fragile functional groups to the 
reaction conditions would expand the scope of the reaction.  
 In general, the novel hydroamination methodology could provide new synthetic pathways to a 
range of heterycyclic systems in the pharmaceutical sector. Overall, this chemistry is very useful in 
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synthesis of sterically hindered, cyclic amines, which can sometimes be difficult to prepare. There are, 
arguably, too many different themes and potential research areas within the topic to try and cover them 
all, which also demonstrates the potential synthetic utility of this transformation. 
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Chapter 5: Experimental 
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5.1 General Remarks 
 
Reagents were obtained from Aldrich, Alfa Aesar, Lancaster, Across, Fluka, Rieke, and Fluorochem 
chemical companies and used as received unless otherwise stated. Solvents and reagents were purified 
according to the procedures of Armarego and Perrin.
222
 Dichloromethane was dried by distilling over 
calcium hydride under a nitrogen atmosphere. Anhydrous tetrahydrofuran was obtained by refluxing over 
sodium with benzophenone as indicator, followed by distillation or from Sigma-Aldrich (99.9%, 
anhydrous) and titrated on a Karl Fischer still for water content below 0.05%. “Petrol” and “petroleum 
ether” refer to petroleum ether, b.p. 40-60 °C. All aqueous solutions were saturated unless otherwise 
stated. “Dried” refers to the addition of dried magnesium sulfate or sodium sulfate to remove trace 
amounts of water. “Filtered” refers to the removal of solid residues by gravity filtration of organic 
solutions through filter paper. “Evaporated” refers to the distillation of volatiles using a Büchi rotary 
evaporator attached to a 20 L Charles Austen pump operating at approx 15 mbar, heated with a water bath 
typically between 20 and 40 °C. “Degassed” refers to bubbling N2 through the solvent for a minimum of 
30 minutes. All reactions using air/moisture sensitive reagents were performed in oven-dried apparatus, 
under a nitrogen atmosphere.  Solid carbon dioxide and an acetone bath (-78 °C), methanol-ice bath (-20 - 
-15 °C) and an ice-water bath (0 - 5 °C) were used to obtain low temperatures. Heated reactions were 
conducted in a stirred oil bath heated on a magnetically stirred hotplate.  All reactions were followed and 
monitored by HPLC, TLC, 
1
H NMR, 
13
C NMR and mass spectrometry as appropriate. TLC analysis 
refers to analytical thin layer chromatography, using aluminium-backed plates coated with Merck 
Kieselgel 60 GF254.  Product spots were viewed under 254/365 nm UV lamp, by developing in a 2% 
aqueous potassium permanganate solution or 5% solution of phosphomolybdic acid in ethanol. Column 
chromatography refers to flash column chromatography using head pressure by means of compressed air 
according to the procedure of Still,
223
 and using Merck Kieselgel 60 H silica or Matrix silica 60. Melting 
points were recorded using a Kofler Heated Stage Micro Melting Point Apparatus and are uncorrected. 
Infra-red spectra were recorded in the range 4000-600 cm
-1
 using a Perkin-Elmer 1600 series Fourier 
Transform Infrared Spectrometer, as liquid films between sodium chloride plates [film], unless otherwise 
stated, in which case samples were run as a solution in dichloromethane [DCM] between sodium chloride 
plates. All absorptions are quoted in wave numbers (cm
-1
). Proton (
1
H) NMR spectra were recorded using 
an Avance Bruker DPX 500 (500 MHz) instrument, with carbon (
13
C) NMR spectra recorded at 126 MHz 
unless otherwise stated, in which case 
1
H NMR spectra were recorded using an Avance Bruker DPX 400 
instrument (400 MHz) with carbon (
13
C) NMR spectra recorded at 101 MHz or an Avance Bruker DPX 
250 instrument (250 MHz). Spectra were obtained as dilute solutions in deuterated chloroform, unless 
otherwise stated, in which case spectra were obtained in dilute solutions of fully deuterated methanol 
(CD3OD). The chemical shifts were recorded relative to residual chloroform (7.26 ppm or 77.16 ppm) as 
an internal standard unless otherwise stated, in which case spectra were obtained in fully deuterated 
dimethyl sulfoxide (DMSO-d
6
). Abbreviations used for the multiplicities are s (singlet), d (doublet), t 
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(triplet), q (quartet), bs (broad singlet), dd (doublet of doublets), dt (doublet of triplets), td (triplet of 
doublets), quin (quintet), sext (sextet), sept (septet), m (unresolved multiplet), app. (apparent) or as a 
combination of these multiplicities. All coupling constants (J) are recorded in Hertz (Hz), are quoted as 
seen and are not adjusted. Assignments were made on the basis of chemical shift and coupling constant 
data using DEPT-90, DEPT-135, COSY, NOESY, HSQC and HMBC experiments where required. Mass 
spectrometric data were determined using a Waters GCT Premier instrument using electron ionisation 
(EI) unless otherwise stated, in which case such data were determined by a Waters LCT Premier XE 
instrument (LRMS) using atmospheric pressure chemical ionisation (APCI) or electrospray ionisation 
(ES).  High resolution mass spectrometric data were determined with the molecular formula 
corresponding to the observed signal using the most abundant isotopes of each element. A literature 
reference associated with title of compound means it is not a novel compound and any data recorded in 
this thesis matches well with those reported in the associated references, unless otherwise stated. 
 
5.2 General Procedures 
 
General Procedure A1: Wittig Reaction with t-BuOK
224
 
 To a suspension of a triphenylphosphonium salt (1.0 – 2.5 eq.) in tetrahydrofuran (10 mL per 1 g 
phosphonium salt) at 0 °C was added solid potassium tert-butoxide (1.1 – 2.7 eq., 1.1 eq. of phosphine 
salt) portionwise, over five minutes. The reaction mixture was stirred for a further 0.5 h at 0 °C after 
which the aldehyde (1.0 eq.) was added as a solution in tetrahydrofuran (5 mL per 1 g aldehyde) 
dropwise, over 1-5 minutes. The cooling bath was removed and the mixture allowed to warm to room 
temperature overnight (~16 h). The reaction was quenched by addition of aqueous ammonium chloride (1 
volume) and the separated aqueous layer extracted with ethyl acetate or diethyl ether (3 x 1 volume). The 
combined organic extracts were washed with brine, dried, filtered and evaporated. 
 
General Procedure A2: Wittig Reaction with n-BuLi 
 To a suspension of a triphenylphosphonium salt (1.0 – 2.5 eq.) in tetrahydrofuran (10 mL per 1 g 
phosphonium salt) at -78 °C was added n-butyllithium (1.6 – 2.5 M in hexanes, 1.1 – 2.7 eq., 1.1 eq. of 
phosphine salt) dropwise, over five minutes. The reaction mixture was stirred for a further 0.5 h at  
-78 °C after which the aldehyde (1.0 eq.) was added as a solution in tetrahydrofuran (5 mL per 1 g 
aldehyde) dropwise, over 5 – 10 minutes. The cooling bath was removed and the mixture allowed to 
warm to room temperature overnight (~16 h). The reaction was quenched by addition of aqueous 
ammonium chloride (1 volume) and the separated aqueous layer extracted with ethyl acetate or diethyl 
ether (3 x 1 volume). The combined organic extracts were washed with brine, dried, filtered and 
evaporated. 
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General Procedure B: Sulfonamide Protection of an Amine 
 The amine (1.0 eq.) was dissolved in dry dichloromethane (1 mL per 1 mmol) and the solution 
cooled to 0 °C. Triethylamine (1.1 eq.) was added, followed by 4-(dimethylamino)pyridine (a few 
crystals, 1-2 mg) and methanesulfonyl chloride, p-nitrobenzenesulfonyl chlroride or  p-toluenesulfonyl 
chloride (1.05 eq.). The cooling bath was removed and the reaction was allowed to warm to room 
temperature overnight (~16 h). The reaction mixture was then washed with water (1 volume), aqueous 
hydrochloric acid (2M, 1 volume) and aqueous sodium bicarbonate (1 volume), then dried, filtered and 
evaporated. 
 
General Procedure C: Boc Protection of Sulfonamide 
 The sulfonamide (1.0 eq.) was dissolved in dry dichloromethane (1 mL per 1 mmol) at room 
temperature. Dimethylaminopyridine (0.3 eq.) and di-tert-butyl dicarbonate (1.2 eq.) were then added and 
the reaction mixture was allowed to stir at ambient temperature for 3 – 6 h. The reaction was quenched by 
addition of water and stirred vigorously for 0.5 h. The separated organic phase was then washed with 
water (2 x 1 volume), aqueous sodium bicarbonate (1 volume) and brine (1 volume), then dried, filtered 
and evaporated. 
 
General Procedure D: Suzuki Reaction 
 The aryl bromide or iodide (1.0 eq.), a vinylboronic acid or vinylboronic pinacol ester (1.1-1.5 
eq.), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (0.01 – 
0.1 eq.), potassium phosphate (2.0 – 3.0 eq.) were added sequentially to a degassed 1:1 water/ethanol 
solution (1ml per 100 mg aryl bromide/iodide) under an atmosphere of nitrogen and degassed for further 
10 minutes. The mixture was then heated (40-100 °C) and stirred for the desired amount of time (1-12 h). 
Upon completion, the mixture was allowed to cool to ambient temperature and partitioned between 
dichloromethane (1 volume) and water (1 volume). The separated aqueous phase was extracted with 
dichloromethane (3 x 1 volumes) and the combined organic extracts washed with brine (1 volume), dried, 
filtered and evaporated. 
 
General Procedure E: Preparation of LDA 
 To a stirred solution of diisopropylamine (1.0 eq.) in tetrahydrofuran (1 mL per 0.5 mL 
diisopropylamine) at -78 °C was added a solution of n-butyllithium (1.1 eq.). The mixture was kept at  
-78° C for 15 minutes and then at 0 °C for a further 15 minutes. 
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General Procedure F: Modified Kabalka’s Nitroalkene Reduction 
 Monitoring of the internal reaction temperature is recommended if this reaction is carried out on 
large scale. To the suspension of sodium borohydride (4.75 eq) in tetrahydrofuran (10 mL per 10 mmol 
NaBH4) under an atmosphere of nitrogen at 0 °C was added boron trifluoride diethyl etherate (6 eq.) 
dropwise, over several minutes (caution: exothermic!). The ice-bath was then removed and the reaction 
was stirred for 15 minutes. The nitroalkene (1 eq.) was then added as a solution in tetrahydrofuran (5 mL 
per 2 mmol nitroalkene) and the resulting mixture heated to reflux for 6 h. After cooling to room 
temperature, the reaction was quenched by slow (caution: exothermic!) addition of cold water (25 mL per 
10 mmol nitroalkene), then acidified with hydrochloric acid (2M, 25 mL per 10 mmol of nitroalkene), 
heated to reflux for a further hour and allowed to cool to ambient temperature. The resulting aqueous 
solution was washed with diethyl ether (3 x 25 mL per 10 mmol nitroalkene) and then basified using 
aqueous sodium hydroxide (pH 14) and extracted with chloroform (3 x 25 mL per 10 mmol nitroalkene). 
The combined chloroform extracts were washed once with brine (1 volume), dried, filtered and 
evaporated. 
 
General Procedure G: Fieser lithium aluminium hydride reduction work-up
225
 
 The reaction mixture was cooled to 0 °C and vigorous stirring applied. Carefully (caution: 
exothermic!), water (1 mL per 1 g LAH) was added dropwise, followed by 15% sodium hydroxide 
solution (1 mL per 1 g LAH) and again water (3 mL per 1 g LAH). The granular, inorganic precipitate 
was then filtered off on a Buchner funnel and the filter cake washed with diethyl ether. The resulting 
filtrate was then dried, filtered and evaporated. 
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5.3 Experimental Data 
 
2-Ethyl-1-tosylaziridine
226
 154  
 
 
 
2-Amino-1-butanol 155 (1.5 g, 16.83 mmol, 1.0 eq.) was dissolved in dichloromethane (20 mL) and the 
solution cooled to 0 °C. Triethylamine (5.11 g, 50.05 mmol, 3.0 eq.) was added, followed by DMAP (a 
few crystals, 1-2 mg) and p-toluenesulfonyl chloride (8.02 g, 42.08 mmol, 2.5 eq.). The cooling bath was 
removed and the reaction was allowed to warm to ambient temperature overnight (~16 h), and then 
washed with water (25 mL), HCl (2M, 25 mL) and aqueous sodium bicarbonate (25 mL), then dried, 
filtered and evaporated. The crude material was purified by column chromatography (ethyl acetate/petrol 
1:5) to give the aziridine 154 (1.82g, 48%) as a colourless oil; δH (400 MHz) 7.82 (2H, d, J 8.3, 2 x ArH), 
7.33 (2H, d, J 8.0, 2 x ArH), 2.69 (1H, m, CHN), 2.62 (1H, app. d, J 7.0, CH2aN), 2.44 (1H, s, ArCH3), 
2.07 (1H, app. d, J 4.6, CH2bN), 1.65 – 1.54 (1H, m, CH2aCH3), 1.41 – 1.28 (1H, m, CH2bCH3), 0.83 (1H, 
t, J 7.4, CH2CH3); LRMS (EI
+
) m/z 225 ([M]
+
, 5%), 155 ([Ts]
+
 45%), 70 ([M-Ts]
+ 
100%); HRMS (APCI) 
calculated for C11H16NO2S [M+H]
+
 226.0902, found 226.0891. 
 
2-Benzyl-1-tosylaziridine
227
 163  
 
 
 
2-Amino-3-phenylpropan-1-ol (2.0 g, 13.23 mmol, 1.0 eq.) was dissolved in acetonitrile (40 mL) and the 
solution cooled to 0 °C. Triethylamine (4.02 g, 39.69 mmol, 3.0 eq.) was added, followed by 
dimethylaminopyridine (150 mg) and p-toluenesulfonyl chloride (6.30 g, 33.07 mmol, 2.5 eq.). Cooling 
bath was removed and the reaction was allowed to warm to room temperature overnight (~16 h). The 
reaction was then concentrated under reduced pressure and partitioned between ethyl acetate (40 mL) and 
ammonium chloride (30 mL). The organic phase was then washed with water (25 mL), 2M HCl (25 mL) 
and sodium bicarbonate (25 mL), then dried, filtered and evaporated. The crude material was purified by 
recrystallization from ethanol to give the aziridine 163 as a white solid (2.12g, 56%); m.p. 90 - 93 °C (lit. 
m.p.
227
 94-95 °C); δH 7.71 (2H, d, J 8.3, 2 x ArH), 7.24 (2H, d, J 8.4, 2 x ArH), 7.21 – 7.18 (3H, m, 3 x 
ArH), 7.18 (1H, d, J 1.8, ArH), 7.08 (1H, d, J 2.0, ArH), 7.07 - 7.05 (1H, m, ArH), 2.99 – 2.97 (1H, m, 
NCH), 2.83 (1H, dd, J 14.9 and 5.2, NCH2a), 2.72 (2H, dd, J 15.2 and 7.0, NCH2b), 2.72 - 2.71 (1H, m, 
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ArCH2b), 2.45 (3H, s, ArCH3), 2.18 (1H, d, J 4.5, ArCH2b); δC 144.4 (C), 137.15 (C), 135.1 (C), 129.7 (2 
x ArCH), 128.9 (2 x ArCH), 128.6 (2 x ArCH), 128.0 (2 x ArCH), 126.65 (ArCH), 41.3 (NCH), 37.65 
(NCH2), 33.0 (ArCH2), 21.7 (ArCH3). 
 
(E/Z)-1-Bromo-2-(prop-1-en-1-yl)benzene
228, 229
 176 
 
 
 
 
Ethyltriphenylphosphonium bromide (2.74 g, 7.39 mmol) was treated with potassium tert-butoxide (1.02 
g, 9.06 mmol) and 2-bromobenzaldehyde 136 (1.24 g, 6.72 mmol) according to general procedure A1. 
The crude material was purified by column chromatography to yield alkene 176 (1.16 g, 88%) as a a pale 
yellow oil and as a 4:3 mixture of Z and E isomers; major (Z)-isomer δH 7.59 (1H, d, J = 8.0 Hz, ArH), 
7.32-7.28 (2H, m, ArH), 7.10 (1H, m, ArH), 6.49 (1H, d, J 11.4, ArCH=CH), 5.90 (1H, dq, J 11.6 and 
7.1, ArCH=CH), 1.79 (3H, dd, J 7.1 and 1.7,CH3); minor (E)-isomer δH 7.53 (1H, d, J 8.0, ArH), 7.48 
(1H, d, J 7.8, ArH), 7.24 (2H, m, ArH), 7.04 (1H, m, ArH), 6.74 (1H, d, J 15.6, ArCH=CH), 6.19 (1H, 
dq, J 15.5 and 6.7, ArCH=CH), 1.94 (3H, dd, J 6.6 and 1.6, CH3). 
 
(E/Z)-4-Methyl-N-(1-(2-(prop-1-en-1-yl)phenyl)butan-2-yl)benzenesulfonamide 175 
 
 
 
 
Magnesium turnings (95 mg, 3.91 mmol, 2.2 eq.) were dry-stirred under an atmosphere of nitrogen for 24 
hours and then suspended in tetrahydrofuran (5 mL). The suspension was treated with a crystal of iodine 
and 1-bromo-2-(prop-1-en-1-yl)benzene 176 (700 mg, 3.56 mmol, 2.0 eq.) was added as a solution in 
tetrahydrofuran (3 mL). The reaction was stirred for a further 30 minutes, during which time 
decolourisation and disappearance of most of the magnesium turnings was observed. The solution was 
then cooled to -40 °C and copper (I) iodide (102 mg, 0.533 mmol, 0.3 eq.) was added. After a further 30 
minutes the reaction mixture was cooled to -78 °C and 2-ethyl-1-tosylaziridine 154 (400 mg, 1.78 mmol, 
1.0 eq.) in tetrahydrofuran (2 mL) was added. After 15 minutes, the reaction mixture was warmed to 0 °C 
and stirred for another 1.25 h, then quenched by aqueous ammonium chloride (10 mL) and the blue 
aqueous phase extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were washed with 
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brine (10 mL), dried, filtered and evaporated. The crude material was purified by column chromatography 
(dichloromethane/petrol, 1:1) to give sulfonamide 175 (751 mg, 71%) as colourless glass and as a 3.1:1 
mixture of Z and E isomers; νmax 3282 (br, NH); major (Z)-isomer δH (400 MHz) 7.58 (2H, d, J 8.2, 2 x 
ArH), 7.19 - 7.12 (3H, m, 3 x ArH), 7.09 (2H, d, J 7.1, 2 x ArH), 7.00 - 6.98 (1H, m, ArH), 6.35 (1H, d, J 
11.4, ArCH=CH), 5.80 (1H, dq, J 11.5 and 7.0, ArCH=CH), 4.56 (1H, d, J 7.6, NH), 3.32 - 3.29 (1H, m, 
NCH), 2.69 (1H, dd, J 13.5 and 7.5, ArCH2a), 2.63 (1H, dd, J 13.5 and 7.3, ArCH2b), 2.39 (3H, s, ArCH3), 
1.64 (3H, dd, J 7.0 and 1.7, CH=CHCH3), 1.55 - 1.46 (1H, m, CH3CH2a), 1.45 – 1.33 (1H, m, CH3CH2b), 
0.81 (3H, t, J 7.4, CH2CH3); δC (101 MHz) 143.0 (C), 137.85 (C), 136.7 (C), 136.2 (C), 130.35 (ArCH), 
130.0 (ArCH), 129.55 (2 x ArCH), 128.7 (ArCH=C), 128.1 (ArCH=C), 127.1 (2 x ArCH), 127.05 
(ArCH), 126.3 (ArCH), 56.2 (ArCH), 38.7 (CH2), 27.7 (CH2), 21.6 (ArCH3), 14.3 (CH3), 9.7 (CH3); 
LRMS (EI
+
) m/z 343 ([M]
+
, 6%), 213 ([n-PrNHTs]
+
, 100%), 172 ([M–NH2Ts]
+
, 10%); HRMS calculated 
for C20H25NO2S [M]
+
 343.1606, found 343.1600; minor (E)-isomer δH (400 MHz) 7.29 (1H, d, J 7.6, 
ArH), 6.94 (1H, d, J 7.5, ArH), 6.56 (1H, d, J 15.5, ArCH=CH), 5.98 (1H, dq, J 15.3 and 6.6, 
ArCH=CH), 4.51 (1H, d, 7.5, NH), 2.84 (1H, dd, J 13.8 and 6.9, ArCH2a), 2.72 (1H, dd, J 13.7 and 7.5, 
ArCH2b), 2.39 (3H, s, ArCH3), 1.90 (3H, dd, J 6.6 and 1.5, CH=CHCH3), 0.77 (3H, d, J 7.5, CH2CH3) 
only 10 distinct peaks; δC (101 MHz) 143.0 (C), 137.6 (C), 137.3 (C), 134.6 (C), 130.75 (ArCH), 128.5 
(ArCH=C), 128.2 (ArCH=C), 127.0 (ArCH), 127.0 (ArCH), 126.9 (ArCH), 126.3 (ArCH), 56.1 (ArCH), 
38.9 (CH2), 27.6 (CH2), 18.85 (CH3), 9.7 (CH3) only 16 distinct peaks; HRMS calculated for C20H25NO2S 
[M]
+
 343.1606, found 343.1609 
 
1,3-Diethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 178 
 
 
 
 
Method 1: 
The sulfonamide 175 (127 mg, 0.370 mmol, 1.0 eq.) was dissolved in dichloromethane (1.3 mL) under 
atmosphere of nitrogen and the solution cooled to 0 °C. To this was added triflic acid (22 mg, 0.148 
mmol, 0.4 eq.). The resulting solution was stirred for 5 minutes at 0 °C and then kept at 21 °C for 2 hours. 
It was then cooled to room temperature and quenched with aqueous potassium carbonate (2 mL), 
extracted with dichloromethane (3 x 5 mL) and the combined extracts dried, filtered and evaporated. The 
crude material was purified by column chromatography (petrol/dichloromethane 1:1) to give unreacted 
starting material 175 (70 mg, 55%) as the cis isomer and sulfonamide 178 (51 mg, 40%) as a clear oil, as 
a mixture of 1:2 cis and trans diastereomers; νmax 3055 (br., NH); major (trans)-diastereoisomer δH 7.65 
(2H, d, J 8.3, 2 x ArCH), 7.16 (2H, d, J 8.1, 2 x ArCH), 7.15 – 7.10 (2H, m, ArH), 7.06 – 7.02 (2H, m, 
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ArH), 4.85 (1H, t, J 6.9, ArCHN), 3.89 – 3.82 (1H, m, ArCH2CH), 2.85 (1H, dd, J 15.9 and 4.5, ArCH2a), 
2.65 (1H, dd, J 15.9 and 6.7, ArCH2b), 2.36 (3H, s, ArCH3), 2.03 – 1.91 (2H, m, 1’-CH2a and 1’’-CH2a), 
1.78 – 1.65 (1H, m, 1’-CH2b), 1.31 – 1.20 (1H, m, 1’’-CH2b), 0.84 (3H, t, J 7.4, 2’-CH3), 0.79 (3H, t, J 
7.4, 2’’-CH3); δC 142.65 (C), 140.1 (C), 137.4 (C), 133.6 (C), 129.4 (2 x ArCH), 128.9 (ArCH), 127.1 
(ArCH), 127.0 (2 x ArCH), 126.9 (ArCH), 126.75 (ArCH), 126.2  (ArCH), 60.8 (CH), 56.2 (CH), 32.0  
(CH2), 30.35 (CH2) , 26.6 (CH2), 21.5  (ArCH3), 11.4 (CH3), 10.7 (CH3); minor (cis)-diastereoisomer νmax 
3054 (br, NH); δH 7.41 (2H, d, J 8.3, 2 x ArCH), 7.04 – 6.98 (2H, m, 2 x ArH), 6.97 (2H, d, J 8.0, 2 x 
ArH), 6.89 (1H, d, J 7.2, ArH), 6.83 (1H, d, J 7.0, ArH), 4.72 (1H, dd, J 8.6 and 6.9, ArCHN), 3.78 – 
3.74 (1H, m, ArCH2CH), 2.73 (1H, dd, J 15.8 and 7.2, ArCH2a), 2.58 (1H, dd, J 15.8 and 8.5, ArCH2b), 
2.25 (3H, s, ArCH3), 2.11 (1H, m, 1’’-CH2a), 1.86 (1H, m, 1’-CH2a), 1.78 – 1.65 (2H, m, 1’-CH2b and 1’’-
CH2b), 1.09 (3H, t, J 7.4, 2’-CH3), 1.03 (3H, t, J 7.5, 2’’-CH3); δC 142.65 (C), 137.5 (C), 136.8 (C), 132.8 
(C), 129.1 (2 x ArCH), 128.2 (ArCH), 127.3 (2 x ArCH), 126.95 (ArCH), 126.7 (ArCH), 126.0 (ArCH), 
60.2 (CH), 55.7 (CH), 32.2 (CH2), 31.6 (CH2), 30.1 (CH2), 21.4 (ArCH3), 11.7 (CH3), 10.7 (CH3); HRMS 
calculated for C20H25NO2S [M]
+
 343.1606, found 343.1607. 
 
Method 2: 
The sulfonamide 175 (127 mg, 0.370 mmol, 1.0 eq.) was dissolved in dichloromethane (1.3 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (22 mg, 0.148 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to reflux at 41 °C for 3 hours, 
then cooled to ambient temperature and quenched with aqueous potassium carbonate (2 mL), extracted 
with dichloromethane (3 x 5 mL) and the combined extracts dried, filtered and evaporated to give 
sulfonamide 178 (123 mg, 97%) as a clear oil and as a single cis diastereoisomer. All data obtained were 
in accordance with those reported before. 
 
1,3-Diethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 178 
 
 
 
 
 
The cis-sulfonamide 175 (51 mg, 0.149 mmol, 1.0 eq.) isolated from the previous reaction was dissolved 
in dichloromethane (0.5 mL) under an atmosphere of nitrogen and cooled to 0 °C. To this was added 
triflic acid (9.0 mg, 0.059 mmol, 0.4 eq.). The resulting solution was stirred for 5 minutes at 0 °C and 
then heated to reflux at 41 °C for 3 hours, then cooled to ambient temperature and quenched with aqueous 
potassium carbonate (1 mL), extracted with dichloromethane (3 x 3 mL) and the combined organic 
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extracts dried, filtered and evaporated to give sulfonamide 178 (49 mg, 96%) as a clear oil, as a single cis 
diastereoisomer. All data obtained were in accordance with those reported before. 
 
1,3-Diethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 178 
 
 
 
 
 
The 1:2 mixture of the cis and trans sulfonamide 178 (50 mg, 0.146 mmol, 1.0 eq.) from previous 
experiment was dissolved in dichloromethane (0.5 mL) under an atmosphere of nitrogen and cooled to  
0 °C. To this was added triflic acid (9 mg, 0.059 mmol, 0.4 eq.). The resulting solution was stirred for 5 
minutes at 0 °C and then heated to reflux at 41 °C for 3 hours, then cooled to room temperature and 
quenched with aqueous potassium carbonate (1 mL), extracted with dichloromethane (3 x 2 mL) and the 
combined organic extracts dried, filtered and evaporated to give sulfonamide 178 (47 mg, 94%) as a clear 
oil, as a single cis diastereoisomer. All data obtained were in accordance with those reported before. 
 
(E/Z)-1-Bromo-2-(2-methylprop-1-en-1-yl)benzene
230
 188 
 
 
 
 
Isopropyltripthenylphosphonium iodide (16.13 g, 37.3 mmol) was treated with potassium tert-butoxide 
(5.09 g, 45.4 mmol) and 2-bromobenzaldehyde 136 (6.00 g, 32.43 mmol) according to general procedure 
A1. The crude material was purified by column chromatography (petrol) to yield alkene 188 (5.00 g, 
73%) as a a pale yellow oil; δH (250 MHz) 7.58 (1H, d, J 7.8, ArH), 7.34 – 7.22 (2H, m, 2 x ArH), 7.14 – 
7.04 (1H, m, ArH), 6.28 (1H, s, ArCH=C), 1.96 (3H, d, J 1.3, CH3), 1.78 (1 H, d, J 1.2, CH3); δC (63 
MHz) 138.8 (C), 136.9 (C), 132.5 (ArCH), 131.1 (ArCH), 127.75 (ArCH), 126.9 (ArCH), 124.9 (ArCH), 
124.35 (C-Br), 26.3 (CH3), 19.4 (CH3). 
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4-Methyl-N-(1-(2-(2-methylprop-1-en-1-yl)phenyl)butan-2-yl)benzenesulfonamide 189 
 
 
 
Magnesium turnings (143.3 mg, 5.90 mmol, 2.2 eq.) were dry-stirred under an atmosphere of nitrogen for 
24 hours and then suspended in tetrahydrofuran (5 mL). The suspension was treated with a crystal of 
iodine and 1-bromo-2-(2-methylprop-1-en-1-yl)benzene 188 (1.13 g, 5.36 mmol, 2.0 eq.) added as a 
solution in tetrahydrofuran (5 mL). The reaction was stirred for a further 30 minutes, during which time 
decolourisation and disappearance of the most magnesium turnings was observed. The solution was then 
cooled to -40 °C and copper (I) iodide (153 mg, 0.804 mmol, 0.3 eq.) was added. After further 30 
minutes, the reaction mixture was cooled to -78 °C and 2-ethyl-1-tosylaziridine 154 (603 mg, 2.68 mmol, 
1.0 eq.) in tetrahydrofuran (5 mL) was added. After 15 minutes the reaction mixture was warmed to 0 °C 
and stirred for another 1.25 h. The reaction was quenched by addition of aqueous ammonium chloride (10 
mL) and the blue aqueous phase was extracted with ethyl acetate (3 x 10 mL). The combined organic 
extracts were washed with brine, dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/dichloromethane, 1:1) to give sulfonamide 189  (1.02 g, 68%) as an off-
yellow oil; νmax 3275 (br, NH); δH 7.47 (2H, d, J 8.3, 2 x ArH), 7.16 (2H, d, J 8.0, 2 x ArH), 7.13 (1H, dd, 
J 7.4 and 1.3, ArH), 7.07 – 7.02 (2H, m, 2 x ArH),  6.97 (1H, dd, J 7.7 and 1.1, ArH), 6.16 (1H, s, 
ArCH=C), 4.59 (1H, d, J 7.4, NH), 3.33 – 3.25 (1H, m, NCH), 2.68 (1H, dd, J 11.8 and 5.3, ArCH2a), 
2.64 (1H, dd, J 11.8 and 5.3, ArCH2b), 2.38 (3H, s, ArCH3), 1.90 (3H, d, J 1.3, :CCH3), 1.61 (3H, d, J 1.1, 
:CCH3), 1.52 – 1.44 (1H, m, CH3CH2a), 1.45 – 1.36 (1H, m, CH3CH2b), 0.79 (3H, t, J 7.4, CH2CH3); δC 
142.9 (C), 138.1 (C), 137.95 (C), 136.4 (C), 136.3 (C), 130.3 (ArCH), 130.1 (ArCH), 129.5 (2 x ArCH), 
127.0 (2 x ArCH), 126.6 (ArCH), 126.29 (ArCH), 123.9 (ArCH=CH), 56.3 (CH), 38.6 (ArCH2), 27.7 
(CH2), 26.1 (CH3), 21.6 (ArCH3), 19.25 (CH3), 9.7 (CH3); HRMS (APCI) calculated for C21H28NO2S 
[M+H]
+
 358.1841, found 358.1828. 
 
3-Ethyl-1-isopropyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 190 
 
 
 
 
 
Method 1: 
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The sulfonamide 189 (92 mg, 0.258 mmol, 1.0 eq.) was dissolved in dichloromethane (1.0 mL) under 
atmosphere of nitrogen and cooled to 0 °C, to which was added triflic acid (16 mg, 0.103 mmol, 0.4 eq.). 
The resultant solution was stirred for 5 minutes at 0 °C and then allowed to reach 21 °C for 18 hours. The 
reaction mixture was then cooled to room temperature and quenched with saturated potassium carbonate 
solution (2 mL), extracted with dichloromethane (3 x 5 mL), dried, filtered and evaporated. The crude 
reaction mixture was purified by column chromatography (petrol/dichloromethane 1:1) to give the 
unreacted starting material X (28 mg, 30%) and tetrahydroisoquinoline 190 (55 mg, 60%) as colourless 
crystals and as a 1:1 mixture of cis and trans diastereomers; (cis)-diastereoisomer m.p. 76 – 79 °C; δH 
7.29 (2H, d, J 8.1, 2 x ArH), 6.98 (1H, t, J 7.4, ArH), 6.91 – 6.82 (4H, m, 4 x ArH), 6.66 (1H, d, J 7.4, 
ArH), 4.23 (1H, d, J 10.9, ArCHN), 3.60 (1H, dddd, J 4.3, 7.5, 9.7 and 11.1, ArCH2CH), 2.88 (1H, dd, J 
15.3 and 7.3, ArCH2a), 2.61 (1H, dd, J 15.3 and 11.1, ArCH2b), 2.31 (1H, dqd, J 4.3, 7.5 and 13.5 
CH2aCH3), 2.22 (3H, s, ArCH3), 1.93 (1H, d sept, J 6.5 and 10.6, CH(CH3)2), 1.75 (1H, qdd, J 7.3, 9.6 and 
13.5, CH2aCH3), 1.28 (3H, d, J 6.5, CHCH3), 1.04 (3H, t, J 7.5, CH2CH3), 0.74 (3H, d, J 6.5, CHCH3); δC 
142.45 (C), 137.6 (C), 136.2 (C), 133.4 (C), 128.9 (2 x ArCH), 128.2 (ArCH), 127.6 (ArCH), 127.35 (2 x 
ArCH), 127.0 (ArCH), 125.4 (ArCH), 66.8 (NCH), 57.1 (CH), 33.8 (CH2), 32.2 (CH2), 31.5 (CH2), 21.4 
(ArCH3), 20.7 (CH3), 20.6 (CH3), 10.7 (CH3); (trans)-diastereoisomer δH 7.54 (2H, d, J 8.3, 2 x ArH), 
7.14 – 7.09 (2H, m, 2 x ArH), 7.07 (2H, d, J 8.0, 2 x ArH), 6.91-6.85 (2H, m, 2 x ArH), 4.75 (1H, d, J 
7.6, ArCHN), 3.80 (1H, dddd, J 5.4, 8.6, 10.7 and 11.5), 2.79 (1H, dd, J 16.4 and 4.8, ArCH2a), 2.49 (1H, 
dd, J 16.4 and 8.5, ArCH2a), 2.32 (3H, s, ArCH3), 2.09 (1H, d sept, J 1.4 and 7.5,  CH(CH3)2), 1.44 – 1.35 
(1H, m, CH2aCH3), 1.04 (3H, d, J 6.7, CHCH3), 0.91 (3H, t, J 7.4, CH2CH3), 0.82 (3H, d, J 6.7, CHCH3); 
δC  142.5 (C), 140.0 (C), 135.1 (C), 134.0 (C), 129.0 (2 x ArCH), 128.9 (ArCH), 128.3 (ArCH), 126.9 
(ArCH), 126.8 (ArCH), 125.2 (ArCH), 65.2 (NCH), 56.1 (CH), 32.3 (CH2), 26.9 (CH2), 21.3 (ArCH3), 
20.43 (CH3), 18.99 (CH3), 11.66 (CH3); HRMS (APCI) calculated for C21H28NO2S [M+H]
+
 358.1841, 
found 358.1824. 
 
Method 2: 
The sulfonamide 189 (112 mg, 0.313 mmol, 1.0 eq.) was dissolved in dichloromethane (1.1 mL) under 
atmosphere of nitrogen and cooled to 0 °C, to which was added triflic acid (19 mg, 0.125 mmol, 0.4 eq.). 
The resultant solution was stirred for 5 minutes at 0 °C and then heated to 41 °C for 4 hours. The reaction 
mixture was then cooled to ambient temperature and quenched with saturated potassium carbonate 
solution (2 mL), extracted with dichloromethane (3 x 2 mL), dried, filtered and evaporated to give 
tetrahydroisoquinoline 190 (97 mg, 87%) as colourless glass, as a 19:1 mixture of cis and trans 
diastereomers. All data obtained were in accordance with those reported before. 
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3-Ethyl-1-isopropyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 190 
 
 
 
 
 
The sulfonamide product 190 (50 mg, 0.140 mmol, 1.0 eq.) from the previous reaction was dissolved in 
dichloromethane (0.5 mL) under an atmosphere of nitrogen and cooled to 0 °C. To this was added triflic 
acid (8.4 mg, 0.056 mmol, 0.4 eq.). The resulting solution was stirred for 5 minutes at 0 °C and then 
heated to reflux at 41 °C for 3 hours then cooled to ambient temperature and quenched with aqueous 
potassium carbonate (2 mL), extracted with dichloromethane (3 x 2 mL) and combined organic extratcs 
dried, filtered and evaporated to give sulfonamide 190 (40 mg, 80%) as colourless crystals, as a 95:5 
mixture of cis and trans diastereomers. Analytical sample of the cis isomer was obtainer by vapour 
diffusion recrystallization from diethyl ether in a petroleum ether chamber. All data obtained were in 
accordance with those reported before. 
The sulfonamide product 190 (5 mg, 0.014 mmol, 1.0 eq.) from the first reaction was dissolved in 
dichloromethane (0.1 mL) under atmosphere then heated to 84 °C for 5 hours. The reaction mixture was 
then cooled to room temperature dried, filtered and evaporated to give sulfonamide 190 (4 mg, 80%) as 
colourless glass, as a 19:1 mixture of cis and trans diastereomers. All data obtained were in accordance 
with those reported before. 
 
(2-Ethylaziridin-1-yl)diphenylphosphine oxide 192 
 
 
 
A solution of 2-amino-1-butanol 155 (0.8 g, 8.98 mmol, 1.0 eq.) in tetrahydrofuran (20 mL) was cooled 
to 0 °C. Triethylamine (2.77 g, 27.39 mmol, 3.05 eq.) was added, followed by diphenylphosphinic 
chloride (4.85 g, 18.41 mmol, 2.05 eq.). The cooling bath was removed and the reaction allowed to warm 
to ambient temperature overnight (~16 h) and then cooled to 0 °C. Sodium hydride (3.59 g, 89.8 mmol, 
10 eq.) was slowly added and the reaction stirred for a further 20 hours at ambient temperature. The 
reaction was carefully quenched with dropwise addition of a 1:1 water and tetrahydrofuran solution (20 
mL), followed by addition of diethyl ether (50 mL). The organic phase was then washed with water (20 
mL), HCl (2M, 20 mL) and aqueous sodium bicarbonate (20 mL), then dried, filtered and evaporated. The 
crude material was purified by column chromatography (ethyl acetate/petrol 95:5) to give aziridine 192 as 
an off-yellow, viscous oil (1.136 g, 44%); δH (400 MHz) 7.89 – 7.82 (4H, m, 4 x ArH), 7.47 – 7.33 (6H, 
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m, 6 x ArH), 2.67 – 2.55 (1H, m, NCH), 2.45 (1H, ddd, J 17.5, 5.9 and 1.1, NCH2a), 1.87 (1H, ddd, J 
12.4, 3.5 and 1.1, NCH2b), 1.54 – 1.37 (2H, m, CH3CH2), 0.73 (3H, t, J 7.5, CH3CH2). 
 
N-(1-(2-(2-Methylprop-1-en-1-yl)phenyl)butan-2-yl)-P,P-diphenylphosphinic amide 194 
 
 
 
 
Magnesium turnings (110 mg, 4.53 mmol, 4.2 eq.) were dry-stirred under an atmosphere of nitrogen for 
24 hours and then suspended in tetrahydrofuran (5 mL). The suspension was treated with a crystal of 
iodine and 1-bromo-2-(2-methylprop-1-en-1-yl)benzene 188 (925 mg, 4.38 mmol, 4.0 eq.) was added as a 
solution in tetrahydrofuran (5 mL). The reaction was stirred for a further 30 minutes, during which time 
decolourisation and disappearance of the most magnesium turnings was observed. The solution was then 
cooled to -40 °C and copper (I) bromide dimethylsulfide (4.5 mg, 0.022 mmol, 0.02 eq.) was added. After 
a further 30 minutes, the reaction mixture was cooled to -78 °C and (2-ethylaziridin-1-
yl)diphenylphosphine oxide 192 (315 mg, 1.10 mmol, 1.0 eq.) in tetrahydrofuran (5 mL) was added. 
After 15 minutes the reaction mixture was heated to reflux and stirred for another 5 hours. The reaction 
was quenched by addition of aqueous ammonium chloride (10 mL) and the blue aqueous phase extracted 
with ethyl acetate (3 x 10 mL). The combined organic extracts were washed with brine, dried, filtered and 
evaporated. The crude material was purified by column chromatography (petrol/ethyl acetate, 1:1) to give 
phosphinamide 194  (156 mg, 35%) as an off-yellow oil. δH 7.82 – 7.85 (2H, m, 2 x ArH), 7.54 (2H, m, 2 
x ArH), 7.47 – 7.43 (1H, m, ArH), 7.42 – 7.37 (3H, m, 3 x ArH), 7.30 – 7.24 (2H, m, 2 x ArH), 7.22 (1H, 
dd, J 7.3 and 1.6, ArH), 7.19 (1H, td, J 7.4 and 1.7, ArH), 7.14 (1H, dd, J 7.4 and 1.4, ArH), 7.11 (1H, dd, 
J 7.2 and 1.1, ArH), 6.11 (1H, s, ArCH=CH), 3.23 – 3.12 (1H, m, NCH), 2.86 (1 H, ddd, J 13.5, 5.9 and 
2.2, ArCH2a), 2.73 (1H, dd, J 13.6 and 7.9, ArCH2b and NH), 2.73 (1H, br s, NH), 1.75 (3H, d, J 1.1, 
:CCH3), 1.67 (1H, m, CH3CH2a), 1.61 – 1.52 (1H, m, CH3CH2b), 1.46 (1H, d, J 1.0, :CCH3), 0.94 (3H, t, J 
7.4, CH3CH2); δC 138.4 (C), 137.7 (C), 135.9 (C), 133.2 (d, J 45.7, C), 132.5 (d, J 9.4, ArCH), 132.0 (d, J 
9.2, ArCH), 131.7 (d, J 2.7, ArCH), 131.5 (d, J 2.7, ArCH), 130.4 (d, J 36.9, ArCH), (s), 128.5 (d, J 5.6, 
ArCH), 128.4 (d, J 5.8, ArCH), 126.3 (d, J 27.7, ArCH), 123.95 (s, ArCH=C), 54.4 (d, J 1.6, NCH), 40.4 
(d, J 7.3, ArCH2), 30.3 (d, J 3.1, CH2CH3), 26.0 (CH3), 19.0 (CH3), 10.0 (CH3); HRMS calculated for 
C26H31NOP [M+H]
+
 404.2143, found 404.2132. 
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(3-Ethyl-1-isopropyl-3,4-dihydroisoquinolin-2(1H)-yl)diphenylphosphine oxide 195 
 
 
 
 
 
The phosphinamide 194 (27 mg, 0.067 mmol, 1.0 eq.) was dissolved in dichloromethane (0.3 mL) under 
an atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (4 mg, 0.027 mmol, 0.4 eq.). 
The resulting solution was stirred for 30 minutes at 0 °C and quenched with aqueous potassium carbonate 
solution (2 mL), extracted with dichloromethane (3 x 5 mL), dried, filtered and evaporated. The desired 
product could not be detected in the reaction mixture. 
 
Benzyltriphenylphosphonium bromide
231
 196 
 
 
 
A solution of benzyl bromide (7.0 g, 41.25 mmol) and triphenylphosphine (12.3 g, 45.0 mmol) in toluene 
(120 mL) was heated at 110 °C for 24 hours.
232
 The reaction mixture was allowed to cool to ambient 
temperature and the precipitate was collected by vacuum filtration, washed with toluene (2 x 50 mL) and 
diethyl ether (50 mL) to yield salt 196 (17.7 g, 99%) as white powder, which was used without further 
purification. 
 
(E/Z)-1-Bromo-2-styrylbenzene
233
 197 
 
 
 
 
Benzyltriphenylphosphonium bromide 196 (17.7 g, 40.85 mmol) was treated with potassium tert-
butoxide (5.35 g, 47.66 mmol) and 2-bromobenzaldehyde (6.3 g, 34.04 mmol) according to general 
procedure A1. The crude material was purified by column chromatography (petrol/dichloromethane 9:1) 
to yield alkene 197 (8.47 g, 96%) as an 83:17 mixture of cis and trans isomers; major (cis)-isomer δH 
7.69 (1H, m, ArH), 7.30 – 7.25 (4H, m, 4 x ArH), 7.25 – 7.21 (2H, m, ArH), 7.19 – 7.15 (2H, m), 6.74 
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(2H, ABq, J 12.1, ArCH=CH); minor (trans)-isomer δH 7.52 (1H, d, J 16.2, ArCH=CH), 7.08 (1H, d, J 
16.2, ArCH=CH); only 2 distinctive signals. 
  
(E/Z)-4-Methyl-N-(1-(2-styrylphenyl)butan-2-yl)benzenesulfonamide 179 
 
 
 
 
Magnesium turnings (83 mg, 3.40 mmol, 2.2 eq.) were dry-stirred under an atmosphere of nitrogen for 24 
hours and then suspended in tetrahydrofuran (5 mL). Suspension was treated with a crystal of iodine and 
1-bromo-2-styrylbenzene 197 (800 mg, 3.09 mmol, 2.0 eq.) added as a solution in tetrahydrofuran (3 
mL). The suspension was stirred for a further 30 minutes, during which decolourisation and 
disappearance of most magnesium turnings was observed. The solution was then cooled to -40 °C and 
copper (I) iodide (88 mg, 0.464 mmol, 0.3 eq.) was added. After further 30 minutes, the reaction mixture 
was cooled to -78 °C and 2-ethyl-1-tosylaziridine 154 (348 mg, 1.55 mmol, 1.0 eq.) in tetrahydrofuran (2 
mL) was added. After 15 minutes the reaction mixture was warmed to 0 °C and stirred for another 1 hour. 
The reaction was quenched by addition of aqueous ammonium chloride solution (10 mL) and the blue 
aqueous phase extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were washed with 
brine, dried, filtered and evaporated. The crude material was purified by column chromatography 
(dichloromethane/petrol, 1:1) to give sulfonamide 179 (460 mg, 74%) as colourless glass, as a 5:1 mixture 
of cis and trans isomers; νmax 3291 (br, NH); major (cis)-isomer δH 7.64 (2H, d, J 8.3, 2 x ArH), 7.17 (1H, 
s, CHAr), 7.14 (4H, m, ArH), 7.13 – 7.09 (1H, m, ArH), 7.09 – 7.02 (5H, m, ArH), 6.55 (2H, ABq, JAB 
12.2, CH=CH), 4.66 (1H, d, J 7.8, NH), 3.42 (1H, dddd, J 14.5, 8.0, 6.5 and 5.4, ArCH2CH), 2.79 (1H, 
dd, J 13.7 and 6.5, ArCH2a), 2.65 (1H, dd, J 13.8 and 8.0, ArCH2b), 2.38 (3H, s, ArCH3), 1.55 – 1.44 (1H, 
m, CH3CH2a), 1.37 – 1.32 (1H, m, CH3CH2a), 0.73 (3H, t, J 7.4, CH3CH2); δC 143.1 (C), 138.0 (C), 
137.45 (C), 136.7 (C), 135.9 (C), 131.3 (CH=CH), 130.7 (ArCH), 129.8 (ArCH), 129.6 (2 x ArCH), 
129.0 (2 x ArCH), 128.95 (CH=CH), 128.3 (2 x ArCH), 127.6 (ArCH), 127.4 (ArCH), 127.2 (2 x ArCH), 
126.85 (ArCH), 55.9 (CH), 39.4 (CH2), 27.5 (CH2), 21.6 (ArCH3), 9.7  (CH3); LRMS (EI
+
) m/z 405 
([M]
+
, 80%), 234 ([M-Ts]
+
, 72%), 213 ([n-PrNHTs]
+
, 100%); HRMS calculated for C25H27NO2S [M]
+
 
405.1763, found 405.1759. 
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(E)-4-Methyl-N-(1-(2-styrylphenyl)butan-2-yl)benzenesulfonamide 179 
 
 
 
 
The sulfonamide 179 (150 mg, 0.370 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (1.5 mL) under 
atmosphere of nitrogen and cooled to 0 °C, to which was added triflic acid (24 mg, 0.149 mmol, 0.4 eq.). 
The resultant solution was stirred for 5 minutes at 0 °C and then heated to 70 °C for 3 hours. The reaction 
mixture was quenched with saturated potassium carbonate solution (2 mL), extracted with 
dichloromethane (3 x 5 mL), dried, filtered and evaporated to give sulfonamide 179 (132 mg, 88%) as a 
viscous, clear oil, as a sinlge trans isomer; νmax 3280 (br, NH); δH 7.61 (2H, d, J 7.3, 2 x ArH), 7.53 (1H, 
d, J 7.7, ArH), 7.50 (2H, d, J 8.3, 2 x ArH), 7.43 - 7.39 (2H, m, 2 x ArH), 7.41 (1H, d, J 15.7, ArCH=C), 
7.33 – 7.28 (1H, m, ArH), 7.22 (1H, m, ArH), 7.15 (1H, td, J 7.4 and 1.3, ArH), 7.06 – 7.01 (3H, m, 3 x 
ArH), 6.90 (1H, d, J 15.9, ArCH=C), 4.68 (1H, d, J 7.2, NH), 3.28 (1H, m, NCH), 3.14 (1H, dd, J 13.8 
and 6.2, ArCH2a), 2.80 (1H, dd, J 13.8 and 8.2, ArCH2b), 2.34 (3H, s, ArCH3), 1.52 – 1.42 (1H, m, 
CH3CH2a), 1.40 – 1.31 (1H, m, CH3CH2b); 0.69 (3H, t, J 7.4, CH3);
 δC 143.0 (C), 138.0 (C), 137.5 (C), 
136.8 (C), 135.7 (C), 131.1 (ArCH), 131.0 (ArCH), 129.77 (ArCH), 129.42 (ArCH), 128.77 (ArCH), 
127.84 (ArCH), 127.54 (ArCH), 127.11 (ArCH), 127.0 (ArCH), 126.8 (ArCH), 126.0 (ArCH), 125.85 
(ArCH), 56.0 (CH), 39.8 (ArCH2), 27.0 (CH2), 21.5 (ArCH3), 9.7 (CH3); HRMS calculated for 
C25H27NO2S [M]
+
 405.1763, found 405.1755. 
 
(E)-N-(1-(2-(2-Cyclohexylvinyl)phenyl)propan-2-yl)-4-methylbenzenesulfonamide 200 
 
 
 
A solution of N-(1-(2-bromophenyl)propan-2-yl)-4-methylbenzenesulfonamide 207 (600 mg, 1.0 eq.) in 
ethanol/water (1:1, 6 mL) was treated with 2-cyclohexylvinylboronic acid (300 mg, 1.2 eq.), K3PO4 (691 
mg, 2.0 eq) and Pd(dppf)Cl2.DCM (66.5 mg, 0.05 eq) at 80 °C for 2.5 hours according to General 
Procedure D. The crude material was purified by column chromatography (petrol/diethyl ether 1:1) to 
give the sulfonamide 200 (531 mg, 82%) as a colourless oil; νmax 3420 (br, NH); δH 7.54 – 7.50 (2H, d, J 
8.3, 2 x ArH), 7.30 (1H, d, J 7.7, ArH), 7.14 (2H, d, J 7.9, 2 x ArH), 7.13 (1H, m, ArH), 7.06 (1H, td, J 
7.4 and 1.3, ArH), 6.95 (1H, dd, J 7.5 and 1.1, ArH), 6.46 (1H, d, J 15.6, ArCH=C), 5.88 (1H, dd, J 15.7 
and 7.1, ArCH=CH), 4.74 (1H, d, J 6.8, NH), 3.47 – 3.38 (1H, m, NCH), 2.85 (1H, dd, J 13.8 and 7.3, 
 139 
 
ArCH2a), 2.68 (1H, dd, J 13.8 and 7.0, ArCH2b), 2.39 (3H, s, ArCH3), 2.17 – 2.09 (1H, m, ArCH=CH-
CH), 1.83 – 1.75 (4H, m), 1.70 (2H, m), 1.39 – 1.29 (1H, m), 1.26 – 1.14 (2H, m), 1.12 (3H, d, J 6.5, 
CH2CH3); δC 142.9 (C), 139.6 (ArCH=CH), 137.6 (C), 137.5 (C), 134.6 (C), 130.7 (ArCH), 129.6 (2 x 
ArCH), 127.1 (ArCH), 126.95 (3 x ArCH), 126.4 (ArCH), 124.7 (ArCH=CH), 50.7 (NCH), 41.5 (CH), 
41.2 (CH2), 33.1 (CH2), 26.25 (CH2), 26.1 (CH2), 21.9 (CH3), 21.6 (CH3); LRMS (EI
+
) m/z 397 ([M]
+
, 
70%), 300 ([M-CH2cy]
+
, 90%), 242 ([M-Ts]
+
, 90%), 198 ([M-CH3CH2NHTs]
+
, 100%); HRMS (EI
+
) 
calculated for C24H31NO2S [M]
+
 397.2076, found 397.2068. 
 
1-(Cyclohexylmethyl)-3-methyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 201 
 
 
 
 
Method 1: 
The sulfonamide 200 (99 mg, 0.25 mmol, 1.0 eq.) was dissolved in dichloromethane (1.0 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (15 mg, 0.1 mmol, 0.4 eq.). The 
resulting solution was stirred for 5 minutes at 0 °C and then heated to reflux at 41 °C for 4 hours. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated to give 
tetrahydroisoquinoline 201 (80 mg, 81%) as a clear oil, as a 7:5 mixture of trans and cis isomers; major 
(trans)-isomer δH (400 MHz) 7.63 (2H, d, J 8.3, 2 x ArH), 7.15 (2H, d, J 8.0, 2 x ArH), 7.18 – 7.10 (2H, 
m, 2 x ArH), 7.06 – 6.91 (2H, m, 2 x ArH), 5.09 (1H, t, J 7.4, ArCHN), 4.17 – 4.08 (1H, m, ArCH2CH), 
2.89 (1H, dd, J 15.9 and 4.7, ArCH2a), 2.52 (1H, dd, J 15.9 and 7.4, ArCH2b), 2.36 (3H, s, ArCH3), 1.95-
1.10 (13H, m), 1.20 (3H, d, J 6.7, CH2CH3); δC 142.8 (C), 140.1 (C), 137.8 (C), 133.6 (C), 129.3 (2 x 
ArCH), 127.2 (2 x ArCH), 126.9  (ArCH), 126.8 (ArCH), 126.2 (ArCH), 57.0 (ArCHN), 49.3 
(ArCH2CH), 45.4 (ArCH2), 35.5 (CH2), 34.3 (CH2), 33.5 (CH2), 33.2 (CH2), 26.7 (CH2), 26.3 (CH2), 26.2  
(CH2), 21.5 (CH3), 20.7 (ArCH3); minor (cis)-isomer δH 7.38 (2H, d, J 8.3, 2 x ArH), 7.03 – 6.97 (2H, m, 
2 x ArH), 6.95 (2H, d, J 8.0, 2 x ArH), 6.88 (1H, d, J 7.1, ArH), 6.80 (1H, dd, J 7.2 and 0.9, ArH), 4.90 
(1H, dd, J 8.8, 6.6, ArCHN), 3.87 (1H, m, ArCH2CH), 2.77 (1H, dd, J 15.7 and 7.3, ArCH2a), 2.69 (1H, 
dd, J 15.7 and 9.9, ArCH2b), 2.24 (3H, s, ArCH3), 1.96 - 1.90 (1H, m, CH2a), 1.85 – 1.76 (3H, m, 2 x CH2b 
and CH2c), 1.76 – 1.62 (4H, m, CH2d and 2 x CH2e and CH2), 1.58 – 1.52 (1H, m, ArCHCH2CH), 1.55 
(3H, d, J 6.4, CH3), 1.48 – 1.41 (1H, m, CH2c), 1.35 – 1.23 (3H, m, CH2d and 2 x CH2f), 1.00 (1H, CH2b), 
0.91 (1H, m, CH2a); δC 142.6 (C), 138.3 (C), 136.5 (C), 133.2 (C), 129.0 (2 x ArCH), 127.8 (ArCH), 
127.3 (2 x ArCH), 127.0 (ArCH), 126.3 (ArCH), 126.1 (ArCH), 56.8 (ArCHN), 50.6 (ArCH2CH), 44.6 
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(ArCH2), 34.6 (ArCH2), 34.0 (CH), 33.6 (CH2), 33.15 (CH2), 26.7 (CH2), 26.4 (CH2), 26.2 (CH3), 26.1 
(CH2), 21.4 (ArCH3). 
 
Method 2: 
The sulfonamide 200 (217 mg, 0.548 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (2.2 mL) under 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (33 mg, 0.219 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to reflux at 84 °C for 4.5 hours. 
The reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated to give 
sulfonamide 201 (206 mg, 95%) as a clear oil and as a 20:1 mixture of cis and trans isomers. All data 
obtained were in accordance with those reported before. 
 
 (E)-1-Bromo-2-(2-nitroprop-1-en-1-yl)benzene 204 
 
 
 
To a solution of 2-bromobenzaldehyde 136 (17.6 g, 95.1 mmol, 1.0 eq) in nitroethane (100 g, 1.332 mol, 
14 eq.) was added ammonium acetate (5.13 g, 66.6 mmol, 0.7 eq) and the mixture heated to reflux for 4 
hours. The reaction was then allowed to cool to room temperature, and the solvent was removed in vacuo 
at 5 mbar pressure and at 60 °C for 1 hour. The crude reaction mixture was redissolved in toluene (100 
mL) and the residual nitromethane distilled off azeotropically at 1 mbar and 60 °C. Drying overnight in a 
vacuum oven afforded nitroalkene 204 (22.32 g, 97%) as an orange oil which was used without further 
purification; δH (250 MHz) 8.15 (1H, s, ArCH=C), 7.69 (1H, dd, J 8.2 and 1.1, ArH), 7.46 – 7.38 (2H, m, 
2 x ArH), 7.30 (2H, m, 2 x ArH), 2.34 (3H, d, J 1.1, CH3). 
 
1-(2-Bromophenyl)propan-2-amine 205 
 
 
 
To the solution of (E)-1-bromo-2-(2-nitroprop-1-en-1-yl)benzene 204 (0.40 g, 1.65 mmol, 1.0 eq.) in 
tetrahydrofuran (10 mL) at 0 °C under an atmosphere of nitrogen was added portionwise lithium 
aluminium hydride (207 mg, 5.46 mmol, 3.3 eq.) over 1 hour. The reaction mixture was allowed to stir 
for 1 hour at the same temperature after which it was quenched according to the General Procedure F to 
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yield an unseparable 8:1 mixture of amine 205 and amine 206; major (205)-amine δH (400 MHz) 7.57 
(1H, d, J 7.9, ArH), 7.40 – 7.19 (2H, m, 2 x ArH), 7.13 – 7.07 (1H, m, ArH), 3.35 – 3.25 (1H, m, NCH), 
2.89 (1H, dd, J 13.3 and 5.5, ArCH2a), 2.71 (1H, dd, J 13.2 and 7.9, ArCH2b), 1.18 (2H, d, J 6.3, CH3); 
minor (206)-amine: δH (400 MHz) 7.38 – 7.19 (5H, m, 5 x ArH), 3.25 – 3.15 (1H, m, NCH), 2.78 (1H, 
dd, J 14.7 and 5.8, ArCH2a), 2.56 (1H, dd, J 13.2 and 8.1, ArCH2b), 1.15 (3H, d, J 6.3, CH3). 
 
1-(2-Bromophenyl)propan-2-amine 205 
 
 
 
A solution of 1-bromo-2-(2-nitroprop-1-en-1-yl)benzene 204 (22.2 g, 91.78 mmol, 1.0 eq.) in 
tetrahydrofuran was treated with sodium borohydride (920 mg, 24.3 mmol, 0.26 eq.) and boron trifluoride 
diethyl etherate (51.4 g, 367 mmol, 4.0 eq.) according to the General Procedure F to afford amine 205 
(10.88 g, 51%) as a pale brown oil which was used without further purification. All data obtained were in 
accorded with those reported before.  
 
N-(1-(2-Bromophenyl)propan-2-yl)-4-methylbenzenesulfonamide 207 
 
 
 
 
A solution of 1-(2-bromophenyl)propan-2-amine 205 (2.5 g, 11.68 mmol) in dichloromethane was treated 
with triethylamine, DMAP and p-tosyl chloride according to General Procedure B. The crude material 
was purified by column chromatography (petrol/diethyl ether 2:1) to give the sulfonamide 207 (3.74 g, 
87%) as a colourless glass; δH 7.55 (2H, d, J 8.3, 2 x ArH), 7.38 (1H, dd, J 8.0 and 1.1, ArH), 7.14 (2H, d, 
J 8.0, 2 x ArH), 7.16 – 7.12 (1H, m, ArH), 7.06 (1H, dd, J 7.6 and 1.7, ArH), 7.02 (1H, td, J 7.6 and 1.8, 
ArH), 4.59 (1H, d, J 7.5, NH), 3.69 – 3.55 (1H, m, NCH), 2.75 – 2.85 (2H, ABq, J 7.2, ArCH2), 2.38 (3H, 
s, ArCH3), 1.19 (3H, d, J 6.5, CHCH3); δC 143.0 (C), 137.6 (C), 137.25 (C), 133.1 (ArCH), 131.7 
(ArCH), 129.6 (2 x ArCH), 128.4 (ArCH), 127.6 (ArCH), 127.1 (2 x ArCH), 124.8 (C-Br), 50.3 (NCH), 
43.5 (CH2), 22.3 (ArCH3), 21.6 (CH3). 
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(E)-4-Methyl-N-(1-(2-styrylphenyl)propan-2-yl)benzenesulfonamide 208 
 
 
 
 
 
A solution of N-(1-(2-bromophenyl)propan-2-yl)-4-methylbenzenesulfonamide 207 (3.00 g, 8.146 mmol, 
1.0 eq.) in ethanol/water (1:1, 30 mL) was treated with 2-phenylvinylboronic acid (1.688 g, 11.404 mmol, 
1.4 eq.), K3PO4 (3.45 g. 16.25 mmol, 2.0 eq.) and Pd(dppf)Cl2.DCM (333 mg, 0.407 mmol, 0.05 eq) at 80 
°C for 1.5 h according to General Procedure D. The crude material was purified by column 
chromatography (petrol/ethyl acetate 2:1) to give the sulfonamide 208 (2.81 g, 88%) as an off-orange 
glass; νmax 3277 (br, NH); δH 7.60 (2H, d, J 7.8, 2 x ArH), 7.55 (3H, m, 3 x ArH), 7.42 (2H, t, J 7.7, ArH), 
7.40 (1H, d, J 16.2, ArCH=CH), 7.34 – 7.29 (1H, m, ArH), 7.26 – 7.22 (1H, m, ArH), 7.20 – 7.13 (1H, m, 
ArH), 7.06 (3H, m, 3 x ArH), 6.91 (1H, d, J 16.0, ArCH=CH), 4.96 (1H, d, J 6.9, NH), 3.48 – 3.42 (1H, 
m, NCH), 3.20 (1 H, dd, J 13.7 and 6.1, ArCH2a), 2.73 (1H, dd, J 13.7 and 8.4, ArCH2b), 2.35 (3H, s, 
ArCH3), 1.05 (3H, d, J 6.5, CH3); δC 143.0 (C), 137.5 (C), 136.7 (C), 135.6 (C), 131.2 (ArCH), 131.1 
(ArCH), 129.6 (2 x ArCH), 128.8 (2 x ArCH), 127.9 (ArCH), 127.65 (ArCH), 127.3 (ArCH), 127.05 (2 x 
ArCH), 126.9 (2 x ArCH), 126.1 (ArCH), 125.9 (ArCH), 50.5 (NCH), 41.95 (CH2), 21.5 (ArCH3), 21.05 
(CH3); LRMS m/z 396 ([M]
+
, 35%), 300 ([M-Tol]
+
, 33%), 220 ([M-Ts]
+
, 98%), 198 ([CH3CH2NHTs]
+
, 
92%); HRMS (EI
+
) calculated for C24H25NO2S [M]
+
 391.1606, found 391.1602. 
 
1-Benzyl-3-methyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 209 
 
 
 
 
Method 1: 
The sulfonamide 208 (200 mg, 0.511 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (2.0 mL) under 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (31 mg, 0.204 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 12 hours. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extratcs dried, filtered and evaporated to give 
tetrahydroisoquinoline 209 (124 mg, 62%) as a clear oil and as a 20:1 mixture of cis and trans isomers; 
major (cis)-isomer δH (400 MHz) 7.46 (2H, d, J 8.3, 2 x ArH), 7.35 – 7.15 (5H, m, 5 x ArH), 7.11 – 7.05 
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(3H, m, ArH), 7.03 (2H, d, J 8.1, 2 x ArH), 7.00 – 6.93 (1H, m, ArH), 6.87 (1H, t, J 7.4, ArH), 6.39 (1H, 
d, J 7.5, ArH), 5.13 (1H, dd, J 9.7 and 5.1, ArCHN), 3.96 (1H, m, ArCH2CHN), 3.38 (1H, dd, J 13.2 and 
5.1, 1’-CH2a), 3.05 (1H, dd, J 13.2 and 9.7, 1’-CH2b), 2.89 (1H, dd, J 15.7, 6.9, 4-CH2a), 2.78 (1H, dd, J 
15.7 and 9.0, 4-CH2b), 2.29 (3H, s, ArCH3), 1.62 (3H, d, J 6.4, CH2CH3); δC (101 MHz) 142.8 (C), 138.35 
(C), 136.6 (C), 136.1 (C), 132.9 (C), 129.8 (2 x ArCH), 129.2 (2 x ArCH), 128.4 (2 x ArCH), 127.3 (2 x 
ArCH), 127.2 (ArCH), 127.2 (ArCH), 127.2 (ArCH), 126.6 (ArCH), 125.7 (ArCH), 60.4 (ArCHN), 50.3 
(ArCH2CHCH3), 44.7 (CH2), 35.0 (CH2), 25.5 (ArCH3), 21.4 (CH3); minor (trans)-isomer δH (400 MHz) 
7.58 (2H, d, J 8.3, 2 x ArH), 7.29 – 6.88 (10H, m, 10 x ArH), 6.53 (1H, d, J 7.5, ArH), 5.08 (1H, dd, J 9.8 
and 5.1, ArCHN), 4.38 – 4.30 (1H, m, ArCH2CHCH3), 3.41 (1H, dd, J 13.0 and 5.1, 1’-CH2a), 2.89 (1 H, 
dd, J 12.7 and 3.6, 1’-CH2b), 2.86 (1H, m, 4-CH2a), 2.65 (1H, dd, J 15.4 and 5.0, 4-CH2b), 2.36 (3H, s, 
ArCH3), 0.97 (1H, d, J 6.6, CH2CH3); δC (101 MHz) 142.9 (C), 139.9 (C), 138.0 (C), 136.0 (C), 133.55 
(C), 130.0, 129.6 (2 x ArCH), 129.0 (2 x ArCH), 128.5 (2 x ArCH), 128.25 (2 x ArCH), 127.9 (ArCH), 
127.4 (ArCH), 127.3 (ArCH), 126.5 (ArCH), 126.0 (ArCH), 60.7 (ArCHN), 50.1 (ArCH2CHCH3), 44.8 
(CH2), 36.2 (CH2), 21.5 (ArCH3), 20.5 (CH3); HRMS calculated for C24H26NO2S [M+H]
+
 392.1684, 
found 392.1673. 
 
Method 2: 
The sulfonamide 208 (168 mg, 0.430 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (1.7 mL) under 
an atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (39 mg, 0.258 mmol, 0.6 
eq.). The resulting solution was stirred for 5 minutes at 0 °C and then heated to 60 °C for 3 hours. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated to give 
tetrahydroisoquinoline 209 (77 mg, 46%) as a clear oil, as a 2:1 mixture of cis and trans isomers. All data 
obtained were in accordance with those reported before. 
 
1-Benzyl-3-methyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 212 
 
 
 
 
The sulfonamide 208 (200 mg, 0.511 mmol, 1.0 eq.) was dissolved in toluene (2.0 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (31 mg, 0.204 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 110 °C for 24 hours. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
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dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated to give 
sulfonamide 212 (64 mg, 32%) as a white foam; δH (400 MHz) 7.56 (2H, d, J 8.2, 2 x ArH), 7.25 – 7.19 
(2H, m, 2 x ArH), 7.16 (2H, d, J 7.8, 2 x ArH), 7.19 – 7.09 (4H, m, 4 x ArH), 7.08 – 6.94 (7H, m, 7 x 
ArH), 6.91 (1H, dd, J 7.2 and 1.7, ArH), 6.89 – 6.84 (1H, m, dt, J 7.9 and 1.9, ArH), 4.29 (1H, d, J 7.3, 
NH), 4.11 (1H, t, J 7.5, ArCH2CHAr), 3.49 – 3.37 (1H, m, NCH), 3.22 (2H, dd, J 7.5 and 2.8, 
ArCH2CHAr), 2.58 (1H, dd, J 14.1 and 7.0, ArCH2aCHN), 2.39 (3H, s, ArCH3), 2.39 - 2.35 (1H, m, 
ArCH2bCHN), 2.30 (3H, s, ArCH3), 1.04 (3H, d, J 6.4, CHCH3); δC (101 MHz), 144.45 (C), 143.0 (C), 
141.3  (C), 138.7  (C), 137.6 (C), 135.6 (C), 130.2 (C), 130.0 (ArCH), 129.9 (ArCH), 129.6 (2 x ArCH), 
129.1 (ArCH), 129.0 (ArCH), 128.3 (ArCH), 128.3 (ArCH), 128.05 (ArCH), 127.9 (ArCH), 127.9 
(ArCH), 127.0 (2 x ArCH), 126.5 (ArCH), 126.2 (ArCH), 126.2 (ArCH), 126.1 (ArCH), 52.2 (CH), 50.35 
(CH), 40.2 (CH2), 38.3 (CH2), 21.6 (ArCH3), 21.5 (ArCH3), 21.0 (CH3); LRMS m/z 484 ([M]
+
, 35%). 
 
Triphenyl(4-(trifluoromethyl)benzyl)phosphonium bromide 213 
 
 
 
A solution of p-(trifluoromethyl)benzyl bromide 214 (5.0 g, 20.92 mmol) and triphenylphosphine (6.31 g, 
24.06 mmol) in toluene (50 mL) was heated to 65 °C for 12 hours and then at 111 °C for 3 hours.
232
 The 
reaction mixture was allowed to cool to ambient temperature and the precipitate was collected by vacuum 
filtration, washed with toluene (2 x 50 mL) and diethyl ether (50 mL) to yield salt 213 (10.1 g, 96%) as 
white powder and used in the next step without further purification. 
 
(E/Z)-1-Bromo-2-(4-(trifluoromethyl)styryl)benzene 215 
 
 
 
 
 
A suspension of p-(trifuoromethyl)benzyltriphenylphosphonium bromide 213(2.00 g, 4.18 mmol) in 
tetrahydrofuran (15 mL) was treated with potassium tert-butoxide (596 mg, 5.32 mmol) and 2-
bromobenzaldehyde 136 (644 mg, 3.48 mmol) according to general procedure A1. The crude product was 
purified by column chromatography (petrol/dichloromethane 9:1) to yield alkene 215 (1.089 mg, 80%) as 
an off-white glass and as a 7:1 mixture of cis and trans isomers; major (cis)-isomer δH 7.53 – 7.50 (1H, 
m, ArH), 7.32 (2H, d, J 8.2, 2 x ArH), 7.12 (2H, d, J 8.0, 2 x ArH), 7.00 (1H, m, ArH), 6.68 - 6.57 (2H, 
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ABq, J 12.1, ArCH=CH); minor (trans)-isomer δH 7.45 (1H, d, J 16.2, ArCH=CH), 6.94 (1H, d, J 16.2, 
ArCH=CH), only 2 distinct signals. 
 
(E/Z)-2-(4-(Trifluoromethyl)styryl)benzaldehyde 216 
 
 
 
 
 
 
To a solution of (E/Z)-1-bromo-2-(4-(trifluoromethyl)styryl)benzene (907 mg, 2.78 mmol, 1.0 eq.) in 
tetrahydrofuran (5 mL) at -78 °C under an atmosphere of nitrogen was added n-butyllithium (1.9 M, 1.82 
mL, 3.45 mmol, 1.1 eq.) over 10 minutes and the reaction stirred for a further 30 minutes at the same 
temperature. Dimethylformamide (0.61 mL, 7.85 mmol, 2.5 eq.) was added dropwise and the mixture 
allowed to warm to ambient temperature and stirred for a further 2 hours. The reaction was quenched by 
addition of aqueous ammonium chloride (10 mL) and the aqueous layer extracted with diethyl ether (3 x 
10 mL). The combined organic extracts were dried, filtered and evaporated and the crude material 
purified by column chromatography (petrol/diethyl ether 1:4) to give aldehyde 216 (556 mg, 73%) as a 
yellow oil and as a 4.5:1 mixture of cis and trans isomers; νmax 1697 (C=O); major (cis)-isomer δH (400 
MHz) 10.25 (1H, s, CHO), 7.94 – 7.89 (1H, m, ArH), 7.66 – 7.63 (1H, m, ArH), 7.52 – 7.42 (2H, m, 2 x 
ArH), 7.40 (2H, d, J 8.2, ArH), 7.23 (1H, dd, J 6.9 and 1.3, ArH), 7.15 (1H, app. s, ArH), 7.15 (1H, d, J 
12.7, ArCH=CH), 6.84 (1H, d, J 12.2, ArCH=CH); minor (trans)-isomer δH (400 MHz) 10.28 (1H, s, 
CHO), 8.19 (1H, d, J 16.2, ArCH=CH), 7.85 (1H, dd, J 7.6 and 1.3, ArH), 7.75 (1H, d, J 7.8, ArH), 7.08 
(1H, d, J 16.2, ArCH=CH); only 5 distinct signals. 
 
1-((E/Z)-2-Nitroprop-1-en-1-yl)-2-((E)-4-(trifluoromethyl)styryl)benzene 217 
 
 
 
 
 
 
 
To a solution of (E/Z)-2-(4-(trifluoromethyl)styryl)benzaldehyde 216 (556 mg, 2.015 mmol, 1.0 eq) in 
nitroethane (1.16 g, 15.48 mmol, 8 eq.) was added ammonium acetate (89 mg, 1.161 mmol, 0.6 eq) and 
the mixture heated to 100 °C for 4 hours. The reaction was then allowed to cool to room temperature, and 
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the solvent was removed in vacuo at 5 mbar pressure and at 60 °C for 1 hour to afford the crude 
nitroalkene 217 (610 mg, 91%) as a brown oil and as a 4:1 mixture of cis and trans isomers; major (cis)- 
isomer δH 7.85 (1H, s, CH=CNO2), 7.34 – 7.23 (4H, m, 4 x ArH), 7.22 – 7.12 (2H, m, 2 x ArH), 6.99 (2H, 
d, J 8.1, 2 x ArH), 6.72 (2H, s, ArCH=CH), 1.91 (3H, s, CH3); minor (trans)-isomer δH 8.20 (1H, s, 
CH=CNO2), 2.23 (3H, s, CH3); only 2 distinct signals. 
 
(E/Z)-1-(2-(4-(Trifluoromethyl)styryl)phenyl)propan-2-amine 218a 
 
 
 
 
To the solution of 1-((E/Z)-2-nitroprop-1-en-1-yl)-2-((E)-4-(trifluoromethyl)styryl)benzene 217 (610 mg, 
1.83 mmol, 1.0 eq.) in tetrahydrofuran (10 mL) at 0 °C under an atmosphere of nitrogen was added 
portionwise lithium aluminium hydride (208 mg, 5.50 mmol, 3.0 eq) over 10 minutes. The reaction 
mixture was allowed to stir for 30 minutes at the 0 °C and heated to reflux for 2 h. The reaction was 
quenched according to the General Procedure F to yield amine 218a (485 mg, 87%) as a dark, orange oil 
and as a 4:1 mixture of cis and trans isomers and was used in the next step without further purification; 
major (cis)-isomer δH (400 MHz) 7.33 (2H, d, J 8.2, 2 x ArH), 7.18 – 7.13 (2H, m, 2 x ArH), 7.11 (2H, d, 
J 8.3, 2 x ArH),  7.05 – 7.01 (2H, m, 2 x ArH), 6.79 (1H, d, J 12.2, ArCH=CH), 6.56 (1H, d, J 12.2, 
ArCH=CH), 3.24 – 3.13 (1H, m, NCH), 2.68 (1H, dd, J 13.5 and 6.2, ArCH2a), 2.61 (1H, dd, J 13.5 and 
7.6, ArCH2b), 2.24-2.05 (2H, br. s, NH2), 1.08 (1H, d, J 6.3, CH3); minor (trans)-isomer δH (400 MHz) 
7.42 (1H, d, J 16.0, ArCH=CH), 6.94 (1H, d, J 16.2, ArCH=CH); only 2 distinct signals. 
 
(E/Z)-4-Methyl-N-(1-(2-(4-(trifluoromethyl)styryl)phenyl) propan-2-yl)benzenesulfonamide 
218 
 
 
 
 
A solution of (E/Z)-1-(2-(4-(trifluoromethyl)styryl)phenyl)propan-2-amine 218a (485 mg, 1.59 mmol) in 
dichloromethane (10 mL) was treated with triethylamine, DMAP and p-tosyl chloride according to 
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General Procedure B. The crude material was purified by column chromatography (petrol/diethyl ether 
1:1) to give the sulfonamide 218 (378 mg, 52%) as an orange foam and as a 3:1 mixture of cis and trans 
isomers; m.p. 34 – 38 °C; νmax 3572 (NH); major (cis)-isomer δH 7.62 (2H, d, J 8.3, 2 x ArH), 7.38 (2H, d, 
J 8.3, 2 x ArH), 7.17 (1H, m, ArH), 7.16 (2H, d, J 8.0, 2 x ArH), 7.14 – 7.02 (6H, m, 6 x ArH), 6.67 (1H, 
d, J 12.2, ArCH=CH), 6.58 (1H, d, J 12.2, ArCH=CH), 4.82 (1H, d, J 7.5, NH), 3.58 – 3.47 (1H, m, 
NCH), 2.86 (1H, dd, J 13.6 and 6.3, ArCH2a), 2.59 (1H, dd, J 13.6 and 8.1, ArCH2b), 2.37 (3H, s, ArCH3), 
1.03 (3H, d, J 6.5, CHCH3); δC 143.2 (C), 140.1 (C), 137.6 (C), 136.5 (C), 135.8 (C), 131.15 (ArCH), 
130.8 (ArCH), 129.8 (ArCH), 129.6 (2 x ArCH), 129.55 (ArCH), 129.4 (ArCH), 129.05 (2 x ArCH), 
127.9 (ArCH), 127.0 (2 x ArCH), 126.95 (ArCH), 126.9 (ArCH), 125.1 (q, J 3.7, CF3), 50.35 (NCH), 
41.7 (CH2), 21.5 (ArCH3), 21.2 (CH3); minor (trans)-isomer δH 6.94 (1H, d, J 16.0, ArCH=CH), 3.42 
(1H, m, NCH), 3.27 (1H, dd, J 13.7 and 5.5, ArCH2a), 2.70 (1H, dd, J 13.7 and 8.8, ArCH2b), 2.34 (3H, s, 
ArCH3), 1.00 (1H, d, J 6.5, CHCH3); only 5 distinct signals; δC 143.1 (C), 140.8 (C), 137.3 (C), 135.9 
(C), 131.3 (ArCH), 129.55 (2 x ArCH), 129.3 (ArCH), 128.8 (ArCH), 128.3 (ArCH), 128.15 (ArCH), 
127.3 (ArCH), 126.95 (ArCH), 126.9 (2 x ArCH), 126.0  (ArCH),125.7 (q, J 3.8, CF3), 50.5 (NCH), 42.1 
(CH2), 21.4 (ArCH3), 20.6 (CH3). 
 
3-Methyl-2-tosyl-1-(4-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroisoquinoline 219 
 
 
 
 
The sulfonamide 218 (75 mg, 0.163 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (0.8 mL) under 
an atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (15 mg, 0.098 mmol, 0.6 
eq.). The resulting solution was stirred for 5 minutes at 0 °C and then heated to 80 °C for 15 hours. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined extracts dried, filtered and evaporated to give sulfonamide 
219 (49 mg, 65%) as a clear, viscous oil and as a 20:1 mixture of cis and trans isomers; major (cis)-
isomer δH 7.53 (2H, d, J 8.3, 2 x ArH), 7.33 (2H, d, J 8.3, 2 x ArH), 7.12 (2H, d, J 7.2, 2 x ArH), 7.14 – 
6.88 (3H, m, 3 x ArH), 6.92 (2H, d, J 7.8, 2 x ArH), 6.31 (1H, d, J 7.5, ArH), 5.02 (1H, dd, J 9.3 and 5.5, 
ArCHN), 3.85 (1H, ddq, J 8.9, 6.8 and 6.4 NCHCH3), 3.31 (1H, dd, J 13.3 and 5.5, 1’-CH2a), 3.00 (1H, 
dd, J 13.3 and 9.3, 1’-CH2b), 2.79 (1H, dd, J 15.8 and 6.7, 4-CH2a), 2.66 (1H, dd, J 15.8 and 8.9, 4-CH2b), 
2.18 (3H, s, ArCH3), 1.50 (3H, d, J 6.4, CHCH3). δC 143.05 (C), 142.3 (C),  139.45 (C), 135.6 (C), 133.4 
(C), 130.0 (ArCH), 129.5 (ArCH), 129.0 (ArCH), 128.0 (ArCH), 127.1 (ArCH), 127.1 (ArCH), 126.05 
(ArCH), 125.85 (ArCH), 125.2 (q, J 3.9, CF3), 59.9 (ArCHN), 50.1 (CH), 44.65 (CH2), 34.8 (CH2), 25.3 
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(ArCH3), 21.4 (CH3); minor (trans)-isomer δH 7.43 (2H, d, J 8.0, 2 x ArH), 7.36 (2H, d, J 8.8, 2 x ArH), 
7.14 – 7.08 (2H, m, 3 x ArH), 6.96 (4H, m, 4 x ArH), 6.80 (1H, t, J 7.5, ArH), 6.48 (1H, d, J 7.5, ArH), 
4.98 (1H, dd, J 8.5 and 5.0, ArCHN), 4.32 – 4.24 (1H, m, NCH), 3.41 (1H, dd, J 13.0 and 5.0, 1’-CH2a), 
2.93 (1H, dd, J 12.9 and 8.6, 1’-CH2b), 2.84 (1H, dd, J 15.4 and 4.7, 4-CH2a), 2.59 (1H, dd, J 15.4 and 4.8, 
4-CH2b), 2.30 (3H, s, ArCH3), 0.89 (3H, d, J 6.6, CHCH3); δC 142.9 (C), 142.0 (C), 136.3 (C), 135.4 (C), 
132.7 (C), 130.2 (2 x ArCH), 129.0 (ArCH), 127.5 (ArCH), 127.3 (ArCH), 127.0 (2 x ArCH), 126.9 
(ArCH), 124.95 (q, J 3.8, CF3), 61.0 (ArCH), 50.0 (CH), 44.4 (CH2), 36.1 (CH2), 21.3 (ArCH3), 20.25 
(CH3). 
 
(E)-2-Styrylbenzoic acid
234
 221 
 
 
 
 
To a suspension of benzyltriphenylphosphonium bromide 196 (3.46 g, 7.99 mmol, 1.20 eq.) in 
tetrahydrofuran (15 mL) at 0 °C under an atmosphere of nitrogen was added portionwise sodium hydride 
(60%, 0.80 g, 19.98 mmol, 3.0 eq.) and the reaction allowed to stir for one hour at the same temperature. 
A solution of 2-formylbenzoic acid 220 (1.0 g, 6.66 mmol, 1.0 eq.) in tetrahydrofuran (10 mL) was then 
added and the mixture heated to 40 °C for 1 hour. The reaction was cooled to 0 °C and quenched by slow 
addition of water and the separated aqueous layer washed with diethyl ether (2 x 20 mL). The combined 
aqueous extracts were acidified with HCl (2M, pH 1) and extracted with diethyl ether (2 x 20 mL) and the 
organic extracts dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/ethyl acetate 2:1) to yield the carboxylic acid 221 (910 mg, 61%) as an off-white 
solid; m.p. 148-150 °C (lit. m.p.
234
 151-152 °C); δH (400 MHz) 8.12 – 8.09 (1H, m, ArH), 8.07 (1H, d, J 
16.0, ArCH=CH), 7.75 (1H, d, J 7.7, ArH), 7.58 (3H, m, ArH), 7.35 (3H, m, 3 x ArH), 7.28 (1H, m, 
ArH), 7.03 (1H, d, J 16.2, ArCH=CH), 7.03 (1H, d, J 16.2); LRMS (EI
+
) m/z 224 ([M]
+
, 90%), 178 ([M-
CO2]
+
, 70%), 85 (100%). 
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(E)-(2-Styrylphenyl)methanol
143
 222 
 
 
 
 
To a solution of 2-styrylbenzoic acid 221 (170 mg, 0.76 mmol, 1.0 eq.) in tetrahydrofuran (3 mL) at 0 °C 
under an atmosphere of nitrogen was added portionwise lithium aluminium hydride (1.0 M in THF, 0.84 
mL, 0.84 mmol, 1.1 eq.) and the mixture was allowed to warm to ambient temperature. The reaction 
mixture was allowed to stir for 4 hours after which it was quenched according to the General Procedure F 
to yield alcohol 222 (132 mg, 83%) as a white solid; m.p. 99-102 °C (lit. m.p.
143
 103 °C); νmax 3349 (br., 
OH); δH (400 MHz) 7.67 (1H, d, J 7.5, ArH), 7.54 (2H, dd, J 8.1 and 0.9, 2 x ArH), 7.47 (1H, d, J 16.2, 
ArCH=CH), 7.42 – 7.32 (3H, m, 3 x ArH), 7.31 – 7.25 (3H, m, 3 x ArH), 7.06 (1H, d, J 16.2, 
ArCH=CH), 4.84 (2H, s, ArCH2OH). 
 
(E)-2-Styrylbenzaldehyde
235
 223 
 
 
 
 
To a suspension of pyridinium dichromate (487 mg, 1.30 mmol, 1.6 eq.) in dry dichloromethane (10 mLs) 
was added a solution of 2-(styrylphenyl)methanol 222 (170 mg, 0.810 mmol, 1.0 eq.) in dichloromethane 
(5 mL).
236
 After 4 hours diethyl ether (10 mL) was added and the reaction mixture filtered through a pad 
of Celite
©
. The solvent was removed in vacuo and the crude material purififed by silica chromatography 
(petrol/ethyl acetate 20:1) to yield aldehyde 223 (118 mg, 70%) as a white solid; m.p. 42-45 °C (lit. 
m.p.
237
 45 °C); νmax 1694 (C=O);  δH (250 MHz) 10.33 (1H, s, CHO), 8.09 (1H, d, J 16.2, ArCH=CH), 
7.85 (1H, d, J 7.7, ArH), 7.72 (1H, d, J 7.7, ArH), 7.65 – 7.29 (7H, m, 7 x ArH), 7.08 (1H, d, J 16.2, 
ArCH=CH).  
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1-((E)-2-Nitroprop-1-en-1-yl)-2-((E)-styryl)benzene 224 
 
 
 
 
 
 
To a solution of 2-styrylbenzaldehyde 223 (4.0 g, 19.23 mmol, 1.0 eq.) in nitroethane (28.9 g, 385 mmol, 
20 eq.) was added ammonium acetate (1.26 g, 16.35 mmol, 0.85 eq.) and the mixture heated to reflux for 
3 hours. The reaction was then allowed to cool to room temperature, and the solvent was removed in 
vacuo at 5 mbar pressure and at 60 °C for 1 h. The residue was suspended in dichloromethane (75 mL), 
washed with water (50 mL) and brine (50 mL), dried, filtered and evaporated to afford the crude 
nitroalkene 224 (4.68 g, 91%) as a brown oil and was used in the next step without further purification. 
 
(E)-1-(2-Styrylphenyl)propan-2-amine 225 
 
 
 
 
 
To the solution of 1-((E)-2-nitroprop-1-en-1-yl)-2-((E)-styryl)benzene 224 (4.18 g, 17.66 mmol, 1.0 eq.) 
in tetrahydrofuran (60 mL) at 0 °C under an atmosphere of nitrogen was added portionwise lithium 
aluminium hydride (2.15 g, 56.51 mmol, 3.2 eq) over 1 hour. The reaction mixture was allowed to stir for 
1 hour at the same temperature and then heated to reflux at 65 °C for 2.5 hours. The reaction was then 
allowed to cool to room temperature after which it was quenched according to the General Procedure F to 
yield the amine 225 (3.02 g, 72%) as a deep-orange oil; δH 7.60 – 7.57 (1H, m, ArH), 7.46 (2H, d, J 7.7, 2 
x ArH), 7.35 – 7.30 (3H, m, 3 x ArH), 7.25 – 6.99 (7H, m, 7 x ArH), 6.95 (1H, d, J 16.1, ArCH=CH), 
3.20 – 3.12 (1H, m, NCH), 2.83 (1H, dd, J 13.6 and 5.6, ArCH2a), 2.64 (1H, dd, J 13.6 and 8.0, ArCH2b), 
1.20 (2H, br s, NH2), 1.08 (3H, d, J 6.3, CH3); δC 137.6 (C), 136.5 (C), 130.8 (ArCH), 130.3 (ArCH), 
129.0 (ArCH), 128.7 (2 x ArCH), 128.1 (ArCH), 127.65 (ArCH), 127.55 (ArCH), 126.75 (ArCH), 126.6 
(2 x ArCH), 126.0 (ArCH), 48.1 (CH), 44.1 (CH2), 23.8 (CH3). 
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(E)-4-Methyl-N-(1-(2-styrylphenyl)propan-2-yl)benzenesulfonamide 208 
 
 
 
 
A solution of (E)-1-(2-styrylphenyl)propan-2-amine 225 (321 mg, 1.35 mmol, 1.0 eq.) in 
dichloromethane was treated with triethylamine, DMAP and p-tosyl chloride according to General 
Procedure B. The crude material was purified by column chromatography (petrol/diethyl ether 2:1) to 
give the sulfonamide 208 (386 mg, 73%) as a colourless glass. All data obtained were in accordance with 
those reported before. 
 
(E)-4-Nitro-N-(1-(2-styrylphenyl)propan-2-yl)benzenesulfonamide 226 
 
 
 
 
A solution of (E)-1-(2-styrylphenyl)propan-2-amine (710 mg, 3.00 mmol, 1.0 eq.) in dichloromethane 
was treated with triethylamine, DMAP and p-nosyl chloride according to General Procedure B. The crude 
material was purified by column chromatography (petrol/diethyl ether 2:1) to give the sulfonamide 226 
(1.03 g, 84%) as a yellow foam; m.p. 49-52 °C; νmax 3294 (NH); δH 8.01 (2H, d, J 8.9, 2 x ArH), 7.65 (2H, 
d, J 8.9, 2 x ArH), 7.56 – 7.51 (2H, m, 2 x ArH), 7.44 – 7.39 (3H, m, 3 x ArH), 7.35 – 7.31 (1H, m, ArH), 
7.25 (1H, d, J 16.0, ArCH=CH), 7.21 (1H, dt, J 7.6 and 0.9, ArH), 7.13 (1H, dt, J 7.4 and 1.2, ArH), 7.02 
(1H, dd, J 7.5 and 0.9, ArH), 6.82 (1H, d, J 16.0, ArCH=CH), 4.98 (1H, d, J 7.3, NH), 3.52 – 3.41 (1H, 
m, NCH), 3.01 (1H, dd, J 14.0 and 7.7, ArCH2a), 2.82 (1H, dd, J 14.0 and 6.8, ArCH2b), 1.20 (3H, d, J 
6.5, CH3); δC 149.7 (C), 145.8 (C), 137.1 (C), 136.5 (C), 135.1 (C), 131.4 (ArCH=CH), 131.1 (ArCH), 
129.0 (2 x ArCH), 128.25 (ArCH=CH), 128.0 (2 x ArCH), 127.8 (ArCH), 127.6 (ArCH), 126.8 (2 x 
ArCH), 126.2 (ArCH), 125.4 (ArCH), 124.1 (2 x ArCH), 51.2 (CH), 41.7 (CH2), 22.2 (CH3); HRMS (EI
+
) 
calculated for C23H22N2O4S [M]
+
 422.1300, found 422.1311. 
 
 
 
 
 152 
 
(E)-4-Nitro-N-(1-(2-styrylphenyl)propan-2-yl)benzenesulfonamide 228 
 
 
 
 
The sulfonamide 226 (47 mg, 0.115 mmol, 1.0 eq.) was dissolved in dichloromethane (0.5 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (7 mg, 0.046 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 41 °C for 2.5 h. The reaction 
mixture was quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 
mL) and the combined organic extracts dried, filtered and evaporated to give tetrahydroisoquinoline 228 
(30 mg, 63%) as a yellow glass; νmax 1559 (N=O); major (cis)-isomer δH 7.99 (2H, d, J 9.0, 2 x ArCH), 
7.64 (2H, d, J 9.0, 2 x ArH), 7.28 – 7.22 (3H, m, 3 x ArH), 7.07 – 7.00 (3H, m, 3 x ArH), 6.95 (1H, d, J 
7.4, ArH), 6.85 (1H, t, J 7.5, ArH), 6.35 (1H, d, J 7.5, ArH), 5.08 (1H, dd, J 9.5 and 5.7, ArCHN), 3.92 – 
3.89 (1H, m, ArCH2CHCH3), 3.35 (1H, dd, J 13.2 and 5.7, 1’-CH2a), 3.05 (1H, dd, J 13.2 and 9.5, 1’-
CH2b), 2.92 (1H, dd, J 15.9 and 7.1, 4-CH2a), 2.83 (1H, dd, J 15.8 and 9.5, 4-CH2b), 1.64 (3H, d, J 6.4, 
CH3); δC 149.65 (C), 145.05 (C), 137.7 (C), 135.7 (C), 132.7 (C), 129.7 (2 x ArCH), 128.6 (2 x ArCH), 
128.45 (2 x ArCH), 128.1 (ArCH), 127.8 (ArCH), 127.2 (ArCH), 127.0 (ArCH), 126.1 (ArCH), 123.8 (2 
x ArCH), 61.2 (ArCHN), 51.2 (CH3CHN), 44.0 (CH2), 34.9 (CH2), 25.8 (CH3); HRMS (EI
+
) calculated 
for C23H22N2O4S [M]
+
 422.1300, found 422.1304; minor (trans)-isomer δH 5.23 (1H, t, J 7.3, ArCHN), 
4.33 – 4.29 (1H, m, , ArCH2CHCH3), 1.07 (3H, d, J 6.7, CH3); only three distinctive signals; δC 129.9 
(ArCH), 128.2 (ArCH), 61.5 (NCH), 50.4 (CH3CHN), 44.4 (CH2), 20.2 (CH3); only five distinctive 
signals. 
 
Methyl-(E)-(1-(2-styrylphenyl)propan-2-yl)carbamate 227 
 
 
 
 
 
 
A solution of (E)-1-(2-styrylphenyl)propan-2-amine 227 (720 mg, 3.03 mmol, 1.0 eq.) in diethyl ether (4 
mL) was cooled to 0 °C. Water (3 mL) and potassium carbonate (838 mg, 6.07 mmol, 2.0 eq.) was added, 
followed by dropwise addition of methyl chloroformate (344 mg, 3.64 mmol, 1.2 eq.). The cooling bath 
was removed and the reaction was allowed to warm to room temperature over 30 minutes. The separated 
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aqueous phase was then extracted with diethyl ether (3 x 5 mL) and the combined organic extracts 
washed with brine (5 mL), dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/diethyl ether 2:1) to give carbamate 227 (618 mg, 69%) as a colourless glass; δH 
7.54 (1H, d, J 7.6, ArH), 7.52 – 7.39 (3H, m, 2 x ArH and ArCH=CH), 7.28 – 7.24 (2H, m, 2 x ArH), 
7.17 – 7.12 (2H, m, 2 x ArH), 7.09 (1H, dt, J 7.4 and 1.3, ArH), 7.03 (1H, d, J 7.3, ArH), 6.91 (1H, d, J 
16.1, ArCH=CH), 4.59 (1H, d, J 7.5, NH), 3.87 (1H, br s, NCH), 3.47 (3H, s, OCH3), 3.03 (1H, br dd, J 
13.3 and 4.3, ArCH2a), 2.64 (1H, br dd, J 11.5 and 8.1, ArCH2b), 0.98 (3H, d, J 6.6, CH3); δH (250 MHz, 
50 °C) 7.59 – 7.54 (1H, m, ArH), 7.52 – 7.46 (2H, m, 2 x ArH), 7.51 – 7.48 (1H, m, ArCH=CH), 7.34 – 
7.24 (2H, m, ArH), 7.23 – 7.16 (2H, m, 2 x ArH), 7.16 – 7.12 (1H, m, ArH), 7.12 – 7.03 (1H, m, ArH), 
6.93 (1H, d, J 16.1, ArCH=CH), 4.46 (1H, br s, NH), 3.92 – 3.89 (1H, m, NCH), 3.51 (3H, s, OCH3), 
3.06 (1H, dd, J 13.6 and 5.4, ArCH2a), 2.68 (1H, dd, J 13.5 and 7.9, ArCH2a), 1.03 (3H, d, J 6.7, CH3); δC 
156.3 (C=O), 137.7 (C), 136.8 (C), 136.1 (C), 131.1 (ArCH), 130.6 (ArCH=CH), 128.7 (2 x ArCH), 
127.7 (ArCH), 127.5 (ArCH), 127.0 (ArCH), 126.8 (ArCH=CH), 126.2 (ArCH), 125.9 (ArCH), 51.9 
(OCH3), 48.0 (NCH), 40.3 (ArCH2), 20.05 (CH3); LRMS (EI
+
) m/z 263 ([M-OCH3]
+
, 100%); HRMS 
calculated for C19H21NO2 [M]
+
 295.1572, found 295.1565. 
 
(E)-1-(2-Styrylphenyl)propan-2-amine 225 
 
 
 
 
The sulfonamide 227 (101 mg, 0.342 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (1.0 mL) under 
an atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (21 mg, 0.137 mmol, 0.4 
eq.). The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 24 h. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/ethyl acetate 1:1) to give amine 225 (41 mg, 
50%) as off-yellow oil. The sample showed identical spectroscopic and analytical data to the compound 
synthesized before. 
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(E/Z)-1-Bromo-2-(but-2-en-2-yl)benzene
238
 231 
 
 
 
To the suspension of ethyltriphenylphosphonium bromide (12.59 g, 33.91 mmol, 2.7 eq.) in 
tetrahydrofuran (80 mL) at 0 °C was added solid potassium tert-butoxide (3.81 g, 33.91 mmol, 2.7 eq.) 
portionwise, over five minutes. The reaction mixture was stirred for a further 0.5 h at 0 °C after which 2-
bromoacetophenone (2.5g, 12.56 mmol, 1.0 eq.) was added as a solution in tetrahydrofuran (25 mL) 
dropwise, over 5 minutes. The cooling bath was removed and the mixture heated to reflux for 6 hours. 
The reaction was quenched by addition of aqueous ammonium chloride (75 mL) and the separated 
aqueous layer extracted with ethyl acetate or diethyl ether (3 x 20 mL). The combined organic extracts 
were washed with brine, dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol) to give alkene 231 (1.673 g, 63%) as a colourless oil and as a 4:1 mixture of cis 
and trans isomers; major (cis)-isomer δH 7.60 (1H, dd, J 8.5 and 1.2, ArH), 7.30 (1H, td, J 7.6 and 1.2, 
ArH), 7.15 – 7.10 (2H, m, 2 x ArH), 5.62 (1H, qq, 1.5 and 6.7, ArC=CH), 2.01 – 1.99 (3H, m, CH3), 1.42 
(3H, dq, J 6.7 and 1.5, CH3); δC 143.0 (C), 136.9 (C), 132.65 (ArC=CH), 130.0 (ArCH), 128.1 (ArCH), 
127.4 (ArCH), 123.2 (ArCH), 122.65 (C-Br), 24.45 (CH3), 14.7 (CH3); minor (trans)-isomer δH 7.55 (1H, 
dd, J 8.0 and 1.1, ArH), 7.26 (1H, td, J 7.5 and 1.2, ArH), 7.17 (1H, dd, J 7.6 and 1.8, ArH), 7.12 – 7.08 
(1H, m, ArH), 5.48 (1H, qq, J 6.7 and 1.5, ArC=CH), 2.01 – 1.98 (3H, m, CH3), 1.80 (3H, dq, J 6.8 and 
1.1, CH3); δC 146.6 (C), 137.0 (C), 130.2 (ArC=CH), 127.9 (ArCH), 127.2 (ArCH), 125.1 (ArCH), 122.4 
(ArCH), 17.3 (CH3), 13.9 (CH3). 
 
(E/Z)-2-(But-2-en-2-yl)benzaldehyde 232 
 
 
 
 
To a solution of 1-bromo-2-(but-2-en-2-yl)benzene 231 (1.55 g, 7.35 mmol, 1.0 eq.) in tetrahydrofuran 
(15 mL) at -78 °C under an atmosphere of nitrogen was added n-butyllithium (1.9 M, 4.64 mL, 8.82 
mmol, 1.2 eq.) over 10 minutes and the reaction stirred for a further 30 minutes at the same temperature. 
Dimethylformamide (1.42 mL, 18.38 mmol, 2.5 eq.) was added dropwise and the mixture allowed to 
warm to ambient temperature and stirred for a further 2 hours. The reaction was quenched by addition of 
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aqueous ammonium chloride (15 mL) and the aqueous layer extracted with diethyl ether (3 x 15 mL). The 
combined organic extracts were dried, filtered and evaporated and the crude material purified by column 
chromatography (petrol/diethyl ether 15:1) to give aldehyde 232 (1.01 g, 86%) as a yellow oil and as a 
5:1 mixture of cis and trans isomers; νmax 1691 (C=O); major (cis)-isomer δH 10.07 (1H, d, J 0.7, CHO), 
7.93 (1H, dd, J 7.8 and 1.2, ArH), 7.56 (1H, td, J 7.5 and 1.4, ArH), 7.37 (1H, t, J 7.6, ArH), 7.18 (1H, 
dd, J 7.7 and 0.7, ArH), 5.78 – 5.73 (1H, qq, J 6.7 and 1.4, ArC=CH), 2.05 – 2.04 (3H, m, CH3), 1.36 
(3H, dq, J 6.8 and 1.5, CH3); δC 192.5 (CHO), 146.5 (C), 134.2 (ArCCH), 133.4 (C) 132.95 (C), 129.4 
(ArCH), 127.2 (ArCH), 127.1 (ArCH), 125.0 (ArCH), 26.7 (CH3), 14.8 (CH3); minor (trans)-isomer δH 
10.09 (1H, d, J 0.6, CHO), 7.87 (1H, dd, J 7.8 and 1.3, ArH), 7.50 (1 H, td, J 7.5 and 1.4, ArH), 7.33 (1H, 
t, J 7.6, ArH), 7.28 (1H, dd, J 7.7 and 0.7, ArH), 5.40 (1H, qq, J 6.7 and 1.4, ArC=CH), 2.06 – 2.03 (3H, 
m, CH3), 1.82 (3H, dd, J 6.8 and 1.1, CH3); δC 192.6 (CHO), 149.7 (C), 133.7 (C), 133.3 (ArC=CH), 
132.9 (C), 129.0 (ArCH), 128.8 (ArCH), 127.6 (ArCH), 126.8 (ArCH), 18.5 (CH3), 14.3 (CH3). 
 
1-((E/Z)-But-2-en-2-yl)-2-((E)-2-nitroprop-1-en-1-yl)benzene 233 
 
 
 
 
To a solution of (E/Z)-2-(But-2-en-2-yl)benzaldehyde 232 (920 mg, 5.75 mmol, 1.0 eq.) in nitroethane 
(3.45 g, 46.0 mmol, 8 eq.) was added ammonium acetate (266 mg, 3.45 mmol, 0.6 eq.) and the mixture 
heated to reflux for 3 hours. The reaction was then allowed to cool to room temperature, and the solvent 
was removed in vacuo at 5 mbar pressure and at 60 °C for 1 h. The residue was suspended in 
dichloromethane (75 mL), washed with water (50 mL) and brine (50 mL), dried, filtered and evaporated 
to afford the crude nitroalkene 233 (1.00 g, 81%) as a dark, brown oil, as a single cis isomer and was used 
in the next step without further purification; δH 7.91 (1H, s, ArCH=CNO2), 7.34 – 7.30 (1H, m, ArH), 
7.28 – 7.24 (2H, m, 2  ArH), 7.12 (1H, d, J 7.5, ArH), 5.57 (1H, qq, J 6.6 and 1.8, ArC=CH), 2.30 (3H, s, 
NO2CCH3), 1.88 – 1.86 (3H, m, CH3), 1.22 (3H, dd, J 6.7 and 1.6, CH3); δC 147.7 (C), 143.7 (C), 135.2 
(C), 133.3 (ArC=CH), 130.5 (C), 129.9 (CH), 129.0 (CH), 128.9 (CH), 126.9 (CH), 124.5 (CH), 25.6 
(CH3), 14.8 (CH3), 13.8 (CH3). 
 
 
 
 156 
 
(Z)-1-(2-(But-2-en-2-yl)phenyl)propan-2-amine 234a 
 
 
 
To the solution of 1-(but-2-en-2-yl)-2-(-2-nitroprop-1-en-1-yl)benzene 233 (1.00 g, 4.61 mmol, 1.0 eq.) in 
tetrahydrofuran (15 mL) at 0 °C under an atmosphere of nitrogen was added portionwise lithium 
aluminium hydride (525 mg, 13.82 mmol, 3.0 eq) over 5 minutes. The reaction mixture was allowed to 
stir for 1 hour at the same temperature and then heated to reflux at 65 °C for 2.5 hours. The reaction was 
then allowed to cool to room temperature and quenched according to the General Procedure F to yield the 
amine 234a (672 g, 77%) as a brown oil, as a single cis diastereoisomer and was used in the next step 
without further purification. 
 
Methyl (Z)-(1-(2-(but-2-en-2-yl)phenyl)propan-2-yl)carbamate 234 
 
 
 
A solution of 1-(2-(but-2-en-2-yl)phenyl)propan-2-amine (670 mg, 3.55 mmol, 1.0 eq.) in diethyl ether (7 
mL) was cooled to 0 °C. Water (3 mL) and potassium carbonate (1.48 g, 10.64 mmol, 3.0 eq.) was added, 
followed by dropwise addition of methyl chloroformate (503 mg, 5.317 mmol, 1.5 eq.). The cooling bath 
was removed and the reaction was allowed to warm to ambient temperature over 30 minutes. The 
separated aqueous phase was then extracted with diethyl ether (3 x 5 mL) and the combined organic 
extracts washed with brine (5 mL), dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/diethyl ether 2:1) to give carbamate 234 (400 mg, 66%) as an off-yellow 
oil which solidified upon standing to give long, white needles; m.p. 55 – 60 °C; δH 7.25 – 7.21 (1H, m, 
ArH), 7.21 – 7.18 (2H, m, 2 x ArH), 7.02 – 6.99 (1H, m, ArH), 5.58 (1H, q, J 6.6, ArC=CH), 4.51 (1H, br 
s, NH), 3.96 (1H, br s, NCH), 3.61 (3H, br s, OCH3), 2.84 – 2.68 (1H, m, ArCH2a), 2.69 – 2.51 (1H, m, 
ArCH2b), 1.97 (3H, s, ArCCH3), 1.38 (3H, dd, J 6.8 and 1.5, C=CHCH3), 1.10 (3H, d, J 6.5, NCHCH3); δ 
C (126 MHz, CDCl3) 156.3 (C=O), 142.0 (C), 136.8 (C), 135.55 (C), 129.5 (ArC=CH), 128.75 (ArCH), 
126.7 (ArCH), 126.45 (ArCH), 122.6 (ArCH), 51.8 (OCH3), 48.05 (NCH), 39.9 (ArCH2), 25.8 (CH3), 
21.1 (CH3), 14.8 (CH3); HRMS calculated for C15H22NO2 [M+H]
+
 248.1651, found 248.1641. 
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Methyl 1-ethyl-1,3-dimethyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 235  
 
 
 
 
The carbamate 234 (70 mg, 0.283 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (0.7 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (17 mg, 0.113 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 80 °C for 15 h. The reaction 
mixture was quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 
mL) and the combined organic extracts dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/diethyl ether 4:1) to give tetrahydroisoquinoline 235 (30 mg, 43%) as a 
colourless glass and as a 4:1 mixture of cis and trans isomers; major (cis)-isomer δH 7.28 (1H, d, J 7.9, 
ArH), 7.24 (1H, t, J 7.5, ArH), 7.15 (1H, td, J 7.3 and 1.2, ArH), 7.03 (1H, d, J 7.5, ArH), 4.83 (1H, br s, 
NCH), 3.73 (3H, s, OCH3), 3.10 (1H, dd, J 15.5 and 5.3, ArCH2a), 3.06 – 3.04 (1H, m, CH3CH2aC), 2.52 
(1H, dd, J 15.4 and 2.1, ArCH2b), 1.79 (3H, s, ArCCH3), 1.49 (1H, dq, J 14.6 and 7.3, CH3CH2bC), 1.01 
(3H, d, J 6.8, CHCH3), 0.48 (3H, t, J 7.4, CH3CH2C); δC 155.6 (C=O), 141.96 (C), 132.79 (C), 128.32 
(ArCH), 126.62 (ArCH), 125.94 (ArCH), 125.70 (ArCH), 61.54 (C), 52.03 (OCH3), 46.72 (NCH), 35.80 
(ArCH2), 27.28 (CH2), 19.38 (CH3), 8.35 (CH3); minor (trans)-isomer δH 7.32 (1H, d, J 7.9, ArH), 7.26 – 
7.13 (2H, m, 2 x ArH), 7.09 (1H, d, J 7.4, ArH), 4.70 (1H, br s, NCH), 3.73 (3H, s, OCH3), 3.04 (2H, dd, 
J 15.1 and 7.5, ArCH2a), 3.02 (1H, m, CH3CH2aC), 2.56 (1H, dd, J 15.1 and 2.4, ArCH2b), 2.05 (1H, dq, J 
14.8 and 7.3, CH3CH2bC), 1.57 (3H, s, ArCCH3), 0.90 (3H, d, J 6.7, CHCH3), 0.69 (3H, t, J 7.4, 
CH3CH2C); δC 141.2 (C), 133.6 (C), 129.2 (ArCH), 126.9 (ArCH), 126.1 (ArCH), 124.4 (ArCH), 62.1 
(C), 52.0 (OCH3), 47.7 (NCH), 35.9 (ArCH2), 31.1 (CH2), 20.15 (CH3), 9.4 (CH3); HRMS calculated for 
C15H22NO2 [M+H]
+
 248.1651, found 248.1639. 
 
Methyl 3-(2-bromophenyl)-2-phenylpropanoate 239 
 
 
 
To a freshly made solution of lithium diisopropyl amide (3.67 mmol, 1.1 eq.) in tetrahydrofuran prepared 
according to General Procedure E at – 78 °C was added methyl phenylacetate (0.5 g, 3.33 mmol, 1.0 eq.) 
as a solution in tetrahydrofuran (1 mL) over 5 minutes. The reaction was allowed to stir for 30 minutes at 
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the same temperature and 2-bromobenzyl bromide (1.25 g, 5.00 mmol, 1.5 eq.) was added dropwise, as a 
solution in tetrahydrofuran (1 mL) over 5 minutes. The reaction was allowed to warm up to ambient 
temperature over 1 h and quenched with aqueous ammonium chloride (10 mL). The separated aqueous 
phase was extracted with ethyl acetate (3 x 10 mL) and the combined organic extracts washed with brine 
(20 mL), dried, filtered and evaporated. The crude material was purified by column chromatography 
(petrol/dichloromethane 1:1) to give ester 239 (552 mg, 52%) as a colourless oil; νmax 1736 (C=O), 1160 
(C-O); δH (250 MHz) 7.54 (1H, dd, J 7.9 and 1.1, ArH), 7.35 – 7.27 (5H, m, 5 x ArH), 7.15 – 7.01 (3H, 
m, 3 x ArH), 4.05 (1H, dd, J 8.9 and 6.3, ArCHCOOCH3), 3.61 (3H, s, COOCH3), 3.51 (1H, dd, J 13.6 
and 8.9, ArCH2a), 3.14 (1H, dd, J 13.6 and 6.3, ArCH2b); δC 173.7 (C=O), 138.7 (C), 138.4 (C), 133.0 
(ArCH), 131.65 (ArCH), 128.8 (2 x ArCH), 128.35 (ArCH), 128.0 (2 x ArCH), 127.6 (ArCH), 127.35 
(ArCH), 124.8 (C-Br), 52.1 (OCH3), 51.3 (CH), 40.35 (CH2). 
 
3-(2-Bromophenyl)-2-phenylpropanoic acid 240 
 
 
 
 
To a solution of methyl 3-(2-bromophenyl)-2-phenylpropanoate 239 (552 mg, 1.73 mmol) in methanol 
(10 mL) at ambient temperature was added aqueous sodium hydroxide (1 mL) and the reaction mixture 
allowed to stir overnight. Diethyl ether (20 mL) was then added and the separated aqueous layer washed 
with diethyl ether (10 mL). The aqueous phase was then acidified with hydrochloric acid (2M, pH 14) and 
extracted with chloroform (3 x 10 mL). The combined chloroform extracts were dried, filtered and 
evaporated to yield the crude carboxylic acid 240 (354 mg, 67%) as a white glass; δH (250 MHz) 11.05 
(1H, br s, COOH), 7.54 – 7.47 (1H, m, ArH), 7.33 – 7.20 (5H, m, 5 x ArH), 7.11 – 6.96 (3H, m, 3 x 
ArH), 4.03 (1H, dd, J 8.4 and 6.7, ArCH2CH), 3.48 (1H, dd, J 13.7 and 8.5, ArCH2a), 3.11 (1H, dd, J 13.7 
and 6.6, ArCH2b). 
Ethyl (2-(2-bromophenyl)-1-phenylethyl)carbamate 241 
 
 
 
 
Diphenylphosphoryl azide (298 mg, 1.08 mmol, 1.1 eq.) and triethylamine (109 mg, 1.08 mmol, 1.1 eq.) 
were added to a solution of 3-(2-bromophenyl)-2-phenylpropanoic acid 240 (299 mg, 0.982 mmol, 1.0 
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eq.) in toluene (5 mL) under an atmosphere of nitrogen and the reaction mixture heated to reflux for 1 h. 
Copper (II) chloride (13 mg, 0.098 mmol, 0.1 eq.) and anhydrous ethanol (2.5 mL) were then added and 
the mixture heated under reflux for a further 1 h. The reaction mixture was concentrated in vacuo and 
partitioned between dichloromethane (10 mL) and water (10 mL). The separated aqueous phase was 
extracted with dichloromethane (3 x 10 mL) and the combined organic extracts washed with aqueous 
sodium bicarbonate (10 mL), brine (10 mL) and then dried, filtered and evaporated. The crude material 
was purified by column chromatography (dichloromethane) to yield carbamate 241 (146 mg, 56%) as a 
colourless oil; νmax 3398 (br, NH), 1700 (C=O); δH 7.49 (1H, d, J 7.9, ArH), 7.31 – 7.23 (4H, m, 4 x ArH), 
7.23 – 7.19 (1H, m, ArH), 7.13 (1H, td, J 7.5 and 1.2, ArH), 7.08 – 7.00 (2H, m, 2 x ArH), 5.19 (1H, br d, 
J 8.1, NH), 5.04 (1H, br s, NCH), 3.95 (2H, br s, OCH2), 3.15 (2H, br d, J 6.0, ArCH2), 1.14 (3H, br s, 
OCH2CH3); δC 156.0 (C=O), 142.25 (C), 137.35 (C), 133.0 (ArCH), 131.5 (br ArCH), 128.7 (2 x ArCH), 
128.4 (ArCH), 127.5 (ArCH), 127.4 (ArCH), 126.3 (ArCH), 125.1 (C), 60.95 (OCH2), 55.5 (NCH), 43.2 
(br. CH2), 14.6 (CH3); δH (250 MHz, 50 °C) 7.53 – 7.47 (1H, m, ArH), 7.32 – 7.17 (4H, m, 4 x ArH), 7.15 
– 6.97 (3H, m, 3 x ArH), 5.08 (1H, d, J 6.8, NH), 5.13 – 4.97 (1H, m, NCH), 3.96 (2H, q, J 7.1, OCH2), 
3.17 (2H, d, J 6.6, ArCH2), 1.10 (3H, t, J 7.1, OCH2CH3). 
 
Ethyl (E)-(2-(2-(hex-1-en-1-yl)phenyl)-1-phenylethyl)carbamate 242 
 
 
 
 
A solution of ethyl (2-(2-bromophenyl)-1-phenylethyl)carbamate 241 (111 mg, 1.0 eq.) in ethanol/water 
(1:1, 1 mL) was treated with 1-hexenylboronic acid (65 mg, 1.2 eq.), K3PO4 (165 mg, 2.0 eq) and 
Pd(dppf)Cl2.DCM (9 mg, 0.10 eq) at 90 °C for 2.5 h according to General Procedure D. The crude 
material was purified by column chromatography (petrol/ethyl acetate 4:1) to give carbamate 242 (67 mg, 
60%) as a colourless oil; νmax 3392 (br, NH), 1701 (C=O); δH 7.40 (1H, d, J 6.9, ArH), 7.33 – 7.27 (2H, m, 
ArH), 7.26 – 7.17 (3H, m, ArH), 7.18 – 7.14 (1H, m, ArH), 7.08 (1H, td, J 7.5 and 1.3, ArH), 6.94 (1H, 
dd, J 7.6 and 1.0, ArH), 6.58 (1H, d, J 15.6, ArCH=CH), 6.08 (1H, dt, J 15.4 and 6.9, ArCH=CH), 5.09 
(1H, br s, NH), 4.92 (1H, br. s, NCH), 4.02 (2H, d, J 6.6, OCH2), 3.11 (2H, br. d, J 6.5, ArCH2), 2.24 
(2H, q, J 7.1, ArCH=CHCH2), 1.52 – 1.45 (2H, m, ArCH=CHCH2CH2), 1.44 – 1.35 (2H, m, 
CH2CH2CH3), 1.17 (3H, br s, OCH2CH3), 0.95 (3H, t, J 7.2, CH2CH2CH3); δC 156.0 (C=O), 142.5 (C), 
137.8 (C), 134.4 (C), 133.9 (ArCH=CH), 130.5 (ArCH), 128.6 (2 x ArCH), 127.4 (ArCH), 127.4 (ArCH), 
127.05 (ArCH), 126.9 (ArCH=CH), 126.5 (ArCH), 126.4 (ArCH), 60.9 (br, OCH2), 56.3 (NCH) , 40.8 
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(br, ArCH2), 33.1 (C=CCH2), 31.7 (CH2CH2CH3), 22.45 (CH2CH3), 14.65 (OCH2CH3), 14.1 (CH2CH3); 
HRMS calculated for C23H29NO2 [M]
+
 351.2198, found 351.2193. 
 
Ethyl 1-pentyl-3-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 246 
 
 
 
 
The carbamate 242 (50 mg, 0.142 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (0.5 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (8.5 mg, 0.057 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 6 h. The reaction 
mixture was quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 
mL) and the combined organic extracts dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/ethyl acetate 4:1) to give tetrahydroisoquinoline 246 (33 mg, 65%) as a 
yellowish glass and as a 2:1 mixture of isomers; νmax 1698 (C=O); major isomer δH 7.21 – 7.12 (2H, m, 2 
x ArH), 7.12 – 7.03 (5H, m, 5 x ArH), 6.89 – 6.75 (2H, m, 2 x ArH), 5.35 (1H, d, J 4.9, 1-CH), 5.15-5.17 
(1H, m, 3-CH), 3.96 (2H, q, J 6.0, OCH2), 3.56 (1H, dd, J 14.7 and 5.9, ArCH2a), 2.83 (1H, m, ArCH2b), 
1.71 – 1.53 (2H, m, ArCHCH2CH2), 1.43 – 1.11 (6H, m), 0.92 – 0.83 (6H, m, OCH2CH3 and 
CH2CH2CH3); minor isomer δH 5.44 (1H, br. s, 3-CH), 5.01 (1H, br. d, J 6.9, 1-CH), 4.11 (2H, br s, 
OCH2), 3.56 (1 H, dd, J 14.7, 5.9); only 4 distinct signals. 
 
Methyl (2-(2-bromophenyl)-1-phenylethyl)carbamate 243 
 
 
 
 
Diphenylphosphoryl azide (748 mg, 2.72 mmol, 1.15 eq.) and triethylamine (276 mg, 2.72 mmol, 1.15 
eq.) were added to a solution of 3-(2-bromophenyl)-2-phenylpropanoic acid 240 (721 mg, 2.37 mmol, 1.0 
eq.) in toluene (5 mL) under an atmosphere of nitrogen and the reaction mixture heated to reflux for 1 h. 
Copper (II) chloride (32 mg, 0.237 mmol, 0.1 eq.) and anhydrous methanol (2.0 mL) were then added and 
the mixture heated under reflux for a further 1 h. The reaction mixture was concentrated in vacuo and 
partitioned between dichloromethane (10 mL) and water (10 mL). The separated aqueous phase was 
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extracted with dichloromethane (3 x 10 mL) and the combined organic extracts washed with aqueous 
sodium bicarbonate (10 mL), brine (10 mL) and then dried, filtered and evaporated. The crude material 
was purified by column chromatography (petrol/ethyl acetate 3:1) to yield carbamate 243 (484 mg, 61%) 
as a colourless glass; νmax 1702 (C=O); δH (400 MHz) 7.55 (1H, d, J 7.7, ArH), 7.37 – 7.24 (5H, m, 5 x 
ArH), 7.22 – 7.16 (1H, m, ArH), 7.14 – 7.06 (2H, m, 2 x ArH), 5.25 (1H, br s, NCH), 5.07 (1H, d, J 6.5, 
NH), 3.56 (3H, s, OCH3), 3.19 (2H, d, J 7.2, ArCH2); δC 156.3 (C=O), 142.2 (C), 137.2 (ArCH), 133.0 
(ArCH), 131.4 (br C), 128.7 (2 x ArCH), 128.5 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 126.3 (br ArCH), 
125.1 (C), 55.7 (CH), 52.2 (OCH3), 43.1 (CH2); LRMS (EI)
+
 m/z 259 ([M-NHCOOCH3]
+
, 25%), 178 
([PhCHNHCOOMe]
+
, 70%), 162 (100%).  
 
Methyl (E)-(2-(2-(hex-1-en-1-yl)phenyl)-1-phenylethyl)carbamate 244 
 
 
 
 
A solution of methyl (2-(2-bromophenyl)-1-phenylethyl)carbamate (248 mg, 1.0 eq.) in ethanol/water 
(1:1, 2.5 mL) was treated with 1-hexenylboronic acid (142 mg, 1.2 eq.), K3PO4 (315 mg, 2.0 eq) and 
Pd(dppf)Cl2.DCM (20 mg, 0.10 eq) at 60 °C for 1 h according to General Procedure D. The crude 
material was purified by column chromatography (petrol/ethyl acetate 4:1) to give the carbamate 244 
(118 mg, 48%) as a colourless glass; νmax 3392 (br, NH), 1696 (C=O); δH 7.31 (1H, d, J 7.7, ArH), 7.21 
(2H, t, J 7.3, 2 x ArH), 7.16 – 7.14 (1H, m, ArH), 7.12 – 7.09 (2H, m, 2 x ArH), 7.07 (1H, d, J 7.6), 6.98 
(1H, dt, J 7.6 and 1.2, ArH), 6.84 (1H, d, J 7.4, ArH), 6.50 (1H, d, J 15.6, ArCH=CH), 6.00 (1H, dt, J 
15.4 and 6.9, ArCH=CH), 5.06 (1H, br s, NH), 4.83 (1H, br s, NCH), 3.49 (3H, s, OCH3), 3.01 (2H, br d, 
J 6.5, ArCH2), 2.15 (2H, q, J 7.2, CH=CHCH2), 1.43 – 1.36 (2H, m, CH3CH2CH2), 1.32 (2H, ddq, J 14.1, 
7.0 and 2.0, CH3CH2), 0.87 (3H, t, J 7.2, CH3); δC 156.3 (C=O), 142.4 (C), 137.75 (C), 134.3 (C), 133.95 
(ArCH=C), 130.5 (ArCH), 128.6 (2 x ArCH), 127.45 (ArCH), 127.3 (ArCH), 127.1 (ArCH), 126.9 
(ArCH=C), 126.45 (ArCH), 126.4 (ArCH), 56.4 (NCH), 52.15 (OCH3), 40.7 (ArCH2), 33.1 (CH2), 31.6 
(CH2), 29.8 (CH2), 22.4 (CH2), 14.1 (CH3). 
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Methyl 1-pentyl-3-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 245 
 
 
 
 
 
The carbamate 244 (52 mg, 0.154 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (0.5 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (9 mg, 0.062 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 6 h. The reaction 
mixture was quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 
mL) and the combined organic extracts dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/ethyl acetate 4:1) to give carbamate 245 (31 mg, 60%) as a yellowish 
glass and as a 2:1 mixture of isomers; νmax 1702 (C=O); major isomer δH (400 MHz) 7.19 – 7.17 (1H, m, 
ArH), 7.15 – 6.97 (3H, m, 4 x ArH), 6.97 – 6.86 (4H, m, 4 x ArH), 6.69 – 6.67 (1H, m, ArH), 5.23 (1H, 
br d, J 4.4, 3-CH), 5.00 (1H, br d, J 6.9, 1-CH), 3.44 – 3.38 (3H, br s, OCH3), 3.38 (1H, m, ArCH2a), 2.68 
(1H, br d, J 14.9, ArCH2b), 1.97 – 1.86 (2H, m, ArCHCH2CH2), 1.34 – 1.00 (6H, m), 0.78 – 0.69 (6H, m); 
minor isomer δH (400 MHz) 5.29 (1H, s, 3-CH), 4.86 (1H, d, J 7.4, 1-CH), 3.59 (3H, s, OCH3), 3.18 (1H, 
dd, J 15.6 and 7.8, ArCH2a), 3.03 – 2.85 (1H, m, ArCH2b), 1.86 – 1.76 (2H, m, ArCHCH2CH2). 
 
Methyl 3-(2-bromophenyl)-2-methylpropanoate 248 
 
 
 
 
 
To a freshly made solution of lithium diisopropyl amide (22.23 mmol, 1.0 eq.) in tetrahydrofuran 
prepared according to General Procedure E at – 78 °C was added methyl propionate (1.95 g, 22.23 mmol, 
1.0 eq.) as a solution in tetrahydrofuran (5 mL) over 5 minutes. The reaction was allowed to stir for 30 
minutes at the same temperature and 2-bromobenzyl bromide (10.0 g, 40.1 mmol, 1.8 eq.) was added 
dropwise, as a solution in tetrahydrofuran (15 mL) over 5 minutes. The reaction was allowed to warm up 
to ambient temperature over 1 h and quenched with aqueous ammonium chloride (40 mL). The separated 
aqueous phase was extracted with ethyl acetate (3 x 10 mL) and the combined organic extracts washed 
with brine (20 mL), dried, filtered and evaporated to give the ester 248 (3.427 g, 60%) as a colourless oil; 
νmax 1739 (C=O), 1152 (C-O); δH (250 MHz) 7.58 – 7.47 (1H, m, ArH), 7.19 (2H, m, 2 x ArH), 7.08 – 
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7.06 (1H, m, ArH), 3.63 (3H, s, OCH3), 3.13 (1H, dd, J 12.5 and 6.7, ArCH2a), 2.96 – 2.75 (2H, m, 
ArCH2b and CHCOOCH3), 1.19 (3H, d, J 6.8, CH3). 
 
3-(2-Bromophenyl)-2-methylpropanoic acid
239
 249 
 
 
 
To a solution of methyl methyl 3-(2-bromophenyl)-2-methylpropanoate 248 (3.427 mg, 13.34 mmol) in 
methanol (50 mL) at ambient temperature was added aqueous sodium hydroxide (4 mL) and the reaction 
mixture allowed to stir at 60 °C for 2h. The reaction was cooled to ambient temperature and diethyl ether 
(20 mL) was added and the separated aqueous layer washed with diethyl ether (10 mL). The aqueous 
phase was then acidified with hydrochloric acid (2M, pH 1) and extracted with chloroform (3 x 20 mL). 
The combined chloroform extracts were dried, filtered and evaporated to yield crude carboxylic acid 249 
(1.88 g, 58%) as a white solid; δH 12.06 (1H, br. s, COOH), 7.57 (1H, d, J 7.8, ArH), 7.27 – 7.24 (2H, m, 
2 x ArH), 7.12 – 7.09 (1H, m, ArH), 3.23 (1H, dd, J 13.6 and 6.9, ArCH2a), 3.00 – 2.92 (1H, m, NCH), 
2.85 (1H, dd, J 13.6 and 7.7, ArCH2b), 1.26 (3H, d, J 7.0, CH3); δC 182.7 (C=O), 138.6 (C), 133.1 
(ArCH), 131.45 (ArCH), 128.3 (ArCH), 127.5 (ArCH), 124.9 (C-Br), 39.6 (CH), 39.4 (CH2), 16.8 (CH3); 
HRMS (ES
-
)calculated for C10H11BrO2 [M-H]
-
 240.9864, found 240.9868. 
 
Methyl (1-(2-bromophenyl)propan-2-yl)carbamate 250 
 
 
 
Diphenylphosphoryl azide (4.46 g, 16.22 mmol, 1.15 eq.) and triethylamine (1.64 g, 16.22 mmol, 1.15 
eq.) were added to a solution of 3-(2-bromophenyl)-2-methylpropanoic acid 249 (3.20 g, 14.10 mmol, 1.0 
eq.) in toluene (50 mL) under an atmosphere of nitrogen and the reaction mixture heated to reflux for 1 h. 
Copper (II) chloride (190 mg, 1.41 mmol, 0.1 eq.) and anhydrous methanol (20 mL) were then added and 
the mixture heated under reflux for a further 1 h. The reaction mixture was concentrated in vacuo and 
partitioned between dichloromethane (50 mL) and water (50 mL). The separated aqueous phase was 
extracted with dichloromethane (3 x 10 mL) and the combined organic extracts washed with aqueous 
sodium bicarbonate (10 mL), brine (10 mL) and then dried, filtered and evaporated. The crude material 
was purified by column chromatography (petrol/ethyl acetate 4:1) to yield carbamate 250 (1.95 g, 50%) 
as a colourless glass; δH (400 MHz) 7.51 (1H, d, J 8.0, ArH), 7.21 (2H, app d, J 4.5, 2 x ArH), 7.10 – 7.01 
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(1H, m, ArH), 4.87 (1H, br s, NH), 4.10 – 3.98 (1H, br m, NCH), 3.58 (3H, s, OCH3), 3.01 – 2.90 (1H, br. 
m, ArCH2a), 2.85 (1H, br dd, J 13.5 and 6.7, ArCH2a), 1.17 (3H, d, J 6.6, CH3); δC (101 MHz) 156.4 
(C=O), 138.0 (C), 132.95 (ArCH), 131.4 (ArCH), 128.2 (ArCH), 127.5 (ArCH), 125.1 (C-Br), 52.0 
(OCH3), 47.8 (CH), 42.6 (CH2), 20.8 (CH3). 
 
Methyl 3-methyl-1-pentyl-3,4-dihydroisoquinoline-2(1H)-carboxylate  252 
 
 
 
 
The carbamate 251 (57 mg, 0.207 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (0.6 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (12 mg, 0.083 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 10 h. The reaction 
mixture was quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 
mL) and the combined organic extracts dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/ethyl acetate 4:1) to give tetrahydroisoquinoline 252 (41 mg, 60%) as a 
colourless glass and as a 4:1 mixture of isomers; νmax 1697 (C=O), 1222 (C-O); major isomer δH 7.25 – 
7.09 (2H, m, 2 x ArH), 7.06 (1H, br s, ArH), 4.72 (1H, br s, ArCHN), 4.41 (1H, br s, ArCH2CHN), 3.76 
(3H, s, OCH3), 3.23 (1H, dd, J 14.9 and 5.3, ArCH2a), 2.55 (1H, br. d, J 13.6, ArCH2b), 1.33 – 1.05 (8H, 
m, 4 x CH2), 0.83 (6H, m, CH2CH3 and CHCH3); δH (DMSO, 90 °C) 7.33 – 7.18 (4H, m, 4 x ArH), 4.73 
(1H, dd, J 9.5 and 3.0, ArCHN), 4.39 – 4.35 (1H, m, ArCH2CHN), 3.72 (3H, s, OCH3), 3.24 (1H, dd, J 
15.0 and 5.3, ArCH2a), 2.67 (1H, app d, J 15.0, ArCH2a), 1.67 – 1.02 (8H, m, 4 x CH2), 0.86 (6H, m, 
CH2CH3 and CHCH3); δC 156.8 (C=O), 137.2 (C), 128.8 (ArCH), 127.4 (ArCH), 127.8 (ArCH), 126.2 
(C), 126.0 (ArCH), 56.8 (ArCHN), 52.3 (OCH3), 48.0 (ArCH2CH), 35.15 (ArCH2), 31.7 (CH2), 31.5 
(CH2), 25.8 (CH2), 22.6 (CH2), 19.9 (br. CH3), 14.0 (CH3); minor isomer δH 7.23 – 7.02 (4H, m, 4 x ArH), 
5.18 (1H, br s, ArCHN), 4.13 (1H, br s, ArCH2CHN), 3.69 (3H, s, OCH3), 2.97 (1H, dd, J 15.4 and 6.2, 
ArCH2a), 2.81 (1H, dd, J 15.6 and 9.8, ArCH2b), 1.98 – 1.42 (8H, m, 4 x CH2), 1.39 (3H, d, J 6.3, 
CHCH3), 0.96 – 0.85 (3H, m, CH2CH3); δH (DMSO, 90 °C) 7.34 – 7.18 (4H, m, 4 x ArH), 5.13 (1H, br s, 
ArCHN), 4.10 – 4.01 (1H, br m, ArCH2CHN), 3.66 (1H, s, OCH3), 3.07 (1H, dd, J 15.8 and 7.0, ArCH2a), 
2.85 (1H, dd, J 15.8 and 10.0, ArCH2b), 1.88 – 1.42 (8H, m, 4 x CH2), 1.39 (3H, d, J 6.2, CHCH3), 0.94 – 
0.89 (3H, m, CH2CH3); δC 56.6 (ArCHN), 52.4 (OCH3), 47.9 (ArCH2CH), 34.95 (ArCH2), 26.4 (CH2), 
22.5 (CH2), 20.0 (CH3), 14.0 (CH3); only 8 distinctive signals; HRMS calculated for C17H26NO2 [M+H]
+
 
276.1964, found 276.1964 
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1-Bromo-2-(bromomethyl)-4-chlorobenzene
240
 254 
 
 
 
 
To a solution of 1-bromo-4-chloro-2-methylbenzene 253 (5.0 g, 24.3 mmol, 1.0 eq.) in carbon 
tetrachloride (100 mL) at ambient temperature was added N-bromosuccinimide (4.3 g, 24.3 mmol, 1.0 
eq.) and AIBN (40 mg, 0.243 mmol, 0.01 eq.) and the solution was heated to reflux at 80 °C for 8 h. The 
reaction mixture was allowed to cool to ambient temperature, aqueous sodium bicarbonate (100 mL) was 
added and the mixture was stirred for a further 2 h. The separated organic phase was washed with brine 
(50 mL), dried, filtered and evaporated and the crude material purified by Kugelrohr distillation (185 – 
210 °C, 20 mbar) to give bromide 254 (5.25 g, 76%) as a pale yellow oil; δH (250 MHz) 7.50 (1H, d, J 
8.5, ArH), 7.45 (1H, d, J 2.5, ArH), 7.15 (1H, dd, J 8.5 and 2.5, ArH), 4.53 (2H, s, ArCH2); δC (101 MHz) 
138.7 (C), 134.5 (ArCH), 133.85 (C), 131.2 (ArCH), 130.3 (ArCH), 122.4 (C-Br), 32.4 (CH2). 
 
3-(2-Bromo-5-chlorophenyl)-2-methylpropanoic acid 256 
 
 
 
To a freshly made solution of lithium diisopropyl amide (23.83 mmol, 1.5 eq.) in tetrahydrofuran 
prepared according to General Procedure E at – 78 °C was added methyl propionate (2.10 g, 23.83 mmol, 
1.5 eq.) as a solution in tetrahydrofuran (5 mL) over 5 minutes. The reaction was allowed to stir for 30 
minutes at the same temperature and 1-bromo-2-(bromomethyl)-4-chlorobenzene 254 (4.52 g, 15.88 
mmol, 1.0 eq.) was added dropwise, as a solution in tetrahydrofuran (15 mL) over 5 minutes. The reaction 
was allowed to warm up to ambient temperature over 1 h and quenched with aqueous ammonium chloride 
(40 mL). The separated aqueous phase was extracted with ethyl acetate (3 x 10 mL) and the combined 
organic extracts washed with brine (20 mL), dried, filtered and evaporated. The residue was dissolved in 
methanol (70 mL) at ambient temperature and aqueous aqueous sodium hydroxide (4 mL) was added and 
the reaction mixture allowed to stir at 60 °C for 2 h. The reaction was cooled to ambient temperature and 
diethyl ether (20 mL) was added and the separated aqueous layer washed with diethyl ether (10 mL). The 
aqueous phase was then acidified with hydrochloric acid (2M, pH 1) and extracted with chloroform (3 x 
20 mL). The combined chloroform extracts were dried, filtered and evaporated to yield carboxylic acid 
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256 (1.69 g mg, 38%) as a yellow oil; νmax 3468 (OH), 1741 (C=O); δH 10.75 (1H, br s, COOH), 7.45 
(1H, d, J 8.5, ArH), 7.21 (1H, d, J 2.5, ArH), 7.06 (1H, dd, J 8.5 and 2.6, ArH), 3.14 (1H, dd, J 13.6 and 
7.0, ArCH2a), 2.93 – 2.85 (1H, m, NCH), 2.77 (1H, dd, J 13.6 and 7.6, ArCH2b), 1.23 (3H, d, J 7.0, CH3). 
 
Methyl (1-(2-bromo-5-chlorophenyl)propan-2-yl)carbamate 257 
 
 
 
 
Diphenylphosphoryl azide (1.83 g, 6.63 mmol, 1.15 eq.) and triethylamine (671 mg, 6.63 mmol, 1.15 eq.) 
were added to a solution of 3-(2-bromo-5-chlorophenyl)-2-methylpropanoic acid 256 (1.60 g, 5.77 mmol, 
1.0 eq.) in toluene (30 mL) under an atmosphere of nitrogen and the reaction mixture heated to reflux for 
1 h. Copper (II) chloride (77 mg, 0.57 mmol, 0.1 eq.) and anhydrous methanol (2.8 mL) were then added 
and the mixture heated under reflux for a further 1 h. The reaction mixture was concentrated in vacuo and 
partitioned between dichloromethane (50 mL) and water (50 mL). The separated aqueous phase was 
extracted with dichloromethane (3 x 10 mL) and the combined organic extracts washed with aqueous 
sodium bicarbonate (10 mL), brine (10 mL) and then dried, filtered and evaporated. The crude material 
was purified by column chromatography (petrol/diethyl ether 1:1) to yield carbamate 257 (1.95 g, 50%) 
as a colourless glass; νmax 3350 (br, NH), 1681 (C=O), 1103 (C-O); δH 7.43 (1H, d, J 8.5, ArH), 7.20 (1H, 
d, J 1.9, ArH), 7.04 (1H, dd, J 8.5 and 2.6, ArH), 4.78 (1H, br. s, NH), 4.05 – 3.96 (1H, br. m, NCH), 
3.59 (3H, s, OCH3), 2.89 (1H, br. s, ArCH2a), 2.82 (1H, dd, J 13.5 and 6.6, ArCH2b), 1.17 (3H, d, J 6.6, 
CH3); δC 156.35 (C=O), 139.9 (C), 133.9 (ArCH), 133.3 (C), 131.2 (ArCH), 128.3 (ArCH), 122.9 (C-Br), 
52.0 (OCH3), 47.6 (CH), 42.6 (CH2), 20.8 (CH3). 
 
Methyl (E)-(1-(5-chloro-2-(hex-1-en-1-yl)phenyl)propan-2-yl)carbamate 258 
 
 
 
A solution of methyl (1-(2-bromo-5-chlorophenyl)propan-2-yl)carbamate 257 (148 mg, 1.0 eq.) in 
ethanol/water (1:1, 1.5 mL) was treated with 1-hexenylboronic acid (92 mg, 1.2 eq.), K3PO4 (205 mg, 2.0 
eq) and Pd(dppf)Cl2.DCM (8 mg, 0.04 eq) at 90 °C for 2.5 h according to General Procedure D. The 
crude material was purified by column chromatography (petrol/diethyl ether 2:1) to give carbamate 258 
(100 mg, 67%) as a pale yellow solid; m.p. 42 – 44 °C; νmax 3348 (br, NH), 1700 (C=O); δH (400 MHz) 
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7.36 (1H, d, J 8.4, ArH), 7.14 (1H, dd, J 8.4 and 2.2, ArH), 7.08 (1H, d, J 1.9, ArH), 6.63 (1H, d, J 15.5, 
ArCH=CH), 6.08 (1H, dt, J 15.5 and 7.0, ArCH=CH), 4.62 (1H, br d, J 6.0, NH), 3.90 (1H, br m, NCH), 
3.64 (3H, s, OCH3), 2.94 (1H, dd, J 13.6 and 5.9, ArCH2a), 2.63 (1H, br. dd, J 12.8 and 7.7, ArCH2b), 2.24 
(2H, dq, J 7.3 and 1.2, ArCH=CHCH2), 1.50 – 1.42 (2H, m, CH3CH2CH2), 1.37 (2H, ddq, J 14.1, 7.0 and 
1.8, CH3CH2CH2), 1.09 (3H, d, J 6.6, CH3CHN), 0.93 (3H, t, J 7.2, CH3CH2); δC (101 MHz) 156.3 
(C=O), 136.9 (C), 136.0 (C), 134.1 (ArCH=C), 132.2 (C), 130.4 (ArCH), 127.5 (ArCH), 127.0 (ArCH), 
126.4 (ArCH=C), 52.0 (OCH3), 47.85 (NCH), 40.1 (ArCH2), 33.1 (CH2), 31.6 (CH2), 22.4 (CH2), 20.4 
(CH3), 14.1 (CH3); HRMS calculated for C17H25ClNO2 [M+H]
+
 310.1574, found 310.1563. 
 
Methyl 6-chloro-3-methyl-1-pentyl-3,4-dihydroisoquinoline-2(1H)-carboxylate  259 
 
 
 
 
The carbamate 258 (41 mg, 0.134 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (0.4 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (8 mg, 0.054 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 10 h. The reaction 
mixture was quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 
mL) and the combined organic extracts dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/diethyl ether 4:1) to give tetrahydroisoquinoline 259 (31 mg, 76%) as a 
colourless glass and as a 3.5:1 mixture of isomers; νmax 1699 (C=O); major diastereoisomer δH 7.18 – 
7.15 (2H, m, 2 x ArH), 6.99 (1H, d, J 7.0, ArH), 4.73 (1H, br s, ArCHN), 4.39 (1H, br s, ArCH2CH), 3.75 
(3H, s, OCH3), 3.20 (1H, dd, J 15.0 and 5.3, ArCH2a), 2.52 (1H, br d, J 15.0, ArCH2b), 2.00 – 1.80 (2H, 
m, ArCHCH2), 1.34 – 1.02 (6H, m, 3 x CH2), 0.90 (3H, m, CH3CH), 0.82 (3H, t, J 6.8, CH3CH2); δC 
156.1 (C=O), 135.9 (C), 132.8 (C), 129.0 (ArCH), 128.8 (ArCH), 126.35 (ArCH), 56.5 (ArNCH), 52.5 
(OCH3), 47.7 (NCHCH3), 36.39 (CH3), 36.8 (CH2), 34.8 (ArCH2), 31.6 (CH2), 25.9 (CH2), 22.7 (CH2), 
14.1 (CH3);  minor diastereoisomer δH 7.14 – 7.11 (2H, m, 2 x ArH), 7.03 (1H, d, J 8.0, ArH), 5.13 (1H, br 
s, ArCHN), 4.14 (1H, br s, ArCH2CH), 3.70 (3H, s, OCH3), 2.93 (1H, dd, J 15.7 and 6.7, ArCH2a), 2.77 
(1H, dd, J 15.8 and 9.5, ArCH2b), 1.97 – 1.68 (2H, m, CH2), 1.37 (3H, d, J 6.3, CH3CH), 1.31 – 1.13 (6H, 
m, 3 x CH2), 0.90 – 0.86 (3H, m, CH3CH2); δC 135.8 (C), 132.6 (C), 128.1 (ArCH), 127.85 (ArCH), 126.4 
(ArCH), 56.5 (ArNCH), 47.7 (NCHCH3), 36.5 (CH2), 35.0 (ArCH2), 31.8 (CH2), 26.6 (CH2), 22.5 (CH2), 
19.4 (CH3), 14.15 (CH3). 
 
 168 
 
(E)-1-Bromo-4-fluoro-2-(2-nitroprop-1-en-1-yl)benzene 260 
 
 
 
 
To a solution of 2-bromo-5-fluorobenzaldehyde (1.1 g, 5.42 mmol, 1.0 eq.) in nitroethane (7.4 g, 98.5 
mmol, 20 eq.) was added ammonium acetate (304 mg, 3.94 mmol, 0.8 eq.) and the mixture heated to 
reflux for 3 hours. The reaction was then allowed to cool to room temperature, and the solvent was 
removed in vacuo at 5 mbar pressure and at 60 °C for 1 hour. The crude reaction mixture was redissolved 
in diethyl ether (100 mL), washed with water (3 x 25 mL), dried, filtered and evaporated. The crude 
material was recrystallized from hot hexane to give nitroalkene 260 (1.24 g, 88%) as a yellow solid; m.p. 
56 – 59 °C; δH 8.04 (1H, s, ArCH=CH), 7.65 – 7.61 (1H, m, ArH), 7.04 (1H, d, J 8.5, ArH), 7.06 – 6.99 
(1H, m, ArH), 2.33 (3H, d, J 1.1, CH3); δC 161.7 (d, J 248.9, C-F), 149.9 (CH=CNO2), 134.9 (d, J 8.1, 
FC-ArCH-C), 134.7 (d, J 8.2, FC-ArCH-ArCH), 131.7 (CH=CNO2), 119.0 (d, J 3.4, C-Br), 118.3 (d, J 
22.4, FC-ArCHa), 117.45 (d, J 23.9, FC-ArCHb), 13.9 (CH3). 
 
1-(2-Bromo-5-fluorophenyl)propan-2-amine 261 
 
 
 
 
 
A solution of (E)-1-Bromo-4-fluoro-2-(2-nitroprop-1-en-1-yl)benzene 260 (1.24 g, 4.76 mmol, 1.0 eq.) in 
tetrahydrofuran was treated with sodium borohydride (855 mg, 22.61 mmol, 4.75 eq.), and boron 
trifluoride diethyl etherate (4.05 g, 28.56 mmol, 6.0 eq.) according to the General Procedure F to afford 
amine 261 (692 mg, 63%) as a brown oil; δH (250 MHz) 7.49 – 7.46 (1H, m, ArH), 6.98 – 6.95 (1H, m, 
ArH), 6.86 – 6.76 (1H, m, ArH), 3.34 – 3.19 (1H, m, NCH), 2.81 (1H, dd, J 13.3 and 5.6, ArCH2a), 2.65 
(1H, dd, J 13.3 and 7.8, ArCH2b), 2.42 – 1.44 (2H, m, br s, NH2), 1.14 (3H, d, J 6.3, CH3); δC 161.78 (d, J 
246.9, C-F), 141.3 (d, J 7.4, FC-ArCH-ArC), 134.0 (d, J 8.1, FC-ArCH-ArCH), 118.9 (d, J 3.1, C-Br), 
118.2 (d, J 22.2, FC-ArCHa), 115.1 (d, J 22.4, FC-ArCHa), 47.0 (CH), 46.5 (CH2), 23.5 (CH3). 
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Methyl (1-(2-bromo-5-fluorophenyl)propan-2-yl)carbamate 262 
 
 
 
 
A solution of 1-(2-bromo-5-fluorophenyl)propan-2-amine 261 (691 mg, 2.98 mmol, 1.0 eq.) in diethyl 
ether (4 mL) was cooled to 0 °C. Water (4 mL) and potassium carbonate (1.26 g, 9.04 mmol, 3.0 eq.) was 
added, followed by dropwise addition of methyl chloroformate (395 mg, 4.174 mmol, 1.4 eq.). The 
cooling bath was removed and the reaction was allowed to warm to ambient temperature over 30 minutes. 
The separated aqueous phase was then extracted with diethyl ether (3 x 5 mL) and the combined organic 
extracts washed with brine (5 mL), dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/diethyl ether 1:1) to give carbamate 262 (651 mg, 75%) as an off-yellow 
oil; νmax 3345 (br, NH), 1681 (C=O), 1058 (C-O); δH 7.49 – 7.46 (1H, m, ArH), 6.95 (1H, m, ArH), 6.83 – 
6.79 (1H, m, ArH), 4.72 (1H, d, J 7.7, NH), 4.03 (1H, br d, J 6.2, NCH), 3.60 (3H, s, OCH3), 2.92 (1H, br 
d, J 6.3, ArCH2a), 2.84 (1H, dd, J 13.5 and 6.6, ArCH2b), 1.19 (3H, d, J 6.6, CH3); δC 161.8 (d, J 246.9, C-
F), 156.2 (br s, C=O), 140.1 (d, J 7.4, C), 133.9 (d, J 8.0, ArCH), 119.0 (d, J 3.0, C-Br), 118.1 (d, J 22.4, 
ArH), 115.3 (d, J 22.4, ArCH), 52.0 (OCH3), 47.6 (NCH), 42.7 (CH2), 20.7 (CH3). 
 
Methyl (E)-(1-(5-fluoro-2-(hex-1-en-1-yl)phenyl)propan-2-yl)carbamate 263 
 
 
 
A solution of methyl (1-(2-bromo-5-fluorophenyl)propan-2-yl)carbamate 262 (441 mg, 1.0 eq.) in 
ethanol/water (1:1, 4 mL) was treated with 1-hexenylboronic acid (291 mg, 1.5 eq.), K3PO4 (645 mg, 2.0 
eq) and Pd(dppf)Cl2.DCM (41 mg, 0.05 eq) at 85 °C for 2 h according to General Procedure D. The crude 
material was purified by column chromatography (petrol/diethyl ether 2:1) to give the carbamate 263 
(301 mg, 68%) as a pale yellow oil; νmax 3330 (br, NH), 1701 (C=O); δH 7.38 – 7.35 (1H, m, ArH), 6.87 – 
6.86 (1H, m, ArH), 6.81 (1H, d, J 9.4, ArH), 6.62 (1H, d, J 15.5, ArCH=CH), 6.02 (1H, dt, J 15.4 and 7.0, 
ArCH=CH), 4.75 (1H, br s, NH), 3.92 (1H, br s, NCH), 3.63 (3H, s, OCH3), 2.94 (1H, dd, J 13.6 and 6.1, 
ArCH2a), 2.65 (1H, br dd, J 12.2 and 7.3, ArCH2b), 2.23 (2H, qd, J 7.3 and 1.3, ArCH=CHCH2), 1.49 – 
1.41 (2H, m, CH3CH2CH2), 1.37 (2H, dq, J 13.9 and 6.9, CH3CH2), 1.10 (2H, d, J 6.6, CH3CH), 0.92 (3H, 
t, J 7.3, CH3CH2); δH (250 MHz, 50 °C) 7.39 – 7.35 (1H, m, ArH), 6.89 – 6.80 (2H, m, 2 x ArH), 6.62 
(1H, d, J 15.6, ArCH=CH), 6.02 (1H, dt, J 15.5 and 6.9, ArCH=CH), 4.55 (1H, d, J 6.9, NH), 3.95 – 3.92 
(1H, m, NCH), 3.64 (3H, s, OCH3), 2.94 (1H, dd, J 13.7 and 6.2, ArCH2a), 2.67 (1H, dd, J 13.7 and 7.5, 
ArCH2b), 2.24 (2H, qd, J 7.1 and 1.2, ArCH=CHCH2), 1.55 – 1.31 (4H, m, CH3CH2CH2), 1.12 (3H, d, J 
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6.6, CH3CH), 0.94 (3H, t, J 7.1, CH3CH2); δC 161.7 (d, J 245.5, C-F), 156.3 (C=O), 137.3 (d, J 7.2, ArC-
CH=CH), 133.7 (C), 133.3 (ArCH=CH), 127.8 (d, J 8.0, FC-ArCH-ArCH), 126.5 (ArC-CH=CH), 116.95 
(d, J 21.0, FC-ArCHa), 113.7 (d, J 21.1, FC-ArCHb), 51.9 (OCH3), 47.9 (NCH), 40.1 (ArCH2), 33.0 
(CH=CHCH2), 31.6 (CH2), 22.35 (CH2), 20.4 (CH3), 14.0 (CH3); HRMS calculated for C17H25FNO2 
[M+H]
+
 294.1869, found 294.1858. 
 
Methyl 6-fluoro-3-methyl-1-pentyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 264 
 
 
 
The carbamate 263 (83 mg, 0.283 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (0.8 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (17 mg, 0.113 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 6 h. The reaction 
mixture was quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 
mL) and the combined organic extracts dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/diethyl ether 2:1) to give tetrahydroisoquinoline 264 (62 mg, 75%) as a 
colourless glass and as a 2:1 mixture of isomers; νmax 1699 (C=O), 1245 (C-O); major diastereoisomer δH  
7.08 – 6.98 (1H, br m, ArH), 6.90 – 6.81 (2H, m, 2 x ArH), 4.70 (1H, br m, ArCHN), 4.40 (1H, br m, 
ArCH2CH), 3.75 (3H, s, OCH3), 3.21 (1H, dd, J 15.0 and 5.3, ArCH2a), 2.52 (1H, br d, J 13.8, ArCH2b), 
1.82 – 1.71 (2H, m, ArCHCH2), 1.30 – 1.12 (6H, m, CH3CH2CH2CH2), 0.87 (3H, m, CH3CH), 0.82 (3H, 
t, J 6.3, CH3CH2); δH (250 MHz, 50 °C) 7.10 – 6.97 (1H, m, ArH), 6.92 – 6.82 (2H, m, 2 x ArH), 4.74 
(1H, dd, J 9.5 and 3.7, ArCHN), 4.46 – 4.33 (1H, m, ArCH2CHN), 3.75 (3H, s, OCH3), 3.22 (1H, dd, J 
15.0 and 5.3, ArCH2a), 2.52 (1H, dd, J 15.1 and 2.1, ArCH2b), 1.94 – 1.42 (2H, m, ArCHCH2), 1.34 – 1.00 
(6H, m, CH3CH2CH2CH2), 0.90 (3H, d, J 6.4, CHCH3), 0.83 (3H, t, J 6.7, CH3CH2); δC 161.9 (d, J 245.4, 
C-F), 156.1 – 155.7 (br C=O), 136.0 (d, J 7.6, C), 133.0 (C) 128.8 (br ArCH), 115.8 (br ArCH), 113.0 (d, 
J 21.2, ArCH), 56.4 (br s, NCH), 52.5 (OCH3), 47.7 (br s, CH), 36.8 (br s, CH2) 35.3 (br s, Ar-CH2), 31.8 
(CH2), 26.0 (CH2), 22.7 (CH2), 20.5 (CH3), 14.1 (CH3); minor diastereoisomer δH 7.08 – 6.98 (1H, br m, 
ArH), 6.90 – 6.81 (2H, m, 2 x ArH), 5.27 – 4.92 (1H, b s, ArCHN), 4.08 (1H, b s, ArCH2CH), 3.69 (3H, 
s, OCH3), 2.94 (1H, br dd, J 15.4 and 6.2, ArCH2a), 2.52 (1H, br. app d, J 13.8, ArCH2b), 1.48 – 1.40 (2H, 
m, ArCHCH2), 1.38 (3H, d, J 6.3, CH3CH), 1.30 – 1.12 (6H, m, CH3CH2CH2CH2), 0.87 (3H, m, 
CH3CH2); δH (250 MHz, 50 °C) 7.10 – 6.98 (1H, m, ArH), 6.92 – 6.83 (2H, m, 2 x ArH), 5.14 – 5.12 (1H, 
m, ArCHN), 4.22 – 4.07 (1H, m, ArCH2CHN), 3.70 (3H, s, OCH3), 2.94 (1H, dd, J 15.9 and 7.0, 
ArCH2a), 2.79 (1H, dd, J 15.8 and 9.4, ArCH2b), 1.94 – 1.44 (2H, m, ArCHCH2), 1.39 (3H, d, J 6.3, 
CH3CH), 1.35 – 1.00 (6H, m, CH3CH2CH2CH2), 0.90-0.78 (3H, m, CH3CH2); δC 161.8 (d, J 245.0, C-F), 
156.1 – 155.8 (br C=O), 127.75 (br s, ArCH), 114.8 (br s, ArCH), 112.9 (d, J 21.8, ArCH), 56.4 (br s, 
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NCH), 52.6 (OCH3), 47.7 (br s, CH), 20.4 (CH3), 37.7 (br s, CH3), 35.3 (br s, Ar-CH2), 31.6 (CH2), 26.55 
(CH2), 22.7 (CH2), 14.2 (CH3); HRMS calculated for C17H25FNO2 [M+H]
+
 294.1869, found 294.1864. 
 
2-(2-Bromophenyl)acetaldehyde
241
 267 
 
 
 
 
To a suspension of (methoxymethyl)triphenylphosphonium chloride (23.75 g, 69.27 mmol, 2.10 eq.) in 
tetrahydrofuran (80 mL) at 0 °C was added solid potassium tert-butoxide (7.77 g, 69.27 mmol, 2.10 eq.) 
portionwise, over five minutes. The reaction mixture was stirred for a further 0.5 h at 0 °C after which 2-
bromobenzaldehyde 136 (6.0 g, 32.99 mmol, 1.0 eq.) was added as a solution in tetrahydrofuran (30 mL) 
dropwise, over 5 minutes. The cooling bath was removed and the mixture allowed to warm to ambient 
temperature overnight (~16 h). The reaction was quenched by addition of aqueous ammonium chloride 
(50 mL) and the separated aqueous layer extracted with ethyl acetate (3 x 50 mL). The combined organic 
extracts were washed with brine (50 mL), dried, filtered and evaporated. The residue was dissolved in 
tetrahydrofuran (150 mL) and HCl (2M, 25 mL), heated to reflux for 2.5 h and allowed to cool to ambient 
temperature. The separated aqueous layer was extracted with diethyl ether (50 mL) and the combined 
organic extracts washed with aqueous sodium bicarbonate (50 mL) and brine (50 mL) and filtered 
through a pad of silica. The mixture was then dried, filtered and evaporated and the crude material 
purified by column chromatography to give aldehyde 267 (3.41 g, 62%) as a colourless oil; νmax 1709 
(C=O); δH (250 MHz) 9.78 (1H, t, J 1.7, CHO), 7.64 (1H, dd, J 7.9 and 1.2, ArH), 7.39 – 7.30 (1H, m, 
ArH), 7.28 – 7.16 (2H, m, ArH), 3.89 (2H, d, J 1.7, ArCH2). 
 
1-(2-Bromophenyl)-3-methylbutan-2-ol 268a 
 
 
 
To a solution of 2-(2-bromophenyl)acetaldehyde 267 (1.5 g, 7.54 mmol, 1.0 eq.) in tetrahydrofuran (10 
mL) under an atmosphere of nitrogen at 0 °C was added isopropylmagnesium bromide (2.0M in Et2O, 4.5 
mL, 9.0 mmol, 1.2 eq.) and the mixture stirred for 30 minutes. The reaction was quenched by aqueous 
ammonium chloride (10 mL) and the separated organic layer extracted with diethyl ether (3 x 10 mL). 
The combined organic extracts were washed with brine (10 mL), dried, filtered and evaporated to give 
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alcohol 268a (1.76 g, 96%) as a white solid; m.p. 131 – 133 °C; δH (400 MHz) 7.54 (1H, dd, J 8.0 and 
0.9, ArH), 7.29 – 7.21 (2H, m, 2 x ArH), 7.09 – 7.06 (1H, m, ArH), 3.68 (1H, ddd, J 9.8, 5.1 and 2.9, 
OCH), 3.07 (1H, dd, J 13.7 and 2.9, ArCH2a), 2.65 (1H, dd, J 13.7 and 9.8, ArCH2b), 1.78 (1H, d sept, J 
5.0 and 6.8, (CH3)2CH), 1.48 (1H, br s, OH), 1.02 (3H, d, J 6.8, (CH3)aCH), 1.01 (3H, d, J 6.8, 
(CH3)aCH); δC (101 MHz) 138.9 (C), 133.05 (ArCH), 131.9 (ArCH), 128.2 (ArCH), 127.5 (ArCH), 124.9 
(C-Br), 75.8 (OCH), 40.9 (ArCH2), 33.8 (CH), 18.8 (CH3), 17.6 (CH3). 
 
1-(2-Bromophenyl)-3-methylbutan-2-yl methanesulfonate 268b 
 
 
 
 
To a solution of 1-(2-Bromophenyl)-3-methylbutan-2-ol (759 mg, 3.12 mmol, 1.0 eq.) in 
dichloromethane (5 mL) at 0 °C was added methanesulfonyl chloride (394 mg, 3.44 mmol, 1.1 eq.), 
triethylamine (379 mg, 3.74 mmol, 1.2 eq.), DMAP (a few crystals) and the mixture allowed to stir 
overnight. The reaction was quenched by ammonium chloride and the separated organic layer washed 
with HCl (2M, 5 mL), aqueous sodium bicarbonate (5 mL), brine (5 mL) and dried, filtered and 
evaporated to give sulfonamide 268b (960 mg, 96%) as a yellow oil; νmax 1357 (S=O); δH (250 MHz) 7.57 
(1H, dd, J 7.6 and 1.0, ArH), 7.33 – 7.24 (2H, m, 2 x ArH), 7.16 – 7.12 (1H, m, ArH), 4.85 (1H, ddd, J 
10.2, 4.0 and 2.5, OCH), 3.15 (1H, dd, J 14.2 and 3.5, ArCH2a), 2.97 (1H, dd, J 14.2 and 10.2, ArCH2b), 
2.32 (3H, s, SCH3), 2.18 (1H, d sept, J 4.9 and 6.9, (CH3)2CH), 1.12 (3H, d, J 6.9, (CH3)aCH), 1.11 (3H, 
d, J 6.9, (CH3)bCH). 
 
1-(2-Azido-3-methylbutyl)-2-bromobenzene 268c 
 
 
 
To a solution of 1-(2-bromophenyl)-3-methylbutan-2-yl methanesulfonate 268b (960 mg, 2.992 mmol, 
1.0 eq.) in dimethylformamide (5 mL) at ambient temperature was added sodium azide (972 mg, 14.96 
mmol, 5.0 eq.) and the mixture stirred at 40 °C for 16 h. The reaction was quenched by water (20 mL) 
and diethyl ether (30 mL) and the separated aqueous phase extracted with diethyl ether (3 x 15 mL). The 
combined organic extracts were washed with water (3 x 10 mL) and brine (10 mL), dried, filtered and 
evaporated to yield azide 268c (593 mg, 74%) as a brown liquid; δH (250 MHz) 7.54 (1H, dd, J 7.7 and 
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1.0, ArH), 7.32 – 7.19 (2H, m, 2 x ArH), 7.13 – 7.09 (1H, m, ArH), 3.52 (1H, ddd, J 9.9, 4.8 and 3.9, 
NCH), 3.09 (1H, dd, J 13.7 and 3.8, ArCH2a), 2.72 (1H, dd, J 13.7 and 10.0, ArCH2b), 1.89 (1H, d sept, J 
4.7 and 6.8, (CH3)2CH), 1.05 (3H, d, J 6.8, (CH3)aCH), 1.04 (3H, d, J 6.8, (CH3)bCH). 
 
1-(2-Bromophenyl)-3-methylbutan-2-amine 269 
 
To a solution of 1-(2-azido-3-methylbutyl)-2-bromobenzene 268c (591 mg, 2.21 mmol, 1.0 eq.) in 
tetrahydrofuran (5 mL) was added triphenylphosphine (639 mg, 2.44 mmol, 1.1 eq.) and the resulting 
mixture stirred for 30 minutes. Water (0.8 g, 44.3 mmol, 18 eq.) was then added and the reaction mixture 
stirred for a further 2 hours at 50 °C. The solution was then partitioned between dichloromethane (10 mL) 
and water (10 mL) and the separated organic layer extracted with HCl (2M, 2 x 10 mL). The combined 
aqueous extracts were washed with dichloromethane (2 x 5 mL) and basified with aqueous sodium 
hydroxide (pH 14). The aqueous mixture was extracted with chloroform (3 x 10 mL) and the combined 
organic extracts were dried over sodium sulfate, filtered and evaporated to give amine 269 (460 mg, 86%) 
as a dark red oil; δH (250 MHz) 7.54 (1H, d, J 7.9, ArH), 7.28 – 7.20 (2H, m, 2 x ArH), 7.12 – 7.02 (1H, 
m, ArH), 3.02 (1H, dd, J 13.1 and 3.6, ArCH2a), 2.96 – 2.87 (1H, m, NCH), 2.50 (1H, dd, J 13.0 and 9.6, 
ArCH2b), 1.72 (1H, d sept, J 4.7 and 6.8, (CH3)2CH), 1.16 (2H, br s, NH2), 1.00 (2 x 3H, d, J 6.8 
(CH3)2CH). 
 
N-(1-(2-Bromophenyl)-3-methylbutan-2-yl)-4-methylbenzenesulfonamide 270 
 
 
 
A solution of 1-(2-bromophenyl)-3-methylbutan-2-amine 269 (109 mg, 0.451 mmol) in dichloromethane 
was treated with triethylamine, DMAP and p-tosyl chloride according to General Procedure B. The crude 
material was purified by column chromatography (petrol/diethyl ether 2:1) to give the sulfonamide 270 
(168 mg, 94%) as a colourless glass; νmax 3291 (br, NH), 1321 (S=O), 1162 (S=O); δH (250 MHz) 7.44 
(2H, d, J 8.3, 2 x ArH), 7.32 – 7.27 (1H, m, ArH), 7.05 (2H, d, J 8.1, 2 x ArH), 7.08 – 6.91 (3H, m, 3 x 
ArH), 4.65 (1H, d, J 8.2, NH), 3.57 – 3.44 (1H, m, NCH), 2.84 (1H, dd, J 13.9 and 5.2, ArCH2a), 2.60 
(1H, dd, J 13.9 and 9.7, ArCH2b), 2.36 (3H, s, ArCH3), 1.98 (1H, d sept, J 3.5 and 6.9, (CH3)2CH), 0.97 
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(3H, d, J 6.9, (CH3)aCH), 0.93 (3H, d, J 6.9, (CH3)bCH); δC (101 MHz) 142.6 (C), 137.5 (C), 132.95 
(ArCH), 131.65 (ArCH), 129.5 (2 x ArCH), 128.1 (ArCH), 127.5 (ArCH), 126.8 (2 x ArCH), 124.7 (C-
Br), 59.2 (NCH), 37.2 (CH2), 32.2 (CH), 21.6 (ArCH3), 17.95 (CH3), 17.7 (CH3).  
 
(E)-N-(1-(2-(Hex-1-en-1-yl)phenyl)-3-methylbutan-2-yl)-4-methylbenzenesulfonamide  271 
 
 
 
 
A solution of methyl N-(1-(2-bromophenyl)-3-methylbutan-2-yl)-4-methylbenzenesulfonamide 270 (98 
mg, 1.0 eq.) in ethanol/water (1:1, 1 mL) was treated with 1-hexenylboronic acid (47 mg, 1.5 eq.), K3PO4 
(105 mg, 2.0 eq) and Pd(dppf)Cl2.DCM (8 mg, 0.04 eq) at 100 °C for 5 h according to General Procedure 
D. The crude material was purified by column chromatography (petrol/diethyl ether 2:1) to give the 
sulfonamide 271 (80 mg, 81%) as beige crystals; m.p. 56 – 59 °C; νmax 3337 (br, NH); δH 7.44 (2H, d, J 
8.3, 2 x ArH), 7.23 (1H, d, J 7.7, ArH), 7.12 – 7.06 (1H, m, ArH), 7.08 (2H, d, J 7.9, 2 x ArH), 7.03 – 
7.01 (1H, m, ArH), 6.91 (1H, dd, J 7.5 and 1.0, ArH), 6.48 (1H, d, J 15.6, ArCH=CH), 5.91 (1H, dt, J 
15.5 and 7.0, ArCH=CH), 4.60 (1H, d, J 7.3, NH), 3.32 – 3.27 (1H, m, NCH), 2.78 (1H, dd, J 14.0 and 
6.5, ArCH2a), 2.61 (1H, dd, J 14.0 and 8.5, ArCH2b), 2.37 (3H, s, ArCH3), 2.23 (1H, q, J 7.4, 
ArCH=CHCH2), 1.99 – 1.89 (1H, d sept, J 3.2 and 6.9 (CH3)2CH), 1.51 – 1.43 (1H, m, CH3CH2CH2), 
1.43 – 1.35 (1H, m, CH3CH2CH2), 0.98 – 0.94 (3H, t, J 7.4, NCHCH3), 0.94 (3H, d, J 6.8, CH(CH3)a), 
0.82 (3H, d, J 6.9, CH(CH3)b); δC 142.6 (C), 137.5 (C), 137.4 (C), 134.8 (C), 133.8 (ArCH), 130.5 
(ArCH), 129.5 (ArCH), 127.2 (ArCH), 127.0 (ArCH), 127.0 (ArCH), 126.9 (ArCH), 126.5 (ArCH), 59.6 
(NCH), 35.0 (CH2), 33.1 (CH2), 31.7 (CH2), 30.8 (CH), 22.5 (CH2), 21.6 (CH3), 17.9 (CH3), 17.4 (CH3), 
14.1 (CH3); HRMS calculated for C24H34NO2S [M+H]
+
 400.2310, found 400.2298. 
 
Methyl (1-(2-bromophenyl)-3-methylbutan-2-yl)carbamate  272 
 
 
 
A solution of 1-(2-bromophenyl)-3-methylbutan-2-amine 269 (157 mg, 0.679 mmol, 1.0 eq.) in diethyl 
ether (1 mL) was cooled to 0 °C. Water (1 mL) and potassium carbonate (274 mg, 1.97 mmol, 3.0 eq.) 
was added, followed by dropwise addition of methyl chloroformate (85 mg, 0.909 mmol, 1.4 eq.). The 
cooling bath was removed and the reaction was allowed to warm to ambient temperature over 30 minutes. 
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The separated aqueous phase was then extracted with diethyl ether (3 x 5 mL) and the combined organic 
extracts washed with brine (5 mL), dried, filtered and evaporated. The crude material was purified by 
column chromatography (petrol/diethyl ether 2:1) to give carbamate 272 (150 mg, 77%) as a colourless 
oil; νmax 3312 (bNH), 1689 (C=O); δH (250 MHz) 7.52 (1H, d, J 7.9, ArH), 7.24 – 7.19 (2H, m, ArH), 7.09 
– 7.01 (1H, m, ArH), 4.66 (1H, br d, J 9.3, NH), 3.89 – 3.85 (1H, m, NCH), 3.52 (3H, s, OCH3), 2.98 
(1H, dd, J 14.0 and 4.7, ArCH2a), 2.74 (1H, dd, J 13.9 and 10.1, ArCH2a), 1.78 (1H, d sept, J 5.0 and 6.9 
(CH3)2CH), 0.99 (2 x 3H, d, J 6.8, 2 x CH3); δC 155.7 (C=O), 137.3 (C), 131.8 (ArCH), 130.1 (ArCH), 
127.0 (ArCH), 126.35 (ArCH), 124.0 (C-Br), 55.7 (OCH3), 50.9 (NCH), 37.2 (CH), 31.0 (CH2), 18.15 
(CH3), 16.7 (CH3). 
 
Methyl (E)-(1-(2-(hex-1-en-1-yl)phenyl)-3-methylbutan-2-yl)carbamate  273 
 
 
 
A solution of methyl (1-(2-bromophenyl)-3-methylbutan-2-yl)carbamate 272 (197 mg, 1.0 eq.) in 
ethanol/water (1:1, 2 mL) was treated with 1-hexenylboronic acid (125 mg, 1.5 eq.), K3PO4 (277 mg, 2.0 
eq) and Pd(dppf)Cl2.DCM (21 mg, 0.04 eq) at 90 °C for 4 h according to General Procedure D. The crude 
material was purified by column chromatography (petrol/diethyl ether 3:1) to give the carbamate 273 
(145 mg, 73%) as colourless oil; νmax 3319 (br, NH), 1699 (C=O); δH 7.43 – 7.40 (1H, m, ArH), 7.18 – 
7.08 (3H, m, 3 x ArH), 6.67 (1H, d, J 15.5, ArCH=CH), 6.10 (1H, dt, J 15.5 and 6.9, ArCH=CH), 4.61 
(1H, br s, NH), 3.78 (1H, br s, NCH), 3.57 (3H, s, OCH3), 2.88 (1H, dd, J 14.0 and 5.9, ArCH2a), 2.69 
(1H, br dd, J 13.4 and 8.8, ArCH2a), 2.26 (2H, qd, J 7.3 and 1.3, ArCH=CHCH2), 1.83 (1H, br s, 
CH(CH3)2), 1.53 – 1.46 (2H, m, CH3CH2CH2), 1.41 (2H, dq, J 14.1 and 7.1, CH3CH2), 0.96 (9H, m, 
CH(CH3)2 and CH3CH2); δC 156.8 (C=O), 137.6 (C), 135.6 (C), 133.5 (ArCH), 130.2 (ArCH), 127.5 (2 x 
ArCH), 126.8 (2 x ArCH), 126.7 (ArCH), 126.4 (ArCH), 57.0 (NCH), 51.9 (OCH3), 35.6 (ArCH2), 33.06 
(CH2), 31.6 (CH2), 31.0 (CH), 22.3 (CH2), 19.4 (CH3), 17.35 (CH3), 14.0 (CH3). 
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3-Isopropyl-1-pentyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 191 
 
 
 
 
Method 1: 
The sulfonamide 271 (27 mg, 0.068 mmol, 1.0 eq.) was dissolved in dichloromethane (0.3 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (4 mg, 0.027 mmol, 0.4 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then at ambient temperature for 6 h. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/diethyl ether 3:1) to give tetrahydroisoquinoline 
191 (26 mg, 96%) as a colourless glass and as a 2:1 mixture of trans and cis isomers; major (trans)-
diastereoisomer δH 7.55 (2H, d, J 8.3, 2 x ArH), 7.05 (2H, d, J 8.1, 2 x ArH), 7.12 – 6.86 (3H, m, 3 x 
ArH), 6.83 (1H, d, J 7.5, ArH), 4.92 (1H, dd, J 9.3 and 5.1, ArCHN), 3.36 (1H, td, J 10.2 and 4.6, 
ArCH2CHN), 2.78 (1H, dd, J 16.5 and 4.6, ArCH2a), 2.62 (1H, dd, J 16.4 and 10.1, ArCH2b), 2.54 (1H, d 
sept, J 9.7 and 6.7, CH(CH3)2), 2.31 (3H, s, ArCH3), 1.95 – 1.71 (2H, m, CH2), 1.50 – 1.17 (6H, m, 3 x 
CH2), 1.11 (3H, d, J 6.8, CH(CH3)a), 0.65 (3H, t, J  6.9, CH2CH3), 0.82 (3H, d, J 6.7, CH(CH3)b); δC 
142.8 (C), 139.4 (C), 137.9 (C), 134.6 (C), 129.0 (2 x ArCH), 128.9 (ArCH), 127.5 (2 x ArCH), 126.6 
(ArCH), 126.5 (ArCH), 126.1 (ArCH), 61.15 (ArCH2CH), 60.3 (ArCHN), 36.4 (CH2), 31.6 (CH2), 30.7 
(CH(CH3)2), 30.7 (ArCH2), 26.1 (CH2), 22.7 (CH2), 21.6 (ArCH3), 21.5 (CH3), 20.3 (CH3), 14.1 (CH3); 
minor (cis)-diastereoisomer δH (400 MHz) 7.39 (2H, d, J 8.2, 2 x ArH), 6.96 (2H, d, J 8.0, 2 x ArH), 7.07 
– 6.80 (3H, m, 3 x ArH), 6.70 (1H, d, J 7.4, ArH), 4.69 (1H, app t, J 7.1, ArCHN), 3.65 (1H, td, J 8.0 and 
7.8, ArCH2CHN), 2.64 (1H, dd, J 8.0 and 3.8, ArCH2), 2.26 (3H, s, ArCH3), 2.26 – 2.19 (1H, m, 
CH(CH3)2), 1.66 – 1.50 (2H, m, ArCHCH2CH2CH2), 1.41 – 1.23 (6H, m, 3 x CH2), 1.13 (3H, d, J 6.9, 
CH(CH3)a), 1.02 (3H, d, J 6.8, CH(CH3)b), 0.88 (3H, t, J 6.9, CH2CH3); δC (101 MHz) 142.7 (C), 137.5 
(C), 136.5 (C), 133.1 (C), 129.1 (2 x ArCH), 128.1 (ArCH), 127.4 (2 x ArCH), 126.8 (ArCH), 126.7 
(ArCH), 125.80 (ArCH), 60.5 (ArCH2CH), 59.1 (ArCHN), 37.2 (CH2), 34.1 (CH(CH3)2), 31.8 (CH2), 
28.3 (ArCH2), 26.85 (CH2), 22.7 (CH2), 21.5 (ArCH3), 20.45 (CH3), 18.2 (CH3), 14.3 (CH3); HRMS 
calculated for C24H34NO2S [M+H]
+
 400.2310, found 400.2300. 
 
Method 2: 
The sulfonamide 271 (19 mg, 0.048 mmol, 1.0 eq.) was dissolved in dichloromethane (0.2 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (4 mg, 0.067 mmol, 1.4 eq.). 
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The resulting solution was stirred for 5 minutes at 0 °C and then at ambient temperature for 2.5 h. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/diethyl ether 3:1) to give tetrahydroisoquinoline 
191 (18 mg, 95%) as a colourless glass and as a 4:1 mixture of cis and trans isomers. All data obtained 
for the sample were in accordance with those reported before. 
 
Methyl 3-isopropyl-1-pentyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 274 
 
 
 
The carbamate 273 (51 mg, 0.168 mmol, 1.0 eq.) was dissolved in 1,2-dichloromethane (0.5 mL) under 
an atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (10 mg, 0.067 mmol, 0.4 
eq.). The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 10 h. The 
reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/diethyl ether 2:1) to give tetrahydroisoquinoline 
274 (33 mg, 65%) as a colourless glass and as a 5:1 mixture of isomers; νmax 1699 (C=O); major 
diastereoisomer δH (400 MHz) 7.21 – 7.09 (3H, m, 3 x ArH), 7.09 – 7.02 (1H, m, ArH), 4.77 (1H, d, J 
6.4, ArCHN), 4.01 (1H, br s, ArCH2CHN), 3.74 (3H, s, OCH3), 3.03 (1H, dd, J 15.3 and 5.0, ArCH2a), 
2.88 – 2.80 (1H, br m, ArCH2b), 1.52 – 1.45 (1H, br m, CH(CH3)2), 1.39 – 1.05 (8H, m, 4 x CH2), 0.83 
(3H, t, J 6.9, CH3CH2), 0.79 (3H, d, J 6.5, CH(CH3)a), 0.59 (3H, d, J 6.8, CH(CH3)b); δC (101 MHz) 156.8 
(C=O), 138.1 (C), 134.6 (br s, C), 128.6 (ArCH), 127.3 (ArCH), 126.95 (ArCH), 126.0 (ArCH), 57.5 
(ArCHN), 57.5 (br s, ArCH2CH), 52.6 (OCH3), 37.9 (CH(CH3)2), 31.6 (ArCH2), 31.2 (br s, CH2), 27.15 
(CH2), 25.75 (CH2), 22.7 (CH2), 19.8 (CH3), 19.5 (CH3), 14.1 (CH3); minor diastereoisomer δH (400 
MHz) 7.21 – 7.01 (4H, m, 4 x ArH), 5.13 (1H, br s, ArCHN), 3.69 (3H, s, OCH3), 1.00 (3H, d, J 6.8, 
CH(CH3)a), 0.94 (3H, d, J 6.7, CH(CH3)b), 0.89 (3H, t, J 6.9, CH2CH3); only 6 distinct signals; δC (101 
MHz) 133.75 (C), 126.89 (ArCH), 126.24 (ArCH), 57.42 (CH), 52.63 (OCH3), 31.96 (CH2), 20.10 (CH3), 
18.46 (CH3), 14.22 (CH3); only 9 distinct signals; LRMS m/z 304 ([M]
+
, 100%), 232 ([M-NHCOOMe]
+
, 
3%); HRMS (APCI
+
) calculated for C19H30NO2 [M+H]
+
 304.2277, found 304.2262 
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2-Iodobenzaldehyde
242
 275 
 
 
 
 
To a suspension of pyridinium dichromate (25.7 g, 68.3 mmol, 1.0 eq.) in dry dichloromethane (70 mLs) 
at ambient temperature was added a solution of 2-iodobenzyl alcohol (10.0 g, 42.7 mmol, 1.6 eq.) in 
dichloromethane (30 mL) and the resulting mixture stirred for 4 h. Diethyl ether (50 mL) was added and 
the reaction mixture filtered through a pad of Celite
©
. The solvent was removed in vacuo and the crude 
material was purified by silica chromatography (petrol/ethyl acetate 20:1) to yield aldehyde 275 (8.49 g, 
72%) as a white solid; m.p. 33-37 °C (lit. m.p.
243
 37-38 °C); νmax 1697 (C=O); δH (400 MHz) 10.07 (1H, s, 
CHO), 7.96 (1H, d, J 7.9, ArH), 7.88 (1H, dd, J 7.7 and 1.7, ArH), 7.47 (1H, t, J 7.5, ArH), 7.29 (1H, td, 
J 7.6 and 1.8, ArH); δC (101 MHz) 196.0 (CHO), 140.7 (ArCH), 135.65 (ArCH), 135.2 (C), 130.4 
(ArCH), 128.9 (ArCH), 100.9 (C-I). 
 
(E)-1-Iodo-2-(2-nitroprop-1-en-1-yl)benzene 276 
 
 
 
To a solution of 2-iodobenzaldehyde 275 (3.5 g, 15.09 mmol, 1.0 eq.) in nitroethane (45.3 g, 528 mmol, 
40 eq.) was added ammonium acetate (989 mg, 12.83 mmol, 0.85 eq.) and the mixture heated to reflux for 
3 hours. The reaction was then allowed to cool to room temperature, and the solvent was removed in 
vacuo at 5 mbar pressure and at 60 °C for 1 hour. The crude reaction mixture was redissolved in 
dichloromethane (100 mL), washed with water (3 x 25 mL) and brine (25 mL), dried, filtered and 
evaporated to give nitroalkene 276 (4.08 g, 94%) as a yellow oil; δH (400 MHz) 8.01 (1H, s, ArCH=C), 
7.94 (1H, dd, J 8.0 and 1.1, ArH), 7.45 – 7.41 (1H, m, ArH), 7.26 (1H, dd, J 7.7 and 1.4, ArH), 7.11 – 
7.08 (1H, m, ArH), 2.28 (3H, d, J 1.1, CH3); δC (63 MHz) 148.8 (C), 139.6 (ArCH), 136.9 (C), 136.8 
(ArCH), 130.9 (ArCH), 129.8 (ArCH), 128.4 (ArCH), 99.9 (C-I), 13.8 (CH3); HRMS calculated for 
C9H8INO2 [M]
+
 288.9600, found 288.9596. 
 
1-(2-Iodophenyl)propan-2-amine  277 
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A solution of 1-bromo-4-fluoro-2-(2-nitroprop-1-en-1-yl)benzene 276 (4.07 g, 14.09 mmol, 1.0 eq.) in 
tetrahydrofuran was treated with sodium borohydride (2.05 g, 54.10 mmol, 3.84 eq.), and boron 
trifluoride diethyl etherate (11.8 g, 83.26 mmol, 5.9 eq.) according to the General Procedure F to afford 
amine 277 (1.84 g, 50%) as a dark brown oil; δH (400 MHz) 7.83 (1H, dd, J 7.9 and 1.1, ArH), 7.28 (1H, 
dt, J 7.4 and 1.5, ArH), 7.22 – 7.20 (1H, m, ArH), 6.90 (1H, dt, J 7.7 and 1.8, ArH), 3.32 – 3.21 (1H, m, 
NCH), 2.83 (1H, dd, J 13.4 and 5.5, ArCH2a), 2.67 (1H, dd, J 13.3 and 7.9, ArCH2b), 1.16 (3H, d, J 6.3, 
CH3). 
 
N-(1-(2-Iodophenyl)propan-2-yl)acetamide  278 
 
 
 
A solution of 1-(2-iodophenyl)propan-2-amine 277 (620 mg, 2.38 mmol, 1.0 eq.) in dichloromethane (10 
mL) was cooled to 0 °C. Triethylamine (360 mg, 3.56 mmol, 1.5 eq.) was then added, followed by acetyl 
chloride (204 mg, 2.61 mmol, 1.1 eq.) and the resulting mixture stirred for 0.5 h at 0 °C and 1 h at 
ambient temperature. The reaction mixture was quenched by water (10 mL) and the separated organic 
phase was washed with HCl (2M, 10 mL), aqueous sodium bicarbonate (10 mL) and brine (10 mL), dried, 
filtered and evaporated. The crude material was purified by column chromatography (petrol/ethyl acetate 
1:1) to give acetamide 278 (382 mg, 53%) as a white solid; δH (400 MHz) 7.81 (1H, dd, J 7.9 and 1.1, 
ArH), 7.29 – 7.25 (1H, m, ArH), 7.22 (1H, dd, J 7.6, 1.9, ArH), 6.92 – 6.86 (1H, m, ArH), 5.59 (1H, d, J 
7.4, NH), 4.37 – 4.25 (1H, m, NCH), 2.95 (1H, dd, J 13.9 and 7.7, ArCH2a), 2.87 (1H, dd, J 13.9 and 6.5, 
ArCH2b), 1.90 (3H, s, C(O)CH3), 1.20 (3H, d, J 6.6, CH3); δC 169.36 (C=O), 141.5 (C), 139.7 (ArCH), 
130.4 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 101.6 (C-I), 46.7 (ArCH2), 46.6 (NCH), 23.6 (C(O)CH3), 
20.8 (CH3); HRMS calculated for C11H14INO [M]
+
 303.0120, found 303.0114. 
 
(E)-N-(1-(2-(Hex-1-en-1-yl)phenyl)propan-2-yl)acetamide 279 
 
 
 
A solution of N-(1-(2-iodophenyl)propan-2-yl)acetamide 278 (477 mg, 1.0 eq.) in ethanol/water (1:1, 5 
mL) was treated with 1-hexenylboronic acid (357 mg, 1.5 eq.), K3PO4 (792 mg, 2.0 eq) and 
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Pd(dppf)Cl2.DCM (76 mg, 0.05 eq) at 90 °C for 3 h according to General Procedure D. The crude 
material was purified by column chromatography (petrol/ethyl acetate 1:3) to give the acetamide 279 
(416 mg, 86%) as yellow oil; νmax 3311 (NH), 1705 (C=O); δH 7.44 (1H, dd, J 7.6 and 1.2, ArH), 7.17 
(1H, dt, J 7.4 and 1.6, ArH), 7.13 (1H, dt, J 7.3 and 1.6, ArH), 7.09 (1H, dd, J 7.4 and 1.6, ArH), 6.74 
(1H, d, J 15.6 ArCH=CH), 6.11 (1H, dt, J 15.5 and 7.0, ArCH=CH), 5.69 (1H, d, J 7.6, NH), 4.25 – 4.16 
(1H, m, NCH), 2.95 (1H, dd, J 13.7 and 6.0, ArCH2a), 2.70 (1H, dd, J 13.7 and 7.6, ArCH2b), 2.24 – 2.21 
(2H, m, ArCH=CHCH2), 1.89 (3H, s, C(O)CH3), 1.49 – 1.42 (2H, m, CH3CH2CH2), 1.39 – 1.36 (2H, m, 
CH3CH2CH2), 1.09 (3H, d, J 6.6, CHCH3), 0.93 (3H, t, J 7.2, CH3CH2); δC 169.4 (C=O), 137.5 (C), 135.1 
(C), 133.3 (ArCH=CH), 130.6 (ArCH), 127.6 (ArCH), 126.8 (ArCH), 126.75 (ArCH), 126.1 
(ArCH=CH), 46.3 (NCH), 39.6 (CH2), 33.1 (CH2), 31.7 (CH2), 23.45 (C(O)CH3), 22.3 (CH2), 20.1 (CH3), 
14.0 (CH3). 
 
1-(3-Methyl-1-pentyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one 280 
 
 
 
 
The acetamide 279 (76 mg, 0.296 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (0.8 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (22 mg, 0.148 mmol, 0.5 eq.). 
The resulting solution was stirred for 5 minutes at 0 °C and then heated to 84 °C for 24 h. The reaction 
mixture was quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 
mL) and the combined organic extracts dried, filtered and evaporated. No product could be isolated. 
 
2-(Diethoxymethyl)benzaldehyde
244
 288 
 
 
 
 
 
To a solution of 1-bromo-2-(diethoxymethyl)benzene 287 (5 g, 19.3 mmol, 1.0 eq.) in tetrahydrofuran (70 
mL) at -78 °C under an atmosphere of nitrogen was added n-butyllithium (1.9 M, 12.2 mL, 23.16 mmol, 
1.2 eq.) over 10 minutes and the reaction stirred for a further 30 minutes at the same temperature. 
Dimethylformamide (3.1 mL, 40.5 mmol, 2.1 eq.) was added dropwise and the mixture allowed to warm 
to ambient temperature and stirred for a further 2 hours. The reaction was quenched by addition of 
aqueous ammonium chloride (50 mL) and the aqueous layer extracted with diethyl ether (3 x 50 mL). The 
combined organic extracts were dried, filtered and evaporated and the crude material purified by column 
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chromatography (petrol/diethyl ether 1:4) to give aldehyde 288 (3.87 g, 93%) as a colourless oil; 10.52 
(1H, s, CHO), 7.92 (1H, br. d, J  8.0, ArH), 7.69 (1H, br. d, J 8.0, ArH), 7.58 – 7.56 (1H, m, ArH), 7.47 
(1H, br. t, J 8.0, ArH), 5.96 (1H, s, ArCH(OEt)2), 3.72 (1H, q, J 7.0, OCH2aCH3), 3.69 (1H, q, J 7.0, 
OCH2bCH3), 3.59 (1H, q, J 7.0, OCH2cCH3), 3.56 (1H, q, J 7.0, OCH2dCH3), 1.23 (6H, t, J 7.0, 2 x 
OCH2CH3). 
 
(E)-1-(Diethoxymethyl)-2-(2-nitroprop-1-en-1-yl)benzene 289 
 
 
 
 
 
To a solution of 2-(diethoxymethyl)benzaldehyde 288 (3.87 g, 18.61 mmol, 1.0 eq.) in nitroethane (11.2 
g, 149 mmol, 8 eq.) was added ammonium acetate (860 mg, 11.16 mmol, 0.6 eq.) and the mixture heated 
to reflux for 3 hours. The reaction was then allowed to cool to room temperature, and the solvent was 
removed in vacuo at 5 mbar pressure and at 60 °C for 1 hour. The crude reaction mixture was redissolved 
in dichloromethane (100 mL), washed with water (3 x 25 mL) and brine (25 mL), dried, filtered and 
evaporated to give nitroalkene 289 (4.14 g, 84%) as a black oil; δH (400 MHz) 8.23 (1H, s, ArCH=C), 
7.53 (1H, dd, J 7.3 and 1.7, ArH), 7.30 – 7.22 (2H, m, 2 x ArH), 7.11 – 7.07 (1H, m, ArH), 3.48 (1H, q, J 
7.1, OCH2aCH3), 3.46 (1H, q, J 7.1, OCH2bCH3), 3.39 (1H, q, J 7.0, OCH2cCH3), 3.37 (1H, q, J 7.1, 
OCH2fCH3), 2.14 (3H, d, J 1.1, CH3), 1.07 (6H, t, J 7.1, 2 x OCH2CH3). 
 
1-(2-(Diethoxymethyl)phenyl)propan-2-amine 290 
 
 
 
To the solution of 1-(diethoxymethyl)-2-(2-nitroprop-1-en-1-yl)benzene 289 (4.14 g, 15.64 mmol, 1.0 
eq.) in tetrahydrofuran (60 mL) at 0 °C under an atmosphere of nitrogen was added portionwise lithium 
aluminium hydride (1.78 g, 46.9 mmol, 3.0 eq) over 10 minutes. The reaction mixture was allowed to stir 
for 30 minutes at the 0 °C and heated to reflux for 2 h. The reaction was quenched according to the 
General Procedure F to yield amine 290 (3.27 mg, 88%) as a dark, burgundy oil and was used in the next 
step without further purification; δH (250 MHz) 7.65 – 7.58 (1H, m, ArH), 7.31 – 7.17 (3H, m, 3 x ArH), 
5.62 (1H, s, ArCH(OEt)2), 3.70 – 3.45 (4H, m, 2 x OCH2CH3), 3.29 – 3.14 (1H, m, NCH), 2.85 (1H, dd, J 
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13.6 and 5.3, ArCH2a), 2.67 (1H, dd, J 13.6 and 8.2, ArCH2b), 2.10 – 1.90 (1H, br s, NH2), 1.23 (6H, t, J 
7.1, 2 x OCH2CH3), 1.17 (3H, d, J 6.3, CHCH3). 
 
1-Ethoxy-3-methyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 292 
 
 
 
 
 
A solution of 1-(2-(diethoxymethyl)phenyl)propan-2-amine (0.327 g, 1.380 mmol) in dichloromethane 
was treated with triethylamine, DMAP and p-tosyl chloride according to General Procedure B. The crude 
material was purified by column chromatography (petrol/diethyl ether 2:1) to give the 
tetrahydroisoquinoline 292 (433 mg, 91%) as a colourless oil; δH (400 MHz) 7.51 (1H, d, J 8.3, 2 x ArH), 
7.24 – 7.21 (1H, m, ArH), 7.18 – 7.15 (1H, m, ArH), 7.10 (2H, d, J 8.0, 2 x ArH), 6.98 – 6.92 (1H, m, 
ArH), 6.07 (1H, s, O-CH), 4.08 – 4.02 (1H, m, NCHCH3), 4.04 (1H, dq, 9.7 and 7.0, OCH2aCH3), 3.81 
(1H, dq, J 9.6 and 7.0, OCH2bCH3), 2.59 (1H, dd, J 15.9, 5.1, ArCH2a), 2.53 (1H, dd, J 15.9 and 6.4, 
ArCH2b), 2.31 (1H, s, ArCH3), 1.44 (3H, d, J 6.8, CHCH3), 1.28 (3H, t, J 7.1, OCH2CH3). 
 
N-(1-(2-(Diethoxymethyl)phenyl)butan-2-yl)-4-methylbenzenesulfonamide 291 
 
 
 
Magnesium turnings (475 mg, 19.56 mmol, 2.2 eq.) were dry-stirred under an atmosphere of nitrogen for 
24 hours and then suspended in tetrahydrofuran (10 mL). The suspension was treated with a crystal of 
iodine and 1-bromo-2-(diethoxymethyl)benzene 287 (4.60 g, 17.8 mmol, 2.0 eq.) was added as a solution 
in tetrahydrofuran (10 mL). The reaction was stirred for a further 30 minutes, during which time 
decolourisation and disappearance of most of the magnesium turnings was observed. The solution was 
then cooled to -40 °C and copper (I) iodide (508 mg, 2.67 mmol, 0.3 eq.) was added. After further 30 
minutes, the reaction mixture was cooled to -78 °C and 2-ethyl-1-tosylaziridine 154 (2.0 g, 8.89 mmol, 
1.0 eq.) in tetrahydrofuran (10 mL) was added. After 15 minutes, the reaction mixture was warmed to 0 
°C and stirred for a further 1.25 h. The reaction was quenched by aqueous ammonium chloride (30 mL) 
and the blue aqueous phase extracted with diethyl ether (3 x 30 mL). The combined organic extracts were 
washed with brine (50 mL), dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/diethyl ether, 1:1) to give sulfonamide 291 (3.13 g, 87%) as a colourless oil; νmax 
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3235 (br, NH), 1331 (S=O), 1160 (S=O); δH (400 MHz) 7.55 (2H, d, J 8.3, 2 x ArCH), 7.26 (1H, m, 
ArH), 7.21 – 7.15 (2H, m, 2 x ArH), 7.13 (2H, d, J 8.1, 2 x ArH), 6.97 (1H, d, J 7.0, ArH), 6.08 (1H, s, 
ArCH(OCH2)2), 4.07 (1H, dq, J 9.6 and 7.1, (OCH2aCH3)a), 3.89 – 3.79 (1H, m, NCH) 3.88 – 3.78 (1H, 
m, OCH2CH3), 3.72 (2H, q, J 7.0, OCH2CH3), 2.50 (1H, dd, J 16.2 and 3.3, ArCH2a), 2.42 (1H, dd, J 15.7 
and 8.1, ArCH2b), 2.34 (3H, s, ArCH3), 2.00 – 1.86 (1H, m, CHCH2aCH3), 1.62 – 1.50 (1H, m, 
CHCH2aCH3), 1.29 (3H, t, J 7.1, OCH2CH3), 1.24 (3H, t, J 7.0, OCH2CH3), 0.95 (3H, t, J 7.4, 
CHCH2CH3); δC (101 MHz) 143.3 (C), 137.9 (C), 133.5 (C), 132.3 (C), 129.7 (2 x ArCH), 128.85 
(ArCH), 128.5 (ArCH), 128.4 (ArCH), 127.1 (2 x ArCH), 126.6 (ArCH), 83.3 (CH), 64.0 (OCH2), 53.65 
(NCH), 30.9 (CH2), 28.1 (CH2), 21.6 (ArCH3), 15.05 (CH3), 11.1 (CH3); HRMS calculated for 
C22H31NNaO4S [M+Na]
+
 428.1872, found 428.1882. 
 
tert-Butyl (1-(2-(diethoxymethyl)phenyl)butan-2-yl)(tosyl)carbamate 303 
 
 
 
A solution of N-(1-(2-(diethoxymethyl)phenyl)butan-2-yl)-4-methylbenzenesulfonamide 291 (2.38 g, 
5.87 mmol, 1.0 eq.) in dichloromethane (25 mL) was treated with DMAP (143 mg, 1.17 mmol, 0.2 eq.) 
and Boc2O (1.54 g, 7.04 mmol, 1.2 eq.) according to General Procedure C. The crude material was 
purified by column chromatography (petrol/diethyl ether 2:1) to give the carbamate 303 (1.24 g, 82%) as 
a colourless oil; νmax 3025, 1724 (C=O), 1353 (S=O), 1153 (S=O), 1088 (C-O); δH 7.57 (1H, d, J 7.2, 
ArH), 7.25 – 7.16 (3H, m, 3 x ArH), 7.07 (1H, t, J 6.8, ArH), 7.01 (3H, m, 3 x ArH), 5.63 (1H, s, 
CH(OCH2CH3)), 4.70 – 4.61 (1H, m, NCH), 3.63 – 3.48 (3H, m, 3 x OCH2CH3), 3.47 – 3.39 (1H, m, 
OCH2CH3), 3.28 (1H, dd, J 13.8 and 8.7, ArCH2a), 3.21 (1H, dd, J 13.8 and 6.7, ArCH2b), 2.30 (3H, s, 
ArCH3), 2.08 – 1.94 (1H, m, CH3CH2a), 1.71 – 1.63 (1H, m, CH3CH2b), 1.33 (9H, s, C(CH3)3), 1.17 (3H, 
t, J 7.0, OCH2CH3), 1.15 (3H, t, J 7.1, 3 x OCH2CH3), 0.90 (3H, t, J 7.4, CHCH2CH3); δC 151.1 (C=O), 
143.4 (C), 137.75 (C), 137.2 (C), 131.35 (ArCH), 129.0 (2 x ArCH), 128.6 (ArCH), 128.2 (2 x ArCH), 
127.0 (ArCH), 126.5 (ArCH), 100.2 (CH(OCH2CH3)2), 84.1 (C(CH3)3), 62.2 (NCH) 62.1 (OCH2), 62.0 
(OCH2), 35.7 (CH2), 28.2 (C(CH3)3), 26.3 (ArCH2), 21.6 (ArCH3), 15.4 (CH3), 15.3 (CH3), 11.6 (CH3); 
HRMS (ES
-
)calculated for C27H39ClNO6S [M+Cl]
-
 540.2187, found 540.2169 
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(E)-2-(2-(2-Nitrovinyl)phenyl)-1,3-dioxolane 294 
 
 
 
 
 
To a solution of 2-(1,3-dioxolan-2-yl)benzaldehyde 293 (4.76 g, 26.74 mmol, 1.0 eq) in nitromethane 
(13.1 g, 214 mmol, 8 eq.) was added ammonium acetate (1.34 g, 18.72 mmol, 0.7 eq) and the mixture 
heated to 90 °C for 3 hours. The reaction was then allowed to cool to room temperature, and the solvent 
was removed in vacuo at 5 mbar pressure and at 60 °C for 1 hour. The crude reaction mixture was 
redissolved in dichloromethane (100 mL), washed with water (3 x 25 mL) and brine (25 mL), dried, 
filtered and evaporated to give crude nitroalkene 294 (5.63 g, 95%) as a brown oil (5.63 g, 95%); δH (400 
MHz) 8.45 (1H, d, J 13.6, ArCH=CH), 7.57 (1H, dd, J 7.7 and 1.2, ArH), 7.49 – 7.46 (1H, m, ArH), 7.44 
– 7.38 (1H, m, ArH), 7.41 (1H, d, J 13.7, ArCH=CH), 7.37 – 7.33 (1H, m, ArH), 5.87 (1H, s, 
ArCH(OEt)2), 4.15 – 4.10 (2H, m, OCH2CH3), 4.04 – 3.99 (2H, m, OCH2CH3). 
 
1-(2-(1,3-Dioxolan-2-yl)phenyl)ethan-1-amine 294a 
 
 
 
To the solution of 294 (4.76 g, 26.74 mmol, 1.0 eq.) in tetrahydrofuran (75 mL) at 0 °C under an 
atmosphere of nitrogen was added portionwise lithium aluminium hydride (525 mg, 13.82 mmol, 3.0 eq) 
over 5 minutes. The reaction mixture was allowed to stir for 1 hour at the same temperature and then 
heated to reflux at 65 °C for 2.5 hours. The reaction was then allowed to cool to room temperature and 
quenched according to the General Procedure F to yield the amine 294a as a brown oil, and was used in 
the next step without further purification; δH (400 MHz) 7.56 – 7.47 (1H, m, ArH), 7.38 – 7.08 (3H, m, 
ArH), 5.93 (1H, s, ArCH(OEt)2), 4.11 – 4.06 (2H, m, OCH2CH3), 4.00 – 3.95 (2H, m, OCH2CH3), 2.96 – 
2.89 (1H, br m, ArCH2), 2.85 – 2.80 (2H, br m, ArCH2CH2), 2.37 (2H, br s, NH2). 
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2-(2-(1,3-Dioxolan-2-yl)phenethyl)-4-methylbenzenesulfonamide 295 
 
 
 
Method 1: 
A solution of 1-(2-(1,3-dioxolan-2-yl)phenyl)ethan-1-amine 294a from previous reaction (assumed: 25.46 
mmol, 1.0 eq.) in dichloromethane was treated with triethylamine, DMAP and p-tosyl chloride according 
to General Procedure B. The crude material was purified by column chromatography (petrol/diethyl ether 
1:1) to give the sulfonamide 295 (1.85 g, 22% over 2 steps) as a white solid; m.p. 108 – 112 °C; νmax 3275 
(br, NH), 1327 (S=O), 1159 (S=O), 1079 (C-O); δH 7.58 (2H, d, J 8.3, 2 x ArH), 7.50 (1H, dd, J 7.0 and 
2.1, ArH), 7.25 – 7.19 (2H, m, 2 x ArH), 7.18 (2H, d, J 7.9, 2 x ArH), 7.03 (1H, dd, J 7.0 and 1.9, ArH), 
5.85 (1H, s, (CH(OCH2)2), 5.37 (1H, t, J 5.3, NH), 4.17 – 4.11 (2H, m, CH(OCH2a)2), 4.07 – 4.01 (2H, m, 
(CH(OCH2b)2), 3.23 (2H, dd, J 12.3 and 6.8, NCH2), 2.90 (2H, t, J 6.8, ArCH2), 2.39 (3H, s, ArCH3); δC 
143.0 (C), 137.1 (C), 137.1 (C), 135.2 (C), 130.4 (ArCH), 129.6 (2 x ArCH), 129.6 (ArCH), 127.05 (2 x 
ArCH), 127.0 (ArCH), 126.8 (ArCH), 102.4 (CH(OCH2)2), 65.3 (CH(OCH2)2), 44.5 (NCH2), 31.7 
(ArCH2), 21.6 (ArCH3); HRMS calculated for C18H21NNaO4S [M+Na]
+
 370.1089, found 370.1087. 
 
Method 2: 
 
 
 
 
 
Magnesium turnings (542 mg, 22.30 mmol, 2.2 eq.) were dry-stirred under an atmosphere of nitrogen for 
24 hours and then suspended in tetrahydrofuran (5 mL). The suspension was treated with a crystal of 
iodine and 2-(2-bromophenyl)-1,3-dioxolane 296 (4.64 g, 20.27 mmol, 2.0 eq.) was added as a solution in 
tetrahydrofuran (3 mL). The reaction was stirred for a further 30 minutes, during which time 
decolourisation and disappearance of most of the magnesium turnings was observed. The solution was 
then cooled to -40 °C and copper (I) iodide (579 mg, 3.04 mmol, 0.3 eq.) was added. After further 30 
minutes, the reaction mixture was cooled to -78 °C and commercially available 1-tosylaziridine (2.0 g, 
10.14 mmol, 1.0 eq.) in tetrahydrofuran (5 mL) was added. After 15 minutes, the reaction mixture was 
warmed to 0 °C and stirred for another 1.25 h, then quenched by aqueous ammonium chloride (30 mL) 
and the blue aqueous phase extracted with diethyl ether (3 x 30 mL). The combined organic extracts were 
washed with brine (50 mL), dried, filtered and evaporated. The crude material was purified by column 
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chromatography (petrol/diethyl ether 2:1) to give sulfonamide 295 (1.44 g, 41%) as white solid. All data 
obtained were in accordance with those reported previously. 
 
tert-Butyl (2-(1,3-dioxolan-2-yl)phenethyl)(tosyl)carbamate 300 
 
 
 
A solution of 2-(2-(1,3-dioxolan-2-yl)phenethyl)-4-methylbenzenesulfonamide 295 (1.44 g, 41.38 mmol, 
1.0 eq.) in dichloromethane (25 mL) was treated with DMAP (111 mg, 0.2 eq.) and Boc2O (1.19 g, 1.2 
eq.) according to General Procedure C. The crude material was purified by column chromatography 
(petrol/diethyl ether 2:1) to give the carbamate 300 (1.24 g, 67%) as a pale yellow oil which solidified 
upon standing; m.p. 114 – 117 °C; νmax 1728 (C=O), 1355 (S=O), 1155 (S=O); δH 7.82 (2H, d, J 8.3, 2 x 
ArH), 7.62 (1H, d, J 7.4, ArH), 7.36 – 7.28 (5H, m, 5 x ArH), 6.11 (1H, s, (CH(OCH2)2), 4.26 – 4.17 (2H, 
m, (CH(OCH2a)2), 4.13 – 4.04 (4H, m, (CH(OCH2b)2 and NCH2), 3.29 – 3.23 (2H, m, ArCH2), 2.45 (3H, 
s, ArCH3), 1.39 (9H, s, C(CH3)3); δC 150.9 (C=O), 144.1 (C), 137.5 (C), 137.0 (C), 135.7 (C), 130.9 
(ArCH), 129.4 (ArCH), 129.3 (2 x ArCH), 127.8 (2 x ArCH), 126.85 (ArCH), 126.8 (ArCH), 101.8 
(CH(OCH2)2), 84.1 (C(CH3)3), 65.3 (NCH), 48.4 (CH2), 33.5 (CH2), 27.9 (C(CH3)3), 21.6 (ArCH3). 
 
N-(1-(2-(1,3-Dioxolan-2-yl)phenyl)butan-2-yl)-4-methylbenzenesulfonamide 297 
 
 
 
Method 1: 
Magnesium turnings (1.25 g, 51.4 mmol, 2.7 eq.) were dry-stirred under an atmosphere of nitrogen for 24 
hours and then suspended in tetrahydrofuran (10 mL). The suspension was treated with a crystal of iodine 
and 2-(2-bromophenyl)-1,3-dioxolane 296 (10.70 mg, 46.7 mmol, 2.46 eq.) was added as a solution in 
tetrahydrofuran (10 mL). The reaction was stirred for a further 30 minutes, during which time 
decolourisation and disappearance of most of the magnesium turnings was observed. The solution was 
then cooled to -40 °C and copper (I) iodide (1.33 g, 7.0 mmol, 0.37 eq.) was added. After further 30 
minutes, the reaction mixture was cooled to -78 °C and 2-ethyl-1-tosylaziridine 154 (4.27 g, 18.98 mmol, 
1.0 eq.) in tetrahydrofuran (10 mL) was added. After 15 minutes, the reaction mixture was warmed to 0 
°C and stirred for a further 1.25 h, then quenched by aqueous ammonium chloride (30 mL) and the blue 
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aqueous phase extracted with diethyl ether (3 x 30 mL). The combined organic extracts were washed with 
brine (50 mL), dried, filtered and evaporated. The crude material was purified by column chromatography 
(petrol/diethyl ether, 1:1) to give sulfonamide 297 (5.53 g, 78%) as colourless oil; δH 7.40 (1H, dd, J 7.7 
and 1.1, ArH), 7.28 – 7.24 (2H, m, 2 x ArH), 7.12 (1H, td, J 7.6 and 1.1, ArH), 6.96 – 6.92 (3H, m and d 
J 8.0, 3 x ArH), 6.09 (1H, d, J 5.5, NH), 5.84 (1H, s, CH(CH2O)2), 4.26 – 4.24 (1H, m, OCH2aCH3), 4.23 
– 4.20 (1H, m, OCH2bCH3), 4.14 – 4.06 (2H, m, OCH2cCH3 and OCH2dCH3), 3.28 – 3.21 (1H, m, NCH), 
2.85 (1H, dd, J 14.1 and 10.3, ArCH2a), 2.66 (1H, dd, J 14.1 and 4.4, ArCH2b), 2.34 (3H, s, ArCH3), 1.77 
– 1.69 (2H, m, CH3CH2), 0.95 (3H, t, J 7.4, CH3CH2); δC 142.1 (C), 137.3 (C), 137.1 (C), 134.7 (C), 
130.5 (ArCH), 129.5 (ArCH), 129.3 (2 x ArCH), 127.2 (ArCH), 126.7 (2 x ArCH), 126.3 (ArCH), 103.1 
(ArCH(OCH2)2), 65.4 (OCH2), 65.3 (OCH2), 57.2 (NCH), 35.3 (ArCH2), 29.7 (CH2), 21.5 (ArCH3), 9.5 
(CH3). 
 
Method 2: 
To a solution of 2-(2-bromophenyl)-1,3-dioxolane (1.3 g, 5.67 mmol, 2.0 eq.) in tetrahydrofuran (20 mL) 
under an atmosphere of nitrogen at -78 °C was added n-butyllithium (2.4M, 2.48 mL, 5.95 mmol, 2.1 eq.) 
and the mixture stirred for 0.5 h. To the bright orange solution was then added solid magnesium bromide 
(1.10 g, 5.95 mmol, 2.1 eq.) and the resulting mixture stirred at 0 °C for 30 minutes and then cooled to -
40 °C. Copper (I) iodide (160 mg, 0.85 mmol, 0.3 eq.) was then added and the reaction stirred for a 
further 30 minutes at -40 °C and then cooled to -78 °C. 2-Ethyl-1-tosylaziridine 154 (638 mg, 2.84 mmol, 
1.0 eq.) in tetrahydrofuran (5 mL) was then added, the solution stirred for 0.25 h at -78 °C and for a 
further 1h at 0 °C. The reaction was quenched by aqueous ammonium chloride (20 mL) and the separated 
blue aqueous phase extracted with ethyl acetate (3 x 20 mL) and the combined organic extracts washed 
with brine (20 mL), dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/diethyl ether 1:1) to give sulfonamide 297 (532 mg, 50%) as a colourless oil. All 
data obtained were in accordance with those reported previously. 
 
tert-Butyl (1-(2-(1,3-dioxolan-2-yl)phenyl)butan-2-yl)(tosyl)carbamate 301 
 
 
 
Method 1: 
A solution of N-(1-(2-(1,3-dioxolan-2-yl)phenyl)butan-2-yl)-4-methylbenzenesulfonamide 297 (532 mg, 
1.42 mmol, 1.0 eq.) in dichloromethane (10 mL) was treated with DMAP (35 mg, 0.2 eq.) and Boc2O 
(372 mg, 1.2 eq.) according to General Procedure C. The crude material was purified by column 
chromatography (petrol/diethyl ether 2:1) to give the carbamate 301 (533 g, 79%) as a pale yellow oil; 
 188 
 
νmax 1725 (C=O), 1352 (S=O), 1255 (C-O), 1153 (S=O); δH (400 MHz) 7.63 (1H, dd, J 7.7 and 1.2, ArH), 
7.29 (3H, m, 3 x ArH), 7.19 (1H, td, J 7.4 and 1.4, ArH), 7.15 (1H, d, 7.0, ArH), 7.11 – 7.08 (1H, m, 
ArH), 6.10 (1H, s, CH(OCH2)2), 4.76 – 4.74 (1H, m, NCH), 4.18 – 4.11 (2H, m, OCH2), 4.09 – 4.02 (2H, 
m, OCH2), 3.39 (1H, dd, J 13.8 and 8.3, ArCH2a), 3.30 (1H, dd, J 13.8 and 7.1, ArCH2b), 2.37 (3H, s, 
ArCH3), 2.13 – 1.99 (1H, m, CH2aCH3), 1.76 – 1.63 (1H, m, CH2bCH3), 1.39 (9H, s, C(CH3)3), 0.92 (3H, 
t, J 7.5, CH2CH3); δC 151.05 (C=O), 143.4 (C), 137.7 (C), 136.2 (C), 131.3 (C), 129.2, 129.0, 128.1, 
126.8, 126.6, 101.55 (CH(OCH2)2), 84.0 (C(CH3)3), 65.3 (2 x CH2), 62.4 (NCH), 36.0 (ArCH2), 28.1 
(C(CH3)3), 26.0 (CH2), 21.6 (ArCH3), 11.6 (CH3); HRMS calculated for C25H34NO6S [M+H]
+
 476.2107, 
found 476.2095. 
 
Method 2: 
Magnesium turnings (258 mg, 10.6 mmol, 2.2 eq.) were dry-stirred under an atmosphere of nitrogen for 
24 hours and then suspended in tetrahydrofuran (10 mL). The suspension was treated with a crystal of 
iodine and 2-(2-bromophenyl)-1,3-dioxolane 296 (2.21 g, 9.65 mmol, 2.0 eq.) was added as a solution in 
tetrahydrofuran (10 mL). The reaction was stirred for a further 30 minutes, during which time 
decolourisation and disappearance of most of the magnesium turnings was observed. The solution was 
then cooled to -40 °C and copper (I) iodide (276 mg, 1.45 mmol, 0.3 eq.) was added. After further 30 
minutes, the reaction mixture was cooled to -78 °C and 2-ethyl-1-tosylaziridine 154 (4.27 g, 18.98 mmol, 
1.0 eq.) in tetrahydrofuran (10 mL) was added. After 15 minutes, the reaction mixture was warmed to 0 
°C and stirred for a further 1.25 h. Boc2O (2.21 g, 10.14 mmol, 1.05 eq.) in tetrahydrofuran (10 mL) was 
then added and the solution stirred for 16 hours. The reaction was quenched by aqueous ammonium 
chloride (30 mL) and the blue aqueous phase extracted with diethyl ether (3 x 30 mL). The combined 
organic extracts were washed with brine (50 mL), dried, filtered and evaporated. The crude material was 
purified by column chromatography (petrol/diethyl ether, 1:1) to give sulfonamide 301 (1.16 g, 51%) as a 
viscous, colourless oil. All data obtained were in accordance to those reported previously. 
 
tert-Butyl (1-(2-formylphenyl)butan-2-yl)(tosyl)carbamate 302 
 
 
 
Method 1: 
To a solution of tert-butyl (1-(2-(diethoxymethyl)phenyl)butan-2-yl)(tosyl)carbamate 303 (2.71 g, 5.52 
mmol, 1.0 eq.) in dichloromethane (25 mL) at ambient temperature was added iron (III) chloride 
hexahydrate (5.22 g, 19.32 mmol, 3.5 eq.) and the resulting mixture stirred vigorously for 1 hour. The 
reaction was quenched by dropwise addition of aqueous sodium bicarbonate (25 mL) and the separated 
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aqueous phase extracted with dichloromethane (3 x 25 mL). The combined organic extracts were washed 
with aqueous sodium bicarbonate (25 mL), brine (25 mL), dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/diethyl ether 2:1) to give aldehyde 302 (1.99 g, 
84%) as a white solid; m.p. 75 – 77 °C; νmax 3070, 2738 (CHO), 1723 (C=O), 1699 (C=O), 1350 (S=O), 
1152 (S=O); δH 10.22 (1H, s, CHO), 7.87 – 7.80 (1H, m, ArH), 7.39 – 7.35 (2H, m, 2 x ArCH), 7.25 (3H, 
br. s, 3 x ArH), 7.05 (2H, d, J 8.0, ArCH), 4.74 – 4.71 (1H, m, NCH), 3.66 (1H, dd, J 13.3 and 5.5, 
ArCH2a), 3.48 (1H, dd, J 13.1 and 9.9, ArCH2a), 2.33 (3H, s, ArCH3), 2.06 – 2.04 (1H, m, CH3CH2a), 1.89 
– 1.78 (1H, m, CH3CH2b), 1.36 (9H, s, C(CH3)3), 0.97 (3H, t, J 7.5, CH3);  δC 192.7 (CHO), 150.9 (C=O), 
143.5 (C), 141.3 (C), 137.5 (C), 134.6 (C), 133.7 (ArCH), 133.4 (ArCH), 132.6 (ArCH), 128.8 (2 x 
ArCH), 128.0 (2 x ArCH), 127.25 (ArCH), 84.1 (C(CH3)3), 62.1 (NCH), 35.9 (CH2), 28.0 (C(CH3)3), 26.5 
(CH2), 21.5 (ArCH3), 11.5 (CH3); HRMS calculated for C23H29NNaO5S [M+Na]
+
 454.1664, found 
454.1677. 
 
 
 
 
Method 2: 
To a solution of tert-butyl (1-(2-(1,3-dioxolan-2-yl)phenyl)butan-2-yl)(tosyl)carbamate 301 (533 mg, 
1.12 mmol, 1.0 eq.) in dichloromethane (10 mL) at ambient temperature was added iron (III) chloride 
hexahydrate (1.06 g, 7.87 mmol, 3.5 eq.) and the resulting mixture stirred vigorously for 1 hour. The 
reaction was quenched by dropwise addition of aqueous sodium bicarbonate (10 mL) and the separated 
aqueous phase extracted with dichloromethane (3 x 25 mL). The combined organic extracts were washed 
with aqueous sodium bicarbonate (10 mL), brine (10 mL), dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/diethyl ether 2:1) to give aldehyde 302 (329 mg, 
68%) as a white solid. All data obtained were in accordance to those reported previously. 
 
Method 3: 
To a solution of tert-butyl (1-(2-(1,3-dioxolan-2-yl)phenyl)butan-2-yl)(tosyl)carbamate 301 (100 mg, 
0.211 mmol, 1.0 eq.) in dichloromethane (10 mL) at ambient temperature was added amberlyst-15 (20 
mg, 20% wt.) and the resulting mixture stirred vigorously for 1 hour. The reaction was filtered and 
washed with aqueous sodium bicarbonate (10 mL) and the separated aqueous phase extracted with 
dichloromethane (3 x 25 mL). The combined organic extracts were washed with aqueous sodium 
bicarbonate (10 mL), brine (10 mL), dried, filtered and evaporated to give aldehyde 302 (66 mg, 95%) as 
a white solid. All data obtained were in accordance to those reported previously. 
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tert-Butyl (2-formylphenethyl)(tosyl)carbamate 300b 
 
 
 
To a solution of tert-butyl (1-(2-(1,3-dioxolan-2-yl)phenyl)butan-2-yl)(tosyl)carbamate 300 (1.00 g, 2.46 
mmol, 1.0 eq.) in dichloromethane (20 mL) at ambient temperature was added iron (III) chloride 
hexahydrate (2.13 g, 7.87 mmol, 3.5 eq.) and the resulting mixture stirred vigorously for 1 hour. The 
reaction was quenched by dropwise addition of aqueous sodium bicarbonate (25 mL) and the separated 
aqueous phase extracted with dichloromethane (3 x 20 mL). The combined organic extracts were washed 
with aqueous sodium bicarbonate (20 mL), brine (20 mL), dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/diethyl ether 2:1) to give aldehyde 300b (710 
mg, 78%) as a yellow oil; δH 10.34 (1H, s, CHO), 7.87 (1H, dd, J 7.7 and 1.3, ArH), 7.76 (2H, d, J 8.4, 2 
x ArH), 7.55 (1H, td, J 7.5 and 1.5, ArH), 7.45 (1H, td, J 7.5 and 1.0, ArH), 7.40 (1H, d, J 7.5, ArH), 7.29 
(2H, d, J 7.9, 2 x ArH), 4.15 – 4.11 (2H, t, 7.3, NCH2), 3.50 (2H, t, J 7.3, ArCH2), 2.44 (3H, s, ArCH3), 
1.29 (9H, s, C(CH3)3); δC 192.6 (CHO), 150.9 (C=O), 144.3 (C), 140.6 (C), 137.4 (C), 134.5 (C), 134.0 
(ArCH), 132.3 (ArCH), 132.3 (ArCH), 129.3 (2 x ArCH), 128.0 (2 x ArCH), 127.4 (2 x ArCH), 84.3 
(C(CH3)3), 48.2 (CH2), 33.5 (CH2), 27.9 (C(CH3)3), 21.7 (ArCH3). 
 
 
(E)-1-Bromo-4,5-dimethoxy-2-(2-nitrovinyl)benzene
245
 317 
 
 
 
 
To a solution of 2-bromo-4,5-dimethoxybenzaldehyde (10.0 g, 40.8 mmol, 1.0 eq.) in nitromethane (20.0 
g, 326 mmol, 8 eq.) was added ammonium acetate (1.89 g, 24.5 mmol, 0.6 eq.) and the mixture heated to 
90 °C for 4 hours. The reaction was then allowed to cool to room temperature, and the solvent was 
removed in vacuo at 5 mbar pressure and at 50 °C for 0.25 h. The residue was suspended in 
dichloromethane (75 mL), washed with water (50 mL) and brine (50 mL), dried, filtered, evaporated and 
briefly triturated with petroleum ether to afford the crude nitroalkene 317 (7.96 g, 68%) as a yellow solid; 
δH (400 MHz) 8.35 (1H, d, J 13.6, ArCH=CH), 7.51 (1H, d, J 13.6, ArCH=CH), 7.10 (1H, s, ArH), 6.98 
(1H, s, ArH), 3.92 (3H, s, OCH3), 3.91 (3H, s, OCH3). 
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2-(2-Bromo-4,5-dimethoxyphenyl)ethan-1-amine
246
 318 
 
 
 
 
A solution of (E)-1-Bromo-4,5-dimethoxy-2-(2-nitrovinyl)benzene 317 (7.96 g, 27.7 mmol, 1.0 eq.) in 
tetrahydrofuran was treated with sodium borohydride (4.97 g, 131.3 mmol, 4.75 eq.), and boron 
trifluoride diethyl etherate (23.5 g, 165.9 mmol, 6.0 eq.) according to the General Procedure F to afford 
amine 318 (4.2 g, 58%) as a brown oil; δH (400 MHz) 7.00 (1H, s, ArH), 6.74 (1H, s, ArH), 3.85 (3H, s, 
OCH3), 3.85 (3H, s, OCH3), 2.95 (2H, t, J 6.9, NCH2), 2.83 (2H, t, J 6.9, ArCH2), 2.23 – 2.21 (1H, br s, 
NH2). 
 
N-(2-Bromo-4,5-dimethoxyphenethyl)-4-methylbenzenesulfonamide
247
 319 
 
 
 
 
 
A solution of 2-(2-bromo-4,5-dimethoxyphenyl)ethan-1-amine 318 (4.20 g, 16.16 mmol) in 
dichloromethane was treated with triethylamine, DMAP and p-tosyl chloride according to General 
Procedure B. The crude material was purified by column chromatography (petrol/diethyl ether 1:3) to 
give the sulfonamide 319 (5.55 g, 83%) as a white-orange solid; m.p. 114 – 116 °C, lit. m.p.247 127 – 128 
°C (benzene); νmax 3351 (br, NH); δH (400 MHz) 7.70 (2H, d, J 8.3, 2 x ArH), 7.26 (1H, d, J 8.2, 2 x 
ArH), 6.92 (1H, s, ArH), 6.66 (1H, s, ArH), 4.81 (1H, t, J 6.0, NH), 3.82 (3H, s, OCH3), 3.81 (3H, s, 
OCH3), 3.21 (1H, q, J 6.8, NCH2), 2.84 (1H, t, J 7.0, ArCH2), 2.41 (3H, s, ArCH3); δC (101 MHz) 148.4 
(C), 148.4 (C), 143.40 (C), 136.9 (C), 129.7 (2 x ArCH), 129.1 (C), 127.05 (2 x ArCH), 115.5 (ArCH), 
114.1 (C-Br), 113.5 (ArCH), 56.2 (OCH3), 56.1 (OCH3), 42.9 (CH2), 35.95 (CH2), 21.55 (ArCH3). 
 
(E)-1,2-Dimethoxy-4-(2-nitroprop-1-en-1-yl)benzene
248
 321a 
 
 
 
 
 
To a solution of 3,4-dimethoxybenzaldehyde (2.0 g, 12.04 mmol, 1.0 eq.) in nitromethane (45.2 g, 602 
mmol, 50 eq.) was added ammonium acetate (788 mg, 10.23 mmol, 0.85 eq.) and the mixture heated to 
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reflux for 4 hours. The reaction was then allowed to cool to room temperature, and the solvent was 
removed in vacuo at 5 mbar pressure and at 50 °C for 0.25 h. The residue was suspended in 
dichloromethane (75 mL), washed with water (50 mL) and brine (50 mL), dried, filtered and evaporated . 
The crude solid was briefly triturated with petroleum ether and then recrystallized from hot petrol/ethyl 
acetate (1:1) to afford the crude nitroalkene 321a (1.96 g, 73%) as a yellow solid; δH (250 MHz) 8.07 
(1H, s, ArCH=C), 7.09 (1H, dd, J 8.4 and 2.0, ArH), 6.94 (1H, d, J 8.5, ArH), 6.95 – 6.92 (1H, m, ArH), 
3.94 (3H, s, OCH3), 3.92 (3H, s, OCH3), 2.49 (3H, d, J 0.9, CH3).  
 
1-(3,4-Dimethoxyphenyl)propan-2-amine
249
 321 
 
 
 
 
 
To the solution of 321a (1.96 g, 8.79 mmol, 1.0 eq.) in tetrahydrofuran (50 mL) at 0 °C under an 
atmosphere of nitrogen was added portionwise lithium aluminium hydride (1.33 g, 35.16 mmol, 4.0 eq) 
over 5 minutes. The reaction mixture was allowed to stir for 1 hour at the same temperature and then 
heated to reflux at 65 °C for 2.5 hours. The reaction was then allowed to cool to room temperature and 
quenched according to the General Procedure F to yield the amine 321 (1.43 g, 84%) as a beige oil, and 
was used in the next step without further purification; δH (250 MHz) 6.81 – 6.76 (1H, m, ArH), 6.73 – 
6.67 (2H, m, 2 x ArH), 3.85 (3H, s, OCH3), 3.83 (3H, s, OCH3), 3.19 – 3.03 (1H, m, NCH), 2.65 (1H, dd, 
J 13.4 and 5.1, ArCH2a), 2.41 (1H, dd, J 13.4 and 8.3, ArCH2b), 1.80 – 1.70 (2H, br s, NH2), 1.10 (3H, d, J 
6.3, CHCH3). 
 
N-(1-(3,4-Dimethoxyphenyl)propan-2-yl)-4-nitrobenzenesulfonamide
250
  322 
 
 
 
A solution of 1-(3,4-dimethoxyphenyl)propan-2-amine 321 (788 mg, 4.04 mmol) in dichloromethane was 
treated with triethylamine, DMAP and p-nosyl chloride according to General Procedure B. The crude 
material was purified by column chromatography (petrol/ethyl acetate 2:1) to give the sulfonamide 322 
(848 mg, 57%) as a yellow solid; m.p. 69 – 72 °C; lit. m.p.250 74 – 81 °C; νmax 3340 (br, NH), 1529 
(N=O), 1345 (S=O), 1161 (S=O); δH 8.17 (2H, d, J 8.8, 2 x ArH), 7.75 (2H, d, J 8.8, 2 x ArH), 6.63 (1H, 
d, J 8.1, ArH), 6.50 (1H, dd, J 8.1 and 1.8, ArH), 6.44 – 6.42 (1H, m, ArH), 4.66 (1H, d, J 7.5, NH), 3.82 
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(3H, s, ArOCH3), 3.75 (3H, s, ArOCH3), 3.57 – 3.48 (1H, m, NCH), 2.72 (1H, dd, J 14.0 and 5.2, 
ArCH2a), 2.49 (1H, dd, J 14.0 and 8.5, ArCH2b), 1.25 (3H, d, J 6.5, CH3); LRMS (EI
+
) m/z 380 ([M]
+
, 
90%), 229 ([EtNs]
+
, 99%), 151 ([M-EtNs]
+
, 92%); HRMS calculated for C17H20N2O6S [M]
+
 380.1042, 
found 380.1046. 
 
Methyl (1-(3,4-dimethoxyphenyl)propan-2-yl)carbamate 323 
 
 
 
A solution of 1-(3,4-dimethoxyphenyl)propan-2-amine 321 (600 mg, 3.08 mmol, 1.0 eq.) in diethyl ether 
(4 mL) was cooled to 0 °C. Water (3 mL) and potassium carbonate (1.30 g, 9.33 mmol, 3.0 eq.) was 
added, followed by dropwise addition of methyl chloroformate (420 mg, 4.46 mmol, 1.45 eq.). The 
cooling bath was removed and the reaction was allowed to warm to room temperature over 30 minutes. 
The separated aqueous phase was then extracted with dichloromethane (3 x 5 mL) and the combined 
organic extracts washed with brine (5 mL), dried, filtered and evaporated. The crude material was 
purified by column chromatography (petrol/ethyl acetate 2:1) to give carbamate 323 (510 mg, 65%) as a 
viscous beige oil; νmax 3382 (br, NH), 1707 (C=O); δH (400 MHz) 6.79 (1H, d, J 8.3, ArH), 6.72 – 6.68 
(2H, m, 2 x ArH), 4.54 (1H, br s, NH), 3.95 – 3.91 (1H, m, NCH), 3.86 (3H, s, ArOCH3), 3.85 (3H, s, 
ArOCH3), 3.64 (3H, s, COOCH3), 2.78 (1H, br s, ArCH2a), 2.61 (1H, dd, J 13.6 and 7.3, ArCH2b), 1.11 
(3H, d, J 6.6, CHCH3); LRMS (EI
+
) m/z 253 ([M]
+
, 20%), 221 ([M-MeOH]
+
, 95%), 151 ([M-
EtNHCOOMe]
+
, 100%), 102 ([EtNHCOOMe]
+
, 78%). 
 
N-(1-(2-Iodo-4,5-dimethoxyphenyl)propan-2-yl)-4-nitrobenzenesulfonamide  324 
 
 
 
To a solution of N-(1-(3,4-dimethoxyphenyl)propan-2-yl)-4-nitrobenzenesulfonamide 322 (500 mg, 1.32 
mmol, 1.0 eq.) in methanol (10 mL) at 0 °C was added silver sulfate (492 mg, 1.58 mmol, 1.2 eq.) and 
solid iodine (401 mg, 1.58 mmol, 1.2 eq.) and the solution stirred at ambient temperature for 2.5 h. The 
reaction mixture was then cooled to 0 °C and poured over a 0 °C solution of aqueous sodium bicarbonate 
and aqueous sodium thiosulfate (1:1, 10 mL), stirred for 2 minutes and then filtered through a pad of 
Celite
©
 and the filter cake washed with ethyl acetate (2 x 20 mL). The separated aqueous phase was 
extracted with ethyl acetate (2 x 20 mL) and the combined organic extracts washed with aqueous sodium 
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thiosulfate (10 mL), aqueous sodium bicarbonate (10 mL), brine (10 mL) and dried, filtered and 
evaporated to give iodide 324 (608 mg, 90%) as a yellow gum; νmax 3309 (br, NH); δH 8.11 (2H, d, J 8.9, 
2 x ArH), 7.71 (2H, d, J 9.0, ArH), 6.91 (1H, s, ArH), 6.42 (1H, s, ArH), 4.77 (1H, d, J 8.4, NH), 3.77 
(3H, s, ArOCH3), 3.75 (3H, s, ArOCH3), 2.77 (1H, dd, J 14.3 and 4.5, ArCH2a), 2.62 (1H, dd, J 14.3 and 
10.3, ArCH2b), 1.39 (3H, d, J 6.5, CH3); δC 149.6 (C), 149.4 (C), 148.8 (C), 146.25 (C), 132.5 (C), 127.9 
(ArCH), 123.95 (ArCH), 121.6 (ArCH), 113.3 (ArCH), 88.65 (C-I), 56.1 (OCH3), 56.0 (OCH3), 52.0 
(NCH), 47.0 (CH2), 23.6 (CH3); HRMS calculated for C17H19IN2O6S [M]
+
 506.0009, found 506.0026. 
 
Methyl (1-(2-iodo-4,5-dimethoxyphenyl)propan-2-yl)carbamate 325 
 
 
 
To a solution of methyl (1-(3,4-dimethoxyphenyl)propan-2-yl)carbamate 323 (500 mg, 2,00 mmol, 1.0 
eq.) in methanol (10 mL) at 0 °C was added silver sulfate (748 mg, 2.40 mmol, 1.2 eq.) and solid iodine 
(608 mg, 2.40 mmol, 1.2 eq.) and the solution stirred at ambient temperature for 2.5 h. The reaction 
mixture was then cooled to 0 °C and poured over a 0 °C solution of aqueous sodium bicarbonate and 
aqueous sodium thiosulfate (1:1, 10 mL), stirred for 2 minutes and then filtered through a pad of Celite
©
 
and the filter cake washed with ethyl acetate (2 x 20 mL). The separated aqueous phase was extracted 
with ethyl acetate (2 x 20 mL) and the combined organic extracts washed with aqueous sodium 
thiosulfate (10 mL), aqueous sodium bicarbonate (10 mL), brine (10 mL) and dried, filtered and 
evaporated to give iodide 325 (573 mg, 76%) as a yellowish oil; νmax 3373 (br, NH), 1702 (C=O); δH (250 
MHz) 7.17 (1H, s, ArH), 6.69 (1H, s, ArH), 4.74 (1H, d, J 6.5, NH), 4.04 – 3.87 (1H, br m, NCH), 3.80 
(6H, s, 2 x ArOCH3), 3.57 (3H, s, COOCH3), 2.87 (1H, br dd, J 13.1 and 7.5, ArCH2a), 2.74 (1H, dd, J 
13.8 and 6.8, ArCH2b), 1.16 (3H, d, J 6.6, CH3).
 δC 156.4 (C=O), 149.5 (C), 148.3 (C), 133.9 (C), 121.9 
(ArCH), 113.05 (ArCH), 89.1 (C-I), 56.2 (ArOCH3), 56.05 (ArOCH3), 52.0 (COOCH3), 48.35 (NCH), 
46.6 (br s, ArCH2), 20.8 (CH3); HRMS calculated for C13H19IN2O6S [M+H]
+
 380.0359, found 380.0343. 
 
(E)-N-(1-(2-(Hex-1-en-1-yl)-4,5-dimethoxyphenyl)propan-2-yl)-4-nitrobenzenesulfonamide 
326 
 
 
A solution of N-(1-(2-iodo-4,5-dimethoxyphenyl)propan-2-yl)-4-nitrobenzenesulfonamide 324 (150 mg, 
1.0 eq.) in ethanol/water (1:1, 1.5 mL) was treated with 1-hexenylboronic acid (49 mg, 1.3 eq.), K3PO4 
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(126 mg, 2.0 eq) and Pd(dppf)Cl2.DCM (21 mg, 0.10 eq) at 70 °C for 2 h according to General Procedure 
D. The crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to give the 
sulfonamide 326 (99 mg, 72%) as a pale yellow foam; νmax 3352 (br, NH); δH 8.09 (2H, d, J 8.9, 2 x ArH), 
7.63 (2H, d, J 8.9, 2 x ArH), 6.64 (1H, s, ArH), 6.34 (1H, s, ArH), 6.32 (1H, d, J 15.6, ArCH=CH), 5.80 
(1H, dt, J 15.4 and 7.0, ArCH=CH), 4.88 (1H, d, J 7.3, NH), 3.82 (3H, s, ArOCH3), 3.76 (3H, s, 
ArOCH3), 3.48 – 3.38 (1H, m, NCH), 2.73 (1H, dd, J 14.3 and 5.0, ArCH2a), 2.57 (1 H, dd, J 14.3 and 
9.6, ArCH2b), 2.18 (2H, dt , J 7.0 and 7.0, CH2CH=CH), 1.48 – 1.41 (2H, m, CH2CH2CH=CH), 1.38 – 
1.36 (2H, m, CH3CH2), 1.31 (3H, d, J 6.4, CH3CH), 0.95 (3H, t, J 7.2, CH3CH2); δC 149.6 (C), 148.3 (C), 
148.1 (C), 146.0 (C), 132.6 (ArCH=CH), 129.45 (C), 127.8 (2 x ArCH), 126.5 (C), 126.4 (ArCH=CH), 
123.9 (2 x ArCH), 113.4 (ArCH), 108.9 (ArCH), 56.0 (OCH3), 55.8 (OCH3), 52.2 (NCH), 40.25 (CH2), 
33.1 (CH2), 31.7 (CH2), 23.3 (CH3), 22.4 (CH2), 14.0 (CH3); HRMS calculated for C23H30N2O6S [M]
+
 
462.1825, found 462.1828. 
 
Methyl (E)-(1-(2-(hex-1-en-1-yl)-4,5-dimethoxyphenyl)propan-2-yl)carbamate 327 
 
 
 
 
A solution of methyl (1-(2-iodo-4,5-dimethoxyphenyl)propan-2-yl)carbamate 325 (230 mg, 1.0 eq.) in 
ethanol/water (1:1, 2 mL) was treated with 1-hexenylboronic acid (101 mg, 1.3 eq.), K3PO4 (258 mg, 2.0 
eq) and Pd(dppf)Cl2.DCM (50 mg, 0.10 eq) at 80 °C for 1 h according to General Procedure D. The crude 
material was purified by column chromatography (petrol/ethyl acetate 1:1) to give the carbamate 327 
(109 mg, 54%) as a yellow oil; δH 6.94 (1H, s, ArH), 6.60 (1H, d, J 15.4, ArCH=CH), 6.58 (1H, s, ArH), 
6.02 – 5.98 (1H, dt, J 15.5 and 7.0, ArCH=CH), 4.64 (1H, br s, NH), 3.89 – 3.70 (1H, br s, NCH), 3.88 
(3H, s, ArOCH3), 3.84 (3H, s, ArOCH3), 3.53 (3H, s, COOCH3), 2.89 (1H, dd, J 13.8 and 6.0, ArCH2a), 
2.65 (1H, br s, ArCH2b), 2.25 – 2.20 (2H, m, CH=CHCH2), 1.50 – 1.42 (2H, m, CH3CH2CH2), 1.39 – 1.35 
(2H, m, CH2CH3), 1.09 (3H, d, J 6.6, NCHCH3), 0.93 (3H, t, J 7.3, CH2CH3); δC 156.4 (C=O), 148.1 (C), 
147.9 (C), 131.6 (ArCH=CH), 130.0 (C), 127.7 (C), 127.2 (ArCH=CH), 113.7 (ArCH), 109.2 (ArCH), 
56.1 (ArOCH3), 56.0 (ArOCH3), 52.0 (COOCH3), 48.4 (NCH), 39.4 (br ArCH2), 33.1 (CH2), 31.8 (CH2), 
22.4 (CH2), 20.2 (br. CH3), 14.05 (CH3); HRMS calculated for C19H30NO4 [M+H]
+
 336.2175, found 
336.2167 
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(E)-N-(1-(4,5-Dimethoxy-2-styrylphenyl)propan-2-yl)-4-nitrobenzenesulfonamide 328 
 
 
 
 
A solution of N-(1-(2-iodo-4,5-dimethoxyphenyl)propan-2-yl)-4-nitrobenzenesulfonamide 324 (360 mg, 
1.0 eq.) in ethanol/water (1:1, 4 mL) was treated with 1-phenylvinylboronic acid (150 mg, 1.5 eq.), K3PO4 
(286 mg, 2.0 eq) and Pd(dppf)Cl2.DCM (28 mg, 0.05 eq.) at 85 °C for 3 h according to General Procedure 
D. The crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to give the 
sulfonamide 328 (268 mg, 82%) as a yellow foam; νmax 3292 (br, NH); δH 8.04 (2H, d, J 8.8, 2 x ArH), 
7.65 (2H, d, J 8.8, 2 x ArH), 7.51 (2H, d, J 7.5, 2 x ArH), 7.40 (2H, t, J 7.6, 2 x ArH), 7.33 – 7.28 (1H, m, 
ArH), 7.14 (1H, d, J 16.0, ArCH=CH), 6.90 (1H, s, ArH), 6.71 (1H, d, J 16.0, ArCH=CH), 6.47 (1H, s, 
ArH), 4.70 (1H, d, J 7.3, NH), 3.90 (1H, s, OCH3), 3.83 (1H, s, OCH3), 3.49 – 3.40 (1H, m, NCH), 2.89 
(1H, dd, J 14.2 and 8.1, ArCH2a), 2.79 (1H, dd, J 14.2 and 6.3, ArCH2b), 1.23 (3H, d, J 6.5, CH3); δC 
149.8 (C), 148.9 (C), 148.5 (C), 146.0 (C), 137.3 (C), 129.6 (ArCH), 129.0 (2 x ArCH), 128.9 (C), 128.1 
(ArCH), 128.0 (2 x ArCH), 127.8 (C), 126.6 (2 x ArCH), 125.2 (ArCH), 124.1 (2 x ArCH), 113.8 
(ArCH), 108.8 (ArCH), 56.1 (OCH3), 56.0 (OCH3), 51.8 (NCH), 41.1 (CH2), 22.5 (CH3). 
 
(E)-N-(4,5-Dimethoxy-2-(4-methoxystyryl)phenethyl)-4-methylbenzenesulfonamide 330 
 
 
 
 
 
A solution of N-(2-bromo-4,5-dimethoxyphenethyl)-4-methylbenzenesulfonamide 319 (430 mg, 1.00 eq.) 
in ethanol/water (1:1, 4 mL) was treated with (4-methoxystyryl)boronic acid (268 mg, 1.5 eq.), K3PO4 
(426 mg, 2.0 eq) and Pd(dppf)Cl2.DCM (82 mg, 0.10 eq.) at 85 °C for 3 h according to General Procedure 
D. The crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to give the 
sulfonamide 330 (259 mg, 53%) as a white foam; νmax 3372 (br, NH); δH (400 MHz) 7.64 (2H, d, J 8.2, 2 
x ArH), 7.43 (2H, d, J 8.7, 2 x ArH), 7.16 (2H, d, J 8.1, 2 x ArH), 7.07 (1H, d, J 16.1, ArCH=CH), 7.04 
(1H, s, ArH), 6.89 (2H, d, J 8.7, 2 x ArH), 6.79 (1H, d, J 15.9, ArCH=CH), 6.58 (1H, s, ArH), 4.73 (1H, 
t, J 6.1, NH), 3.91 (3H, s, ArOCH3), 3.83 (3H, s, ArOCH3), 3.82 (3H, s, ArOCH3), 3.14 (2H, dd, J 13.8 
and 6.8, NCH2), 2.91 (2H, t, J 7.2, ArCH2), 2.35 (3H, s, ArCH3); δC (101 MHz) 159.4 (C), 148.7 (C), 
 197 
 
148.2 (C), 143.4 (C), 137.0 (C), 130.4 (C), 129.7 (2 x ArCH), 129.2 (C), 128.9 (CH=C), 128.1 (C), 127.8 
(2 x ArCH), 127.1 (2 x ArCH), 123.2 (CH=C), 114.3 (2 x ArCH), 113.2 (ArCH), 108.8 (ArCH), 56.1 
(ArOCH3), 56.1 (ArOCH3), 55.4 (ArOCH3), 44.1 (CH2), 33.55 (CH2), 21.55 (ArCH3);  
 
6,7-dimethoxy-3-methyl-2-((4-nitrophenyl)sulfonyl)-1-pentyl-1,2,3,4-tetrahydroisoquinoline  
331 
 
 
 
The sulfonamide 326 (20 mg, 0.043 mmol, 1.0 eq.) was dissolved in dichloromethane (0.2 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (2.5 mg, 0.017 mmol, 0.4 eq.). 
The resulting solution was stirred for 30 minutes at 0 °C and then quenched with aqueous potassium 
carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, 
filtered and evaporated. The crude material was purified by column chromatography (petrol/diethyl ether 
3:1) to give tetrahydroisoquinoline 331 (17 mg, 84%) as a colourless glass and as a 10:1 mixture of cis 
and trans diastereoisomers; major (cis)-diastereoisomer δH (250 MHz) 8.06 (2H, d, J 8.9, 2 x ArH), 7.72 
(1H, d, J 9.0, 2 x ArH), 6.42 (1H, s, ArH), 6.38 (1H, s, ArH), 4.75 (1H, dd, J 8.7 and 6.1, ArCHN), 3.88 – 
3.75 (1H, m, NCH), 3.78 (3H, s, ArOCH3), 3.76 (3H, s, ArOCH3), 2.70 (1H, dd, J 14.2 and 5.8, ArCH2a), 
2.61 (1H, dd, J 14.1 and 7.2, ArCH2b), 1.95 – 1.78 (1H, m, CH2), 1.74 – 1.58 (2H, m, CH2), 1.55 (3H, d, J 
6.4, CHCH3), 1.50 – 1.14 (5H, m, CH2), 0.90 (3H, t, J 6.3, CH2CH3); minor (trans)-diastereoisomer δH 
(250 MHz) 8.23 (2H, d, J 8.9, 2 x ArH), 7.93 (2H, d, J 9.0, 2 x ArH), 6.56 (1H, s, ArH), 6.47 (1H, s, 
ArH), 4.95 (1H, app t, J 6.9, ArCHN), 3.88 (3H, s, ArOCH3), 3.81 (3H, s, ArOCH3), 2.86 (1H, dd, J 16.0 
and 4.6, ArCH2a), 2.37 (1H, dd, J 15.8 and 6.8, ArCH2b). 
 
Method 2: 
The sulfonamide 326 (42 mg, 0.083 mmol, 1.0 eq.) was dissolved in dichloromethane (0.2 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added sulfuric acid (1 drop, approx. 12 mg, 0.12 
mmol, 1.2 eq.). The resulting solution was stirred for 30 minutes at 0 °C and then quenched with aqueous 
potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic 
extracts dried, filtered and evaporated. The crude material was purified by column chromatography 
(petrol/diethyl ether 1:2) to give tetrahydroisoquinoline 331 (18 mg, 87%) as a colourless glass and as a 
10:1 mixture of cis and trans diastereoisomers. All data obtained were in accordance with those reported 
previously. 
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1-Benzyl-6,7-dimethoxy-3-methyl-2-nosyl-1,2,3,4-tetrahydroisoquinoline 332  
 
 
 
 
The sulfonamide 328 (53 mg, 0.110 mmol, 1.0 eq.) was dissolved in dichloromethane (0.5 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (6.6 mg, 0.044 mmol, 0.4 eq.). 
The resulting solution was stirred for 30 minutes at 0 °C and then quenched with aqueous potassium 
carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, 
filtered and evaporated. The crude material was purified by column chromatography (petrol/ethyl acetate 
1:1) to give tetrahydroisoquinoline 332 (18 mg, 87%) as a yellow foam and as a 20:1 mixture of cis and 
trans diastereoisomers; major (cis)-diastereoisomer δH 8.09 (2H, d, J 8.9, 2 x ArH), 7.74 (2H, d, J 8.9, 2 
x ArH), 7.30 – 7.20 (3H, m, 3 x ArH), 7.11 – 7.09 (2H, m, 2 x ArH), 6.46 (1H, s, ArH), 5.82 (1H, s, 
ArH), 5.06 (1H, dd, J 9.9 and 4.9, ArCHCH2Ar), 4.05 – 3.97 (1H, app sext, J 6.9, ArCH2CHCH3), 3.77 
(3H, s, OCH3), 3.45 (3H, s, OCH3), 3.36 (1H, dd, J 13.2 and 4.9, ArCH2aCHAr), 3.02 (1H, dd, J 13.1 and 
9.9, ArCH2bCHAr), 2.80 (1H, dd, J 15.8 and 6.9, ArCH2aCHCH3), 2.68 (1H, dd, J 15.9 and 7.6, 
ArCH2bCHCH3), 1.58 (3H, d, J 6.5, CH3); δC 149.8 (C), 148.5 (C), 147.1 (C), 145.8 (C), 138.3 (C), 129.9 
(2 x ArCH), 128.6 (2 x ArCH), 128.4 (2 x ArCH), 127.4 (C), 126.9 (ArCH), 124.1 (C), 124.0 (2 x ArCH), 
111.45 (ArCH), 110.7 (ArCH), 60.1 (CH), 56.05 (OCH3), 55.9 (OCH3), 50.2 (CH), 45.1 (CH2), 34.3 
(CH2), 25.0 (CH3); major (cis)-diastereoisomer δH 8.16 (2H, d, J 8.9, 2 x ArH), 7.69 (2H, d, J 8.9, 2 x 
ArH), 7.30 – 7.20 (3H, m, 3 x ArH), 7.01 (2H, dd, J 6.5 and 2.9, 2 x ArH), 6.59 (1H, s, ArH), 6.09 (1H, s, 
ArH), 5.14 (1H, dd, J 7.6 and 7.0, ArCHCH2Ar), 4.31 – 4.24 (1H, m, ArCH2CHCH3), 3.85 (3H, s, 
OCH3), 3.61 (3H, s, OCH3), 1.11 (3H, d, J 6.7, CH3); δC 150.8 (C), 148.9 (C), 147.2 (C), 138.3 (C), 
129.95 (ArCH), 128.2 (ArCH), 127.5 (C), 126.9 (ArCH), 125.2 (ArCH), 124.2 (ArCH), 112.05 (ArCH), 
110.7, 61.15 (CH), 56.1 (OCH3), 56.0 (OCH3), 50.4 (CH), 44.5 (CH2), 35.6 (CH2), 20.3 (CH3); LRMS 
(EI+) m/z 391 ([M-CH2Ph]
+
, 100%), 361 ([M-PhNO2]
+
, 3%); HRMS (ES
-
) calculated for 
C25H26BrClN2O6S [M+Cl]
-
 517.1200, found 517.1197. 
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Methyl 6,7-dimethoxy-3-methyl-1-pentyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 333 
 
 
 
The carbamate 327 (31 mg, 0.093 mmol, 1.0 eq.) was dissolved in dichloromethane (0.3 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added sulfuric acid (1 drop, approx. 12 mg, 0.12 
mmol, 1.2 eq.). The resulting solution was stirred for 30 minutes at 0 °C and then quenched with aqueous 
potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic 
extracts dried, filtered and evaporated. The crude material was purified by column chromatography 
(petrol/ethyl acetate 1:1) to give tetrahydroisoquinoline 333 (22 mg, 72%) as a colourless glass and as a 
3:2 mixture of diastereoisomers; major diastereoisomer δH (400 MHz) 6.67 (1H, s, ArH), 6.64 (1H, s, 
ArH), 4.64 (1H, br s, 1-H), 4.37 (1H, d, 3-H), 3.88 (3H, s, ArOCH3), 3.86 (3H, s, ArOCH3), 3.74 (3H, s, 
COOCH3), 3.17 (1H, dd, J 14.9, 5.2, ArCH2a), 2.44 (1H, br s, ArCH2b), 1.79 – 1.67 (2H, m, CH2), 0.90 – 
1.50 (6H, 3 x CH2), 1.21 (3H, t, J 6.9, CH3), 0.86 (3H, d, J 6.7, CH3); minor diastereoisomer δH (400 
MHz) 6.64 (1H, s, ArH), 6.59 (1H, s, ArH), 5.14 (1H, br. s, ArCHN), 4.05 (1H, s, 3-H), 3.86 (3H, s, 
ArOCH3), 3.85 (3H, s, ArOCH3), 3.69 (3H, s, COOCH3), 2.89 (1H, br. s, ArCH2a), 2.73 (1H, dd, J 15.4 
and 9.6, ArCH2b), 1.65 – 1.60 (2H, m, CH2), 1.37 (3H, d, J 6.3, CH3), 1.21 – 1.11 (3H, m, CH3), 0.99 – 
0.80 (6H, m, 3 x CH2). 
 
(E)-5-Bromo-6-(3,4-dimethoxystyryl)benzo[d][1,3]dioxole 335  
 
 
 
 
A suspension of ((6-bromobenzo[d][1,3]dioxol-5-yl)methyl)triphenylphosphonium bromide (3.82 g, 7.46 
mmol) in tetrahydrofuran (15 mL) was treated with potassium tert-butoxide (906 mg, 8.08 mmol) and 2-
bromobenzaldehyde 136 (1.03 g, 6.22 mmol) according to general procedure A1. The crude product was 
purified by column chromatography (petrol/diethyl ether 2:1) to yield alkene 335 (1.915 g, 85%) as an 
off-white glass and as a 3:1 mixture of cis and trans isomers; m.p. 118-120 °C; νmax 3004, 2917, 2850, 
1266 (C-O), 1036 (C-O); major (cis)-isomer δH 6.77 (1H, dd, J 8.3, 1.8, ArH), 6.73 (1H, d, J 8.3, ArH), 
6.69 (1H, s, ArH), 6.54 (1H, d, J 11.9, ArCH=CH), 6.42 (1H, d, J 11.9, ArCH=CH), 5.91 (2H, s, 
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OCH2O), 3.85 (3H, s, ArOCH3), 3.66 (3H, s, ArOCH3); δC 148.46 (C), 147.55 (C), 147.0 (C), 131.4 (C), 
130.6 (ArCH), 129.1 (C), 127.8 (ArCH), 122.0 (ArCH), 114.7 (C-Br), 112.5 (ArCH), 112.0 (ArCH), 
110.9 (ArCH), 110.3 (ArCH), 101.4 (OCH2), 55.8 (OCH3), 55.6 (OCH3); minor (trans)-isomer δH 7.24 
(1H, d, J 16.0, ArCH=CH), 6.86 (1H, d, J 8.8, ArH), 6.83 (1H, d, J 16.1, ArCH=CH), 5.98 (2H, s, 
OCH2O), 3.94 (3H, s, ArOCH3), 3.90 (3H, s, ArOCH3), only 6 distinct signals; δC (126 MHz, CDCl3) 
149.2 (C), 147.8 (C), 147.7 (C), 129.6 (ArCH), 125.5 (ArCH), 120.0 (ArCH), 112.8 (ArCH), 111.4 
(ArCH), 109.2 (ArCH), 105.7 (ArCH), 101.6 (OCH2), 56.0 (OCH3), 55.9 (OCH3), only 13 distinct 
signals; HRMS calculated for C17H16BrO4 [M+H]
+
 363.0232, found 363.0237 
 
(E)-6-(3,4-Dimethoxystyryl)benzo[d][1,3]dioxole-5-carbaldehyde 336  
 
 
 
 
To a solution of 5-bromo-6-(3,4-dimethoxystyryl)benzo[d][1,3]dioxole 335 (1.92 g, 5.28 mmol, 1.0 eq.) 
in tetrahydrofuran (20 mL) at -78 °C under an atmosphere of nitrogen was added n-butyllithium (1.5 M, 
3.74 mL, 5.81 mmol, 1.1 eq.) over 10 minutes and the reaction stirred for a further 30 minutes at the same 
temperature. Dimethylformamide (1.23 mL, 15.8 mmol, 3.0 eq.) was added dropwise and the mixture 
allowed to warm to ambient temperature and stirred for a further 2 hours. The reaction was quenched by 
addition of aqueous ammonium chloride (20 mL) and the aqueous layer extracted with diethyl ether (3 x 
20 mL). The combined organic extracts were dried, filtered and evaporated and the crude material 
purified by column chromatography (petrol/diethyl ether 1:1) to give aldehyde 288 (859 mg, 52%) as a 
yellow oil, as a 2:1 mixture of cis and trans isomers; νmax 1711 (C=O); major (cis)-isomer δH 10.12 (1H, s, 
CHO), 7.37 (1H, s, ArH), 6.75 (1H, d, J 12.1, ArCH=CH), 6.72 (1H, d, J 12.2, ArCH=CH), 6.72 (1H, s, 
ArH), 6.70 (1H, d, J 1.4, ArH), 6.58 (2H, s, OCH2O), 3.83 (3H, s, ArOCH3), 3.60 (3H, s, ArOCH3); δC 
190.0 (CHO), 152.6 (C), 148.8 (C), 148.5 (C), 147.6 (C), 139.2 (C), 133.6 (ArCH), 128.45 (C), 123.7 
(ArCH), 122.5 (ArCH), 112.1 (ArCH), 111.0 (ArCH), 109.7 (ArCH), 106.7 (ArCH), 102.0 (OCH2), 55.8 
(OCH3), 55.5 (OCH3); minor (trans)-isomer δH (400 MHz) 10.24 (1H, s, ArCHO), 6.93 (1 H, d, J 8.0, 
ArCH), 6.80 (1H, dd, J 8.0 and 0.8, ArCH), 6.62 (1H, s, ArCH), 6.14 (2H, s, OCH2O), 3.83 (3H, s, 
ArOCH3), 3.62 (3H, s, ArOCH3); HRMS calculated for C17H16BrO4 [M+H]
+
 363.0232, found 363.0237. 
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5-((E)-3,4-Dimethoxystyryl)-6-((E)-2-nitrovinyl)benzo[d][1,3]dioxole 337  
 
 
 
 
 
To a solution of 6-(3,4-dimethoxystyryl)benzo[d][1,3]dioxole-5-carbaldehyde 336 (859 mg, 2.75 mmol, 
1.0 eq.) in nitromethane (1.7 g, 27.5 mmol, 10 eq.) was added ammonium acetate (128 mg, 1.65 mmol, 
0.6 eq.) and the mixture heated to reflux for 3 hours. The reaction was then allowed to cool to room 
temperature, and the solvent was removed in vacuo at 5 mbar pressure and at 60 °C for 1 h. The residue 
was suspended in dichloromethane (25 mL), washed with water (50 mL) and brine (50 mL), dried, 
filtered and evaporated to afford the crude nitroalkene 233 (500 mg g, 51%) as a viscous, red oil, as a 
single cis isomer and was used in the next step without further purification; δH 8.10 (1H, d, J 13.5, 
ArCH=CHNO2), 7.23 (1H, d, J 13.5, ArCH=CHNO2), 6.88 (1H, s, ArH), 6.71 (1H, s, ArH), 6.68 (1H, d, 
J 11.9, ArCH=CH), 6.62 (1H, d, J 8.3, ArH), 6.60 – 6.57 (1H, m, ArH), 6.48 (1H, d, J 12.0, ArH), 6.47 
(1H, d, J 1.8, ArH), 5.96 (2H, s, OCH2O), 3.75 (3H, s, OCH3), 3.54 (3 H, s, OCH3); δC 151.1 (C), 148.75 
(C), 148.5 (C), 147.65 (C), 137.3 (ArCH), 135.8 (ArCH), 134.0 (ArCH), 125.0 (ArCH), 122.4 (ArCH), 
112.05 (ArCH), 111.05 (ArCH), 110.1 (ArCH), 106.1 (ArCH), 102.0 (OCH2), 55.8 (OCH3), 55.55 
(OCH3). 
 
(E)-2-(6-(3,4-Dimethoxystyryl)benzo[d][1,3]dioxol-5-yl)ethan-1-amine 338 
 
 
 
 
To the solution of 5-(3,4-dimethoxystyryl)-6-(2-nitrovinyl)benzo[d][1,3]dioxole 337 (500 mg, 1.41 
mmol, 1.0 eq.) in tetrahydrofuran (5 mL) at 0 °C under an atmosphere of nitrogen was added portionwise 
lithium aluminium hydride (161 mg, 4.23 mmol, 3.0 eq) over 5 minutes. The reaction mixture was 
allowed to stir for 1 hour at the same temperature and then heated to reflux at 65 °C for 2.5 hours. The 
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reaction was then allowed to cool to room temperature and quenched according to the General Procedure 
F to yield the amine 338 (160 mg, 35%) as a brown oil which was used in the next step without further 
purification; δH (400 MHz) 6.77 – 6.73 (3H, m, 3 x ArH), 6.69 (1H, s, ArH), 6.66 (1H, d, J 1.6, ArH), 
6.55 – 6.50 (2H, m, 2 x ArH), 5.91 (1H, s, OCH2O), 3.86 (3H, s, ArOCH3), 3.61 (1H, s, ArOCH3), 2.90 
(2H, t, J 7.2, ArCH2CH2N), 2.72 (2H, t, J 7.2, ArCH2), 1.71 (2H, br. s, NH2). 
 
(E)-N-(2-(6-(3,4-Dimethoxystyryl)benzo[d][1,3]dioxol-5-yl)ethyl)-4-
methylbenzenesulfonamide 339 
 
 
 
 
 
A solution of (E)-2-(6-(3,4-dimethoxystyryl)benzo[d][1,3]dioxol-5-yl)ethan-1-amine 338 (1.26 g, 3.85 
mmol, 1.0 eq.) in dichloromethane was treated with triethylamine, DMAP and p-tosyl chloride according 
to General Procedure B. The crude material was purified by column chromatography (petrol/diethyl ether 
2:1) to give the sulfonamide 339 (860 mg, 46%) as a colourless glass; δH 7.54 (2H, d, J 8.3, 2 x ArH), 
7.08 (2H, d, J 8.2, 2 x ArH), 7.05 – 7.01 (2H, m, 2 x ArH), 7.04-7.02 (1H, m, ArH ), 6.57 – 6.55 (1H, m, 
ArH), 6.50 (1H, d, J 1.7, ArH), 6.31 (1H, d, J 12.0, ArCH=CH), 6.25 (1H, d, J 11.9, ArCH=CH), 5.74 
(2H, s, OCH2O), 4.92 (1H, t, J 6.2, NH), 3.70 (3H, s, OCH3), 3.44 (1H, s, OCH3), 2.98 – 2.93 (1H, m, 
ArCH2CH2N), 2.58 (1H, t, J 7.4, ArCH2CH2N), 2.25 (3H, s, ArCH3); δC 149.0 (C), 148.5 (C), 148.4 (C), 
148.3 (C), 146.9 (C), 146.45 (C), 143.3 (C), 137.1 (C), 136.9 (C), 130.9 (ArCH), 129.6 (2 x ArCH), 127.0 
(2 x ArCH), 127.0 (ArCH), 126.5 (ArCH), 122.1 (ArCH), 111.8 (ArCH), 110.9 (ArCH), 109.7 (ArCH), 
101.0 (OCH2), 55.8 (OCH3), 55.4 (OCH3), 43.6 (NCH2), 33.65 (ArCH2), 21.4 (ArCH3); HRMS (ES
-
) 
calculated for C26H26NO6S [M-H]
-
 480.1481, found 480.1501. 
 
 
 
 
 
 
 203 
 
 
 
5-(3,4-Dimethoxybenzyl)-6-tosyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g] 
isoquinolinebenzenesulfonamide 340 
 
 
 
 
 
The sulfonamide 339 (105 mg, 0.218 mmol, 1.0 eq.) was dissolved in toluene (2.1 mL) under an 
atmosphere of nitrogen at 0 °C. To this was added p-toluenesulfonic acid (46 mg, 0.240 mmol, 1.1 eq.). 
The resulting solution was heated to 65 °C, stirred for 18 hours and then quenched with aqueous 
potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic 
extracts dried, filtered and evaporated. The crude material was purified by column chromatography 
(petrol/ethyl acetate 1:1) to give tetrahydroisoquinoline 340 (43 mg, 41%) as a viscous, off-yellow glass; 
δH 7.42 (2H, d, J 8.2, 2 x ArH), 7.06 (2H, d, J 8.0, 2 x ArH), 6.65 (1H, d, J 8.1, ArH), 6.50 (1H, dd, J 8.2, 
1.9, ArH), 6.42 (1H, d, J 1.8, ArH), 6.35 (1H, s, ArH), 6.30 (1H, s, ArH), 5.81 (1H, dd, J 3.7 and 1.3, 
ArH), 4.99 (1H, t, J 6.3, NCH), 3.79 (3H, s, OCH3), 3.68 (3H, s, OCH3), 3.47 – 3.42 (1H, ddd, J 4.8, 5.8 
and 13.5, 3-CH2a), 3.28 – 3.19 (1H, ddd, J 5.0, 9.9 and 13.5, 3-CH2b), 2.95 (2H, d, J 6.3, 1’-CH2), 2.48 
(1H, ddd, J 15.9, 7.9 and 4.4, 4-CH2a), 2.28 (3H, s, ArCH3), 2.24 (1H, dt, J 16.0 and 4.4, 4-CH2b). δC  
148.7 (C), 147.9 (C), 146.45 (C), 145.8 (C), 143.0 (C), 137.1 (C), 130.0 (C), 129.35 (2 x ArCH), 128.8 
(C), 127.1 (2 x ArCH), 126.5 (C), 121.9 (ArCH), 113.0 (ArCH), 111.0 (ArCH), 108.4 (ArCH), 107.2 
(ArCH), 100.8 (OCH2), 57.85 (NCH), 55.85 (OCH3), 55.7 (OCH3), 44.1 (CH2), 39.9 (CH2), 27.3 (CH2), 
21.4 (CH3); HRMS calculated for C26H28NO6S [M+H]
+
 482.1637, found 482.1631 
 
6,7-Dimethoxy-2-tosyl-1-(4-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroisoquinoline  341 
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A solution of N-(2-bromo-4,5-dimethoxyphenethyl)-4-methylbenzenesulfonamide 319 (200 mg, 1.00 eq.) 
in ethanol/water (1:1, 2 mL) was treated with (4-trifluoromethylstyryl)boronic acid (121 mg, 1.2 eq.), 
K3PO4 (198 mg, 2.0 eq) and Pd(dppf)Cl2.DCM (19 mg, 0.05 eq.) at 85 °C for 3 h according to General 
Procedure D. The crude material was purified by filtration through a silica plug (petrol/diethyl ether 1:6) 
to give the sulfonamide 329 (181 mg, 77%) as a white solid which was used without further purification; 
m.p. 53-56 °C. 
The sulfonamide 329 (175 mg, 0.347 mmol, 1.0 eq.) was dissolved in dichloromethane (1.7 mL) under an 
atmosphere of nitrogen at 0 °C. To this was added triflic acid (21 mg, 0.139 mmol, 0.4 eq.). The resulting 
solution was allowed to warm up to room temperature and stirred for 6 hours and then quenched with 
aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined 
organic extracts dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/diethyl ether 1:3) to give tetrahydroisoquinoline 341 (165 mg, 95%) as a white 
solid; νmax 3063, 2860, 1325 (S=O), 1246 (Ar-O), 1159 (S=O); δH 7.42 – 7.38 (4H, m, 4 x ArH), 7.08 (2H, 
d, J 8.0, 2 x ArH), 7.03 (2H, d, J 8.1, 2 x ArH), 6.38 (1H, s, ArH), 6.05 (1H, s, ArH), 5.03 (1H, t, J 6.9, 
ArCHN), 3.72 (3H, s, ArOCH3), 3.60 – 3.53 (1H, m, ArCH2CH2aN), 3.55 (3H, s, ArOCH3), 3.34 (1H, 
ddd, J 13.6, 10.2 and 4.7, ArCH2CH2b), 3.16 (1H, dd, J 13.4 and 6.6, ArCH2aCH), 3.03 (1H, dd, J 13.4 
and 7.1, ArCH2bCH), 2.58 (1H, ddd, J 16.2, 10.2 and 6.0, ArCH2aCH2N), 2.38 (1H, app. dt, J 16.2 and 
4.3, ArCH2bCH2N), 2.26 (3H, s, ArCH3); δC 148.1 (C), 147.1 (C), 143.2 (C), 142.0 (C), 137.0 (C), 130.3 
(2 x ArCH), 129.4 (2 x ArCH), 128.9 (q, J 32.0, C-CF3) 127.0 (2 x ArCH), 126.9 (C), 125.1 (q, J 3.9, 2 x 
ArCH-C-CF3), 124.8 (q, J 271.0, CF3), 111.4 (ArCH), 110.05 (ArCH), 57.4 (NCH), 55.8 (ArOCH3), 55.7 
(ArOCH3), 44.1 (CH2), 39.9 (CH2), 26.8 (CH2), 21.4 (ArCH3); HRMS calculated for C26H26F3NNaO4S 
[M+Na]
+
 528.1448, found 528.1432. 
 
6,7-Dimethoxy-2-tosyl-1-(4-(trifluoromethyl)benzyl)-1,2,3,4-tetrahydroisoquinoline  342  
 
 
 
 
A solution of N-(2-bromo-4,5-dimethoxyphenethyl)-4-methylbenzenesulfonamide 319 (450 mg, 1.00 eq.) 
in ethanol/water (1:1, 4.5 mL) was treated with (4-chlorostyryl)boronic acid (230 mg, 1.2 eq.), K3PO4 
(446 mg, 2.0 eq) and Pd(dppf)Cl2.DCM (43 mg, 0.05 eq.) at 85 °C for 2.5 h according to General 
Procedure D. The crude material was purified by filtration through a silica plug (petrol/diethyl ether 1:5) 
to give the sulfonamide 342a (337 mg, 77%) as a white solid which was used without further purification;  
m.p. 129-132 °C. 
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The sulfonamide 342a (170 mg, 0.352 mmol, 1.0 eq.) was dissolved in dichloromethane (1.7 mL) under 
an atmosphere of nitrogen at 0 °C. To this was added triflic acid (21 mg, 0.141 mmol, 0.4 eq.). The 
resulting solution was allowed to warm up to room temperature and stirred for 6 hours and then quenched 
with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined 
organic extracts dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/diethyl ether 1:3) to give tetrahydroisoquinoline 342 (165 mg, 95%) as a white 
solid; m.p. 117-120 °C; HRMS calculated for C25H26ClNNaO4S [M+Na]
+
 494.1169, found 494.1166. 
 
(E)-N-(2-(3,5-Dimethoxystyryl)-4,5-dimethoxyphenethyl)-4-methylbenzenesulfonamide 343  
 
 
 
 
 
 
A solution of N-(2-bromo-4,5-dimethoxyphenethyl)-4-methylbenzenesulfonamide 319 (1.00 g, 1.00 eq.) 
in ethanol/water (1:1, 10 mL) was treated with 2-(3,5-dimethoxyphenyl)vinylboronic acid (813 mg, 1.2 
eq.), K3PO4 (991 mg, 2.0 eq) and Pd(dppf)Cl2.DCM (95 mg, 0.05 eq.) at 85 °C for 1.5 h according to 
General Procedure D. The crude material was purified by column chromatography (petrol/ethyl acetate 
1:1) to give the sulfonamide 343 (1.079 g, 93%) as a beige solid; m.p. 145-146 °C; δH (400 MHz) 7.64 
(2H, d, J 8.2, 2 x ArH), 7.24 (1H, d, J 15.9, ArCH=CH), 7.19 (2H, d, J 8.0, 2 x ArH), 7.07 (1H, s, ArH), 
6.79 (1H, d, J 15.9, ArCH=CH), 6.68 (2H, d, J 2.1, 2 x ArH), 6.59 (1H, s, ArH), 6.40 (1H, s, ArH), 4.45 
(1H, t, J 6.1, NH), 3.93 (3H, s, ArOCH3), 3.86 (3H, s, ArOCH3), 3.84 (6H, s, 2 x ArOCH3), 3.14 (2H, dd, 
J 13.8 and 6.9, ArCH2), 2.94 (2H, app. t, J 7.1, NCH2), 2.36 (3H, s, ArCH3); δC (101 MHz) 161.2 (2 x C), 
149.2 (C), 148.3 (C), 143.5 (C), 139.65 (C), 137.1 (C), 129.8 (2 x ArCH), 129.4 (ArCH=C), 128.8 (C), 
128.5 (C), 127.15 (2 x ArCH=C), 125.9 (ArCH), 113.2 (ArCH), 109.0 (ArCH), 104.75 (ArCH), 100.1 
(ArCH), 56.2 (OCH3), 56.1 (OCH3), 55.6 (2 x OCH3), 44.2 (CH2), 33.8 (CH2), 21.6 (ArCH3). 
 
1-(3,5-Dimethoxybenzyl)-6,7-dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinoline 344 
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The sulfonamide 343 (119 mg, 0.239 mmol, 1.0 eq.) was dissolved in toluene (1.2 mL) under an 
atmosphere of nitrogen at 0 °C. To this was added p-toluenesulfonic acid (27.3 mg, 0.143 mmol, 0.6 eq.). 
The resulting solution was heated to 100 °C for 1 hour and then quenched with aqueous potassium 
carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, 
filtered and evaporated to give tetrahydroisoquinoline 344 (105 mg, 88%) as a viscous, colourless glass;  
δH (400 MHz) 7.53 (2H, d, J 7.9, 2 x ArH), 7.13 (2H, d, J 7.9, 2 x ArH), 6.45 (1H, s, ArH), 6.32 (1H, s, 
ArH), 6.21 (2H, s, 2 x ArH), 6.18 (1H, s, ArH), 5.11 (1H, t, J 6.7, ArCHN), 3.79 (3H, s, ArOCH3), 3.73 – 
3.63 (1H, m, ArCH2CH2aN), 3.71 (6H, s, 2 x ArOCH3), 3.65 (3H, s, ArOCH3), 3.44 – 3.34 (1H, m, 
ArCH2CH2bN), 3.12 (1H, dd, J 13.2 and 6.0, ArCH2aCHAr), 2.95 (1H, dd, J 13.3 and 7.5, ArCH2bCHAr), 
2.68 (1H, ddd, J 16.5, 10.3 and 6.3, ArCH2aCH2N), 2.53 – 2.39 (1H, m, ArCH2bCH2N), 2.34 (3H, s, 
ArCH3); δC (101 MHz) 160.8 (C), 148.05 (C), 147.0 (C), 143.1 (C), 140.2 (C), 137.5 (C), 129.55 (2 x 
ArCH), 127.6 (ArCH), 127.2 (2 x ArCH), 125.4 (ArCH), 111.4 (ArCH), 110.5 (ArCH), 107.9 (2 x 
ArCH), 99.1 (ArCH), 57.5 (NCH), 56.0 (OCH3), 55.85 (OCH3), 55.4 (2 x OCH3), 44.7 (CH2), 39.8 (CH2), 
27.1 (CH2), 21.6 (ArCH3); HRMS calculated for C27H31NNaO6S [M+Na]
+
 520.1770, found 520.1761 
 
Method 2: 
The sulfonamide 343 (894 mg, 1.799 mmol, 1.0 eq.) was dissolved in toluene (9.0 mL) under an 
atmosphere of nitrogen at 0 °C. To this was added p-toluenesulfonic acid (205 mg, 1.08 mmol, 0.6 eq.). 
The resulting solution was heated to 100 °C for 1 hour and then quenched with aqueous potassium 
carbonate (15 mL), extracted with dichloromethane (3 x 15 mL) and the combined organic extracts dried, 
filtered and evaporated to give tetrahydroisoquinoline 344 (745 mg, 83%) as a colourless glass. All data 
obtained were in accordance with those reported before. 
 
(E)-N-(4,5-Dimethoxy-2-(4-methoxystyryl)phenethyl)-4-methylbenzenesulfonamide 345 
 
 
 
 
 
 
A solution of N-(2-bromo-4,5-dimethoxyphenethyl)-4-methylbenzenesulfonamide 319 (416 mg, 1.00 eq.) 
in ethanol/water (1:1, 4 mL) was treated with 2-(4-methoxyphenyl)vinylboronic acid (268 mg, 1.5 eq.), 
K3PO4 (426 mg, 2.0 eq.) and Pd(dppf)Cl2.DCM (82 mg, 0.10 eq.) at 95 °C for 1.5 h according to General 
Procedure D. The crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to 
give the unreacted starting material 319 (97 mg, 23%) and sulfonamide 345 (259 mg, 53%, 76% brsm) as 
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a colourless glass; δH (400 MHz) 7.64 (2H, d, J 8.2, 2 x ArH), 7.43 (2H, d, J 8.7, 2 x ArH), 7.16 (2H, d, J 
8.1, 2 x ArH), 7.07 (1H, d, J 16.0, ArCH=CH), 7.04 (1H, s, ArH), 6.89 (2H, d, J 8.7, 2 x ArH), 6.79 (1H, 
d, J 15.9, ArCH=CH), 6.58 (1H, s, ArH), 4.73 (1H, t, J 6.1, NH), 3.91 (1H, s, ArOCH3), 3.83 (3H, s, 
ArOCH3), 3.82 (3H, s, ArOCH3), 3.14 (2H, dd, J 13.8 and 6.8, NCH2), 2.91 (2H, t, J 7.2, ArCH2), 2.35 
(3H, s, ArCH3); δC (101 MHz) 159.4 (C), 148.7 (C), 148.2 (C), 143.4 (C), 137.0 (C), 130.4 (C), 129.7 (2 x 
ArCH), 129.2 (C), 128.9 (ArCH=C), 128.1 (C), 127.8 (2 x ArCH), 127.1 (2 x ArCH), 123.2 (ArCH=CH), 
114.3 (2 x ArCH), 113.2 (ArCH), 108.8 (ArCH), 56.1 (ArOCH3), 56.1 (ArOCH3), 55.4 (ArOCH3), 44.0 
(CH2), 33.55 (CH2), 21.55 (ArCH3); HRMS (APCI) calculated for C26H29NO5S [M]
+
 467.1766, found 
467.1766. 
 
6,7-Dimethoxy-1-(4-methoxybenzyl)-2-tosyl-1,2,3,4-tetrahydroisoquinoline 346  
 
 
 
 
 
 
The sulfonamide 345 (30 mg, 0.062 mmol, 1.0 eq.) was dissolved in toluene (0.3 mL) under an 
atmosphere of nitrogen. To this was added p-toluenesulfonic acid (7.1 mg, 0.037 mmol, 0.6 eq.). The 
resulting solution was stirred for 1 hour at 100 °C and then quenched with aqueous potassium carbonate 
(2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and 
evaporated to give tetrahydroisoquinoline 341 (28.5 mg, 95%) as a colourless oil; δH (400 MHz) 7.53 
(2H, d, J 8.2, 2 x ArH), 7.13 (2H, d, J 8.1, 2 x ArH), 6.94 (1H, d, J 8.5, 2 x ArH), 6.77 (2H, d, J 8.6, 2 x 
ArH), 6.43 (1H, s, ArH), 6.11 (1H, s, ArH), 5.06 (1H, t, J 6.7, ArCH2CHN), 3.80 (3H, s, OCH3), 3.78 
(3H, s, OCH3), 3.63 (3H, s, OCH3), 3.63 – 3.61 (1H, m, NCH2a) 3.43 – 3.35 (1H, m, NCH2b), 3.13 (1H, 
dd, J 13.5 and 5.9, ArCH2aCH), 2.98 (1H, dd, J 13.5 and 7.6, ArCH2bCH), 2.62 (1H, ddd, J 16.2, 6.1 and 
4.1, ArCH2aCHN), 2.44 (1H, app. dt, J 16.1 and 6.1, ArCH2bCHN), 2.35 (3H, s, ArCH3); δC (101 MHz)  
143.1 (C), 131.1 (2 x ArCH), 129.9 (C), 129.55 (2 x ArCH), 127.5 (C), 127.2 (2 x ArCH), 125.5 (C), 
113.8 (2 x ArCH), 111.2 (ArCH), 110.4 (ArCH), 57.8 (CH), 55.9 (OCH3), 55.8 (OCH3), 55.4 (OCH3), 
43.55 (CH2), 39.9 (CH2), 27.0 (CH2), 21.6 (ArCH3); HRMS calculated for C26H29NNaO5S [M+Na]
+
 
490.1664, found 490.1659 
 
2-(2-Bromo-4,5-dimethoxyphenyl)-1,3-dioxolane
251
 347  
 
 208 
 
 
 
A solution of 2-bromoveratraldehyde (25.0 g, 102 mmol, 1.0 eq.), ethylene glycol (35.4 g, 408 mmol, 4.0 
eq.) and p-toluenesulfonic acid (1.95 g, 10.2 mmol, 0.1 eq.) in toluene (120 mL) was reflux for 24 hours 
and cooled to ambient temperature. The reaction mixture was then washed with saturated sodium 
bicarbonate (100 mL) and brine (100 mL), dried filtered and evaporated. The final product was purified 
by recrystallization from ethyl acetate/heptane to give acetal 347 (22.5 g, 76.3%) as a white solid; m.p. 
104 – 107, lit.252 m.p. 105 – 111 °C; νmax 1597, 1264, 1209 (C-O); δH (400 MHz) 7.11 (1H, s, ArH), 7.01 
(1H, s, ArH), 5.99 (1H, s, ArCH(OCH2)2), 4.22 – 4.11 (2H, m, 2 x OCH2a), 4.10 – 4.01 (2H, m, 2 x 
OCH2b), 3.88 (3H, s, OCH3), 3.87 (3H, s, OCH3). 
 
N-(1-(2-(1,3-Dioxolan-2-yl)-4,5-dimethoxyphenyl)butan-2-yl)-4-methylbenzenesulfonamide 
348 
 
 
 
To a solution of 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxolane 347 (5.65 g, 19.55 mmol, 2.0 eq.) in 
tetrahydrofuran (80 mL) under an atmosphere of nitrogen at -78 °C was added n-butyllithium (2.4M, 8.33 
mL, 20.0 mmol, 2.25 eq.) and the mixture stirred for 0.5 h. To the bright orange solution was then added 
solid magnesium bromide (3.68 g, 20.0 mmol, 2.25 eq.) and the resulting mixture stirred at 0 °C for 0.5 h 
and then cooled to -40 °C. Copper (I) iodide (253 mg, 1.333 mmol, 0.15 eq.) was then added and the 
reaction stirred for a further 0.5 h at -40 °C and then cooled to -78 °C. 2-Ethyl-1-tosylaziridine 154 (2.0 g, 
8.89 mmol, 1.0 eq.) in tetrahydrofuran (20 mL) was then added, the solution stirred for 0.25 h at -78 °C 
and for a further 1 h at 0 °C. The reaction was quenched by aqueous ammonium chloride (40 mL) and the 
separated blue aqueous phase extracted with ethyl acetate (3 x 50 mL) and the combined organic extracts 
washed with brine (50 mL), dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/diethyl ether 1:1) and recrystallization from ethyl acetate/heptane to give acetal 
impurity 347a (2.20 g, 53%) and sulfonamide 348 (1.724 g, 45%) as a white solid; sulfonamide 348 m.p. 
102 – 107 °C; νmax 3236 (br, NH), 1324 (S=O), 1266 (C-O), 1160 (S=O); δH 7.21 (2H, d, J 8.2, 2 x ArH), 
6.91 (2H, d, J 8.2, 2 x ArH), 6.90 (1H, s, ArH), 6.32 (1H, d, J 5.1, NH), 6.06 (1H, s, ArH), 5.76 (1H, s, 
CH(OCH2)2), 4.30 – 4.21 (2H, m, CH(OCH2a)2), 4.14 – 4.06 (2H, m, CH(OCH2b)2), 3.90 (3H, s, OCH3), 
3.58 (3H, s, OCH3), 3.15 – 3.11 (1H, m, NCH), 2.76 (1H, dd, J 14.2 and 11.1, ArCH2a), 2.54 (1H, dd, J 
14.2 and 3.9, ArCH2b), 2.35 (3H, s, ArCH3), 1.80 – 1.74 (2H, app. pent., CH2CH3), 0.99 (3H, t, J 7.4, 
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CH2CH3); δC 149.4 (C), 147.6 (C), 142.5 (C), 137.1 (C), 129.4 (C), 128.9 (2 x ArCH), 126.75 (2 x 
ArCH), 126.5 (C), 112.3 (ArCH), 109.65 (ArCH), 102.8 (CH(OCH2)2), 65.4 (OCH2), 65.3 (OCH2), 57.0 
(NCH), 55.9 (OCH3), 55.2 (OCH3), 34.5 (CH2), 30.1 (CH2), 21.5 (ArCH3), 9.4 (CH3); acetal 347a δH 7.03 
(2H, m, 2 x ArH), 6.87 – 6.84 (1H, d, J 8.0, ArH), 5.75 (1H, s, ArCH), 4.17 – 4.09 (2H, m, OCH2a), 4.07 
– 3.98 (2H, m, OCH2b), 3.90 (3H, s, OCH3), 3.88 (3H, s, OCH3); δC 149.8 (C), 149.1 (C), 130.3 (C), 119.3 
(ArCH), 110.8 (ArCH), 109.2 (ArCH), 103.7 (CH(OCH2)2), 65.2 (2 x CH2), 55.95 (CH3), 55.85 (CH3). 
 
tert-Butyl (1-(2-(1,3-dioxolan-2-yl)-4,5-dimethoxyphenyl)butan-2-yl)(tosyl)carbamate 349  
 
 
 
A solution of N-(1-(2-(1,3-dioxolan-2-yl)-4,5-dimethoxyphenyl)butan-2-yl)-4-methylbenzenesulfonamide 
348 (1.62 g, 3.78 mmol, 1.0 eq.) in dichloromethane (75 mL) was treated with DMAP (92 mg, 0.756 
mmol, 0.2 eq.) and Boc2O (992 mg, 4.54 mmol, 1.2 eq.) according to General Procedure C. The crude 
material was purified by column chromatography (petrol/ethyl acetate 1:1) to give the carbamate 349 
(1.375 g, 70%) as a white solid; m.p. 93 - 96 °C; νmax 1722 (C=O), 1354 (S=O), 1269 (C-O), 1152 (S=O); 
δH (400 MHz) 7.29 (2H, br. d, J 6.0, 2 x ArH), 7.15 (1H, s, ArH), 7.06 (2H, d, J 8.0, 2 x ArH), 6.48 
(1H,br s, ArH), 6.00 (1H, s, ArCH(OCH2)2), 4.74 – 4.61 (1H, m, NCH), 4.22 – 4.13 (2H, m, 
OCH2aCH2aO), 4.08 – 4.01 (2H, m, OCH2bCH2bO), 3.93 (1H, s, ArOCH3), 3.60 (1H, s, ArOCH3), 3.26 
(1H, dd, J 14.1 and 9.0, ArCH2a), 3.18 (1H, dd, J 14.2 and 6.2, ArCH2b), 2.13 – 1.99 (1H, m, CH2aCH3), 
1.80 – 1.68 (1H, m, CH2bCH3), 1.43 (9H, s, C(CH3)3), 0.96 (1H, t, J 7.5, CH2CH3); δC (101 MHz) 151.1 
(C=O), 149.2 (C), 147.7 (C), 143.6 (C), 130.3 (C), 128.7 (2 x ArCH), 128.1 (C), 128.1 (2 x ArCH), 127.9 
(C), 114.0 (ArCH), 109.3 (ArCH), 101.3 (ArCH(OCH2)2), 84.0 (C(CH3)3), 65.2 (OCH2CH2O), 62.7 (CH), 
35.1 (CH2), 28.1 (C(CH3)3), 26.3 (CH2), 21.5 (ArCH3), 11.5 (CH3). 
 
tert-Butyl (2-(1,3-dioxolan-2-yl)-4,5-dimethoxyphenethyl)(tosyl)carbamate 352 
 
 
 
 
 
To a solution of 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxolane 347 (6.46 g, 22.35 mmol, 2.0 eq.) in 
tetrahydrofuran (120 mL) under an atmosphere of nitrogen at -78 °C was added n-butyllithium (2.3M, 
9.96 mL, 22.9 mmol, 2.05 eq.) and the mixture stirred for 0.5 h. To the bright orange solution was then 
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added solid magnesium bromide (4.32 g, 23.5 mmol, 2.1 eq.) and the resulting mixture stirred at 0 °C for 
0.5 h and then cooled to -40 °C. Copper (I) iodide (638 mg, 3.35 mmol, 0.3 eq.) was then added and the 
reaction stirred for a further 0.5 h at -40 °C and then cooled to -78 °C. 1-Tosylaziridine 173 (2.20 g, 11.17 
mmol, 1.0 eq.) in tetrahydrofuran (40 mL) was then added, the solution stirred for 0.25 h at -78 °C and for 
a further 1 h at 0 °C. The reaction was quenched by aqueous ammonium chloride (40 mL) and the 
separated blue aqueous phase extracted with ethyl acetate (3 x 70 mL) and the combined organic extracts 
washed with brine (80 mL), dried, filtered and evaporated. The crude material was purified by filtration 
through a plug of silica and was then redissolved in dichloromethane (100 mL) and treated with DMAP 
(273 mg, 2.23 mmol, 0.2 eq.) and Boc2O (2.96 g, 13.41 mmol, 1.2 eq.) according to General Procedure C. 
The crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to give the 
carbamate 352 (4.553 g, 80%) as a colourless glass; δH (400 MHz) 7.77 (2H, d, J 8.2, 2 x ArH), 7.28 (1H, 
d, J 8.1, 2 x ArH), 7.12 (1H, s, ArH), 6.76 (1H, s, ArH), 6.01 (1H, s, CH(OCH2)2), 4.19 (2H, t, J 6.9, 
OCH2a), 4.06 (2H, t, J 7.1, OCH2b), 4.05 – 3.99 (2H, br. m, NCH2), 3.89 (3H, s, OCH3), 3.86 (3H, s, 
OCH3), 3.18 – 3.08 (2H, br. m, ArCH2), 2.43 (3H, s, ArCH3), 1.33 (9H, s, C(CH3)3); δC (101 MHz) 151.0 
(C), 149.5 (C), 147.7 (C), 144.1 (C), 137.5 (C), 129.6 (C), 129.2 (ArCH), 127.8 (ArCH), 127.5 (C), 113.6 
(ArCH), 109.6 (ArCH), 101.4 (CH(OCH2)2), 84.1 (C(CH3)3),  65.2 (2 x OCH2) , 55.9 (2 x OCH3), 48.4 
(NCH2), 33.1 (ArCH2), 27.9 (C(CH3)3), 21.6 (ArCH3). 
 
tert-Butyl (2-formyl-4,5-dimethoxyphenethyl)(tosyl)carbamate 353 
 
 
 
 
 
To a solution of tert-butyl (1-(2-(1,3-dioxolan-2-yl)-4,5-dimethoxyphenyl)butan-2-yl)(tosyl)carbamate 
352 (2.00 g, 3.94 mmol) in dichloromethane (50 mL) was added Amberlyst-15 (200 mg, 10% wt.) and the 
resulting mixture stirred vigorously for 16 hours at ambient temperature. The solution was then filtered, 
washed with aqueous sodium hydrogen carbonate (20 mL), dried, filtered and evaporated to give 
aldehyde 353 (1.63 g, 89%) as a colourless glass; δH (400 MHz) 10.27 (1H, s, CHO), 7.75 (2H, d, J 8.0, 2 
x ArH), 7.40 (1H, s, ArH), 7.29 (2H, d, J 8.2, 2 x ArH), 6.84 (1H, s, ArH), 4.10 (2H, dd, J 15.1 and 8.0, 
NCH2), 3.95 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.44 (2H, t, J 7.2, ArCH2CH2N), 2.43 (3H, s, ArCH3), 
1.27 (9H, s, C(CH3)3); δC (101 MHz) 190.2 (CHO), 153.8 (C), 150.8 (C), 148.3 (C), 144.4 (C), 137.35 
(C), 136.0 (C), 129.4 (2 x ArCH), 128.0 (2 x ArCH), 127.5 (C), 114.2 (ArCH), 111.9 (ArCH), 84.4 
(C(CH3)3), 56.3 (OCH3), 56.2 (OCH3), 48.1 (CH2), 32.2 (CH2), 27.9 (C(CH3)3), 21.7 (ArCH3). 
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tert-Butyl (4,5-dimethoxy-2-vinylphenethyl)(tosyl)carbamate 354 
 
 
 
 
 
A suspension of methyltriphenylphosphonium bromide (385 mg, 1.08 mmol, 1.25 eq.) was treated with n-
butyllithium (1.6M in hexanes, 0.68 mL, 1.08 mmol, 1.25 eq.) and tert-butyl (2-formyl-4,5-
dimethoxyphenethyl)(tosyl)carbamate 353 (400 mg, 0.863 mmol, 1.0 eq.) according to general procedure 
A2. The crude material was purified by column chromatography (petrol/diethyl ether 1:1) to give alkene 
354 (358 mg, 90%) as a white solid; m.p. 86 – 89 °C; νmax 1727 (C=O), 1351 (S=O), 1156 (S=O); δH (400 
MHz) 7.75 (2H, d, J 8.4, 2 x ArH), 7.28 (2H, d, J 8.1, 2 x ArH), 7.07 (1H, dd, J 17.2 and 10.9, 
ArCH=CH2), 7.04 (1H, s, ArH), 6.71 (1H, s, ArH), 5.59 (1H, dd, J 17.2, 1.1, ArCH=CH2a), 5.26 (1H, dd, 
J 10.9 and 1.1, ArCH=CH2b), 3.95 – 3.90 (2H, m, NCH2), 3.90 (3H, s, OCH3), 3.85 (3H, s, OCH3), 3.10 – 
3.08 (2H, m, NCH2), 2.42 (3H, s, ArCH3), 1.33 (9H, s, C(CH3)3); HRMS calculated for C24H31NNaO6S 
[M+Na]
+
 484.1770, found 484.1764. 
 
6,7-Dimethoxy-1-methyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline
253
 355 
 
 
 
 
 
The sulfonamide 354 (69 mg, 0.150 mmol, 1.0 eq.) was dissolved in toluene (0.15 mL) under an 
atmosphere of nitrogen. To this was added p-toluenesulfonic acid (17 mg, 0.90 mmol, 0.6 eq.). The 
resulting solution was stirred for 1 hour at 100 °C and then quenched with aqueous potassium carbonate 
(2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and 
evaporated. The residue was purified by column chromatography (diethyl ether/petrol 1:1) to give 
tetrahydroisoquinoline 355 (19 mg, 35%) as a colourless glass; δH (400 MHz) 7.66 (1H, d, J 8.3, 2 x 
ArH), 7.20 (1H, d, J 8.0, 2 x ArH), 6.51 (1H, s, ArH), 6.44 (1H, s, ArH), 5.06 (1H, q, J 6.7, NCH), 3.88 
(1H, ddd, J 14.1, 6.5 and 2.1, NCH2a), 3.84 (3H, s, OCH3), 3.80 (3H, s, OCH3), 3.38 (1H, ddd, J 14.0, 
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11.6 and 4.0, NCH2b), 2.63 (1H, ddd, J 17.0, 11.6 and 6.4, ArCH2a), 2.50 (1H, ddd, J 16.8, 4.1 and 2.1, 
ArCH2b), 2.37 (1H, s, ArCH3), 1.45 (3H, d, J 6.8, CHCH3). 
 
(3-Hydroxypropyl)triphenylphosphonium bromide
254
 359 
 
 
A solution of 3-bromo-1-propanol (3.54 g, 25.47 mmol) and triphenylphosphine (6.68 g, 25.47 mmol) in 
toluene (75 mL) was heated at 111 °C for 24 hours.
255
 The reaction mixture was allowed to cool to 
ambient temperature and the precipitate was collected by vacuum filtration, washed with toluene (2 x 50 
mL), heptane (50 mL) and diethyl ether (50 mL) to yield salt 359 (7.09 g, 68%) as white powder, which 
was used without further purification. 
 
tert-Butyl (E)-(1-(2-(4-hydroxybut-1-en-1-yl)phenyl)butan-2-yl)(tosyl)carbamate 360 
 
 
 
 
 
A suspension (3-hydroxypropyl)triphenylphosphonium bromide 359 (236 mg, 0.588 mmol, 1.4 eq.) was 
treated with n-butyllithium (1.6M in hexanes, 0.51 mL, 1.18 mmol, 2.8 eq.) and tert-butyl (1-(2-
formylphenyl)butan-2-yl)(tosyl)carbamate 302 (181 mg, 0.420 mmol, 1.0 eq.) according to general 
procedure A2. The crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to 
give alkene 360 (82 mg, 41%) as a colourless glass, as a 1:5 mixture of cis and trans isomers; νmax 3425 
(OH), 1722 (C=O); major (trans)-isomer δH (400 MHz) 7.49 (1H, d, J 7.7, ArH), 7.28 (1H, d, J 6.2, 
ArH), 7.09 (6H, m, 6 x ArH), 6.85 (1H, d, J 15.5, ArCH=CH), 6.09 (1H, dt, J 15.3 and 7.2, ArCH=CH), 
4.73 – 4.66 (1H, m, CH2OH), 3.79 – 3.75 (1H, m, NCH), 3.37 (1H, dd, J 13.8 and 9.3, ArCH2a), 3.19 (1H, 
dd, J 13.8 and 6.3, ArCH2b), 2.51 (2H, dd, J 7.1 and 6.3, CH=CHCH2), 2.36 (3H, s, ArCH3), 2.12 – 1.99 
(1H, m, CH2aCH3), 1.76 (1H, ddq, J 6.5, 7.4 and 14.4, CH2bCH3), 1.34 (9H, s, C(CH3)3), 0.98 (3H, t, J 
7.5, CH2CH3);  δC (101 MHz) 150.8 (C=O), 143.45 (C), 137.8 (C), 137.6 (C), 136.1 (C), 131.2 (ArCH), 
130.5 (ArC=C), 130.0 (ArC=C), 129.0 (2 x ArCH), 128.0 (2 x ArCH), 127.5 (ArCH), 127.2 (ArCH), 
126.7 (ArCH), 84.1 (C(CH3)3), 62.1 (OCH2), 61.3 (NCH), 37. 05 (CH2), 37.1 (CH2), 28.1 (C(CH3)3), 26.3 
(CH2), 21.6 (ArCH3), 11.7 (CH3); HRMS (APCI) calculated for C26H34NO5S [M-H]
-
 472.2158, found 
472.2158. 
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(E)-N-(1-(2-(4-Hydroxybut-1-en-1-yl)phenyl)butan-2-yl)-4-methylbenzenesulfonamide 361a  
 
 
 
 
 
 
The sulfonamide 360 (41 mg, 0.087 mmol, 1.0 eq.) was dissolved in dichloromethane (0.4 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (5.2 mg, 0.035 mmol, 0.4 eq.). 
The resulting solution was allowed to warm to ambient temperature and was stirred for 2 h and then 
quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the 
combined organic extracts dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/diethyl ether 2:1) to give sulfonamide 361a (19 mg, 59%) as a colourless glass 
and as a 10:1 mixture of trans and cis diastereoisomers; major (trans)-diastereoisomer δH (400 MHz) 
7.47 (2H, d, J 8.2, 2 x ArH), 7.31 (1H, d, J 7.7, ArH), 7.18 – 7.13 (2H, m, 2 x ArH), 7.11 (2H, d, J 7.9, 2 
x ArH), 7.09 – 7.03 (1H, m,  ArH), 6.96 (1H, m, ArH), 6.72 (1H, d, J 15.6, ArCH=CH), 5.95 (1H, dd, J 
8.2 and 7.2, ArCH=CH), 4.82 (1H, d, J 7.7, CH2OH), 3.84 – 3.74 (1H, m, NCH), 2.86 (1H, dd, J 13.8 and 
7.6, ArCH2a), 2.72 (1H, dd, J 13.8 and 6.6, ArCH2b), 2.50 (2H, q, J 6.4, CH=CH2), 2.37 (3H, s, ArCH3), 
1.59 – 1.47 (1H, m, CH2aCH3), 1.42 (1H, m, CH2bCH3), 0.79 (3H, t, J 7.3, CH2CH3). 
 
3-(3-Ethyl-2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propan-1-ol  361 
 
 
 
 
 
 
The sulfonamide 360 (41 mg, 0.087 mmol, 1.0 eq.) was dissolved in dichloromethane (0.4 mL) under an 
atmosphere of nitrogen and cooled to 0 °C. To this was added triflic acid (5.2 mg, 0.035 mmol, 0.4 eq.). 
The resulting solution was heated to reflux for 4 h and then quenched with aqueous potassium carbonate 
(2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and 
evaporated. The crude material was purified by column chromatography (petrol/diethyl ether 2:1) to give 
tetrahydroisoquinoline 361 (13 mg, 40%) as a colourless glass and as a 20:1 mixture of trans and cis 
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diastereoisomers; major (cis)-diastereoisomer δH (400 MHz) 7.40 (2H, d, J 8.2, 2 x ArCH), 7.06 – 7.00 
(2H, m, 2 x ArH), 6.98 (2H, d, J 7.8, 2 x ArH), 6.89 (1H, d, J 7.1, ArH), 6.85 (1H, d, J 7.1, ArH), 4.87 
(1H, dd, J 8.6 and 5.7, ArCHN), 3.81 – 3.66 (3H, m, OHCH2 and ArCH2CHN), 2.73 (1H, dd, J 15.9 and 
7.2, ArCH2a), 2.59 (1H, dd, J 15.8 and 8.3, ArCH2b), 2.26 (3H, s, ArCH3), 2.18 – 2.02 (1H, m, CH3CH2a), 
1.98 – 1.86 (2H, m, OHCH2CH2CH2), 1.85 – 1.77 (2H, m, OHCH2CH2CH2), 1.77 – 1.64 (1H, m, 
CH3CH2b), 1.03 (1H, t, J 7.5, CH2CH3); δC (101 MHz) 142.9 (C), 137.45 (C), 136.7 (C), 129.2 (2 x 
ArCH), 128.3 (ArCH), 127.3 (2 x ArCH), 127.1 (ArCH), 126.6 (ArCH), 126.2 (ArCH), 62.9 (OCH2), 
58.4 (ArCHN), 55.8 (CH2NCH), 33.8 (CH2), 32.2 (CH2), 31.5 (CH2), 29.9 (CH2), 21.5 (ArCH3), 10.8 
(CH3). 
 
tert-Butyl (E)-(2-(4-hydroxybut-1-en-1-yl)-4,5-dimethoxyphenethyl)(tosyl)carbamate 360 
 
 
 
 
 
A suspension (3-hydroxypropyl)triphenylphosphonium bromide (856 mg, 2.13 mmol, 1.20 eq.) was 
treated with n-butyllithium (2.5M in hexanes, 1.97 mL, 4.4 mmol, 2.5 eq.) and tert-butyl (2-formyl-4,5-
dimethoxyphenethyl)(tosyl)carbamate 353 (824 mg, 1.78 mmol, 1.0 eq.) according to general procedure 
A2. The crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to give alkene 
360 (315 mg, 35%) as a colourless oil; νmax 3390 (OH), 1728 (C=O); δH (400 MHz) 7.65 (1H, d, J 8.4, 2 x 
ArH), 7.13 (2H, d, J 8.3, 2 x ArH), 6.92 (1H, s, ArH), 6.83 (1H, s, ArH), 6.80 (1H, J 15.8, ArCH=CH) 
5.99 (1H, dt, J 15.6, 7.0, ArCH=CH), 3.85 – 3.79 (2H, m, OCH2), 3.80 (3H, s, OCH3), 3.78 (3H, s, OCH-
2), 3.05 – 2.99 (2H, m, NCH2), 2.85 – 2.71 (2H, m, CH=CHCH2), 2.71 – 2.63 (1H, m, ArCH2a), 2.46 (1H, 
dd, J 12.8 and 6.2, ArCH2b), 2.36 (3H, s, ArCH3), 1.26 (9H, s, C(CH3)3). 
 
3-(6,7-Dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propan-1-ol 361 
 
 
 
 
 
 
The alcohol 360 (18 mg, 0.36 mmol, 1.0 eq.) was dissolved in toluene (0.2 mL) under an atmosphere of 
nitrogen at 0 °C. To this was added p-toluenesulfonic acid (3.4 mg, 0.018 mmol, 0.5 eq.). The resulting 
solution was heated to 100 °C, stirred for 0.5 h and then quenched with aqueous potassium carbonate (2 
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mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and 
evaporated. The crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to give 
tetrahydroisoquinoline 361 (10 mg, 70%) as a colourless glass; νmax 3412 (OH); δH 7.58 (2H, d, J 8.3, 2 x 
ArH), 7.10 (2H, d, J 8.2, 2 x ArH), 6.54 (1H, s, ArH), 6.32 (1H, s, ArH), 4.96 (1H, dd, J 7.8 and 6.1, 
NCH), 3.91 – 3.86 (1H, m, NCH2a), 3.85 (3H, s, OCH3), 3.82 – 3.77 (1H, m, OCH2a), 3.76 (3H, s, OCH3), 
3.76 – 3.67 (1H, m, OCH2b), 3.42 (1H, dt, J 14.5 and 8.5, NCH2b), 2.39 (2H, dd, J 8.4 and 4.3, ArCH2a), 
2.32 (3H, s, ArCH3), 1.90 – 1.83 (2H, m, CH2), 1.83 – 1.76 (2H, m, CH2); δC 150.1 (C=O), 147.9 (C), 
147.6 (C), 143.0 (C), 138.0 (C), 129.3 (2 x ArCH), 128.8 (C), 127.0 (2 x ArCH), 124.6 (C), 111.4 
(ArCH), 109.8 (ArCH), 62.7 (OCH2), 56.2 (OCH3), 56.1 (OCH3), 55.85 (NCH), 38.6 (NCH2), 33.9 (CH2), 
29.7 (CH2), 25.65 (CH2), 21.4 (ArCH3). 
 
(E)-4-(2-(2-((N-(tert-Butoxycarbonyl)-4-methylphenyl)sulfonamido)ethyl)-4,5-
dimethoxyphenyl)but-3-en-1-yl acetate 363 
 
 
 
 
 
To a solution of tert-butyl (E)-(2-(4-hydroxybut-1-en-1-yl)-4,5-dimethoxyphenethyl)(tosyl)carbamate 360 
(170 mg, 0.336 mmol, 1.0 eq.) in dichloromethane was added acetic anhydride (171 mg, 158 l, 1.681 
mmol, 5.0 eq.) and the mixture stirred overnight at ambient temperature. Aqueous sodium bicarbonate 
was added (5 mL) and the separated aqueous layer extracted with dichloromethane (3 x 5 mL). The 
combined organic mixtures were washed with aqueous sodium bicarbonate (10 mL) and brine (10 mL). 
The crude material was purified by column chromatography (petrol/ethyl acetate 3:2) to give acetate 363 
(136 mg, 74%) as a colourless glass; δH (400 MHz) 7.67 (2H, d, J 8.3, 2 x ArH), 7.21 (2H, d, J 8.1, 2 x 
ArH), 6.90 (1H, s, ArH), 6.78 (1H, d, J 15.6, ArCH=CH), 6.62 (1H, s, ArH), 5.93 (1H, dt, J 15.5 and 7.0, 
ArCH=CH), 4.14 (1H, t, J 6.8, CH2OAc), 3.86 – 3.80 (2H, m, NCH2), 3.82 (3H, s, OCH3), 3.76 (3H, s, 
OCH3), 3.02 – 2.97 (2H, m, ArCH2), 2.51 (1H, qd, J 6.7 and 0.9, CH=CHCH2), 2.35 (3H, s, OCOCH3), 
2.27 (3H, s, ArCH3), 1.25 (9H, s, C(CH3)3); δC 171.0 (OCOCH3), 150.85 (COOt-Bu), 148.6 (C), 148.0 
(C), 144.1 (C), 137.5 (C), 129.4 (C), 129.2 (2 x ArCH), 129.0 (C), 127.9 (ArCH), 127.8 (2 x ArCH), 
125.9 (ArCH), 113.4 (ArCH), 109.0 (ArCH), 84.1 (C), 63.9 (OCH2), 56.0 (OCH3), 55.9 (OCH3), 55.9 
(OCH3), 47.7 (NCH2), 33.8 (CH2) 32.6 (CH2), 27.8 (CH3), 21.5 (CH3). 
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3-(6,7-Dimethoxy-2-tosyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propyl acetate 364 
 
 
 
 
 
The sulfonamide 363 (58 mg, 0.106 mmol, 1.0 eq.) was dissolved in toluene (0.2 mL) under an 
atmosphere of nitrogen at 0 °C. To this was added p-toluenesulfonic acid (10.1 mg, 0.053 mmol, 0.5 eq.). 
The resulting solution was heated to 100 °C, stirred for 0.5 h and then quenched with aqueous potassium 
carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, 
filtered and evaporated. The crude material was purified by column chromatography (petrol/ethyl acetate 
1:1) to give tetrahydroisoquinoline 364 (28 mg, 59%) as a colourless glass; νmax 1752 (C=O); δH 7.57 (2H, 
d, J 8.3, 2 x ArH), 7.10 (2H, d, J 8.1, 2 x ArH), 6.52 (1H, s, ArH), 6.32 (1H, s, ArH), 4.92 (1H, dd, J 8.5 
and 4.6, NCH), 4.18 (1H, ddd, J 11.0, 6.3 and 6.3, OCH2a), 4.13 – 4.07 (1H, m, OCH2b), 3.89 (1H, dt, J 
14.5 and 4.5, NCH2a), 3.85 (3H, s, OCH3), 3.75 (3H, s, OCH3), 3.40 (1H, dt, J 14.5 and 8.5, NCH2b), 2.39 
(2H, dd, J 8.4 and 4.4, ArCH2), 2.32 (3H, s, ArCH3), 2.04 (3H, s, COOCH3), 1.88 – 1.84 (2H, m, CH2), 
1.82 – 1.73 (2H, m, CH2); δC 171.1 (C=O), 147.95 (C), 147.6 (C), 143.0 (C), 138.0 (C), 129.3 (2 x 
ArCH), 128.5 (C), 127.0 (2 x ArCH), 124.7 (C), 111.5 (ArCH), 109.7 (ArCH), 63.9 (OCH2), 56.05 
(NCH), 55.9 (OCH3), 55.9 (OCH3), 38.6 (CH2), 33.7 (CH2), 25.75 (CH2), 25.6 (CH2), 21.4 (CH3), 20.9 
(CH3); HRMS calculated for C23H29NO6S [M+H]
+
 447.1716, found 447.1719. 
 
1-Butyl-3-ethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 378 
 
 
 
 
To a solution of tert-butyl (1-(2-formylphenyl)butan-2-yl)(tosyl)carbamate 302 (271 mg, 0.628 mmol, 1.0 
eq.) in tetrahydrofuran (5 mL) at -78 °C under an atmosphere of nitrogen was added butylmagnesium 
chloride (2M, 471 l, 0.942 mmol, 1.5 eq.) and the mixture stirred for an hour. Aqueous ammonium 
chloride (5 mL) was added and the separated aqueous layer was extracted with ethyl acetate (3 x 5ml). 
The combined organic mixtures were washed with brine (10 mL), dried, filtered and evaporated. The 
crude material was dissolved in 1,2-dichloroethane (0.8 mL) under an atmosphere of nitrogen and cooled 
to 0 °C. To this was added triflic acid (38 mg, 0.251 mmol, 0.4 eq.). The resulting solution was stirred for 
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5 minutes at 0 °C and then heated to 60 °C for 16 h. The reaction mixture was quenched with aqueous 
potassium carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic 
extracts dried, filtered and evaporated. The crude material was purified by column chromatography 
(petrol/diethyl ether 6:1) to give tetrahydroisoquinoline 378 (49 mg, 21%); δH 7.32 (2H, d, J 8.3, 2 x 
ArH), 6.97 – 6.91 (1H, m, ArH), 6.89 (2H, d, J 8.0, 2 x ArH), 6.82 (1H, d, J 7.2, 2 x ArH), 6.75 (1H, d, J 
7.2, ArH), 4.71 (1H, dd, J 8.6 and 6.4, 1-CH), 3.66 (1H, dddd, J 8.9, 8.7, 7.5 and 4.9, 3-CH), 2.67 (1H, 
dd, J 15.8 and 7.3, ArCH2a), 2.52 (1H, dd, J 15.8 and 8.7, ArCH2b), 2.19 (3H, s, ArCH3), 2.06 – 2.03 (1H, 
m, CH2), 1.79 – 1.75 (1H, m, CH2), 1.64 – 1.48 (3H, m, CH2), 1.37 – 1.30 (1H, m, CH2), 1.32 – 1.25 (2H, 
m, CH2), 0.96 (3H, t, J 7.5, CH3), 0.84 (3H, t, J 7.2, CH3); δC 142.5 (C), 137.7 (C), 136.5  (C), 132.7 (C), 
129.0 (2 x ArCH), 128.0 (ArCH), 127.1 (2 x ArCH), 126.8 (ArCH), 126.5 (ArCH), 125.9 (ArCH), 58.7 
(NCH), 55.6 (NCH), 36.7 (CH2), 32.25 (CH2), 31.4 (CH2), 29.0 (CH2), 22.5 (CH2), 21.4 (ArCH3), 14.05 
(CH3), 10.6 (CH3). 
 
3-Ethyl-1-phenyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 382 
 
 
 
 
 
To a solution of tert-butyl (1-(2-(1,3-dioxolan-2-yl)phenyl)butan-2-yl)(tosyl)carbamate 302 (50 mg, 
0.116 mmol, 1.0 eq.) in tetrahydrofuran (2 mL) at -78 °C under an atmosphere of nitrogen was added 
phenylmagnesium chloride (2M, 122 l, 0.244 mmol, 2.1 eq.) and the mixture stirred for 1 h. Aqueous 
ammonium chloride (5 mL) was added and the separated aqueous layer was extracted with ethyl acetate 
(3 x 5ml). The combined organic mixtures were washed with brine (5 mL), dried, filtered and evaporated. 
The crude material was dissolved in methanol (1.8 mL) and cooled to 0 °C. To this was added potassium 
carbonate (40 mg, 0.290 mmol, 2.5 eq.) and the resulting solution was stirred for 16 h at 60 °C. The 
reaction mixture was cooled to ambient temperature and partitioned between water (5 mL) and ethyl 
acetate (5 mL). The separated aqueous phase was extracted with ethyl acetate (3 x 5 mL) and the 
combined organic extracts washed with brine (10 mL), dried, filtered and evaporated. The crude material 
was dissolved in dichloromethane (1 mL) under an atmosphere of nitrogen and cooled to 0 °C. To this 
was added triflic acid (7.0 mg, 0.046 mmol, 0.4 eq.) and the resulting solution was stirred for 0.5 h at 0 
°C. The reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/ethyl acetate 6:1) to give tetrahydroisoquinoline 
382 (36 mg, 79%) as a colourless glass, as a single diastereoisomer. A solid sample of the material was 
obtainer by vapour diffusion recrystallization from diethyl ether in a petroleum ether chamber; m.p. 118 – 
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121 °C; νmax 3019, 2964, 1331 (S=O), 1155 (S=O); δH (400 MHz) 7.44 (2H, d, J 8.2, 2 x ArH), 7.28 – 
7.24 (3H, m, 3 x ArH), 7.14 – 7.10 (2H, m, 2 x ArH), 7.00 (2H, d, J 8.0, 2 x ArH), 6.14 (1H, s, 1-CH), 
4.00 – 3.92 (1H, m, 3-CH), 2.94 (1H, dd, J 16.2 and 4.5, ArCH2a), 2.70 (2H, dd, J 16.3 and 6.7, ArCH2b), 
2.30 (3H, s, ArCH3), 2.06 – 1.88 (1H, m, CH2aCH3), 1.52 – 1.41 (1H, m, CH2bCH3), 0.84 (3H, t, J 7.4, 
CH3); δC (101 MHz) 142.3 (C), 141.7 (C), 139.7 (C), 136.0 (C), 132.8 (C), 129.1 (ArCH), 128.9 (2 x 
ArCH), 128.6 (2 x ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.1 (ArCH), 126.9 (ArCH), 
126.75 (2 x ArCH), 126.4 (ArCH), 61.8 (1-CH), 56.2 (3-CH), 32.3 (CH2), 26.35 (CH2), 21.4 (CH3), 11.3 
(CH3); HRMS (APCI) calculated for C24H25NNaO2S [M+Na]
+
 414.1504, found 414.1488. 
  
3-Ethyl-1-(4-fluorophenyl)-2-tosyl-1,2,3,4-tetrahydroisoquinoline 386 
 
 
 
 
 
 
To a solution of tert-butyl (1-(2-(1,3-dioxolan-2-yl)phenyl)butan-2-yl)(tosyl)carbamate 302 (57.6 mg, 
0.134 mmol, 1.0 eq.) in tetrahydrofuran (2 mL) at -78 °C under an atmosphere of nitrogen was added 4-
fluorophenylmagnesium bromide (1M, 140 l, 0.140 mmol, 1.05 eq.) and the mixture stirred for 1 h. 
Aqueous ammonium chloride (2 mL) was added and the separated aqueous layer was extracted with ethyl 
acetate (3 x 5ml). The combined organic mixtures were washed with brine (5 mL), dried, filtered and 
evaporated. The crude material was dissolved in methanol (1 mL) and cooled to 0 °C. To this was added 
aqueous sodium hydroxide (50%, 0.1 mL) and the resulting solution was stirred for 2.5 h at 60 °C. The 
reaction mixture was cooled to ambient temperature and partitioned between water (5 mL) and ethyl 
acetate (5 mL). The separated aqueous phase was extracted with ethyl acetate (3 x 5 mL) and the 
combined organic extracts washed with brine (10 mL), dried, filtered and evaporated. The crude material 
was dissolved in dichloromethane (1 mL) under an atmosphere of nitrogen and cooled to 0 °C. To this 
was added triflic acid (8.7 mg, 0.056 mmol, 0.4 eq.) and the resulting solution was stirred for 0.5 h at 0 
°C. The reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/ethyl acetate 7:1) to give tetrahydroisoquinoline 
386 (39 mg, 82%) as a white foam, as a single diastereoisomer; νmax 3065, 2950, 1509, 1331 (S=O), 1161 
(S=O); δH 7.55 (2H, d, J 8.4, 2 x ArH), 7.19 - 7.08 (6H, m, 6 x Ar), 7.00 - 6.91 (4H, m, 4 x ArH), 6.22 
(1H, s, 1-CH), 3.81-3.73 (1H, m, 3-CH), 2.98 (1H, dd, J 15.7 and 4.9, ArCH2a), 2.68 (2H, dd, J 15.9 and 
6.8, ArCH2b), 2.32 (3H, s, ArCH3), 2.03 – 1.89 (1H, m, CH2aCH3), 1.50 – 1.39 (1H, m, CH2bCH3), 0.89 
(3H, t, J 7.5, CH3); HRMS (APCI) calculated for C24H26FNNaO3S [M+Na]
+
 450.1515, found 450.1517. 
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3-Ethyl-1-(4-methoxyphenyl)-2-tosyl-1,2,3,4-tetrahydroisoquinoline 389 
 
 
 
 
 
 
To a solution of tert-butyl (1-(2-(1,3-dioxolan-2-yl)phenyl)butan-2-yl)(tosyl)carbamate 302 (54.0 mg, 
0.125 mmol, 1.0 eq.) in tetrahydrofuran (2 mL) at -78 °C under an atmosphere of nitrogen was added 4-
methoxyphenylmagnesium chloride (0.25M, 530 l, 0.131 mmol, 1.05 eq.) and the mixture stirred for 1 
h. Aqueous ammonium chloride (2 mL) was added and the separated aqueous layer was extracted with 
ethyl acetate (3 x 5ml). The combined organic mixtures were washed with brine (5 mL), dried, filtered 
and evaporated. The crude material was dissolved in methanol (1.5 mL) and cooled to 0 °C. To this was 
added aqueous sodium hydroxide (50%, 0.15 mL) and the resulting solution was stirred for 2 h at 70 °C. 
The reaction mixture was cooled to ambient temperature and partitioned between water (5 mL) and ethyl 
acetate (5 mL). The separated aqueous phase was extracted with ethyl acetate (3 x 5 mL) and the 
combined organic extracts washed with brine (10 mL), dried, filtered and evaporated. The crude material 
was dissolved in dichloromethane (1 mL) under an atmosphere of nitrogen and cooled to 0 °C. To this 
was added triflic acid (8.7 mg, 0.056 mmol, 0.4 eq.) and the resulting solution was stirred for 1 min. at 0 
°C. The reaction mixture was quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/ethyl acetate 6:1) to give tetrahydroisoquinoline 
389 (24 mg, 46%) as a white foam, as a single diastereoisomer; δH (400 MHz) 7.43 (2H, d, J 8.2, 2 x 
ArH), 7.16 (2H, d, J 8.5, 2 x ArH), 7.10 (1H, d, J 6.7, ArH), 7.04 – 6.96 (4H, m, 4 x ArH), 6.82 (2H, d, J 
7.8, 2 x ArH), 6.79 (2H, d, J 8.6, 2 x ArH), 6.01 (1H, s, ArCHN), 3.78 (3H, s, ArOCH3), 3.73 (1H, m, 
NCHCH2), 2.71 (1H, dd, J 15.4 and 6.8, ArCH2a), 2.28 (3H, s, ArCH3), 2.27 (1H, dd, J 15.4 and 8.8, 
ArCH2b), 1.96 – 1.85 (1H, m, CH2aCH3), 1.39 – 1.26 (1H, m, CH2aCH3), 0.78 (3H, t, J 7.4, CH3); δC (101 
MHz) 158.85 (C), 142.7 (C), 136.4 (C), 135.5 (C), 134.3 (C), 132.7 (C), 129.2 (2 x ArCH), 129.1 (2 x 
ArCH), 128.1 (ArCH), 127.7 (ArCH), 127.4 (ArCH), 127.2 (2 x ArCH), 125.8 (ArCH), 113.5 (ArCH), 
59.5 (ArCHN), 57.0 (NCH), 55.25 (OCH3), 32.1 (CH2), 31.5 (CH2), 21.4 (CH3), 10.6 (CH3); HRMS 
(APCI) calculated for C25H27NNaO3S [M+Na]
+
 444.1609, found 444.1619. 
 
 
 220 
 
 
 
 
tert-Butyl (E)-(1-(2-(2-bromostyryl)phenyl)butan-2-yl)(tosyl)carbamate 396 
 
 
 
 
To a suspension of (2-bromo)benzylphosphonium bromide (1.66 g, 3.24 mmol, 1.2 eq.) in 
tetrahydrofuran (20 mL) at 0 °C was added solid potassium tert-butoxide (394 mg, 3.51 mmol, 1.3 eq.) 
portionwise, over five minutes. The reaction mixture was stirred for a further 0.5 h at 0 °C after which 
tert-butyl (1-(2-formylphenyl)butan-2-yl)(tosyl)carbamate 302 (1.17g, 2.70 mmol, 1.0 eq.) in 
tetrahydrofuran (15 mL) was added dropwise, over 5 minutes. The cooling bath was removed and the 
mixture was stirred at ambient temperature for 16 h. The reaction was quenched by addition of aqueous 
ammonium chloride (25 mL) and the separated aqueous layer extracted with ethyl acetate (3 x 20 mL). 
The combined organic extracts were washed with brine, dried, filtered and evaporated. The crude material 
was purified by column chromatography (dichloromethane) to give alkene 396 (1.244 g, 79%) as a 
colourless oil and as a 3:1 mixture of trans and cis isomers; νmax 1725 (C=O), 1351 (S=O), 1152 (S=O); 
major (trans)-isomer δH (400 MHz) 7.79 (1H, dd, J 7.9 and 1.5, ArH), 7.71 (1H, d, J 7.7, ArH), 7.56 (1H, 
dd, J 8.0 and 1.1, ArH), 7.49 (1H, d, J 16.0, ArCH=CH), 7.36 (1H, d, J 16.0, ArCH=CH), 7.33 – 7.25 
(3H, m, 3 x ArH), 7.22 – 7.18 (2H, m, 2 x ArH), 7.10 (2H, d, J 7.0, 2 x ArH), 7.12 – 7.03 (2H, m, 2 x 
ArH), 4.72 – 4.63 (1H, m, NCH), 3.47 (1H, dd, J 13.8 and 8.0, ArCH2a), 3.29 (1H, dd, J 13.8 and 7.5, 
ArCH2b), 2.37 (3H, s, ArCH3), 2.17 – 2.00 (1H, m, CH3CH2a), 1.77 – 1.64 (1H, m, CH3CH2b), 1.34 (9H, s, 
C(CH3)3), 0.89 (3H, t, J 7.4, CH3CH2); δC (101 MHz) 150.8 (C=O), 143.5 (C), 137.5 (C), 137.2 (C), 136.9 
(C), 136.7 (C), 132.9 (ArCH), 131.3 (ArCH), 129.6 (ArCH), 128.9 (2 x ArCH), 128.8 (ArCH), 128.8 
(ArCH), 128.1 (ArC=CH), 128.0 (2 x ArCH), 127.65 (ArCH), 127.3 (ArCH), 127.2 (ArCH), 126.35 
(ArCH), 124.1 (C-Br), 84.0 (C(CH3)3), 61.9 (NCH), 37.0 (ArCH2), 27.9 (C(CH3)3), 25.6 (CH2), 21.5 
(ArCH3), 11.5 (CH3); minor (cis)-isomer δH (400 MHz) 7.55 (2H, d, J 8.0, 2 x ArH), 7.01 (1H, d, J 7.6, 
ArH), 6.94 (1H, d, J 12.1, ArCH=CH), 6.89 – 6.65 (1H, m, ArH), 6.79 (1H, d, J 12.1, ArCH=CH), 4.80 – 
4.70 (1H, m, NCH), 3.33 (1H, dd, J 14.0 and 9.2, ArCH2a), 3.12 (1H, dd, J 13.9 and 6.2, ArCH2b), 2.37 
(3H, s, ArCH3), 2.12 – 2.03 (1H, m, CH3CH2a), 1.86 – 1.74 (1H, m, CH3CH2b), 1.37 (9H, s, C(CH3)3), 
1.00 (3H, t, J 7.5, CH3CH2); δC (101 MHz) 143.3 (C), 137.8 (C), 137.4 (C), 137.3 (C), 136.3 (C), 132.5 
(ArCH), 131.0 (ArCH), 130.9 (ArCH), 130.6 (ArCH), 130.0 (ArCH), 129.9 (ArCH), 128.6 (ArCH), 
127.7 (ArCH), 126.8 (ArCH), 126.4 (ArCH), 124.1 (C-Br), 83.95 (C(CH3)3), 61.5 (NCH), 36.8 (ArCH2), 
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28.0 (C(CH3)3), 26.3 (CH2), 22.7 (ArCH3), 11.6 (CH3); HRMS calculated for C30H34BrNO4S [M+H]
+
 
583.1392, found 583.1393 
 
(E)-N-(1-(2-(2-Bromostyryl)phenyl)butan-2-yl)-4-methylbenzenesulfonamide 397 
 
 
 
 
To a solution of tert-butyl (E)-(1-(2-(2-bromostyryl)phenyl)butan-2-yl)(tosyl)carbamate 396 (265 mg, 
0.476 mmol, 1.0 eq.) in dichloromethane (5 mL) at 0 °C was added trifluoroacetic acid (367 l, 4.76 
mmol, 10.0 eq.) and the mixture allowed to stir at ambient temperature for 5 h. The reaction mixture was 
then concentrated and purified by column chromatography (petrol/diethyl ether 3:1) to give sulfonamide 
397 (185 mg, 86%) as a colourless oil, as a 3:1 mixture of trans and cis isomers; νmax 3279 (br, NH), 1325 
(S=O), 1158 (S=O); major (trans)-isomer δH 7.76 (1H, dd, J 7.9 and 1.5, ArH), 7.58 (1H, d, J 8.3, ArH), 
7.54 (1H, dd, J 8.0 and 1.2, ArH), 7.39 (2H, d, J 8.3, ArH), 7.30 (1H, d, J 16.1, ArCH=CH), 7.20 (1H, d, 
J 16.0, ArCH=CH), 7.16 – 7.14 (1H, m, ArH), 7.09 – 7.04 (3H, m, 3 x ArH), 6.99 – 6.94 (3H, m, ArH), 
4.68 (1H, d, J 7.4, NH), 3.23 – 3.13 (1H, m, NCH), 3.07 (1H, dd, J 13.8 and 6.1, ArCH2a), 2.70 (1H, dd, J 
13.8 and 8.4, ArCH2b), 2.26 (3H, s, ArCH3), 1.48 – 1.33 (1H, m, CH3CH2a), 1.33 – 1.20 (1H, m, 
CH3CH2b), 0.60 (3H, t, J 7.4, CH3); δC 142.95 (C), 137.2 (C), 137.1 (C), 136.2 (C), 135.9 (C), 133.0 
(ArCH), 131.2 (ArCH), 129.5 (2 x ArCH), 129.0 (ArCH), 128.6 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 
127.3 (ArCH), 127.2 (ArCH), 127.0 (ArCH), 126.9 (2 x ArCH), 126.4 (ArCH), 124.1 (C-Br), 56.05 
(NCH), 39.9 (ArCH2), 27.0 (CH2), 21.5 (ArCH3), 9.7 (CH3); minor (cis)-isomer δH 7.51 – 7.46 (3H, m, 3 
x ArH), 7.30 – 7.26 (1H, m, ArH), 6.86 (3H, m, 3 x ArH), 6.75 (1H, dd, J 7.7 and 1.6, ArH), 6.62 (1H, d, 
J 12.1, ArCH=C), 6.55 (1H, d, J 12.1, ArCH=CH), 4.63 (1H, d, J 7.9, NH), 3.41 – 3.30 (1H, m, NCH), 
2.71 (1H, dd, J 13.8 and 6.4, ArCH2a), 2.56 (1H, dd, J 13.8 and 8.0, ArCH2b), 2.30 (3H, s, ArCH3), 1.48 – 
1.36 (1H, m, CH3CH2a), 1.32 – 1.23 (1H, m, CH3CH2b), 0.70 (3H, t, J 7.4, CH3); δC 143.1 (C), 137.9 (C), 
137.0 (C), 136.1 (C), 135.9 (C), 132.7 (ArCH), 130.6 (ArCH), 130.5 (ArCH), 130.4 (ArCH), 129.95 
(ArCH), 129.8 (ArCH), 129.5 (ArCH), 127.5 (ArCH), 126.8 (ArCH), 124.15 (C-Br), 55.8 (NCH), 39.1 
(ArCH2), 27.3 (CH2), 21.5 (ArCH3), 9.6 (CH3); HRMS calculated for C25H26BrNO2S [M]
+
 483.0868, 
found 483.0875. 
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1-(2-Bromobenzyl)-3-ethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 398 
 
 
 
 
The sulfonamide 397 (147 mg, 0.311 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (1.5 mL) under 
an atmosphere of nitrogen at 0 °C. To this was added triflic acid (18.1 mg, 0.125 mmol, 0.4 eq.). The 
resulting solution was heated to 60 °C, stirred for 7 h and then quenched with aqueous potassium 
carbonate (2 mL), extracted with dichloromethane (3 x 5 mL) and the combined organic extracts dried, 
filtered and evaporated. The crude material was purified by column chromatography (petrol/ethyl acetate 
3:1) to give tetrahydroisoquinoline 398 (103 mg, 70%) as a colourless glass, as a 9:1 mixture of cis and 
trans isomers; νmax 3050, 3027, 2965, 2931, 2875, 1597, 1337 (S=O), 1160 (S=O); major (cis)-isomer δH 
7.48 (1H, dd, J 8.0 and 1.1, ArH), 7.41 (2H, d, J 8.3, 2 x ArH), 7.19 (1H, td, J 7.4 and 1.2, ArH), 7.14 
(1H, dd, J 7.6 and 1.8, ArH), 7.06 (1H, td, J 7.8 and 1.8, ArH), 7.01 (1H, td, J 7.4 and 1.1, ArH), 6.96 
(2H, d, J 8.1, 2 x ArH), 6.93 (1H, d, J 7.4, ArH), 6.81 (1H, t, J 7.5, ArH), 6.37 (1H, d, J 7.5, ArH), 5.15 
(1H, dd, J 8.8 and 6.7, 1-CH), 3.81 – 3.78 (1H, m, 3-CH), 3.32 (1H, dd, J 13.3 and 6.6, ArCH2aCHAr), 
3.26 (1H, dd, J 13.3 and 8.9, ArCH2bCHAr), 2.89 (1H, dd, J 15.8 and 7.1, 4-CH2a), 2.81 (1H, dd, J 15.8 
and 9.0, 4-CH2b), 2.30 – 2.19 (1H, m, CH3CH2a), 2.24 (3H, s, ArCH3), 1.93 – 1.83 (1H, m, CH3CH2b), 
1.10 (3H, t, J 7.5, CH3); δC 142.8 (C), 137.55 (C), 136.5 (C), 135.85 (C), 133.1 (C), 132.8 (ArCH), 132.1 
(ArCH), 129.2 (2 x ArCH), 128.4 (ArCH), 127.9 (ArCH), 127.4 (ArCH), 127.35 (2 x zArCH), 127.2 
(ArCH), 126.9 (ArCH), 125.8 (ArCH), 125.35 (C-Br), 58.45 (ArCH2CHAr), 56.0 (ArCH2CHCH2), 43.2 
(ArCH2CHCH2), 32.5 (ArCH2CHAr), 31.85 (CH2), 21.4 (ArCH3), 10.8 (CH3); minor (trans)-isomer δH 
7.49 (2H, d, J 8.3, 2 x ArH), 7.44 – 7.42 (1H, m, ArH), 7.14 (2H, m, 2 x ArH), 7.10 (2H, d, J 8.0, 2 x 
ArH), 7.08 – 7.04 (3H, m, 3 x ArH), 7.03 – 6.99 (1H, m,  ArH), 6.70 (1H, d, J 7.5, ArH), 5.30 (1H, t, J 
7.6, ArCHCH2Ar), 3.99 (1H, dddd, J 9.4, 7.8, 7.1 and 4.5, ArCH2CHCH2), 3.49 (1H, dd, J 13.4 and 7.6, 
ArCH2aCHAr), 3.12 (1H, dd, J 13.4 and 7.7, ArCH2bCHAr), 3.02 (1H, dd, J 15.9 and 4.4, 1H, 
ArCH2aCHCH2), 2.94 (1H, dd, J 15.9 and 7.1, ArCH2bCHCH2), 2.36 (3H, s, ArCH3), 1.93 – 1.82 (1H, m, 
CH3CH2a), 1.39 – 1.36 (1H, m, CH3CH2b), 0.84 (3H, t, J 7.4, CH3); δC 137.7  (C), 136.0 (C), 134.0 (C), 
132.75 (ArCH), 132.2 (ArCH), 129.4 (ArCH), 128.9 (ArCH), 128.2 (ArCH), 127.3 (ArCH), 127.2 
(ArCH), 127.1 (ArCH), 126.1 (ArCH), 125.3 (C-Br), 59.4 (ArCH2CHAr), 56.7 (ArCH2CHCH2), 3.0 
(ArCH2CHCH2), 32.1 (ArCH2CHAr), 26.4 (CH2), 21.45 (ArCH3), 11.5 (CH3); HRMS calculated for 
 223 
 
C25H26BrNO2S [M]
+
 483.0868, found 483.0860; LRMS m/z 483 ([M]
+
, 70%), 232 ([M-NHCOOMe]
+
, 
3%). 
 
5-Ethyl-6-tosyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolone 399 
 
 
 
 
To a solution of 1-(2-bromobenzyl)-3-ethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 398 (75 mg, 0.155 
mmol, 1.0 eq.) in dimethylacetamide (2 mL) was added palladium acetate (1.7 mg, 0.0077 mmol, 0.05 
eq.), potassium carbonate (42.7 mg, 0.309 mg, 2.0 eq.) and tricyclohexylphosphine (5.4 mg, 0.0193 
mmol, 0.125 eq.) and the resulting mixture heated to 130 °C for 16 h. The reaction was then cooled to 
ambient temperature and partitioned between ethyl acetate (10 mL) and water (5 mL). The separated 
organic phase was washed with water (4 x 5 mL), brine (5 mL), dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/ethyl acetate 1:3) to give aporphine 399 (42 mg, 
67%) as a colourless glass; νmax 3064, 3029, 2966, 2931, 2874, 1596 (S=O), 1338 (S=O); δH (400 MHz) 
7.71 (1H, d, J 8.3, ArH), 7.65 (1H, d, J 7.7, ArH), 7.61 (2H, d, J 8.3, 2 x ArH), 7.51 (1H, d, J 7.8, ArH), 
7.28 – 7.15 (3H, m, 3 x ArH), 7.13 (2H, d, J 8.5, 2 x ArH), 6.85 (1H, d, J 7.5, ArH), 4.67 (1H, dd, J 14.3 
and 4.8, 6a-CH), 4.13 – 4.07 (1H, m, 5-CH), 3.38 (1H, dd, J 14.4 and 4.8, 7-CH2a), 2.92 (1H, t, J 14.4, 7-
CH2b), 2.42 (1H, dd, J 15.6 and 1.7, 4-CH2a), 2.33 – 2.29 (1H, m, 4-CH2b), 2.27 (3H, s, ArCH3), 1.52 – 
1.40 (1H, m, CH3CH2a), 1.32 – 1.28 (1H, m, CH3CH2b), 0.92 (3H, t, J 7.4, CH3); δC (101 MHz) 142.2 (C), 
136.6 (C), 134.5 (C), 133.1 (C), 132.6 (C), 130.4 (C), 129.6 (C), 128.8 (2 x ArCH), 128.6 (ArCH), 127.7 
(ArCH), 127.3 (ArCH), 127.1 (ArCH), 126.5 (ArCH), 126.35 (ArCH), 126.0 (2 x ArCH), 125.7 (ArCH), 
122.7 (ArCH), 121.7 (ArCH), 52.25 (NCH), 51.05 (NCH), 38.4 (CH2), 31.3 (CH2), 26.1 (CH2), 21.7 
(ArCH3), 9.9 (CH3); HRMS calculated for C25H25NO2S [M]
+
 403.1606, found 403.1602. 
 
2-(2-((tert-Butoxycarbonyl)oxy)-2-(2-(2-((4-methylphenyl)sulfonamido)butyl)phenyl)ethyl) 
benzoic acid 407 
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To a solution of 2-methylbenzoic acid (207 mg, 1.52 mmol, 2.0 eq.) in tetrahydrofuran (3 mL) at -78 °C 
under an atmosphere of nitrogen was added butyllithium (2.35 M, 1.28 mL, 3.20 mmol, 4.2 eq.) dropwise 
over 0.5 h and the resulting deep red solution allowed to warm to -50 °C over 0.5 h. The reaction mixture 
was then cooled to -78 °C and cannulated to a -78 °C solution of tert-butyl (1-(2-formylphenyl)butan-2-
yl)(tosyl)carbamate 302 (328 mg, 0.761 mmol, 1.0 eq.) in tetrahydrofuran (2 mL) until the red colour 
persisted for a period of several seconds. The reaction was quenched by aqueous ammonium chloride (5 
mL) and ethyl acetate (5 mL) and the separated aqueous layer extracted with ethyl acetate (3 x 10 mL). 
The combined organic mixtures were washed with brine (15 mL), dried, filtered and exaporated. The 
crude material was then dissolved in dichloromethane (5 mL) and trifluoroacetic acid (116 l, 2.0 eq.) 
was added at 0 °C and the mixture allowed to warm to ambient temperature and stirred for 1.5 h. The 
mixture was then washed with aqueous sodium bicarbonate (5 mL), dried, filtered and evaporated. The 
crude material was purified by column chromatography (petrol/ethyl acetate 1:1) to give sulfonamide 407 
(140 mg, 41%) as a viscous, colourless glass; δH (400 MHz) 8.14 (1H, d, J 7.7, ArH), 7.73 (1H, d, J 7.8, 
ArH), 7.57 (1H, td, J 7.5 and 1.0, ArH), 7.42 (2H, t, J 7.5, 2 x ArH), 7.31 (2H, br. d, J 8.8, 2 x ArH), 7.25 
(1H, t, J 8.6, ArH), 7.11 – 7.07 (4H, s, 4 x ArH), 5.96 (1H, dd, J 12.4 and 2.7, ArCHOH), 4.58 (1H, dddd, 
J 5.0, 6.6, 8.2 and 9.8, NCH), 3.48 – 3.36 (2H, m, AraCH2a and ArbCH2a), 3.24 – 3.14 (2H, m, AraCH2b 
and ArbCH2b), 2.38 (3H, s, ArCH3), 2.09 – 1.96 (1H, qdd, J 7.5, 8.2 and 14.4, CH2aCH3), 1.76 – 1.64 (1H, 
m, dqd, J 5.1, 7.5 and 14.6, CH2aCH3), 1.30 (9H, s, C(CH3)3), 0.87 (3H, t, J 7.3, CH3); δC (101 MHz) 
165.61 (C=O), 150.76 (C=O), 143.62 (C), 139.31 (C), 137.40 (C), 137.37 (C), 136.34 (C), 133.90 
(ArCH), 131.42 (ArCH), 130.35 (ArCH), 129.02 (2 x ArCH), 128.94 (ArCH), 127.84 (2 x ArCH), 127.45 
(ArCH), 127.41 (ArCH), 127.20 (ArCH), 125.14 (C), 84.28 (C(CH3)3), 76.46 (OCH), 62.06 (NCH), 36.27 
(ArCH2), 35.04 (ArCH2), 27.9 (C(CH3)3), 25.84 (CH2), 21.52 (ArCH3), 11.42 (CH3). 
 
2-(2-Hydroxy-2-(2-(2-((4-methylphenyl)sulfonamido)butyl)phenyl)ethyl)benzoic acid 408 
 
 
 
 
To a solution of 2-methylbenzoic acid (347 mg, 2.55 mmol, 1.1 eq.) in tetrahydrofuran (10 mL) at -78 °C 
under an atmosphere of nitrogen was added butyllithium (1.6 M, 3.5 mL, 5.56 mmol, 2.4 eq.) dropwise 
over 0.5 h and the resulting deep red solution allowed to warm to -20 °C over 0.5 h. The reaction mixture 
was then cooled to -78 °C and tert-butyl (1-(2-formylphenyl)butan-2-yl)(tosyl)carbamate 302 (1.00 g, 
2.32 mmol, 1.0 eq.) in tetrahydrofuran (5 mL) was added and the solution stirred for a further 0.5 h at -78 
°C. The reaction was quenched by 10% aqueous sulfuric acid (5 mL) and ethyl acetate (5 mL) and the 
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separated aqueous layer extracted with ethyl acetate (3 x 10 mL). The combined organic mixtures were 
washed with brine (15 mL), dried, filtered and exaporated. The crude material was then dissolved in 
dichloromethane (8 mL) and trifluoroacetic acid (1.6 mL) was added at 0 °C and the mixture allowed to 
warm to ambient temperature and stirred for 16 h. The mixture was then washed with aqueous sodium 
bicarbonate (5 mL), dried, filtered and evaporated. The crude material was purified by column 
chromatography (petrol/ethyl acetate 1:1) to give alcohol 408 (313 mg, 29%) as a yellow oil, as a 2:1 
mixture of diastereoisomers; major diastereoisomer δH (400 MHz) 8.16 – 8.12 (1H, m, ArH), 7.60 – 7.55 
(2H, m, 2 x ArH), 7.54 – 7.46 (3H, m, 3 x ArH), 7.47 – 7.40 (1H, m, ArH), 7.32 – 7.24 (2H, m, 2 x ArH), 
7.21 – 7.18 (1H, m, ArH), 7.07 (2H, d, J 8.0, 2 x ArH), 5.67 (1H, dd, J 12.6 and 2.8, ArCH(OH)), 5.25 
(1H, d, J 8.2, NH), 3.34 (1H, dd and, J 17.6 and 12.6, ArCH2aCH(OH)), 3.33 (1H, m, NCH), 3.40 – 3.18 
(1H, m, ArCH2bCH(OH)), 2.89 (1H, dd, J 14.1 and 6.1, ArCH2aCHN), 2.67 (1H, dd, J 14.2 and 8.3, 
ArCH2bCHN), 2.35 (3H, s, ArCH3), 1.53 – 1.40 (1H, m, CH3CH2a), 1.35 – 1.21 (1H, m, CH3CH2b), 0.72 
(3H, t, J 7.4, CH3); δC (101 MHz) 165.4 (C=O), 143.0 (C), 139.15 (C), 138.0 (C), 136.8 (C), 135.45 (C), 
134.0 (ArCH), 130.85 (ArCH), 130.4 (ArCH), 129.5 (2 x ArCH), 127.9 (ArCH), 127.5 (ArCH), 127.1 
(ArCH), 127.1 (ArCH), 126.8 (2 x ArCH), 125.0 (ArCH), 76.8 (OCH), 57.1 (NCH), 38.2 (ArCH2), 35.3 
(ArCH2),  27.0 (CH2), 21.5 (ArCH3), 10.0 (CH3); minor diastereoisomer δH (400 MHz) 8.19 – 8.13 (1H, 
m, ArH), 7.60 – 7.55 (1H, m, ArH), 7.54 – 7.46 (2H, m, 2 x ArH), 7.47 – 7.40 (1H, m, ArH), 7.32 – 7.24 
(2H, m, 2 x ArH), 7.20 (1H, m, ArH), 7.11 (2H, d, J 8.1, 2 x ArH), 7.08 – 7.05 (2H, m, 2 x ArH), 5.90 
(1H, dd, J 12.4 and 2.8, ArCH(OH)), 5.19 (1H, d, J 7.6, NH), 3.40 – 3.18 (2H, m, ArCH2aCH(OH) and 
NCH), 3.06 (1H, dd, J 14.0 and 5.7, ArCH2bCH(OH)), 3.02 – 2.91 (1H, m, ArCH2aCHN), 2.70 (1H, dd, J 
14.5 and 8.5, ArCH2bCH), 2.35 (3H, s, ArCH3), 1.53 – 1.40 (1H, m, CH3CH2a), 1.35 – 1.21 (1H, m, 
CH3CH2b), 0.64 (1H, t,  J 7.4, CH3); δC (101 MHz) 165.6 (C=O), 143.1 (C), 139.3 (C), 137.4 (C), 136.7 
(C), 135.6 (C), 134.1 (ArCH), 131.2 (ArCH), 130.3 (ArCH), 128.7 (2 x ArCH), 127.9 (ArCH), 127.6 
(ArCH), 127.3 (ArCH), 127.05 (ArCH), 126.9 (ArCH), 124.95 (ArCH), 76.6 (OCH), 56.4 (NCH), 39.1 
(ArCH2), 34.7 (ArCH2), 26.85 (CH2), 22.7 (ArCH3), 9.8 (CH3); HRMS calculated for C26H27NNaO4S [M-
H2O+Na]
+
 472.1559, found 472.1545. 
 
6-Ethyl-5,6,13,13a-tetrahydro-8H-isoquinolino[3,2-a]isoquinolin-8-one 409  
 
 
 
 
To a solution of 2-methylbenzoic acid (63 mg, 0.464 mmol, 2.0 eq.) in tetrahydrofuran (1 mL) at -78 °C 
under an atmosphere of nitrogen was added butyllithium (2.3 M, 0.40 mL, 0.92 mmol, 4.0 eq.) dropwise 
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over 0.5 h and the resulting deep red solution allowed to warm to -50 °C over 0.5 h. The reaction mixture 
was then cooled to -78 °C and cannulated to a -78 °C solution of tert-butyl (1-(2-formylphenyl)butan-2-
yl)(tosyl)carbamate 302 (100 mg, 0.232 mmol, 1.0 eq.) in tetrahydrofuran (1 mL) until the red colour 
persisted for a period of several seconds. The reaction was quenched by aqueous ammonium chloride (2 
mL) and ethyl acetate (3 mL) and the separated aqueous layer extracted with ethyl acetate (3 x 5 mL). 
The combined organic mixtures were washed with brine (10 mL), dried, filtered and exaporated. The 
crude material was then dissolved in toluene (2.3 mL) under an atmosphere of nitrogen at 0 °C. To this 
was added triflic acid (52 mg, 0.348 mmol, 1.0 eq.). The resulting solution was heated to 110 °C, stirred 
for 18 h and then quenched with aqueous potassium carbonate (2 mL), extracted with dichloromethane (3 
x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude material was purified 
by column chromatography (petrol/ethyl acetate 1:1) to give berberinone 409 (39 mg, 65%) as a 
colourless glass, as a 4:1 mixture of cis and trans diastereoisomers. Vapour diffusion recrystallisation 
from diethyl ether/heptane gave berberinone 409 (29 mg, 45%) as colourless needles and as a single, cis 
diastereoisomer; m.p. 160-163; νmax 3045, 2956, 1635 (C=O), 1400, 1307; major (cis)-diastereoisomer δH 
(400 MHz) 8.15 (1H, d, J 7.7, ArH), 7.47 (1H, t, J 7.4, ArH), 7.42 – 7.35 (2H, m, 2 x ArH), 7.35 – 7.28 
(3H, m, 3 x ArH), 7.24 (1H, d, J 7.4, ArH), 4.89 (1H, dddd, J 8.4, 6.7 and 3.4 and 3.0, 6-CH), 4.76 (1H, 
dd, J 13.7 and 3.2, 13a-CH), 3.57 (1 H, dd, J 14.9 and 3.3, 13-CH2a), 3.21 (1H, dd, J 14.8 and 13.8, 13-
CH2b), 2.98 (2H, app. d, J 3.3, 5-CH2), 1.53 – 1.42 (1H, m, CH2aCH3), 1.06 – 0.94 (1H, m, CH2bCH3), 
0.84 (3H, t, J 7.4, CH3); δC (101 MHz) 164.8 (C=O), 136.8 (C), 135.5 (C), 135.5 (C), 131.7 (ArCH), 
129.8 (C), 128.5 (ArCH), 128.3 (ArCH), 127.7 (ArCH), 127.4 (ArCH), 127.1 (ArCH), 126.8 (ArCH), 
123.5 (ArCH), 52.6 (CH), 51.6 (CH), 32.6 (CH2), 32.0 (CH2), 27.05 (ArCH2), 10.5 (CH3); minor (trans)-
diastereoisomer δH (400 MHz) 5.24 – 5.12 (1H, m, 6-CH), 3.03 (1H, d, J 13.6), 2.84 (1H, dd, J 15.9 and 
1.8), 1.44 – 1.32 (1H, m, CH2aCH3), 1.28 – 1.17 (1 H, m), 0.90 (2 H, t, J 7.4); only 6 distinct signals; 
HRMS (APCI) calculated for C19H19NO [M]
+
 277.1467, found 277.1468. 
 
 
5,6,13,13a-tetrahydro-8H-isoquinolino[3,2-a]isoquinolin-8-one 410 
 
 
 
 
To a solution of 2-methylbenzoic acid (195 mg, 1.434 mmol, 2.0 eq.) in tetrahydrofuran (2 mL) at -78 °C 
under an atmosphere of nitrogen was added butyllithium (2.35 M, 1.22 mL, 2.87 mmol, 4.0 eq.) dropwise 
over 0.5 h and the resulting deep red solution allowed to warm to -50 °C over 0.5 h. The reaction mixture 
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was then cooled to -78 °C and cannulated to a -78 °C solution of tert-butyl (2-
formylphenethyl)(tosyl)carbamate 300b (289 mg, 0.717 mmol, 1.0 eq.) in tetrahydrofuran (2 mL) until 
the red colour persisted for a period of several seconds. The reaction was quenched by aqueous 
ammonium chloride (5 mL) and ethyl acetate (5 mL) and the separated aqueous layer extracted with ethyl 
acetate (3 x 10 mL). The combined organic mixtures were washed with brine (15 mL), dried, filtered and 
exaporated. The crude material was then dissolved in toluene (3.5 mL) under an atmosphere of nitrogen at 
0 °C. To this was added triflic acid (108 mg, 0.717 mmol, 1.0 eq.). The resulting solution was heated to 
110 °C, stirred for 18 h and then quenched with aqueous potassium carbonate (2 mL), extracted with 
dichloromethane (3 x 5 mL) and the combined organic extracts dried, filtered and evaporated. The crude 
material was purified by column chromatography (petrol/ethyl acetate 1:1) to give berberinone 410 (136 
mg, 76%) as an off-white solid; m.p. 172-174; νmax 3028, 2930, 2886, 1637 (C=O), 1401, 1288; δH (400 
MHz) 8.15 (1H, d, J 7.6, ArH), 7.46 (1H, td, J 7.4 and 1.1, ArH), 7.38 (1H, t, J 7.5, ArH), 7.31 – 7.20 
(5H, m, 5 x ArH), 4.98 – 4.94 (2H, m, ArCHN and ArCH2aCH2), 3.25 (1H, dd, J 15.7 and 3.7, 
ArCH2aCH), 3.09 – 2.94 (3H, m ArCH2bCH2 and NCH2), 2.94 – 2.81 (1H, m, ArCH2bCH); δC 164.7 
(C=O), 137.5 (C), 136.1 (C), 135.2 (C), 131.9 (ArCH), 129.2 (C), 129.1 (ArCH), 128.7 (ArCH), 127.5 
(ArCH), 127.0 (ArCH), 127.0 (ArCH), 126.9 (ArCH), 126.1 (ArCH), 55.35 (CH), 38.8 (CH2), 38.0 
(CH2), 29.9 (CH2); HRMS (APCI) calculated for C17H16NO [M+H]
+
 250.1232, found 250.1221. 
 
6-ethyl-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline 411 
 
 
 
 
 
To a solution of 6-ethyl-5,6,13,13a-tetrahydro-8H-isoquinolino[3,2-a]isoquinolin-8-one 409 (17 mg, 
0.0614 mmol, 1.0 eq.) in tetrahydrofuran (4 mL) was added lithium aluminium hydride (1M, 0.49 mL, 
0.491 mmol, 8.0 eq.) and the resulting mixture heated to 70 °C for 0.5 h. The reaction was quenched 
according to General Procedure G and the crude material was purified by column chromatography 
(petrol/ethyl acetate 1:5) to give berberine 411 (10 mg, 62%) as a colourless oil, as a 4:1 mixture of cis 
and trans diastereoisomers; major (cis)-diastereoisomer δH (400 MHz) 7.27 (1H, d, J 7.5, ArH), 7.23 – 
7.07 (7H, m, ArH), 4.33 (1H, d, J 14.7, 8-CH2a), 3.78 (1H, dd, J 10.9 and 3.2, 13a-CH), 3.54 (1H, d, J 
14.7, 8-CH2b), 3.38 (1H, dd, J 16.2 and 3.3, 13-CH2a), 2.99 (1H, dd, J 16.0 and 11.1, 13-CH2b), 2.87 (1H, 
dd, J 15.9 and 10.4, 5-CH2a), 2.80 (1H, dd, J 15.8 and 3.3, 5-CH2b), 2.56 (1H, dddd, J 10.4, 7.2, 3.9 and 
3.3, 6-CH), 1.97 (1H, dqd, J 14.8, 7.5 and 3.9, CH2aCH3), 1.61 (1H, dqd, J 15.1, 7.5 and 7.2 CH2bCH3), 
1.03 (3H, t, J 7.5, CH3); δC (101 MHz) 137.8 (C), 135.0 (C), 134.9 (C), 134.6 (C), 128.7 (ArCH), 128.6 
(ArCH), 126.7 (ArCH), 126.3 (ArCH), 126.2 (ArCH), 126.1 (ArCH), 125.9 (ArCH), 125.5 (ArCH), 61.0 
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(CH), 59.7 (CH), 53.9 (CH2), 37.8 (CH2), 34.4 (CH2), 25.8 (CH2), 9.8 (CH3); minor (trans)-
diastereoisomer δH (400 MHz) 7.23 – 7.05 (8H, m, ArH), 4.19 (1H, d, J 15.1, 8-CH2a), 3.99 (1H, dd, J 
11.0 and 3.9, ArCHN), 3.88 (1H, d, J 15.2, 8-CH2b), 3.26 (1H, dd, J 16.1 and 3.9, 5-CH2a), 3.19 (1H, dd, J 
15.9 and 4.6, 13-CH2a), 3.07 (1H, dddd, J 7.8, 5.5, 3.9 and 2.9, 6-CH), 2.90 (1H, dd, J 16.1 and 11.1, 13-
CH2b), 2.79 (1H, dd, J 15.9 and 2.9, 5-CH2b), 1.82 – 1.78 (1H, m, CH2aCH3), 1.24 – 1.12 (1H, m, 
CH2bCH3), 0.91 (3H, t, J 7.4, CH3); δC (101 MHz) 138.4 (C), 135.1 (C), 134.7 (C), 133.3 (C), 129.75 
(ArCH), 128.9 (ArCH), 126.4 (ArCH), 126.3 (ArCH), 126.3 (ArCH), 125.9 (2 x ArCH), 125.7 (ArCH), 
58.3 (CH), 55.3 (CH), 53.95 (CH2), 37.4 (CH2), 33.1 (CH2), 17.1 (CH2), 11.7 (CH3); HRMS (APCI) 
calculated for C19H22N [M+H]
+
 264.1752, found 264.1743. 
 
5,8,13,13a-Tetrahydro-6H-isoquinolino[3,2-a]isoquinoline 412 
 
 
 
 
To a solution of 5,6,13,13a-tetrahydro-8H-isoquinolino[3,2-a]isoquinolin-8-one 410 (21 mg, 0.0843 
mmol, 1.0 eq.) in tetrahydrofuran (5 mL) was added lithium aluminium hydride (1M, 0.68 mL, 0.68 
mmol, 8.0 eq.) and the resulting mixture heated to 70 °C for 0.25 h. The reaction was quenched according 
to General Procedure G and the crude material was purified by column chromatography (petrol/ethyl 
acetate 1:5) to give berberine 412 (18 mg, 62%) as an off-yellow solid; m.p. 78- 81; δH (400 MHz) 7.21 
(1H, d, J 7.5, ArH) 7.17 – 7.02 (6H, m, 6 x ArH), 7.01 (1H, d, J 5.1, ArH), 3.96 (1H, d, J 14.9, ArCH2aN), 
3.68 (1H, d, J 15.6, ArCH2bN), 3.65 – 3.60 (1H, m, 13a-CH), 3.31 (1H, dd, J 16.2 and 3.7, 13-CH), 3.13 
(2H, m, 5-CH2a and 6-CH2a), 2.86 (1H, dd, J 16.0 and 11.6, 13-ArCH2b), 2.69 (1H, dd, J 17.3 and 5.1 5-
CH2b), 2.63 – 2.53 (1H, m, 6-CH2a); δC (101 MHz) 138.1 (C), 134.7 (C), 134.6 (C), 134.6 (C), 129.0 
(ArCH), 128.9 (ArCH), 126.4 (ArCH), 126.3 (ArCH), 126.3 (ArCH), 126.2 (ArCH), 126.0 (ArCH), 
125.6 (ArCH), 60.0 (CH), 58.8 (CH2), 51.4 (CH2), 36.8 (CH2), 29.7 (CH2); HRMS (APCI) calculated for 
C17H18N [M+H]
+
 236.1439, found 236.1434. 
Hydrochloride salt was prepared by dissolving 5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline 
412 (10 mg) in methanol (0.1 mL) followed by addition of HCl (10 M, 11 l, 2.5 eq.). The solvents were 
removed under reduced pressure and the material dried in a vacuum oven overnight to afford salt 412-
HCl (10 mg) as a white solid; m.p. 197 – 201 °C (lit. m.p.256 223 °C).  
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